



**FUNGIOUS DISEASES  
AND THEIR TREATMENT**

<i>AFRICA</i>	BUTTERWORTH & CO. (AFRICA) LTD. DURBAN : 33-35 BEACH GROVE
<i>AUSTRALIA</i>	BUTTERWORTH & CO (AUSTRALIA) LTD. SYDNEY · 8 O'CONNELL STREET MELBOURNE . 430 BOURKE STREET BRISBANE . 240 QUEEN STREET
<i>CANADA</i>	BUTTERWORTH & CO. (CANADA) LTD. TORONTO · 1367 DANFORTH AVENUE
<i>NEW ZEALAND</i>	BUTTERWORTH & CO (AUSTRALIA) LTD. WELLINGTON 49-51 BALLANCE STREET AUCKLAND 35 HIGH STREET

# FUNGOUS DISEASES AND THEIR TREATMENT

*Edited by*

R. W. RIDDELL

M.D (LOND.), F.R.C.P.(EDIN.)

CONSULTANT BACTERIOLOGIST, BROMPTON HOSPITAL,  
LONDON, HONORARY CONSULTANT MYCOLOGIST,  
ST. JOHN'S HOSPITAL FOR DISEASES OF THE SKIN,  
LONDON, SENIOR LECTURER MEDICAL MYCOLOGY,  
INSTITUTE OF DERMATOLOGY, LONDON

*and*

G. T. STEWART

B SC, M D (GLAS.), D T.M. AND H.

CONSULTANT PATHOLOGIST,  
CROYDON GROUP OF HOSPITALS AND QUEEN MARY'S  
HOSPITAL FOR CHILDREN, CARSHALTON

LONDON

BUTTERWORTH & CO. (PUBLISHERS) LTD.

1958



THE SEVERAL CONTRIBUTORS LISTED ON PAGES XI-XIII  
1958

Made and printed in Great Britain by  
William Clowes and Sons, Limited, London and Beccles

## FOREWORD

THE Symposium whose proceedings are reported in this book was held, under the aegis of the British Postgraduate Medical Federation, at the Institute of Diseases of the Chest, Brompton Hospital, in July, 1957. It owed its origin to an offer to the Federation by Messrs E. R. Squibb and Sons to give financial support to such a symposium. An organizing committee was constituted by representatives of those Institutes of the Federation in whose special work fungous diseases are important, as follows:

Dr. J. G. Scadding (Chairman)	Institute of Diseases of the Chest
Dr R. W. Riddell	Institutes of Diseases of the Chest and Dermatology
Dr F. R. Bettley	Institute of Dermatology
Dr S. Gold	Institute of Dermatology
Dr N. F. Norris	Institute of Obstetrics and Gynaecology
Dr A. P. Norman	Institute of Child Health
Dr G. T. Stewart (co-opted)	

Dr Riddell and Dr Stewart acted as Honorary Secretaries of the Committee and subsequently as Editors of the Proceedings

The Symposium brought together the experience of workers from several parts of the world. The Organizing Committee, in order to encourage full and free discussion, decided to limit invitations to workers active in the study of various aspects of fungous diseases. While some fungous infections of man are widespread throughout the world, others seem to have a restricted geographical distribution. Where the more serious diseases are endemic, for example, coccidioidomycosis and histoplasmosis in the United States, the locally endemic diseases have been studied intensively, and this has stimulated interest in the general problems of fungous infections. At the same time, interest in these diseases is increasing in Great Britain. The importance of fungi has long been recognized in dermatology, and the clinical aspects of the more frequent systemic fungous infections, such as actinomycosis, are well known. The clinical pictures of some of the less frequent pulmonary infections, such as aspergillosis, are at present being elucidated in this country, and the widespread use of antibiotics has focused attention upon the problem of fungous super-infections in patients so treated. Nevertheless,



THE SEVERAL CONTRIBUTORS LISTED ON PAGES XI-XIII  
1958

Made and printed in Great Britain by  
William Clowes and Sons, Limited, London and Beccles

# CONTENTS

FOREWORD BY J. G. SCADDING	Page v
EDITORS' PREFACE	xv

## Part 1

### PATHOLOGY, CLINICAL FEATURES, AND EPIDEMIOLOGY

THE ROLE OF FUNGI AS HUMAN PATHOGENS . . . R. W. Riddell	3
HISTOPATHOLOGICAL OBSERVATIONS IN SOME CASES OF FUNGAL INFECTION SEEN IN BRITAIN W. St. C. Symmers	25
PATHOGENESIS OF TINEA INFECTIONS . . . R. Vanbreuseghem	50
<i>TRICHOPHYTON RUBRUM</i> INFECTION . . . C. D. Calnan	56
EPIDEMIOLOGY OF <i>TRICHOPHYTON RUBRUM</i> INFECTION . . . Mary P. English	63
TINEA PEDIS IN MINERS J. G. Holmes	67
PIGMENTS OF <i>TRICHOPHYTON RUBRUM</i> A. Tickner	72
IMMUNITY IN YEAST INFECTION H. I. Winner	75
FUNGOUS INFECTIONS FOLLOWING ANTIBIOTIC THERAPY . . . T. Anderson	84
VULVO-VAGINAL MONILIASIS . . . Ian Donald	88
<i>CANDIDA ALBICANS</i> IN VAGINAL SECRETIONS IN PREGNANCY . . . Sylvia M. Dawkins, Joan M. B. Edwards, and Yvonne M. Clayton	94



## FOREWORD

the therapy of fungal infections, with the exception of actinomycosis, is poorly defined, in spite of the range of agents, old and new, which have been brought forward for consideration.

The Symposium gave an opportunity, unique in this country, for defining both the present state of knowledge and outstanding problems in the study of fungi in relation to human disease. Its work was divided into sessions on pathology, under the chairmanship of Professor Robert Cruickshank; on dermatology (Dr. G. B. Dowling); on medicine (Dr. J. G. Scadding); on therapeutics (Professor L. P. Garrod), on gynaecology (Professor W. C. W. Nixon); and on paediatrics (Professor A. A. Moncrieff). Discussion sessions were opened by Dr J. L. Livingstone (London), Dr C. H. Whittle (Cambridge), Professor Roger Baker (Durham, N. Carolina), Mr. Aleck Bourne (London) and Professor Hans Götz (Munich)

It is fortunate indeed that it has proved possible to publish the Proceedings of the Symposium, and thanks are due to the participants who agreed not only to provide the scripts of their papers for publication (which more than doubled the labour of contributing to a symposium of this sort), but also to permit editing in order to secure some uniformity of presentation. It is hoped that these Proceedings will constitute not only a useful summary of current knowledge and views concerning fungous diseases and their treatment, but also a worthy record of the collaboration which the Symposium represented between the participants from this country and overseas, the several Institutes of the British Postgraduate Medical Federation which were concerned in its organization, and the Pharmaceutical House without whose financial support it would not have been possible

J. G. SCADDING

*August, 1958*

## CONTENTS

	<i>Page</i>
PRACTICAL ASPECTS OF TREATMENT OF FUNGOUS INFECTIONS OF THE SKIN . . . . .	213
Brian Russell	
TREATMENT AND CONTROL OF CHILDHOOD RINGWORM . . . . .	217
J. M. Beare	
TREATMENT OF VAGINAL MONILIASIS . . . . .	221
R. F. Jennison	
TREATMENT OF ACTINOMYCOSIS . . . . .	226
O. S. Tubbs	
TREATMENT OF ASPERGILLOSIS . . . . .	234
N. S. Plummer	
EXPERIENCES WITH THE THERAPY OF 60 CASES OF DEEP MYCOTIC INFECTIONS . . . . .	241
M. L. Furcolow	

## INDEX

## CONTENTS

	<i>Page</i>
SKIN MONILIASIS IN INFANTS . . . . .	102
J. P. Bound	
MORBID ANATOMY OF INFANTILE MONILIASIS .	105
Martin Bodian	
PATHOLOGY OF INFANTILE MONILIASIS . . .	111
I. A. B. Cathie	
INFECTIONS DUE TO AEROBIC ACTINOMYCETES .	114
F. Mariat	
BRONCHO-PULMONARY ASPERGILLOSIS . . .	123
K. F. W. Hinson	
PULMONARY ASPERGILLOSIS: SOME ASPECTS OF THE PARASITIC FORMS OF <i>ASPERGILLUS</i> . .	128
G. Segretain	
DIRECT BRONCHIAL SENSITIVITY TESTS IN BRONCHO-PULMONARY ASPERGILLOSIS . . .	134
K. Citron and J. Pepys	
FARMER'S LUNG . . . . .	138
C. J. Fuller	
SEROLOGICAL DIAGNOSIS AND EPIDEMIOLOGICAL ASPECTS OF HISTOPLASMOSIS . . . . .	142
Charlotte C. Campbell	
HISTOPLASMIN TESTING IN DIFFERENT GEOGRAPHIC AREAS . . . . .	158
Phyllis Q. Edwards	
RADIOLOGY OF PULMONARY MYCOSES . . .	170
J. W. Pierce	

### *Part 2*

## TREATMENT

THE MODE OF ACTION OF ANTI-FUNGAL DRUGS	183
G. T. Stewart	
THE THERAPEUTIC USE OF ANTI-FUNGAL AGENTS	192
E. Drouhet	
THEORETICAL ASPECTS OF TREATMENT OF FUNGOUS INFECTIONS OF THE SKIN . . . .	208
A. J. E. Barlow	

## LIST OF CONTRIBUTORS

- T. ANDERSON, M.D. (GLAS.), F.R.C.P. (ED)**  
 Reader in Infectious Diseases, University of Glasgow; Ruchill Hospital, Glasgow
- A. J. E. BARLOW, M.D. (LEEDS), M.R.C.S. (ENG)**  
 Consultant Dermatologist, Royal Infirmary, Huddersfield
- J. MARTIN BEARE, M.D. (BELF.), M.R.C.P. (LOND)**  
 Assistant Physician, Dermatology Department, Royal Victoria Hospital, Belfast; Assistant Dermatologist, Royal Belfast Hospital for Sick Children
- MARTIN BODIAN, M.D., M.R.C.P. (LOND)**  
 Pathologist in Charge of Department of Morbid Anatomy, The Hospital for Sick Children, Great Ormond Street, London
- J. P. BOUND, M.D. (LOND), M.R.C.P. (LOND), M.R.C.S. (ENG.)**  
 Consultant Paediatrician, Victoria Hospital, Blackpool
- C. D. CALNAN, M.A. (CAMB.), M.B., B.CHIR. (CAMB), M.R.C.P. (LOND.)**  
 Consultant Dermatologist, Royal Free Hospital; Consultant Physician, St John's Hospital for Diseases of the Skin, London; Senior Lecturer, Institute of Dermatology, London
- CHARLOTTE C CAMPBELL, B.S.**  
 Department of Bacteriology, Walter Reed Army Institute of Research, Washington
- I. A. B. CATHIE, M.D., M.R.C.P. (LOND)**  
 Clinical Pathologist, The Hospital for Sick Children, London
- K. M. CITRON, M.D. (LOND.), M.R.C.P. (LOND)**  
 Senior Medical Registrar, Brompton Hospital, London
- YVONNE M. CLAYTON, B.Sc. (LOND)**  
 Research Assistant in Mycology, Brompton Hospital, London
- SYLVIA M. DAWKINS, M.B., B.S. (LOND)**  
 Clinical Assistant, Fertility Clinic, University College Hospital, London
- IAN DONALD, M.B.E., M.D. (LOND), F.R.C.O.G., F.R.F.P.S.G.**  
 Regius Professor of Midwifery, University of Glasgow
- E. DROUHET**  
 Institut Pasteur, Paris
- JOAN M. B. EDWARDS, M.B., B.S. (LOND)**  
 Bacteriologist, Public Health Laboratory, Neasden



## LIST OF CONTRIBUTORS

- G. T. STEWART, B SC., M D. (GLAS.), D.T.M. and H.  
Consultant Pathologist, Croydon Group of Hospitals and Queen  
Mary's Hospital for Children, Carshalton
- W. ST. C. SYMMERS, M D. (BELF.), PH D (BIRM)  
Professor of Morbid Anatomy, University of London; Honor-  
ary Consultant Pathologist and Lecturer in Morbid Anatomy  
and Histopathology, Charing Cross Hospital, London
- A. TICKNER, M B, B S, B SC. (LOND)  
Senior Lecturer in Biochemistry, Institute of Dermatology,  
London
- O. S. TUBBS, M A. (CAMB), F.R.C.S. (ENG)  
Thoracic Surgeon, St. Bartholomew's Hospital and Brompton  
Hospital, London
- R. VANBREUSEGHEM  
Professor, Institut de Médecine Tropicale, Antwerp; Head of  
the Mycological Department, Institut de Médecine Tropicale,  
Antwerp, Professor of Tropical Parasitology, Université Libre  
de Bruxelles, Brussels
- H. I. WINNER, M.A., M D  
Bacteriologist, Charing Cross Hospital, London

## LIST OF CONTRIBUTORS

- PHYLLIS Q EDWARDS, M.D. (CALIF), M.P.H (HARVARD)**  
 Medical Officer, Tuberculosis Program, United States Public Health Service, Washington, D.C.
- MARY ENGLISH, M sc.**  
 Mycologist, Bristol Royal Hospital, Bristol
- C J. FULLER, F.R C.P. (LOND)**  
 Physician, Royal Devon and Exeter Hospital, Exeter
- M. L. FURCOLOW, A B, M D, M.A.**  
 Medical Director, Chief, Kansas City Field Station, Department of Health, Education and Welfare, Public Health Service, Bureau of State Services, Communicable Disease Center, University of Kansas Medical Center, Kansas City, Kansas
- K F. W. HINSON, M.R C S (ENG), L R C.P. (LOND)**  
 Director of Pathology, London Chest Hospital
- J G HOLMES, M.D (CAMB), M.R C.P. (LOND.)**  
 Coventry and South Warwickshire Groups of Hospitals
- R** .....
- F. MARIAT**  
 Institut Pasteur, Paris
- J. PEPYS, M B., CH B. (W'W'RAND), M.R.C.P. (LOND.), M R.C.P.(ED.)**  
 Senior Lecturer in Allergy, Institute of Diseases of the Chest, London
- J W PIERCE, M D (LOND), M R.C P (LOND)**  
 Radiologist, St Thomas's Hospital and Brompton Hospital, London
- N S PLUMMER, M D (LOND), F R C P (LOND)**  
 Physician, Chest Clinic, Charing Cross Hospital, and London Chest Hospital
- R W RIDDELL, M D (LOND), F R C P (ED)**  
 Consultant Bacteriologist, Brompton Hospital; Honorary Consultant Mycologist, St. John's Hospital for Diseases of the Skin, London, Senior Lecturer in Medical Mycology, Institute of Dermatology, London
- BRIAN F RUSSELL, M D (LOND), F R C P (LOND)**  
 Physician, London Hospital and St John's Hospital for Diseases of the Skin, London
- G SEGRETAİN**  
 Institut Pasteur, Paris

## EDITORS' PREFACE

OUR aim in preparing this book has been to condense the papers read at the Symposium on Fungous Diseases into a useful work of reference. The Symposium was designed to bring together individuals with different approaches to each topic, and was characterized by contrasts in subject-matter. Thus, papers on the clinical aspects were followed by others dealing with the wider problems of industrial and epidemiological management of fungous infections, while the criteria used in the diagnosis of isolated cases were set against the background of geographical and communal incidence.

A book prepared from so many sources can hardly be systematic but it can highlight the principal advances in the subject and, equally important, emphasize the main gaps in present-day knowledge and approach. On reading the various papers delivered at the Symposium, we have been impressed by the need for re-assessment of the pathogenicity of some well-known fungous species such as *Candida albicans* and *Aspergillus fumigatus*, and by the unsuspected prevalence in some communities of organisms like *Histoplasma capsulatum*. The imaginative methods recently developed, particularly in the United States, for early case detection and epidemiological study in histoplasmosis deserve special emphasis both as examples of the handling of localized incidents and as a pattern for dealing with certain other infections. In contrast, it is apparent that traditional methods have done much to control many of the commoner infections of the skin and hair.

Perhaps the least rational topic in this field is that of therapy. Some contributors spoke of new chemotherapeutic agents, others, with equal conviction and authority, spoke of classical empirical therapy with dyes and tars. The dermatologists in particular seemed convinced of the adequacy and even superiority of the older medicaments. The modern has so often gained by re-assessment of the traditional that we have felt it a duty in this volume to give heed to both. But we have also found ourselves driven to the conclusion that a more critical study was required of the mode of action of the few effective drugs used for treating mycotic diseases. The treatment of ringworm infections due to anthropophilic species of dermatophytes has not altered over the years and is still inadequate, much has yet to be learnt about the treatment of the pulmonary and systemic mycoses.





**PART I**

**PATHOLOGY, CLINICAL FEATURES  
AND EPIDEMIOLOGY**



# THE ROLE OF FUNGI AS HUMAN PATHOGENS

R. W. RIDDELL

ONLY very few species of fungi which exist as saprophytes in Nature have the ability to infect man though many of them can evoke allergic reactions in hypersensitive subjects. The few which do produce disease may be considered in 3 morphological groups and this separates them broadly in their roles as pathogens.

## MORPHOLOGICAL GROUPS

**Filamentous fungi.**—These are mostly only locally invasive, but rarely some produce disseminated infections. The spores they form comprise the infective elements by which disease is acquired. Examples are the dermatophytes (or ringworm fungi) and *Aspergillus fumigatus* (Fig 1)

**Yeasts.**—These are unicellular fungi which reproduce by budding and which are, by virtue of their structure, relatively readily disseminated in the tissues. There is one important example, namely *Cryptococcus neoformans* (Fig 2)

Organisms which under the same cultural conditions grow both as



FIG 1 — *Aspergillus fumigatus* Mycelium and spore structure (Lactophenol blue,  $\times 336$ )



## THE ROLE OF FUNGI AS HUMAN PATHOGENS

yeasts and elongated filamentous cells are called *yeast-like fungi*. They are exemplified by *Candida (Monilia) albicans* (Fig. 3).

**Dimorphic fungi.**—This small group grow either as filaments or as yeasts according to whether the temperature of culture is approximately 22° C. or 37° C., or whether the fungus is existing as a saprophyte or parasite. These two forms do not occur simultaneously under the same environmental conditions. *Blastomyces dermatitidis* is an example (Fig. 4a and b).

In addition to these groups of true fungi, the actinomycetes are usually considered among the causative agents of mycotic diseases. They should, however, properly be classified among the bacteria.

acceptance of a uniform terminology for pathogenic fungi and this is depicted in the Medical Research Council Memorandum No. 23<sup>4</sup>. In summarizing the properties of fungi which produce disease in man, these organisms will be grouped according to their role as pathogens (Tables 1, 4, 5); the clinical pathology of mycotic diseases is summarized elsewhere<sup>6, 7, 9, 10</sup>.

### SKIN INFECTIONS

**The dermatophytes.**—The fungi which exhibit the highest degree of specialization from the point of view of parasitic habitat are those which invade the keratin of skin and its appendages (Table 1)

TABLE 1  
KERATIN INVADERS

<i>Fungus</i>	<i>Disease</i>	<i>Classification</i>
Fungi causing superficial mycoses		
<i>Malassezia furfur</i>	Pityriasis versicolor	Y-L
<i>Nocardia minutissima</i>	Erythrasma	B
<i>Nocardia tenuis</i>	Trichonocardiosis axillaris	B
<i>Piedraia</i> species, etc	Piedra	F
Fungi causing ringworm		
<i>Microsporum</i> species	} Tinea of skin, hair and nails	F
<i>Trichophyton</i> species		
<i>Epidermophyton</i> species		
<i>Candida albicans</i>	Moniliasis	Y-L

B = Bacterium, Y = Yeast, Y-L = Yeast-like fungus; F = Filamentous fungus

## THE ROLE OF FUNGI AS HUMAN PATHOGENS




FIG 2—*Cryptococcus neoformans* Yeast cells with surrounding capsules (Periodic acid Schiff,  $\times 420$ )



FIG 3—*Candida albicans* Yeast cells, some elongated to form pseudomycelium (Lactophenol blue,  $\times 565$ )




FIG 5—*Actinomyces israeli* Fine branching mycelium ( $\times 900$ )

The dermatophytes are the most successful parasites from this point of view because of their ability to lyse keratin. When invading skin structures they may advance to the vicinity of, but never into, the zone of living keratogenous cells (Fig 6). Distinct differences in potentiality for invasion are apparent within this closely related group of fungi, especially in connexion with the keratin of nails and hair (Table 2). *Microsporum audouinii*, for example, shows a great affinity for the hair of young subjects yet it does not attack nails, *Trichophyton rubrum* on the other hand only rarely attacks hair but produces deep and intractable infection of nails.

Only when hair is invaded *in vivo* by certain ringworm organisms is a fluorescent chemical material produced in amounts detectable to the naked eye under ultra-violet light (Table 2). Considerable differences are apparent also in host reactions in these infections, the most important single factor concerned being the fungous species responsible. Some ringworm fungi, especially those zoophilic species which infect animals as well as man (Table 3), produce acute inflammatory lesions with erythema, vesiculation and even suppuration (Fig 7).

Other species, generally the anthropophilic strains which only very rarely infect animals, excite only a slight tissue reaction consisting of hyperkeratosis (Fig 8) and slight infiltration of the epidermis



## THE ROLE OF FUNGI AS HUMAN PATHOGENS



(a)



(b)

FIG 4—*Blastomyces dermatitidis* (a) Saprophytic phase. Mycelium with single-celled spherical spores from culture grown at 22° C (Lactophenol blue,  $\times 900$ ) (b) Parasitic phase. Yeasts from culture grown at 37° C (Lactophenol blue,  $\times 900$ )



FIG 6—*Trichophyton rubrum* infection of skin. Section shows fungous filaments deep in keratin layer (Periodic acid Schiff,  $\times 350$ ) (By courtesy of Dr C. D. Calnan)

by mononuclear cells. *Trichophyton schoenleinii* is an exception to this generalization as is obvious in the clinical syndrome of favus; exceptions also occasionally occur in various other ringworm species<sup>5</sup>

*Uncultured fungi*—In contrast to the ringworm fungi, organisms like *Malassezia furfur* (Fig 9) and *Nocardia minutissima* (Fig 10) colonize only the most superficial layers of keratin and are responsible only for mildly inflammatory lesions typical of pityriasis versicolor and erythrasma respectively. These fungi have not been cultured.

*Candida albicans*—Requiring separate and special mention among the keratin invading fungi is *C. albicans*, a potential pathogen which appears to need the existence of certain predisposing factors before

# THE ROLE OF FUNGI AS HUMAN PATHOGENS

TABLE 2  
SUSCEPTIBILITY OF HAIR AND NAIL TO INFECTION BY  
DERMATOPHYTE SPECIES

	Hair invasion			Nail invasion
	Degree	Spore arrangement	Fluorescence	Degree
<i>Microsporum</i> :				
<i>M. audouinii</i>	++	SSE	++	-
<i>M. canis</i>	++	SSE	++	-
<i>M. gypseum</i>	=	SSE	-	-
<i>Trichophyton</i> :				
<i>T. mentagrophytes</i>	+	SSE	-	+
<i>T. rubrum</i>	-	-	-	++
<i>T. verrucosum</i>	+	LSE	-	-
<i>T. sulphureum</i>	++	E	-	+
<i>T. violaceum</i>	++	E	-	+
<i>T. schoenleini</i>	++	E	+	+
<i>Epidermophyton</i> *				
<i>E. floccosum</i>	-	-	-	±

SSE = Small-spored ectothrix hair infection, LSE = Large-spored ectothrix infection, E = Endothrix hair infection

TABLE 3  
NATURAL HABITAT OF RINGWORM SPECIES RELATED TO TYPE  
OF HUMAN LESIONS

Anthropophilic species producing non-inflammatory lesions	Zoophilic species producing inflammatory lesions	Soil species producing inflammatory lesions
<i>Microsporum</i> species		
<i>M. audouinii</i>	<i>M. canis</i> (cat and dog) <i>M. equinum</i> (horse)	<i>M. gypseum</i>
<i>Trichophyton</i> species		
<i>T. rubrum</i>	<i>T. mentagrophytes</i> (cat, cattle, dog and horse)	
<i>T. sulphureum</i>	<i>T. verrucosum</i> (cattle and horse)	
<i>T. violaceum</i>	<i>T. quinckeanum</i> (mouse)	
<i>T. schoenleini</i>	<i>T. equinum</i> (horse)	
<i>Epidermophyton</i> species		
<i>E. floccosum</i>		

## THE ROLE OF FUNGI AS HUMAN PATHOGENS




FIG 9 —*Malassezia furfur* in skin scrapings from patient with pityriasis versicolor (Periodic acid Schiff,  $\times 900$ )



FIG 10 —*Nocardia minutissima* in skin scrapings from patient with erythrasma ( $\times 900$ )

## THE ROLE OF FUNGI AS HUMAN PATHOGENS



FIG. 7—*Trichophyton verrucosum* infection of skin of forearm Contracted from cattle (By courtesy of Dr A D Porter)



FIG. 8—*Trichophyton rubrum* infection of palm of hand Limited to humans (By courtesy of Dr F R Bettley)

## THE ROLE OF FUNGI AS HUMAN PATHOGENS

it can become established in skin. Maceration is probably the most important of these, and prior antibiotic therapy and diabetes are others. Nails are very rarely invaded by this fungus and hairs never. Compared with most fungi infecting skin, it is an inefficient parasite but, unlike other skin pathogens, it also infects mucosae and, on rare occasions, produces disseminated disease.

**Parasitic and saprophytic comparison.**—The dermatophytes are markedly inhibited in their parasitic life in skin compared with their saprophytic growth in culture. *In vivo* in keratin, hyphae segmenting into chains of arthrospores are formed (Fig 11b) whereas on culture media luxuriant growth usually develops in which a variety of spore forms appear (Fig 11a). This growth and sporulation is, in certain species only, influenced by added growth factors such as thiamin<sup>3</sup>. It is only by study of the saprophytic phase of the ringworm fungi that it is possible to identify them. Dermatophytes will grow on hairs *in vitro* producing the same kind of structures as are obtained on culture media<sup>3</sup>. The lytic action of enzymes of many dermatophytes growing in this way leads to the formation of transverse wedges in the hair shafts (Fig 12), it does not occur, however, in the case of *T. rubrum*<sup>1</sup>. This appearance differs from the longitudinal tunnelling of hairs which develops in



FIG 12 —*Trichophyton mentagrophytes*. Hair invasion *in vitro* showing multiple transverse perforations produced by fungus seen growing on surface (Lactophenol blue,  $\times 450$ )

## THE ROLE OF FUNGI AS HUMAN PATHOGENS



(a)



(b)

Fl

## THE ROLE OF FUNGI AS HUMAN PATHOGENS

it can become established in skin. Maceration is probably the most important of these, and prior antibiotic therapy and diabetes are others. Nails are very rarely invaded by this fungus and hairs never. Compared with most fungi infecting skin, it is an inefficient parasite but, unlike other skin pathogens, it also infects mucosae and, on rare occasions, produces disseminated disease.

**Parasitic and saprophytic comparison.**—The dermatophytes are markedly inhibited in their parasitic life in skin compared with their saprophytic growth in culture. *In vivo* in keratin, hyphae segmenting into chains of arthrospores are formed (Fig 11b) whereas on culture media luxuriant growth usually develops in which a variety of spore forms appear (Fig 11a). This growth and sporulation is, in certain species only, influenced by added growth factors such as thiamin<sup>3</sup>. It is only by study of the saprophytic phase of the ringworm fungi that it is possible to identify them. Dermatophytes will grow on hairs *in vitro* producing the same kind of structures as are obtained on culture media<sup>3</sup>. The lytic action of enzymes of many dermatophytes growing in this way leads to the formation of transverse wedges in the hair shafts (Fig 12), it does not occur, however, in the case of *T. rubrum*<sup>1</sup>. This appearance differs from the longitudinal tunnelling of hairs which develops in



FIG 12—*Trichophyton mentagrophytes*. Hair invasion *in vitro* showing multiple transverse perforations produced by fungus seen growing on surface (Lactophenol blue,  $\times 450$ )



# THE ROLE OF FUNGI AS HUMAN PATHOGENS



(a)



(b)

FIG. 11. The histological section of tissue showing the presence of *Aspergillus* hyphae and spores. (a) shows the hyphae and spores in the tissue. (b) shows the hyphae and spores in the tissue.

## THE ROLE OF FUNGI AS HUMAN PATHOGENS

it can become established in skin. Maceration is probably the most important of these, and prior antibiotic therapy and diabetes are others. Nails are very rarely invaded by this fungus and hairs never. Compared with most fungi infecting skin, it is an inefficient parasite but, unlike other skin pathogens, it also infects mucosae and, on rare occasions, produces disseminated disease.

**Parasitic and saprophytic comparison.**—The dermatophytes are markedly inhibited in their parasitic life in skin compared with their saprophytic growth in culture. *In vivo* in keratin, hyphae segmenting into chains of arthrospores are formed (Fig 11b) whereas on culture media luxuriant growth usually develops in which a variety of spore forms appear (Fig 11a). This growth and sporulation is, in certain species only, influenced by added growth factors such as thiamin<sup>3</sup>. It is only by study of the saprophytic phase of the ringworm fungi that it is possible to identify them. Dermatophytes will grow on hairs *in vitro* producing the same kind of structures as are obtained on culture media<sup>3</sup>. The lytic action of enzymes of many dermatophytes growing in this way leads to the formation of transverse wedges in the hair shafts (Fig 12), it does not occur, however, in the case of *T. rubrum*<sup>1</sup>. This appearance differs from the longitudinal tunnelling of hairs which develops in



FIG 12—*Trichophyton mentagrophytes*. Hair invasion *in vitro* showing multiple transverse perforations produced by fungus seen growing on surface. (Lactophenol blue,  $\times 450$ )

## THE ROLE OF FUNGI AS HUMAN PATHOGENS

natural or experimental infections, a pattern probably determined by the intrafollicular position of the hair shaft and by chemotactic influences in the region of the hair bulb. The pathogenesis of tinea infections is described more fully elsewhere<sup>8</sup>.

### SUBCUTANEOUS INFECTIONS

Certain fungi and actinomycetes have the ability to parasitize subcutaneous tissues when they are introduced by trauma (Table 4)

TABLE 4  
FUNGI CAUSING SUBCUTANEOUS INFECTIONS


<i>Fungus</i>	<i>Disease</i>	<i>Classification</i>
<i>Actinomyces israeli</i>	Actinomycosis	B
<i>Nocardia</i> species	Actinomycetoma	B
<i>Madura</i> species, etc	Maduromycetoma	F
<i>Phialophora</i> species	Chromoblastomycosis	F
<i>Sporotrichum schenckii</i>	Sporotrichosis	D

B = Bacterium, F = Filamentous fungus, D = Dimorphic fungus


These organisms differ one from another in their ability to colonize at this site and in the tissue reaction and damage they elicit. In actinomycosis and actinomycetoma, small colonies or "granules" are formed which lead to the production of micro-abscesses in their vicinity. In maduromycetoma similar lesions can be seen histologically around discrete colonies composed of true fungal mycelium (Fig. 13b). on culture media the same fungi grow profusely (Fig. 13a).

In chromoblastomycosis, fungous growth in the tissues is much more restricted so that only small and dysgonic elements develop which proliferate slowly by a peculiar process of septation (Fig. 14b). The presence of these small cells is, however, sufficient to give rise to micro-abscess formation and to granulomatous disease extending by histiocytic and lymphatic spread of the fungus. The tissue form of the fungus bears no similarity to its original saprophytic mycelial phase (Fig. 14a).

Sporotrichosis, another example of a subcutaneous mycosis, comes closer to an infection in the bacterial sense. The infecting mycelial fungus (Fig. 15a) traumatically introduced into the tissues becomes converted to a yeast form (Fig. 15b). In proliferating, the yeasts give rise to an intractable subacute inflammatory disease and are carried by lymphatics to form further subcutaneous granulomata at sites distant from the primary lesion.



(a)




(b)

FIG 13—*Madurella mycetomi* (a) Saprophytic phase Coarse mycelium bearing lateral spores truncated by septa (A) and thick-walled chlamydospores (B) (Lactophenol blue,  $\times 900$ ) (b) Parasitic phase Fungal colony in subcutaneous tissues in mycetoma consisting of coarse mycelium and thick-walled cells (chlamydospores) (A) Colony embedded in brown matrix secreted by the fungus forming a dark coloured "grain" (Periodic acid Schiff,  $\times 250$ )

## THE ROLE OF FUNGI AS HUMAN PATHOGENS




(a)



(b)



(a)




(b)

FIG 15 — *Sporotrichum schenckii* (a) Saprophytic phase Mycelium and sporing structures (Lactophenol blue,  $\times 900$ ) (b) Parasitic phase Yeast cells mostly oval in shape proliferating in pus from sporotrichotic lesion ( $\times 800$ )

# THE ROLE OF FUNGI AS HUMAN PATHOGENS




(a)




(b)

FIG. 14. *Pl. of saprophytes*. (a) Saprothia on a branch. (b) Saprothia on a surface.

## THE ROLE OF FUNGI AS HUMAN PATHOGENS



(a)



(b)

FIG 16—*Histoplasma capsulatum*. (a) Saphrophytic phase. Mycelium and thick-walled tuberculate spores from culture grown at 22° C (Lactophenol blue,  $\times 800$ ) (b) Parasitic phase. Minute yeasts from culture grown at 37° C (Lactophenol blue,  $\times 420$ )



## THE ROLE OF FUNGI AS HUMAN PATHOGENS

### PULMONARY AND SYSTEMIC INFECTIONS

The final group of fungi to be considered show well-developed pathogenic properties, the majority capable of producing disseminating diseases (Table 5)

**Endogenous infection.**—Infection may be endogenous in origin as in actinomycosis. Here *A. israeli* departs from its usual role as a harmless commensal of the oropharynx or alimentary tract and becomes invasive in a new habitat. *C. albicans* is similar in this respect but, though its invasive potentialities are not infrequently seen in the respiratory or alimentary mucosae at autopsy, it only rarely produces systemic infection, and pneumonitis due to *C. albicans* is probably non-existent.

**Infection by dust inhalation.**—Distinct from these endogenous infections are the pulmonary and systemic diseases acquired by inhalation of fungus-infected dust. They are usually benign, but are fatal in the rare cases where fungus cells are disseminated to brain, skeletal structures, skin and elsewhere. The invading fungus in each case is unicellular, this being its natural form in torulosis (Fig 2) and its parasitic form by adaptation in histoplasmosis (Fig 16b), coccidioidomycosis (Fig 17b), and blastomycosis (Fig 4b)

TABLE 5  
FUNGI CAUSING PULMONARY INFECTIONS

<i>Fungus</i>	<i>Disease</i>	<i>Classification</i>
Endogenous		
<i>Actinomyces israeli</i>	Actinomycosis	B
<i>Candida albicans</i>	Moniliasis	Y-L
Exogenous		
Primary pathogens		
<i>Cryptococcus neoformans</i>	Torulosis	Y
<i>Histoplasma capsulatum</i>	Histoplasmosis	D
<i>Coccidioides immitis</i>	Coccidioidomycosis	D
<i>Blastomyces dermatitidis</i>	Blastomycosis	D
Secondary invaders		
<i>Aspergillus fumigatus</i>	Aspergillosis	F
<i>Rhizopus</i> species	Mucormycosis	F

B=Bacterium, Y=Yeast, Y-L=Yeast-like fungus, F=Filamentous fungus, D=Dimorphic fungus

By contrast, in aspergillosis and mucormycosis the causative fungi are not dimorphic and, in consequence, produce only localized disease rarely metastasizing.


## THE ROLE OF FUNGI AS HUMAN PATHOGENS

It is not known how frequently *C. neoformans* is inhaled in dust, nor how often it produces minimal pulmonary lesions. Since laboratory-acquired infections appear to be unknown, it would seem that this yeast has only low pathogenicity for man. In susceptible subjects it gives rise to pulmonary granulomata which may progress to form widespread areas of pneumonitis. Where proliferation of yeasts is in advance of the tissue reaction a tumour-like mass (toruloma), consisting almost entirely of yeasts and capsular material, is produced (Fig. 18). The commonest sites for distant lesions are the meninges and brain and, in these, as well as in pulmonary




FIG. 18—Toruloma of lung. Resected specimen (left lower lobe) from male, aged 55 years, who had not travelled outside Britain (B) courtesy of Mr W P Cleland)

## THE ROLE OF FUNGI AS HUMAN PATHOGENS



(a)



(b)

Fi

## THE ROLE OF FUNGI AS HUMAN PATHOGENS

It is not known how frequently *C. neoformans* is inhaled in dust, nor how often it produces minimal pulmonary lesions. Since laboratory-acquired infections appear to be unknown, it would seem that this yeast has only low pathogenicity for man. In susceptible subjects it gives rise to pulmonary granulomata which may progress to form widespread areas of pneumonitis. Where proliferation of yeasts is in advance of the tissue reaction a tumour-like mass (toruloma), consisting almost entirely of yeasts and capsular material, is produced (Fig 18). The commonest sites for distant lesions are the meninges and brain and, in these, as well as in pulmonary

FIG 18—Toruloma of lung. Resected specimen (left lower lobe) from male, aged 55 years, who had not travelled outside Britain (By courtesy of Mr W P Cleland)



## THE ROLE OF FUNGI AS HUMAN PATHOGENS

lesions, the similarity of the parasitic and saprophytic forms of the fungus is seen. There is frequently comparatively little reaction in tissues infected by this yeast, which may in some way be connected with the presence of its capsule. On the other hand, it is possible that the pathogenicity of *C. neoformans* may be attributable to its ability to form a capsule.

In histoplasmosis, the infective spores inhaled from *Histoplasma capsulatum* mycelium have a typical tuberculate appearance (Fig. 16a); these then undergo a remarkable transformation into minute yeasts on reaching the pulmonary tissues (Fig. 16b). The granulomatous lesions which they invoke usually heal spontaneously, but on the rare occasions when the fungus spreads the outcome is often fatal; disseminated disease frequently takes the form of a reticulo-endotheliosis. In coccidioidomycosis, thick-walled arthrospores, or chlamydospores (Fig. 17a), constitute the infective elements, and in North American blastomycosis spherical spores borne singly are responsible (Fig. 4a). The corresponding tissue forms of the fungi are respectively spherical cells (sporangia), dividing internally to produce endospores (Fig. 17b), and thick-walled yeast cells (Fig. 4b). The pulmonary pathology in these three diseases is somewhat similar and has been mistaken for tuberculosis. Caseation and calcification are features particularly of coccidioidomycosis and histoplasmosis respectively. The diseases due to dimorphic fungi cannot be diagnosed histologically with any certainty unless the causative organisms are demonstrated in the infected tissues.

*Aspergillus fumigatus* (Fig. 1) does not appear to produce primary aspergillosis in human subjects of the kind which occurs in birds. It may, however, invade and sporulate within the lumina of lung cavities and proliferate to form colonial masses sometimes reaching large dimensions (aspergillus mycetoma) (Fig. 19). Similar proliferation may occur within bronchi distal to stenoses due, for example, to sarcoidosis or carcinoma, it may also take place in zones of bronchiectasis. *A. fumigatus* will colonize lung tissues damaged by bacterial infection, infarction, asbestosis and other processes. It is believed that, as is the case for ringworm fungi in relation to viable skin structures, the signs and symptoms of aspergillosis result from the effects of diffusible fungous products in the lung.

*Rhizopus* species (Fig. 20) are responsible for mucormycosis, a disease of the antra, orbits, or lungs, sometimes disseminating to the brain<sup>2</sup>. It tends to occur in subjects debilitated by diabetes and leukaemia, and in patients receiving cortisone, antileukaemic drugs and certain antibiotics.

In aspergillosis and mucormycosis the causative fungi are present

## THE ROLE OF FUNGI AS HUMAN PATHOGENS



Fig. 10. Dependence of the rate of polymerization on the concentration of the initiator.



FIG 20—*Rhizopus* species. Mycelium with characteristic rhizoids (A) and sporangia (B). (Lactophenol blue,  $\times 214$ )

## THE ROLE OF FUNGI AS HUMAN PATHOGENS

in the tissues as mycelium, occasionally producing sporing structures in air-containing spaces such as cavities

### CONCLUSION

The pathogenic fungi comprise a small number of species which vary in behaviour between being little more than superficial skin saprophytes and active tissue parasites. Though their morphological characteristics may, to a certain extent, be equated with such differences, relatively little is known of the chemical and biological factors which render them pathogenic for man.

### ACKNOWLEDGEMENTS

Acknowledgements are made to Mr R J Lunnion, Institute of Dermatology, for the photomicrographs, and to Mr. D. Kemp, Institute of Diseases of the Chest, for Figs 18 and 19.

### REFERENCES

- <sup>1</sup> Ajello, L., and Georg, L. K. (1957) "In vitro Hair Cultures for Differentiating between Atypical Isolates of *T. mentagrophytes* and *T. rubrum*" *Mycopathologia (Den Haag)*, 8, 3
- <sup>2</sup> Baker, R. D. (1957) "Mucormycosis" *J. Amer. med. Ass.*, 163, 805.
- <sup>3</sup> Georg, L. K., and Camp, L. B. (1957) "Routine Nutritional Tests for the Identification of Dermatophytes" *J. Bact.*, 74, 1130
- <sup>4</sup> Medical Research Council Memorandum No. 23 (1958) "Nomenclature of Fungi Pathogenic to Man and Animals" London, H.M.S.O.
- <sup>5</sup> Partridge, B. M. (1952) "The Diversity of Ringworm Infections" *Trans. St. John's Hosp. Derm. Soc. (Lond.)*, 31, 34
- <sup>6</sup> Riddell, R. W. (1951) "Laboratory Diagnosis of Common Fungous Infections" In *Recent Advances in Clinical Pathology* Chap. 2 2nd ed. London, Churchill
- <sup>7</sup> — (1952) "Fungous Infections of the Lungs" In *Diseases of the Chest* Chap. 8 London, Butterworth
- <sup>8</sup> — (1954) "The Pathogenesis of *Tinea Capitis*" In *Modern Trends in Dermatology* Chap. 10 London, Butterworth
- <sup>9</sup> — (1956) "Fungous Diseases of Britain" *Brit. med. J.*, 2, 783
- <sup>10</sup> — and Clayton, Y. M. (1958) "Pulmonary Mycoses Occurring in Britain" *Brit. J. Tuberc.*, 52, 34

## HISTOPATHOLOGICAL OBSERVATIONS

### SOME CASES OF FUNGAL INFECTION SEEN IN GREAT BRITAIN

W. ST. C. SYMMERS

THE histopathological features of various deep-seated fungal infections will be considered under four headings: tissue reactions; aids to the histological detection and identification of fungal infections; simulation of fungi by other structures in tissues; the comparative morphology of some non-myceliate forms of fungi in tissue sections.

#### TISSUE REACTIONS IN FUNGAL INFECTIONS

The morphological manifestations of the response of the tissues to infection by fungi range from the practically complete absence of any reaction to the severest of inflammatory changes. To some

is no variety of tissue reactions which is in itself pathognomonic of infection by any particular fungus, and, conversely, the same organism may evoke different reactions in different circumstances. The reasons for these variations in response are still largely obscure.

The types of reaction listed in the following paragraphs are mentioned as a reminder of the variety of histological changes which may be seen, listing them in this way is certainly not intended to suggest that they necessarily have any specific aetiological or diagnostic significance, but merely that fungal infections may be manifested by various tissue reactions and, therefore, that the possibility of this cause must not be overlooked when interpreting such findings, particularly in biopsy material.

**No reactions.**—Absence of any detectable reaction is unusual. There may be no reaction around colonies of *Cryptococcus neoformans*, particularly in the brain (Fig 21). Similarly, although there is thrombosis of infected blood vessels in cases of mucormycosis, and leucocytic accumulation may be seen around the mycelium within the thrombus, there is sometimes no reaction around the mycelial threads which have grown into the tissues around the vessels (Fig 22). This lack of response does not merely reflect



## HISTOPATHOLOGICAL OBSERVATIONS



FIG. 21 —Torulosis Colonies of *Cryptococcus neoformans* in brain, no tissue reaction present (Biopsy, haematoxylin-eosin,  $\times 105$  )




FIG. 22 —Mucormycosis Mycelium of *Rhizopus* species in thrombosed arteriole and surrounding brain tissue, little or no tissue reaction present (Haematoxylin-eosin,  $\times 400$  )

## SOME CASES OF FUNGAL INFECTION SEEN IN BRITAIN

growth of the organism after death of the host tissue, for it may be seen in viable tissues in freshly fixed biopsy material.

**Intracellular parasitism.**—Parasitization of macrophages is the most characteristic feature of the infected tissues in cases of histoplasmosis. Simple histiocytosis is characteristic of infection by *Histoplasma capsulatum* (Figs. 23 and 51). In cases of infection by the larger form of *Histoplasma*, which is often designated as a distinct species (*Histoplasma duboisii*), the parasitized cells are multinucleated giant cells of the type seen in banal foreign-body granulomas (Fig. 52). In either type of histoplasmosis the number




FIG. 23. Histoplasma capsulatum. (H. & E. stain, × 1000.)

of cells affected and the number of organisms in them vary greatly, a long search maybe necessary before a single organism is found, or field after field may be completely filled by heavily parasitized cells.

**Chronic non-specific, non-suppurative inflammatory reaction.**—The chronic non-specific inflammatory reaction characterized by the accumulation of "small round cells", that is, lymphocytes and plasma cells, without suppuration or tuberculoid reaction, and tending to lead to fibrosis, is unusual in fungal infections other than rhinosporidiosis, of which it is characteristic. Sometimes this sort of

## HISTOPATHOLOGICAL OBSERVATIONS

reaction is all that is seen in the tissues around colonies of *Cryptococcus neoformans*, particularly in the meninges and around the so-called cerebral "torulomas" (Fig 24), and in some pulmonary lesions

**Acute suppurative reaction.**—Acute abscess formation is rare in fungal infections. Such lesions occur in some fulminating infections, such as a case of acute septicaemic torulosis and in the metastatic lesions in a case of acute monilial endocarditis in a drug addict who had been taking cocaine intravenously and whose supply of the drug was heavily contaminated by *Candida albicans*




FIG 24 —Torulosis. Margin of meningo-cerebral "toruloma", showing chronic non-specific inflammatory reaction (Haematoxylin-eosin,  $\times 105$ )

**Chronic suppurative reaction.**—Chronic suppuration, with pus-filled sinuses surrounded by organizing granulation tissue devoid of specific features, is the typical tissue reaction in actinomycosis (Fig 25) and nocardiosis, and in the various forms of maduromycosis. When such lesions are found in biopsy material it may be necessary to examine step sections through many blocks of tissue before colonies of the causative organism are seen, sometimes only sparse mycelial threads are to be found and colonies as such may be lacking. It is worth noting, too, that colonies of *Nocardia* in the tissues may be difficult to distinguish morphologically from *Actinomyces* in haematoxylin-eosin preparations, and that *Nocardia* may lose its acid-fast staining characteristic during processing of the tissues for histological examination



FIG 25 — Naturally-occurring actinomycosis in a ferret. Colony of *Actinomyces* in pus in sinus lined by granulation tissue (Haematoxylin-eosin,  $\times 150$ )



FIG 26 — Maduromycotic granuloma of the hand. Darkly stained colony of *Allescheria boydi* in pus-filled sinus, with many large pale histiocytes in the pus and in the surrounding granulation tissue (Haematoxylin-eosin,  $\times 170$ )

## HISTOPATHOLOGICAL OBSERVATIONS

**Chronic suppuration with histiocytosis.**—Intermediate between the simple chronic suppurative reaction and a suppurating form of tuberculoid granuloma which will be described in the next paragraph is a variety of tissue response in which large histiocytes are a major constituent of the cellular reaction in the tissues around the pus-filled sinuses of some cases of maduromycosis (Fig. 26).

**Suppurating tuberculoid granulomatous reaction.**—This suppurating tuberculoid reaction (Figs. 27 and 28) is particularly important because it has considerable diagnostic value. The characteristic



FIG. 27 —Sporotrichosis. *Sporotrichum schenckii* was cultivated from this tissue. Tubercle-like aggregates of epithelioid histiocytes and multinucleated giant cells, with extensive suppuration. (Haematoxylin-eosin,  $\times 90$ .)

“unit-lesion” of this type of reaction is the “suppurating tubercle” (“suppurating pseudotubercle” is a more accurate term), consisting of a rounded aggregate of epithelioid histiocytes with a central micro-abscess. Whenever this type of lesion is found unexpectedly the possibility of a fungal infection must always be considered along with the other types of infection which may cause the reaction, such as viral infections, including lymphogranuloma inguinale and cat-scratch fever, and certain unusual bacterial infections, for example, tularaemia and *Pasteurella septica* infection.

In the severer forms of this reaction, whether due to fungal, viral, or bacterial infection, the reaction is seen in septic

## SOME CASES OF FUNGAL INFECTION SEEN IN BRITAIN

infection. The fungal infections in which it occurs include sporotrichosis, North American blastomycosis, South American blastomycosis, and coccidioidomycosis, and often the organism concerned is to be found at the middle of the purulent focus

**Tuberculoid granulomatous reaction.**—This is the most usual form of reaction to infection by the fungi which occur in the tissues in a yeast-like form; it is the typical response in the North and South American types of blastomycosis, and in chromoblastomycosis, coccidioidomycosis, and the so-called African (*Histoplasma duboisii*)




FIG. 28.—Section from same specimen as Fig. 27. Micro-abscess at centre of aggregate of epithelioid histiocytes ('suppurating pseudotubercle'), sporotrichotic "asteroid" in pus (Haematoxylin-eosin,  $\times 400$ )

type of histoplasmosis. Tuberculoid granulomas are also seen in many cases of torulosis (Fig. 29)

Essentially, the reaction consists of focal aggregates of epithelioid histiocytes, with occasional multinucleated giant cells among them. The general appearance may be similar to the classical tubercle, although usually without caseation, but commonly the tuberculoid reaction in the fungal infections is neither so well circumscribed nor so uniformly well developed as the usual "unit-lesion" of banal tuberculosis or of, for instance, sarcoidosis. Caseation appears to be unusual in fungal granulomas, it occurs most characteristically in the tuberculoma-like, encapsulated lesions which are sometimes found, especially, in the lungs, as a solitary manifestation of coccidioidomycosis or histoplasmosis or, more rarely, torulosis. In such

## HISTOPATHOLOGICAL OBSERVATIONS




FIG 29 —Torulosis Organizing tuberculoid granuloma with multinucleated giant cells containing typical cryptococci. An unencapsulated cryptococcus is also seen (arrowed) (Haematoxylin-eosin,  $\times 400$ )



FIG 30 —Maduromycosis Foreign body giant cells around dead material (inspissated colony of *Allescheria boydii*) (Haematoxylin-eosin,  $\times 400$ )

## SOME CASES OF FUNGAL INFECTION SEEN IN BRITAIN

instances, the lesions may possibly be mistaken for old Ghon foci or other tuberculous lesions, or even for gummas, unless fungi are specifically sought. Caseation may, however, occur also in some more active fungal infections; it may develop, for instance, in military pneumonic lesions caused by *Blastomyces dermatitidis*.

**Foreign-body reaction.**—Occasionally, dead fungal material may become inspissated and evoke a typical foreign-body reaction: thus, in a biopsy specimen (Fig 30) from a mass in a foot, brownish-yellow amorphous foreign material surrounded by foreign-body giant cells caused much speculation until it was seen to contain curious channels and little vesicle-like spaces, suggesting the outlines of a spore-bearing mycelium. Further investigation led to isolation of *Allescheria boydi*, confirming the presence of maduromycosis.

## AIDS TO THE HISTOLOGICAL DETECTION AND IDENTIFICATION OF FUNGAL INFECTIONS

Often, the presence of fungi in the tissues is readily apparent in the first sections examined, and special methods of investigation then provide confirmatory evidence only. For obvious reasons, if the possibility of a fungal infection has been raised and biopsy is contemplated, steps should always be taken to try to isolate the organism by culture; reliance should not be placed wholly on histological study, invaluable though this can be.

The histological methods which can profitably be applied to the investigation of fungal infections are representative of the whole range of histological techniques. They may be discussed briefly under the headings of optical methods and staining.

**Optical methods.**—Some yeasts and yeast-like organisms may be readily demonstrated in polarized light because of bi-refrinent effects which they produce (Figs 31 and 32), and this characteristic is sometimes invaluable in disclosing the presence of fungi in sections. Such organisms are among the unsuspected structures which can easily escape observation unless the microscopist makes it a regular practice to keep a Polaroid filter constantly in position between the light source and the object. The amount of inherent polarization ordinarily present in the prism system of binocular microscopes is then quite sufficient to show up bi-refrinent material in the preparation examined, even against the ordinary bright field. This simple procedure can be of great value in diagnostic histology, particularly in interpreting the significance of granulomatous lesions.

The bi-refringence of fungi seems often to be induced by the procedures involved in processing tissues for sectioning, or in staining, thus, the organisms in frozen sections of formalin-fixed



## HISTOPATHOLOGICAL OBSERVATIONS

material may show no bi-refringence while those in paraffin sections of the same specimen may be strikingly revealed in polarized light

Phase-contrast microscopy does not seem to have any special value in studying sections of mycotic lesions. However, by using conventional objectives of low magnifying power with the substage phase rings appropriate to high-power phase objectives, a low-




FIG. 31 —Cutaneous histoplasmosis (*Histoplasma duboisii* infection) The pale fungi contrast with the darkly stained nuclei of the phagocytic giant cells (Haematoxylin-eosin,  $\times 196$ )




FIG. 32 —Same field as Fig. 31 photographed in polarized light. The white spots are yeast cells of *Histoplasma capsulatum*, only some of the organisms appear to be doubly refractile

magnification dark-ground effect is obtainable which may occasionally be helpful in revealing scanty organisms, as well as in studying the topography and development of the tissue reaction

**Staining.**—Although fungi in tissue sections are usually readily detectable in haematoxylin-eosin preparations (Fig. 33), there is no doubt that other stains often reveal them more strikingly, the periodic acid Schiff reaction, with haemalum as a counterstain, and various comparable procedures such as the Gridley stain, are among the most useful

### SOME CASES OF FUNGAL INFECTION SEEN IN BRITAIN

[illegible]

## HISTOPATHOLOGICAL OBSERVATIONS

Silver methods, such as the Foot or Robb-Smith techniques for silvering reticulin fibres, show up some fungi very well, including most of the yeast-like organisms and also *Aspergillus* (Fig 34). Gram's stain, on the other hand, is more valuable in disclosing some of the finer details of the inner structure of the organisms than as a selective stain (Fig 35). Mucicarmine is often used to stain the capsular mucopolysaccharide substance of cryptococci. At least some strains of *Blastomyces dermatitidis* and *Blastomyces brasiliensis*



FIG 35.—Torulosis Internal structure in yeasts demonstrated by Gram's stain ( $\times 400$ )

are also mucicarmineophilic, their cell surface having a distinct affinity for the stain. This affinity is most readily demonstrated and most intense in preparations which have been exposed as little as possible to watery solutions, the mucicarmineophilic material being evidently fairly readily extracted by water.

A valuable "battery" of stains for demonstrating fungi consists of Mayer's haemalum and eosin, periodic acid Schiff and Mayer's haemalum, Southgate's mucicarmine and Mayer's haemalum, and Robb-Smith's method for silvering reticulin.

*Other important factors*—It is perhaps appropriate to mention two other obvious but most important factors which help towards the histological recognition of fungal infections: these are curiosity and patience.

Curiosity is required to encourage adequate investigation of unexplained inflammatory processes, and to inquire into the reasons for

## SOME CASES OF FUNGAL INFECTION SEEN IN BRITAIN

unexpected histological appearances. A case of histoplasmosis was, for example, recognized because a pathologist was curious to know the reason for the profusion of multinucleated giant cells in the tuberculoid granulomas in a fresh biopsy specimen in contrast with the absence of giant cells at biopsy some years earlier when the patient had been shown to have sarcoidosis.

Patience is necessary where examinations of many hundreds of sections for the presence of recognizable organisms has to be carried



FIG 36—Chromoblastomycosis (*Phialophora* (*Hormodendrum*) *pedrasii* infection). In this unstained section the fungal bodies are clearly seen because of their natural yellow-brown pigmentation ( $\times 850$ ) (See also Fig 55)

out, as in looking for the rare "asteroid" of sporotrichosis, and as in some cases of other fungal infections in which the organisms may occasionally be very scanty

### SIMULATION OF FUNGI BY OTHER STRUCTURES

Many structures can simulate fungi, but care and a little experience should prevent confusion. The following are by no means the only simulants, but they are noted to illustrate the sort of problems which occur.

(a) Cross-section of a nerve in a granulomatous lesion mistaken for the endosporulating spherule stage of *Coccidioides* (Figs 37 and 46) (b) Groups of nerve fibres mistaken for colonies of cryptococci because the axons, each with its surrounding clear myelin sheath, mimicked encapsulated yeasts (Fig 38) (c) Calcific spherules in tuberculous lesions (Fig 39), or tumours (Fig 40) mistaken for yeasts




FIG 37—Bundle of nerve fibres in a chronically inflamed tissue. This nerve was mistaken for the endosporulating spherule of *Coccidioides* (Haematoxylin-eosin,  $\times 400$ ) (See also Fig 46)



FIG 38—Dense field of inflammatory cells, likely macrophages or monocytes, characteristic of chronic inflammation.




FIG 39 — Calcifying bodies in an oligodendroglioma. The calcifying mycelium-like structures are probably nerve fibres. (Haematoxylin-eosin,  $\times 400$ )




FIG 40 — Calcifying bodies simulating yeasts in an oligodendroglioma. The calcifying mycelium-like structures are probably nerve fibres. (Haematoxylin-eosin,  $\times 400$ )

## HISTOPATHOLOGICAL OBSERVATIONS

Can easily be mistaken for yeast (Fig. 41) may be mistaken for

macrophages in the germinal centres of lymphoid follicles in reactive hyperplasia, mistaken for *Histoplasma* (Fig. 42) (e) Intracellular globules of mucin in scirrhous mucigenic carcinomas (Figs. 43, 44, and 45) mistaken for phagocytosed cryptococci (f) Cytoplasmic vacuoles of all sorts, particularly in the epithelioid histiocytes of tuberculoid granulomas, mistaken for yeasts What




FIG 41 —Torulosis. Calcifying cryptococci in cerebellar granuloma, *Cryptococcus neoformans* was isolated from this lesion (Haematoxylin-eosin;  $\times 400$ )

is important is not just that fungi can be simulated by other structures but that as much care must be taken before dismissing the fungal nature of a debatable structure as must be taken when making the histological diagnosis of a mycosis

### COMPARATIVE MORPHOLOGY OF SOME NON-MYCELIATE FUNGI AS SEEN IN SECTIONS

Photographs of various organisms at the same high magnification (Figs. 46–56) illustrate that neither size nor general appearance is enough to identify these fungi specifically in every case. However,



FIG 42 — Micrograph showing a dense field of small, dark, circular structures, likely fungal hyphae or spores, stained with haematoxylin-eosin.




FIG 43 — Intracellular bodies simulating yeasts in a swelling of an eyelid of as yet unidentified nature (Haematoxylin-eosin,  $\times 400$ ) (See also Fig 44) (B: courtesy of Professor D. M. Pryce)



## HISTOPATHOLOGICAL OBSERVATIONS




FIG 44—Same specimen as Fig 43. The intracellular bodies may be mucicarmineophilic fungi in macrophages or droplets of mucin in tumour cells (Southgate's mucicarmine and Mayer's haemalum,  $\times 600$ ) (See also Fig 45)




FIG 45—Preparation of a scirrhous mucigenic carcinoma for comparison with Fig 44. Some of the mucinous vacuoles in the tumour cells have a mucicarmineophilic rim and contain an eccentric mucicarmineophilic globule; this appearance is also seen in Fig 44, but see also Figs 35 and 52 (Southgate's mucicarmine and Mayer's haemalum,  $\times 600$ )

# SOME CASES OF FUNGAL INFECTION SEEN IN BRITAIN




FIG. 46 —Coccidioidomycosis Endosporulating spherule of *Coccidioides immitis* in a lymph node thought clinically to be tuberculous, from a British nurse who had lived in California (Haematoxylin-eosin,  $\times 850$ )



FIG. 47 —Same specimen as Fig. 46 Groups of maturing spherules of *Coccidioides immitis* in macrophages (Haematoxylin-eosin,  $\times 850$ )

## HISTOPATHOLOGICAL OBSERVATIONS




FIG 48 —Rhinosporidiosis in an Indian student working in Britain. Parts of two sporangia of *Rhinosporidium seeberi* containing spores of different sizes (Haematoxylin-eosin,  $\times 850$ )



FIG 49 —Torulosis. Typical yeasts of the classical large-cell type of *Cryptococcus neoformans* with broad capsular zone (Haematoxylin-eosin,  $\times 850$ )




FIG 50—Torulosis. Small-cell type of *Cryptococcus neoformans* with narrow capsular zone in giant cells of a tuberculoid reaction in a skin lesion (Haematoxylin-eosin;  $\times 850$ )




FIG 51—Histoplasmosis. Macrophages in sinus of a lymph node heavily parasitized by classical small-cell type of *Histoplasma capsulatum* (Periodic acid Schiff reaction, Mayer's haemalum,  $\times 850$ )

## HISTOPATHOLOGICAL OBSERVATIONS




FIG 52—"African" type of histoplasmosis. Large-cell type of *Histoplasma* (*H. duboisii*) in multinucleated giant cells of dermal granuloma (Haematoxylin-eosin,  $\times 850$ )



FIG 53—South American blastomycosis. Yeasts of *Blastomyces brasiliensis* within a multinucleated giant cell in a subcutaneous granuloma from a British engineer who had worked in Brazil (Periodic acid Schiff reaction and haemalum,  $\times 850$ )

SOME CASES OF FUNGAL INFECTION SEEN IN BRITAIN





FIG. 54.—North American blastomycosis. Yeasts of *Blastomyces dermatitidis* within a multinucleated giant cell in a dermal nodule from an American resident in London (Periodic acid Schiff and haemalum,  $\times 850$ )



FIG. 55.—Chromoblastomycosis. Group of organisms (*Phialophora* (*Hormodendrum*) *pedrosoi*) at one pole of a multinucleated giant cell (Haematoxylin-eosin,  $\times 850$ )

## HISTOPATHOLOGICAL OBSERVATIONS



blastomycoses and histoplasmosis, and in cases of coccidioidomycosis when the endosporulating spherule stage is found in the tissues. Whenever cultivation is possible, however, isolation of the organism is necessary for definitive diagnosis, and for pathogenicity studies. That even seemingly pathognomonic pictures may prove to be equivocal is shown by the recent observations of Capponi, Sureau and Segretain. It could once be confidently said that a macrophage filled with small, double-contoured, yeast-like bodies was typical of histoplasmosis. This picture no longer has the same absolute diagnostic import since Capponi and his colleagues observed an identical appearance in animals infected with a pathogenic species of *Penicillium*, *Penicillium marneffe*, isolated from a naturally occurring infection in the Vietnamese bamboo-rat. This observation reflects the care necessary to ensure by all possible means the correct and complete diagnosis of fungal infections.

## BIBLIOGRAPHY

The following deal with the histopathology of fungous infections

- Baker, R. D. (1957) "Fungus Infections." In *Pathology* Chap. 15 3rd ed.  
Ed by W. A. D. Anderson. London, Kimpton.  
Capponi, M., Sureau, P., and Segretain, G. (1956) "Penicilliose de *Rhizomys*  
*sinensis*." *Bull. Soc. Path. exot.*, 49, 418.

## BIBLIOGRAPHY

- Conant, N. F. (1948) "Medical Mycology" In *Bacterial and Mycotic Infections of Man*. Chap 32. Ed by R. J. Dubos. Philadelphia, London, Montreal, Lippincott
- and Rosebury, T. (1948) "The Actinomycetes" In *Bacterial and Mycotic Infections of Man*. Chap 31. Ed by R. J. Dubos. Philadelphia, London, Montreal, Lippincott
- Smith, D. T., Baker, R. D., Callaway, J. L., and Martin, D. S. (1954) *Manual of Clinical Mycology* 2nd ed. Philadelphia and London, Saunders
- Forbus, W. D. (1943) *Reaction to Injury—Pathology for Students of Disease Based on the Functional and Morphological Responses of Tissues to Injurious Agents*. Baltimore, Williams & Wilkins
- Lacaz, C. da S. (1956) *Manual de Micologia Medica* 2nd ed. São Paulo, Organização "Liteci".



# TINEA INFECTIONS

## PATHOGENESIS

R. VANBREUSEGHEM

ALTHOUGH the word "dermatophyte" has been used in the past to cover every type of the vegetable micro-organisms living on the surface of the skin, bacteria as well as fungi, it is now usually restricted to the pathogenic fungi which produce ringworm in man and animals. They constitute a group of fungi which have for morphological reasons been related to the Ascomycetes, but no real proof of their relation with this class of fungi has yet been found. Until such proof exists, they must be considered as *Fungi imperfecti* in that they do not exhibit any sexual form of reproduction. Although from the microscopical point of view they have a rather characteristic morphology, they distinguish themselves from the other fungi by their ability to produce tinea infections and by their power to attack and digest keratin *in vitro* as well as *in vivo*. As parasitic agents they manifest a true keratinophilia, this fact being demonstrated long ago by Sabouraud<sup>23</sup> and more recently by Kligman<sup>17, 18</sup>.

For 100 years, the dermatophytes have been considered as strict parasites living on the skin, hair, nails, feathers, and horns of various animals, although their ability to grow on widely differing types of culture media was well recognized. Although they could be true parasites, they were also able to live outside of the body as saprophytes. This interchange between saprophytism and parasitism is a characteristic of the dimorphic pathogenic fungi, and the question arises as to whether it applies also to the dermatophytes.

## RECENT FINDINGS

In the last few years it has been shown that, like other pathogenic fungi, some dermatophytes live normally in the soil. This has been demonstrated in the case of 3 species in 3 different genera: *Keratinomyces ajelloi*, a non-pathogenic dermatophyte, *Microsporum gypseum*, and *Trichophyton mentagrophytes*. From recent studies made by Georg<sup>12</sup> it appears that, although strains of *K. ajelloi* as described by Vanbreuseghem<sup>26</sup> are mostly non-pathogenic, certain strains are probably able to produce ringworm in some animals.

## PATHOGENESIS

This fungus, and also *Mic. gypseum*, has been isolated repeatedly from the soil in various parts of the world<sup>1, 7, 9</sup>. *T. mentagrophytes* has been isolated in South Africa from soil<sup>20</sup> and also from the air of a cave<sup>21</sup>.

Dermatophytes, like many other fungi, may be cultured in the laboratory on sterile soil<sup>30</sup>. The real proof that at least one of them grows naturally in the soil has been provided by Gordon<sup>13</sup> in the case of *Mic. gypseum*, for this author was able to demonstrate macroconidia typical of this fungus in the soil itself.

*T. mentagrophytes*, *T. rubrum*, and *Epidermophyton floccosum* have been isolated from the surroundings of animals, and from the floors of swimming pools<sup>2, 10</sup>. As Gentles has pointed out, it should not be assumed that these dermatophytes live on floor structures, for they may merely persist in desquamated keratin fragments. Similarly, dermatophytes growing in a natural state on animal droppings do not have the same significance as dermatophytes growing within the soil<sup>29</sup>.

Many more attempts have been made to isolate dermatophytes from the soil than is reflected in the literature, yet successes have been few. It would seem unlikely, however, that only a few species of dermatophytes are able to thrive away from the human or animal environment. Immense quantities of dermatophyte spores fall out of the integuments of infected humans and animals and become, for short or long periods, a living part of the environment. It cannot be assumed that the spores develop further in such surroundings, for it could be that they are destroyed by antibiotics<sup>14</sup>, or by other agents or conditions. But dermatophytes must exist in our environment if only for short periods and our inability to isolate them merely indicates the present imperfection of our methods.

**Means of infection.**—It was postulated some years ago that "the soil might constitute the great well of human and animal dermatophytosis epidemics"<sup>27</sup>. While tinea infections are usually acquired by transmission of infection from man to man, from animals to animals, and from animals to man or the reverse, these are certainly not the only ways<sup>29, 33</sup>. Thus, the observations by Gentles and Holmes<sup>11</sup> favour the view that infection is readily acquired in bathing places.

The dermatophytes are very specialized parasites in being limited to keratinaceous structures by virtue of their keratinolytic power and their keratinophilia. Some exceptions have been noted, as for example in rare cases where *T. schoenleini* has invaded the deeper tissues of the skin, lymph nodes, and even the blood stream<sup>15</sup>. When dermatophytes are introduced into the bodies of experimental

## TINEA INFECTIONS

animals by ways other than through the skin, they manifest a very selective epidermotropism. This fact has been illustrated experimentally by Brocq-Rousseu, Urbain and Barotte<sup>4</sup>. These authors were able to produce ringworm in guinea-pigs by administering an emulsion of spores of *T. mentagrophytes* or *T. equinum* by intravenous, intraperitoneal, subcutaneous, and oral routes if, at the same time, they slightly traumatized the skin of these animals. The delay in the development of the skin lesions by this routine, compared with that after direct inoculation in the skin, was only 2 or 3 days.

Lurie and Way<sup>21</sup> have demonstrated that spores of dermatophytes may be introduced into animals by inhalation and remain alive *in vivo* for at least 8 weeks. *Ep. floccosum* has been isolated from sputum<sup>31</sup> but contamination of the sputum sample had most likely occurred after expectoration.

LaTouche<sup>19</sup> has studied the transmission of ringworm by contact and Kligman<sup>17</sup> has indicated the need for slight trauma in establishing experimental ringworm infections. The contagiousness of tinea pedis and of onychomycosis is much debated. Maceration of the feet and repeated exposure in places where infected skin scales are present appear to be the commonest aetiological factors; trauma too may be important. Degrees of contagiousness are difficult to assess and it is also difficult to ascertain the time of onset of an infection and the reasons why clinical symptoms become manifest. The reason for the apparent immunity to ringworm infection of some nails of a hand compared with the vulnerability of others is unknown. It is possible that trauma to some particular part of the nail plate is an important prerequisite before infection occurs<sup>32</sup>. In contrast, tinea capitis is usually acquired by close contact, and the same is usually true for tinea corporis. There remain the possibilities that transmission of infection by inhalation and by ingestion may occur.

In spite of numerous studies upon the keratinolytic properties and keratinophilia of dermatophytes<sup>3, 5, 6, 22, 24, 25</sup>, precise knowledge of the mode of keratinolytic action is scanty. Little is known either of the mechanism of inflammatory reactions in ringworm or of the factors involved in immunity, allergy, or cure of these diseases. On the other hand, the morphology of tissue reactions of all types has been described with a high degree of precision.

**Living conditions and susceptibility.**—The susceptibility to ringworm of different peoples living under different conditions would repay careful study. Under the conditions most favourable for transmission of infection in civilized countries, tinea capitis does not spread to more than 5 per cent of children. Boys are more often

## PATHOGENESIS

affected by tinea capitis than girls, and the disease tends to cease at puberty in some types of infection though not in others; tinea capitis caused by *T. violaceum* persists in female adults more often than in males<sup>15</sup>. These are some of the unsolved problems met with in temperate countries. Personal observations<sup>28</sup> on native children of Central Africa have demonstrated a very large variation in the incidence of dermatophyte infections among them. Thus, 5 per cent of some groups of children suffered from tinea capitis, while up to 40 per cent of others were involved. These differences could not be explained by standards of housing, education, or hygiene; nor could they be attributed to variations in virulence of the dermatophyte strains concerned. Dietary factors could, however, have explained the difference, for the less affected children had

be expected to be most affected by tinea capitis. It has been shown in one study that nearly 95 per cent of kwashiorkor children suffered from tinea capitis. It does not necessarily follow that protein deficiency is in itself the essential predisposing factor in this high incidence; avitaminosis, such as vitamin A deficiency, so often accompanying protein deficiency states, could also be important. This might lead to deficiency in the quantity or quality of sebaceous gland secretion or to some alteration in the physical structure of hairs or skin which make for susceptibility to disease. It is of interest that work carried out in France by de Graciansky and his colleagues<sup>8</sup> suggested that a diet deficient in protein favours the development of *Candida albicans* infection in experimental animals.

**Conclusions.**—A better understanding of the mode of transmission of ringworm would help to prevent spread of disease, a more complete knowledge of the physiology of pathogenic fungi would help towards the discovery of more efficient therapeutic agents, and a greater knowledge of natural and acquired immunity mechanisms in dermatophyte infections would help to explain much of the behaviour of these diseases.

## REFERENCES

- <sup>1</sup> Ajello, L. (1953) "The Dermatophyte *Microsporum gypseum* as a Saprophyte and Parasite." *J. invest. Derm.*, **21**, 157.
- <sup>2</sup> — and Getz, M. (1954) "Recovery of Dermatophytes from Shoes and Shower Stalls." *J. invest. Derm.*, **22**, 17.
- <sup>3</sup> Barlow, A. J. E., and Chattaway, F. W. (1955) "The Attack of Chemically Modified Keratin by Certain Dermatophytes." *J. invest. Derm.*, **24**, 65.

## TINEA INFECTIONS

- 4 Brocq-Rousseau, Urozin, A., and Barotte, J (1927) "Etude des teignes du cheval et de l'immunité dans les teignes expérimentales" *Ann Inst Pasteur*, 41, 513
- 5 Chattaway, F. W., Thompson, C. C., and Barlow, A. J. E. (1954) "Enzymes of *Microsporum canis*" *Acta Biochem Biol*, 4, 583
- 6 Daniels, G (1953) "The Digestion of Human Hair Keratin by *Microsporum canis* Bodin" *J gen Microbiol*, 8, 289
- 7 — (1954) "The Isolation of *Keratinomyces ajelloi* from Soils in Great Britain" *Nature, Lond*, 174, 224
- 8 de Graciansky, P., Leclercq, R., Delaporte, J., and Gouvin de Roumilly, P. (1955) "Les dermatoses à levures au cours des traitements par les antibiotiques" *Sem Hôp Paris*, 37, 5.
- 9 Durie, E. B., and Frey, D (1955) "Isolation of *Microsporum gypseum* and of *Keratinomyces ajelloi* from Australian Soil" *Nature, Lond*, 176, 936
- 10 Gentles, J. G (1956) "The Isolation of Dermatophytes from the floors of Communal Bathing Places" *J clin Path*, 9, 374
- 11 — and Holmes, J. G (1957). "Foot Ringworm in Coal Miners" *Brit. J Industr Med*, 14, 22
- 12 Georg, L. K (1957) Unpublished observations
- 13 Gordon, M. A (1953) "The Occurrence of the Dermatophyte *Microsporum gypseum* as a Saprophyte in Soil" *J invest Derm*, 20, 201.
- 14 Gottlieb, D., and Siminoff, P (1952) "The Production and Role of Antibiotics in the Soil II, Chloromycetin" *Phytopathology*, 42, 91
- 15 Grin, E (1956) "Superficialna trihofitija kapilicija kod odraslih" *Rad IV Odel med nauk, Krujiga*, 2, 23
- 16 Hadida, F., Marill, F. G., and Morere, P (1948) "Favus généralisé avec déterminations dermo-hypodermiques, ganglionnaires et septicémie favique" *Bull Soc franç Derm Syph*, 55, 28
- 17 Kligman, A. M (1952) "The Pathogenesis of Tinea Capitis due to *Microsporum audouinii* and *Microsporum canis*" *J invest Derm*, 18, 231
- 18 — (1955) "Tinea Capitis due to *Microsporum audouinii* and *Microsporum canis*" *Arch Derm Syph, Chicago*, 71, 313
- 19 LaTouche, C. J (1955) "The Importance of the Animal Reservoir of Infection in the Epidemiology of Animal-type Ringworm in Man" *Vet Rec*, 67, 666
- 20 Lurie, H. I., and Brook, R (1955) "*Trichophyton mentagrophytes* Isolated from the Soil of Caves" *Mycologia*, 47, 506
- 21 — and Way, M (1957) "The Isolation of Dermatophytes from the Atmosphere of Caves" *Mycologia*, 49, 178
- 22 Page, R. M (1947) "Keratin Digestion by *Microsporum gypseum*" *Amer J Bot*, 34, 595
- 23 Sabouraud, R (1910) *Les Teignes* Paris, Masson
- 24 Tate, P (1929) "On the Enzymes of Certain Dermatophytes or Ringworm Fungi" *Parasitology*, 21, 31
- 25 Vanbreuseghem, R (1949) "Lésions déterminées in vitro par les dermatophytes sur des cheveux isolés" *C R Soc Biol (Paris)*, 143, 1302
- 26 — (1952) "Intérêt théorique et pratique d'un nouveau dermatophyte isolé du sol *Keratinomyces ajelloi* gen nov sp nov" *Bull Acad Belg Cl Sci, 5e série*, 38, 1068
- 27 — (1952) "Le cycle biologique des dermatophytes et l'épidémiologie des dermatophytes" *Arch belges Derm* 8 258

## REFERENCES

- <sup>24</sup> Vanbreuseghem, R. (1957) "Note préliminaire sur l'endémie teigneuse au Congo Belge et au Randa Urundi et ses rapports avec la nutrition" *Bull Acad. Roy. Sci. Col.*, 3, 394
- <sup>25</sup> — (1957) *Relation between Pathogenic Fungi and Soil* Naučno Društvo Bosni i Hercegovine Odjevičen je Medicinski nauka Sarajevo (Not yet published)
- <sup>26</sup> — and Van Brussel, M. (1952) "Emploi et signification des cultures de dermatophytes sur terre et milieux à base de terre" *Ann Parasit. hum. comp.*, 27, 541
- <sup>27</sup> — and Willaert, L. (1952) "A propos de l'isolement d'un dermatophyte. *Epidermophyton floccosum* des crachats d'un malade" *Arch. belges Derm.*, 8, 209
- <sup>28</sup> Vilanova, X., Casanovas, M., and Francino, J. (1956) "Onychomycosis" *J. invest. Derm.*, 27, 77
- <sup>29</sup> Walker, J. (1955) "Possible Infection of Man by Indirect Transmission of *Trichophyton discoides*" *Brit. med. J.*, 2, 1430

## TRICHOPHYTON RUBRUM INFECTION

C. D. CALNAN

IN company with many other European countries such as Germany, Holland and Switzerland, as well as the United States, we in Great Britain have experienced over the past decade a remarkable increase in the incidence of *Trichophyton rubrum* infection. It is likely that this infection has been endemic in China, Japan and the Far East<sup>2, 4</sup> for a long time, and that during the last 20 or 30 years it has spread progressively westwards over Asia and Europe, and eastwards to Australia and America. In New York, according to Sulzberger<sup>7</sup>, *T. rubrum* infections are five times as common as those due to *T. mentagrophytes*, and because of their intractability they are causing anxiety. The disease was seen only sporadically before the second world war at St. John's Hospital for Diseases of the Skin in London. Between 100 and 200 new patients infected with *T. rubrum* are now registered each year. This increase is both real and apparent. Some of the real increase is due to immigrants and troops returning from overseas, but many new cases have never been abroad. Some of the increase is probably due to a raised index of suspicion in connexion with this particular fungus. Apart from this, however, one knows that fungal infections in various countries do change their incidence over a period of years without any satisfactory explanation.

### EXCEPTIONS TO GENERAL CLINICAL PICTURE

From the work of Lewis and Hopper<sup>3</sup> and others in the United States the clinical picture typical of these infections was well known (Fig. 57), but a number of exceptions to this general pattern occur. The clinical features alone are not diagnostic of the infection for it is now agreed that more than one fungus species may produce the same signs.

**Feet.**—Ordinary toe-web maceration may be caused by *T. rubrum* but the webs are usually considered to be spared. In fact, the toe spaces show scaling more often than not, and fungus mycelium is present. The dorsa of the feet and ankles are commonly involved, sometimes accompanied by an acute turgid papular erythema with little or no scaling, this may cause difficulty in diagnosis from erythema multiforme or chronic annular erythema. Vesicular and

## TRICHOPHYTON RUBRUM INFECTION

pustular lesions, sometimes of the acute type, may occur on the feet more like those associated with *T. mentagrophytes*. But, however acute the lesion, a genuine secondary trichophytide eruption on the hands does not appear to occur. Involvement of the toenails is extremely common though not invariably present

**Hair.**—Hair infection is being found more often, the fungus producing either an ectothrix or endothrix invasion. It occurs in the coarse hair of the beard and scalp, occasionally causing kerion, as well as in lanugo hairs, especially on the legs and hands. Frequently, however, this fungus spreads extensively over hairy parts of the skin




FIG 57 —*Trichophyton rubrum* infection. Fine scaling of sole of foot (By courtesy of Dr H Wallace)

without any attempt to penetrate hair follicles. On the legs follicular invasion which is confined mainly to women simulates erythema induratum or nodular vasculitis, or banal folliculitis. Pustules on the legs do not always indicate hair infection, sometimes these do not represent follicular involvement and the roof of the pustule contains a mat of fungus similar to the pustules of ordinary ringworm of the feet. The diagnosis will not usually be missed if the feet are examined, for the feet are rarely spared

**Hands.**—The hands may show 5 different types of lesions: hyperkeratotic palm and fingers (Fig 58), crescentic exfoliating scales, as occur on soles of feet, vesicular circumscribed patches, discrete red



## TRICHOPHYTON RUBRUM INFECTION

papular and follicular scaly patches; and erythematous scaly sheet on dorsum.




FIG 58 —*Trichophyton rubrum* infection. Hyperkeratotic palm and fingers (By courtesy of Dr R M B Mackenna)

The hyperkeratotic palm type is the commonest and is unilateral in 50 per cent of cases, the vesicular eczema-like patches are the

## TRICHOPHYTON RUBRUM INFECTION

most unusual. Hand infections are readily misdiagnosed, especially in the absence of nail involvement. Infections of the hand due to fungi other than *T. rubrum* are very rare in England, and finger-nail infections are almost invariably caused by this fungus.

On the glabrous skin, *T. rubrum* may cause typical annular lesions of body ringworm, but other patterns appear to be more frequent. Crural infections may be indistinguishable from those produced by *Epidermophyton floccosum*, but *T. rubrum* infection often spreads



FIG. 59—*Trichophyton rubrum* infection. Circinate lesion of glans penis. (By courtesy of Dr R. Bettley.)

down the thighs and over the perineum to the buttocks. Penile infections are very rare (Fig. 59). Distribution tends to be asymmetrical. Tinea cruris is almost unknown in women<sup>1</sup> but when it does occur *T. rubrum* seems to be almost invariably responsible. Any part of the trunk, head (Fig. 60), or limbs may be affected. There may be very large sheets of scaling with or without a well-defined margined border, and sometimes there is lichenification suggestive of a diagnosis of neurodermatitis.

A variant which is troublesome from the point of view of diagnosis is the raised turgid papular erythema without scaling. It appears

## TRICHOPHYTON RUBRUM INFECTION

as papules, plaques, crescents or rings. After a few days this type of reaction may subside spontaneously leaving some scaling. Alternatively, there may be large rings or plaques on the trunk or



FIG 60 —*Trichophyton rubrum* infection. Erythematous scaly lesion of ear. (By courtesy of Dr B Russell)

elsewhere, with virtually no erythema and a minimum of scaling at the edges. Such a lesion occurring in a patient presenting with pruritis may be extremely difficult to see and is readily overlooked.

Mixed infections are not uncommon, *T mentagrophytes* and *Ep*

## TRICHOPHYTON RUBRUM INFECTION

*floccosum* being the most common additional fungi present<sup>3</sup>. *Microsporum canis*, *T. tonsurans* and *T. violaceum* also occur together with *T. rubrum*. In patients with clinical appearances of *T. rubrum* infection but from whom only other fungi were grown, the species concerned have been *Ep. floccosum* and *T. mentagrophytes*. Nails were not involved in these patients and several, but not all, were cured with treatment.

Familial infections are not as rare as is sometimes supposed. Relatives are often reluctant to be examined and usually deny the existence of skin abnormalities even on their feet. An appreciable percentage of marital partners, however, have the infection, if only in the toe webs. In the case of children and adolescents parental infection will almost always be found; infection has been seen in a baby of 10 months.

In 1946, Rothman in Chicago noted an increased glucose tolerance in 2 patients with *T. rubrum* infection and reported similar findings on 20 patients in 1953<sup>6</sup>. At St. John's Hospital for Diseases of the Skin, of 23 patients examined only 3 showed similar flat glucose tolerance curves.

Another apparent aetiological factor is acrocyanosis. Many of the patients with this disease have a pernicious circulation, especially those with hand involvement and nodular follicular infections on the legs. But chilblain circulation is a common disorder in Britain, and its relation to this disease is difficult to assess without statistical evidence.

The trichophytin test is not widely used in Britain. A delayed positive reaction at 48 hours is associated with trichophytide reactions. While most *T. rubrum* infected cases give negative delayed trichophytide reactions, a small proportion give positive results, these exceptions did not have vesicular lesions, nor were they any less resistant to therapy. The majority of cases show an immediate positive urticarial wheal reaction the reason for which is obscure; circulating antibodies have occasionally been demonstrated in such patients.

Inoculation of the skin of *T. rubrum* infected patients or of normal subjects with a culture of this fungus produces only an acute inflammatory lesion which easily resolves either spontaneously or with the aid of a fungistatic substance, it does not seem possible to produce in this way lesions which are typical clinically of *T. rubrum* infection.

### TREATMENT

The challenge in this disease is its resistance to treatment. Body lesions, apart from the palms and soles, are often cured remarkably

## TRICHOPHYTON RUBRUM INFECTION

as papules, plaques, crescents or rings. After a few days this type of reaction may subside spontaneously leaving some scaling. Alternatively, there may be large rings or plaques on the trunk or



FIG 60—*Trichophyton rubrum* infection Erythematous scaly lesion of ear (By courtesy of Dr B Russell)

elsewhere, with virtually no erythema and a minimum of scaling at the edges. Such a lesion occurring in a patient presenting with pruritis may be extremely difficult to see and is readily overlooked.

Mixed infections are not uncommon, *T mentagrophytes* and *Ep*

# EPIDEMIOLOGY OF *TRICHOPHYTON RUBRUM* INFECTION

MARY P. ENGLISH

THE problem of the epidemiology of *Trichophyton rubrum* infection is, by and large, the problem of all other dermatophyte infections of the glabrous skin, with certain additional special features

Dermatophytosis due to *T. rubrum* was undoubtedly originally a disease of the tropics. Sabouraud had never seen it when he wrote his classic *Les Teignes*<sup>13</sup> which appeared in 1910. In that year Castellani<sup>4</sup> and Bang<sup>2</sup> (the latter working in Sabouraud's laboratory) published, quite independently, descriptions of the fungus found in Ceylon, Mexico and Indo-China. Sabouraud<sup>14</sup> a year later concluded that they were the same fungus, namely, *T. rubrum*. Sabouraud also recorded the fungus from India and Siam, so that it is probable that it was widespread in the tropics at that time.

Unfortunately, little is known about *T. rubrum* in its native environment, even today. Clarke and Walker<sup>5</sup> in 1953 found that it was the most frequent agent of tinea of the glabrous skin in Nigeria, and Vanbreuseghem<sup>17</sup> reported 3 different strains of the fungus from the Belgian Congo. Sanderson and Sloper<sup>15</sup> found it to be the cause of skin lesions in 7 out of 9 Asiatic soldiers in Malaya and Chakraborty (quoted by Maskin and others)<sup>11</sup> stated, though no evidence was given, that 80 per cent of dermatophytosis in India was due to this fungus.

## RISE IN INCIDENCE

The figures for the spread of *T. rubrum* into Europe and North America since 1910 are striking. In Canada in 1947, 23.3 per cent of all fungous infections were attributed to *T. rubrum*<sup>7</sup>. Maskin and his colleagues<sup>11</sup> showed that at the New York Clinic the incidence of the fungus has increased from 20 per cent to 80 per cent of fungous infections of the glabrous skin since 1935. In Europe a great increase has been recorded in Germany<sup>10</sup>, Switzerland<sup>3</sup> and Holland<sup>6</sup>. In Britain, Walker<sup>18</sup> isolated the fungus 97 times between 1946 and 1949, and over the last 3 years in Bristol skin clinics, *T. rubrum* has been isolated more often than any other single fungus species<sup>8</sup>. These figures, mostly obtained through clinics or medical practitioners, should not be taken to indicate that *T. rubrum* is the chief

## TRICHOPHYTON RUBRUM INFECTION

easily by clinical standards even when they have been present for many years, but the success rate falls considerably if repeatedly negative skin scrapings are demanded as the index of cure. *T. rubrum* infection of the palms and soles is equally resistant whether the nails are involved or not. The fungus is often surprisingly persistent and readily found in the skin during treatment with fungistatic agents. Nail infection is at present virtually incurable, but individual infected finger-nails do sometimes return to normal as other nails become involved. Though a nail may appear to have returned to normal it may yet contain fungus. Palm and sole infections are rarely cured, and examples of cure may, in fact, have been spontaneous remissions.

No one fungicide is preferred to another, irrespective of its ability to inhibit *in vitro*. Surgical removal of nails has, in general, been abandoned for there is almost invariably an associated persistent infection on the adjacent skin from which re-infection may occur. The chemical removal of a nail appears to give no better results. Histological examination of a chronically infected nail using periodic acid Schiff technique for staining shows penetration of the fungus to the deepest crevices of the nail plate and illustrates the difficulties of treatment.

## REFERENCES

- <sup>1</sup> Ingram, J. T. (1955) "Tinea of Vulva" *Brit med J*, 2, 1500
- <sup>2</sup> Langeron, M. (1945) *Precis de Mycologie* Paris, Masson
- <sup>3</sup> Lewis, G. M., and Hopper, M. E. (1938) "The Trichophyton Test its Value as a Diagnostic Aid" *Arch Derm Syph*, Chicago, 38, 713
- <sup>4</sup> Ota, M. (1922) "Contribution to the Study of *Trichophyton purpureum* Bang, *T. interdigitale* Priestley, and *Trichophyton 'B'* Hodges." *Arch Derm Syph*, Chicago, 5, 693
- <sup>5</sup> Partridge, B. M. (1955) "Multiple Fungous Infections" *Trans St John's Hosp Derm Soc*, 34, 41
- <sup>6</sup> Rothman, S. (1953) "Systemic Disturbances in Recalcitrant *Trichophyton rubrum* Infections. Studies and Short Report on Therapeutic Experiments" *Arch Derm Syph*, Chicago, 67, 239
- <sup>7</sup> Sulzberger, M. B. (1944) *Yearbook of Dermatology* Chicago, Year Book Publishers

## EPIDEMIOLOGY OF *TRICHOPHYTON RUBRUM* INFECTION

first noticed while the patient was using swimming baths frequently, or taking an active part in sports. The remaining 8 had no idea where they might have contracted the disease

Women appeared to be just as susceptible as men, and children as adults, provided the opportunity for infection was there. In the great majority of cases the original infection was in the feet. Nail infections occurred in 78 per cent of all patients. Eruptions elsewhere on the body appeared to be more often the result of auto-inoculation from the feet than cross-infection from another person.

The evidence from this investigation shows conclusively that the home is a likely place for cross-infection by *T. rubrum*, contrary to the opinions of Sulzberger, and other American workers<sup>16</sup>. It also bears out the results of Baer and others<sup>1</sup> who showed that most individuals have a considerable resistance to infections. The evidence is in agreement with the view of Gentles and Holmes<sup>9</sup> that some breakdown in personal immunity must precede the onset of clinical disease, and that this breakdown must coincide with inoculation by a viable fungus. Such a coincidence is more likely to occur if the subject is in daily contact with infective particles either in his home or elsewhere.

It appears possible that *T. rubrum* is, in fact, less infectious than *T. mentagrophytes*, and that it owes its spread in recent years more to the persistence of clinical infections than to any unusual degree of infectivity. This fungus is more likely to become a nuisance in a family, a residential home, in barracks, or pit-head baths used daily by the miners, than in such places as swimming baths and sports pavilions which are mostly frequented only once or twice a week by any one person (athletes, swimming instructors and similar persons must obviously be excepted). In a recent, unpublished survey carried out in day schools in Bristol, only 13 cases of tinea pedis due to *T. rubrum* were found as against 154 due to *T. mentagrophytes*, and there were never more than 2 cases of *T. rubrum* infection in any one school.

## REFERENCES

- <sup>1</sup> Baer, R. L., Rosenthal, S. A., Rogachefsky, H., and Litt, J. Z. (1955) "Nail Infections in the Feet of Athletes." *J. Invest. Derm.*, **25**, 1-10.
- <sup>2</sup> B. . . . .
- <sup>3</sup> Blank, F. (1951) "Zur Dermatophyten-Flora der Schweiz." *Dermatologica*, **102**, 88.
- <sup>4</sup> Castellani, A. (1910) "Observation on a New Species of *Epidermophyton* Found in Tinea Cruris." *Brit. J. Derm.*, **22**, 147.



## EPIDEMIOLOGY OF *TRICHOPHYTON RUBRUM* INFECTION

cause of dermatophytosis in temperate climates. Surveys of sections of the public who may not have requested medical advice show that *T. mentagrophytes* is still the predominant cause of ringworm, but as the symptoms it causes are less chronic and disfiguring, its victims seek medical aid less often.

There is little doubt that the two world wars and the consequent wholesale movements of troops and civilian populations have contributed to the spread of *T. rubrum*. It has probably been aided by the consequent increase in communal living, often in very crowded conditions, by lack of medical attention and, according to some workers<sup>12</sup>, by certain predisposing diseases. An important factor, and one in which *T. rubrum* differs in degree from other dermatophytes, is its great resistance to treatment, particularly once the nails have become involved; an infected person is likely to be a source of infection for others for the rest of his life.

### INVESTIGATION OF SOURCES

Many patients are unable to account for their infection in the ways referred to above, and neither have they been regular frequenters of swimming baths or sports grounds.

It was partly in an attempt to find other sources of infection that from 1955 to 1956 an investigation was carried out of Bristol families, in each of which one person was known to be infected with *T. rubrum*. The families were visited in their homes in order to examine the feet and hands of each member, to record relevant personal and family histories, and to obtain scrapings from all suspicious lesions. A spread of infection within the family was recorded only when mycologically similar cultures of *T. rubrum* were obtained from two or more persons in it. In 19 families concerned, a spread of infection was recorded in 9, and of the 48 contacts seen, 13 (27 per cent) were infected. The rate of spread was very high among children brought up in infected families, for of the 8 subjects between the ages of 14 and 35 who had been exposed as children, 6 had contracted the disease. The minimum duration of exposure before clinical infection occurred was 1 year and the maximum 15 years. Two wives who had been in contact with their infected husbands for 30 years had not contracted the disease. Unhygienic standards seemed to have little to do with spread of infection, for over half the families were of middle class, and in the only really filthy household among the remainder, only one of 7 contacts was infected.

Seven of the original patients could trace their infections to residence or active service abroad, and in 4 others the disease was

## TINEA PEDIS IN MINERS

J. G. HOLMES

IN 1911 the first pithead bath was constructed in Britain. In the same year, a joint meeting of British and French dermatologists was held at the Royal Society of Medicine in London to discuss "Eczematoid Ringworm of the Extremities". The Chair was taken by Malcolm Morris and the opening speakers were Sabouraud and Whitfield. Assuming that white soggy skin between the toes was evidence of tinea pedis, Malcolm Morris gave as his opinion that ringworm of the extremities was common; Whitfield, on the other hand, considered it to be rare.

Prosser White, who lived and worked in Wigan near a pithead bath which has been in continuous use since 1913, made no mention of ringworm in miners in the 1939 edition of his well-known book. The first description of this condition was made by Knowles<sup>3</sup> who, in 1943 while in general practice in a colliery village, wrote a thesis in which he expressed the view that tinea pedis was a new disease of the miners. He attributed this to cross-infection in the bath-houses which had been erected for the first time in his district only a few years previously.

In 1951, Riddell<sup>4</sup> referred to tinea pedis in miners and considered that the problem arose not so much by cross-infection but by a change in susceptibility of the skin to infection brought about by bathing.

### EPIDEMIOLOGICAL FIELD SURVEY

It was about this time that the Industrial Epidermophytosis Committee of the Medical Research Council was constituted. It was decided that a field survey should be carried out to study the epidemiology of tinea pedis. Gentles and Holmes<sup>1, 2</sup> were appointed as mycologist and clinician respectively and work began with a pilot survey at pits which had baths. These pilot studies confirmed that tinea pedis was common and that it was necessary to have laboratory corroboration of clinical diagnoses.

The survey proper lasted throughout 1953 and 1954. During that time 12 pits and 2 power stations of the British Electricity Authority were visited. It was not possible to select these at random but the places chosen were widely separated geographically. The

# EPIDEMIOLOGY OF *TRICHOPHYTON RUBRUM* INFECTION

- <sup>5</sup> Clarke, G H V., and Walker, J (1953) "Superficial Fungus Infections in Nigeria" *J trop Med (Hyg)*, **56**, 117.
- <sup>6</sup> Cremer, G (1953) "Epidemiology of Fungal Infections in the Tropics" Caused by
- <sup>7</sup> Danby, C  
*Canad med Ass J.*, **50**, 641
- <sup>8</sup> English, Mary P. (1957) "*Trichophyton rubrum* Infection in Families" *Brit med J.*, **1**, 744
- <sup>9</sup> Gentles, J C., and Holmes, J G (1957) "Foot Ringworm in Coal Miners" *Brit J Industr Med.*, **14**, 22
- <sup>10</sup> Grimmer, H. (1956) "Der wandel der epidemiologie der Epidermophytien in den jahren von 1952 bis 1956 in Berlin" *Arch klin exp Derm.*, **203**, 125.
- <sup>11</sup> Maskin, I L., Taschidjian, C L., and Franks, A C (1957) "The Etiology of Dermatophytosis Shift from *Trichophyton mentagrophytes* to *T rubrum*, 1935-1954" *Arch Derm Syph, Chicago*, **75**, 66
- <sup>12</sup> Rothman, S (1953) "Systemic Disturbances in Recalcitrant *Trichophyton rubrum* Infections Studies and Short Report on Therapeutic Experiments" *Arch Derm Syph, Chicago*, **67**, 239
- <sup>13</sup> Sabouraud, R (1910) "*Les Teignes*" Paris, Masson.
- <sup>14</sup> — (1911) "Trichophytic Eruption caused by the *Trichophyton rubrum* of Castellani (*Epidermophyton purpureum* Bang)" *Brit J Derm.*, **23**, 389
- <sup>15</sup> Sanderson, P H., and Sloper, J C (1953) "Skin Disease in the British Army in S E Asia II Tinea Corporis Clinical and Pathological Aspects, with Particular Reference to the Relationships between *Trichophyton interdigitale* and *T mentagrophytes*" *Brit J Derm.*, **65**, 300
- <sup>16</sup> Sulzberger, M B., Baer, R L., and Hecht, R (1942) "Common Fungous Infections of the Feet and Groins" *Arch Derm Syph, Chicago*, **45**, 670
- <sup>17</sup> Vanbreuseghem, R (1949) "A propos de *Trichophyton rubrum* Sa présence en Belgique et au Congo Belge" *Arch belges Derm.*, **5**, 240
- <sup>18</sup> Walker, J (1950) "The Dermatophytoses of Great Britain Report of a 3 Years' Survey" *Brit J Derm.*, **62**, 239

## EPIDEMIOLOGICAL FIELD SURVEY

these were recorded as similar on the two occasions in 63 subjects, as more severe on the first examination than the second in 16, and as more severe on the second examination in 20.

TABLE 6  
DETAILED LABORATORY FINDINGS

Ringworm fungi	Microscopy + } Culture + } Culture only + } Microscopy only + }	346 (79 per cent) 57 (13 per cent) 32 (7 per cent)	{ 403 cultured (92 per cent of total infected)
<i>Candida albicans</i>		2	
Doubtful microscopy		1	
Total personnel infected		438 (21 per cent of those examined)	

At one pit which had the highest incidence rate for tinea pedis, a further examination was made about 1 year after the first. The results for 80 of the 99 men re-examined remained unchanged, 46 being infected on both occasions and 34 being apparently free of disease both times. Ten were positive for fungous infection on the first occasion only and 9 on the second only. The total infected at one time or another was 65.

### EFFECT OF ENVIRONMENT

The prevalence rates of infection proved by laboratory findings varied from 3.5 per cent at one pit to 50 per cent at another<sup>1 (Table 1)</sup>. The incidences at 2 pits in Scotland were similar as were those at 2 power stations in London. On the other hand, results at some neighbouring places were dissimilar (for example, 50 per cent at one compared with 12 per cent at another). It was, therefore, necessary to look for reasons which would explain why this occurred, such as seasonal factors, conditions peculiar to mining, or the presence of pithead baths.

Seasonal variation was ruled out as a factor from a study of results over the period of the survey. When attention was paid to the effect of mining conditions, it appeared at first that those who worked underground were most likely to contract infection. The incidence of tinea amongst surface workers who had never been underground was 12 per cent compared with 17 per cent in those who had, and with 24 per cent in underground miners. This last figure is, however, no higher than that recorded at power stations, and all the apparent differences disappeared when the bathing histories of

## TINEA PEDIS IN MINERS

personnel included in the trial at each pit or power station were selected at random from wage sheets using tables of sampling numbers; they were notified and given appointments in writing. The response rate was satisfactory. of the 2,160 selected, 97 per cent were seen, 2 per cent were not readily available and only 1 per cent refused to co-operate.

History-taking and physical examination were standardized as far as possible and the results entered on a record card. Approximately 5 minutes was the maximum time available for these examinations. Skin scrapings were taken during this time from each foot irrespective of the clinical findings. The scrapings were wrapped in numbered slips of paper and posted off daily to the mycologist, who remained unaware of their origin until after he had made his report. The material was cultured in every case and whenever possible was also examined microscopically. "Mosaic fungus" was not counted as evidence of infection.

### CLINICAL AND LABORATORY FINDINGS

Only 10 per cent of the men examined had clinically normal feet and of these 2.5 per cent were found by laboratory tests to be infected. Infection of the feet as assessed from mycological examination was recorded in 21 per cent of subjects. The detailed laboratory results are shown in Tables 6 and 7 and clinical findings have been described elsewhere<sup>2</sup>. *Trichophyton rubrum* predominated greatly at one pit and at another no case of infection by this organism was detected.

While conducting this survey an attempt was made to assess observer error. When the laboratory findings were negative in a subject suspected clinically as being infected, a further examination was made of surplus skin material left over from the initial tests. It was not possible to obtain fresh material from such cases owing to the extensive travel from place to place which this survey entailed. From 98 such re-examinations, only 1 extra case of infection was recorded. From a clinical standpoint, 99 men were examined on two occasions and the results compared. These men were taken in three separate groups of 30, 34, and 35 respectively, and were examined while sitting behind a screen so that only their legs were visible. On the first occasion, the subjects were seen in any order, and on the second in order of random selection. In the first series of examinations 18 were recorded as having normal feet compared with 20 at the second examination. Ninety-three of the 99 men were classified in the same way on the two occasions, including 16 normals. Degrees of abnormality proved more difficult to assess;

## REFERENCES

- <sup>2</sup> Holmes, J. G., and Gentles, J. C. (1956) "Diagnosis of Foot Ringworm" *Lancet*, 2, 62.
- <sup>3</sup> Knowles, R. B. (1953) *Dermatitis in Coal Miners* Page 10 M.D. Thesis, Sheffield
- <sup>4</sup> Riddell, R. W. (1951) "Survey of Fungus Diseases in Britain." *Brit med. Bull.*, 7, 197
- <sup>5</sup> Vanbreuseghem, R., Peeters, P., and Tritsmans, E. (1952) "Note préliminaire sur l'athlete's foot chez des sportifs belges" *Arch belges Derm.*, 8, 343

## TINEA PEDIS IN MINERS

personnel were taken into account. Similarly, though the peak incidence of infection in the groups studied occurred at the age of 45 years, the fall in incidence of tinea which was observed after this age coincided with a rise in the proportion of "non-bathers" in the older age groups. Men who used the baths at places visited in the survey are referred to as "bathers" and the others as "non-bathers". The regularity of bathing had little effect on the figures for incidence of tinea provided a man bathed at least once weekly. Past bathing history had little influence on the infection rate amongst bathers but affected greatly this incidence among non-bathers<sup>1</sup> (Table 2). The rates at pits without baths depended very much on whether or not there were other baths in the vicinity.

TABLE 7  
SPECIES ISOLATED FROM 403 SUBJECTS FROM WHOM  
RINGWORM FUNGI WERE GROWN

<i>Trichophyton mentagrophytes</i>	224
<i>Trichophyton rubrum</i>	148
<i>Epidermophyton floccosum</i>	11
<i>T. mentagrophytes</i> and <i>T. rubrum</i>	13
<i>Ep. floccosum</i> and <i>T. rubrum</i>	4
<i>Ep. floccosum</i> and <i>T. mentagrophytes</i>	3
Total	<hr/> 403

Length of employment could be used as a rough measure of length of exposure. The infection rate rose relatively steeply over the first few years of employment (a rise not apparent over weeks or months) before becoming stabilized. Similar conclusions were reached by Vanbreuseghem, Peeters and Tritsmans in their studies<sup>5</sup>

Gentles was successful in isolating *T. rubrum* from the floor of one bath-house and *T. mentagrophytes* from floors at various other places. Measures designed to prevent spread of infection proved useless probably because they were undertaken too late.

By these investigations it was shown that it is possible to obtain a reasonable estimate of the incidence of tinea pedis in a community even when, as in mining groups, only a limited time for interview and examination is available. It was concluded that while personal immunity is an important factor in this disease, exposure is of even greater moment. Though common, tinea pedis is, fortunately, seldom disabling.

## REFERENCES

- <sup>1</sup> Gentles, J. C., and Holmes, J. G. (1957) "Foot Ringworm in Coal-Miners" *Brit. J. Industr. Med.*, 14, 22

## PIGMENTS OF *TRICHOPHYTON RUBRUM*

extract was washed repeatedly with water until no traces of acetic acid remained. It was then concentrated by evaporation under reduced pressure to about one-sixth of its original volume, further concentration resulting in precipitation of the pigment.

A small quantity of this extract, about 50 microlitres, was streaked across a 2-inch strip of Whatman No. 3MM paper for chromatography and the paper was then placed in a mixture of 2 parts chloroform to 1 part petroleum ether (b.p. 60–80°). The composition of this mixture was critical for satisfactory separation of the pigments and by using it 3 pigments were clearly distinguished. The fastest-moving pigment (A) is bright yellow, the second (B) is an orange-red pigment and the third is a deep bluish-red pigment (C). Another very faint yellow band can be seen travelling more slowly still, but the amounts of this are very small.

The three main pigments were eluted from the paper with chloroform and their colour noted when alkali was added. Pigment A turned mauve, pigment B turned violet, and pigment C turned blue. When reduced in alkaline solution the colours of the pigments change, decrease greatly in intensity, and become fluorescent, A, B and C having a green, a yellow and a yellowish-green fluorescence respectively. These reduced forms are unstable and readily revert to the oxidized forms in air.

The separation of these pigments on a larger scale was effected in the following way. Petroleum ether was added to the chloroform extract, thereby precipitating pigments B and C but leaving pigment A in solution. This solution was evaporated to small bulk and cooled but so far crystals of pigment have not been obtained, probably due to the presence of contaminating fatty material. Pigment B was obtained by dissolving the precipitate in chloroform and carrying out repeated fractional precipitation with methyl alcohol until only one pigment could be detected on the chromatogram, this pigment has been obtained in crystalline form. The final supernatant was evaporated to dryness under reduced pressure and the residue was dissolved in the smallest possible volume of hot 90 per cent acetic acid. When this was allowed to cool, pigment C crystallized out as sheaths of fine purple needles.

The absorption spectra of these 3 pigments have been studied and have been found to be very closely related. Their spectra, the colour reactions, the solubilities and other properties strongly suggest that these pigments are substituted anthraquinones. Most of the fungal pigments which have been isolated are, in fact, anthraquinones and most of them have contained at least 2 substitutes. Since the particular spectra observed by Mier have not been recorded



# PIGMENTS OF *TRICHOPHYTON RUBRUM*

A TICKNER

ALTHOUGH fungal pigments in general have been quite extensively studied, chiefly by Raistrick and his colleagues, not much is known about the pigments produced by pathogenic fungi. The earliest work was by Tate in 1929<sup>2</sup> who described what he thought was a single substance produced by 5 species of dermatophytes apparently including *Trichophyton rubrum* although this was not mentioned by name. He described the properties of the crude material as a red to reddish-brown substance in its natural state, soluble in dilute acid and in acid-alcohol but not in dilute alkali. In acid solution it was yellow, becoming red on addition of alkali. It could be extracted from acid solution by chloroform. Alkaline solutions could be reduced to a clear yellow solution with sodium dithionite; the reduced solution was re-oxidized spontaneously and rather quickly by atmospheric oxygen. Guided by his biochemical colleague Hill, Tate made the percipient observation that the substance appeared to be an anthracene pigment.

Thompson<sup>3</sup> stated that the pigment (*sic*) of *T. purpureum* (*T. rubrum*) and of *T. gypseum* (*T. mentagrophytes*) was readily soluble in acetone. Oxygen caused it to change to a bright cherry colour, and addition of water caused partial precipitation of the pigment. The soluble portion was cherry coloured, turning lavender if the pH was above 9. On standing in alkaline solution the pigment turned yellow, but the lavender colour could be restored by the addition of oxygen but not nitrogen, hydrogen sulphide or carbon dioxide.

## ISOLATION OF PIGMENTS

An attempt was made to isolate and identify these pigments, in the chemical pathology laboratory of the Institute of Dermatology, by Mier<sup>1</sup>. Cultures of *T. rubrum* grown on 50-millilitre plates of Sabouraud's medium were sterilized by heat and the pooled contents of 12 plates were then scraped into a mortar where they were thoroughly ground in about 250 millilitres of glacial acetic acid. By protracted grinding it was possible to extract all of the pigment originally present in the plates. This extract was diluted to 2 litres with water. The pigment could be extracted from the glacial acetic extract by chloroform and was a reddish colour. The chloroform

## PIGMENTS OF *TRICHOPHYTON RUBRUM*

extract was washed repeatedly with water until no traces of acetic acid remained. It was then concentrated by evaporation under reduced pressure to about one-sixth of its original volume, further concentration resulting in precipitation of the pigment.

A small quantity of this extract, about 50 microlitres, was streaked across a 2-inch strip of Whatman No. 3MM paper for chromatography and the paper was then placed in a mixture of 2 parts chloroform to 1 part petroleum ether (b.p. 60-80°). The composition of this mixture was critical for satisfactory separation of the pigments and by using it 3 pigments were clearly distinguished. The fastest-moving pigment (A) is bright yellow, the second (B) is an orange-red pigment and the third is a deep bluish-red pigment (C). Another very faint yellow band can be seen travelling more slowly still, but the amounts of this are very small.

The three main pigments were eluted from the paper with chloroform and their colour noted when alkali was added. Pigment A turned mauve, pigment B turned violet, and pigment C turned blue. When reduced in alkaline solution the colours of the pigments change, decrease greatly in intensity, and become fluorescent, A, B and C having a green, a yellow and a yellowish-green fluorescence respectively. These reduced forms are unstable and readily revert to the oxidized forms in air.

The separation of these pigments on a larger scale was effected in the following way. Petroleum ether was added to the chloroform extract, thereby precipitating pigments B and C but leaving pigment A in solution. This solution was evaporated to small bulk and cooled but so far crystals of pigment have not been obtained, probably due to the presence of contaminating fatty material. Pigment B was obtained by dissolving the precipitate in chloroform and carrying out repeated fractional precipitation with methyl alcohol until only one pigment could be detected on the chromatogram, this pigment has been obtained in crystalline form. The final supernatant was evaporated to dryness under reduced pressure and the residue was dissolved in the smallest possible volume of hot 90 per cent acetic acid. When this was allowed to cool, pigment C crystallized out as sheaths of fine purple needles.

The absorption spectra of these 3 pigments have been studied and have been found to be very closely related. Their spectra, the colour reactions, the solubilities and other properties strongly suggest that these pigments are substituted anthraquinones. Most of the fungal pigments which have been isolated are, in fact, anthraquinones and most of them have contained at least 2 substitutes. Since the particular spectra observed by Mier have not been recorded

## PIGMENTS OF *TRICHOPHYTON RUBRUM*

elsewhere, it is quite possible that these particular substituted anthraquinones are peculiar to the *Trichophyton* genus and perhaps to the *T. rubrum* species

Mier has also carried out preliminary studies on *T. violaceum* and has shown, again by paper chromatography and by plotting the absorption spectra, that there are at least 3 pigments and perhaps as many as 7 or 8. These pigments are very similar to those of *T. rubrum* and also appear to be substituted anthraquinones. He has investigated the pigment of one other fungus, *Microsporum canis*. This pigment was very different from the *Trichophyton* pigments and was much more difficult to isolate, present indications are that it is an unsaturated dicarboxylic acid

As to the reason why the trichophyta are so lavish in the production of pigments, two possibilities suggest themselves. First, since the anthraquinones are manifestly able to act as electron acceptors they could take some part in oxidation-reduction mechanisms in the respiratory chain. It may be that under certain circumstances this particular group of organisms may make too much pigment for their own needs, analogous to the excessive production of riboflavine by *Eremothecium ashbyi*. Anthraquinone co-enzymes appear, on the other hand, to be unknown. Alternatively, it is possible that the trichophyta may secrete substances harmful to other fungi and thus be more successful in their struggle for existence. This effect has not been demonstrated with these pigments, but a preliminary screening for bactericidal action was negative. It is also possible that fungi living under unusually rich growth conditions may produce pigments in the same way as the overfed human produces fat.

The work described was carried out with very small quantities of material, but conventional chemical analysis is awaiting the availability of larger amounts.

*Addendum*—Since this work was completed we have communicated with Dr J. C. Wirth of Brooklyn<sup>4</sup> who has been carrying out similar investigations, in particular he has been successful in producing a pure specimen of pigment A.

## REFERENCES

- 1 Mier, P. D. (1957) "Pigments in *Trichophyton rubrum*" *Nature*, 179, 1084
- 2 Tate, P. (1929) "The Dermatophytes or Ringworm Fungi" *Biol. Rev.*, 4, 41
- 3 Thompson, K. W. (1943) National Research Council Conference on Dermatophytosis. Page 13
- 4 Wirth, J. C., O'Brien, P. J., Schmitt, F. L., and Sohler, A. (1957) "The Isolation in Crystalline Form of Two of the Pigments of *Trichophyton rubrum*" *J. Invest. Derm.*, 29, 47

## IMMUNITY IN YEAST INFECTION

H. I. WINNER

THE STUDY of infections due to fungi has mainly concerned itself with the recognition and systematic study of etiological agents and of clinical syndromes. Immunological aspects of these diseases have received little attention, and there has been a tendency to borrow ready-made concepts from bacterial infections. In the literature there are accounts of human moniliasis treated with antimonilial rabbit serum on assumptions deduced from certain bacterial and virus infections. On similar assumptions, attempts have been made to actively immunize against blastomycosis by injecting killed vaccines of the causative fungus. Such classical immunological concepts cannot, however, be applied to all bacterial infections; for example, one does not try to immunize against *Treponema pallidum* infection in this way.

An important difference between fungal and bacterial infections is the relative size of the infecting organisms. It can be assumed that the infecting agent in bacteriological and virus diseases is smaller than the smallest host cells, small enough to pass between cells, across cellular membranes such as the glomerular basement membrane without causing appreciable mechanical disturbance, and small enough to pass across capillary walls. In the case of the fungi such assumptions cannot be made. Pathogenic yeasts, like *Candida albicans* and *Cryptococcus neoformans*, have approximately the diameter of an erythrocyte and a volume which is usually greater. Their very physical existence in the host, were they merely inert particles, would raise mechanical problems by virtue of size alone, problems which do not arise in the case of bacteria and viruses except in the most unusual circumstances. The proliferating yeasts of *C. albicans* form large masses inside the host tissues and these organisms may also produce filamentous structures (Fig. 61).

There is a further difference between fungi and bacteria in the nature of their cell walls. The tough polysaccharide wall of yeasts might well be expected to render such cells resistant to damage by the protective mechanisms of the host. The yeasts are likely to be relatively immune to the digestive action of the host enzymes, to surface-acting antibodies, to such agents as lysozyme, and also probably to phagocytosis.

## IMMUNITY IN YEAST INFECTION

Again, fungi are different in being saprophytic organisms with a complex metabolism involving enzyme systems more complex than those of the smaller micro-organisms. The existence of such systems operating inside a metazoan host would itself create special biochemical problems. The fungal cell, by virtue of its size as much as anything else, probably possesses a very large number of antigens.




FIG. 61.—Section showing yeasts proliferating in tubule of rabbit kidney 24 hours after infection with *C. albicans*. Note absence of inflammatory response ( $\times 392$  Periodic acid Schiff and haematoxylin.)

Since a cell of *Salmonella*, with a volume of the order of  $1\mu^3$ , contains a battery of several flagellar antigens and another of somatic antigens, it is likely that a yeast cell, with a volume some hundreds of times as great, would be much more complex antigenically. Skin hypersensitivity reactions to whole fungus, or to extracts of fungus, can often be demonstrated in mycotic infections, though their significance is not understood and their occurrence is inconstant.

*formans*, provide an instructive contrast in this aspect of immunology.

## INNATE IMMUNITY

*C. albicans* is best regarded as a normal commensal organism of humans and of many other animals. This is amply shown by the

## INNATE IMMUNITY

frequency with which it is isolated from the skin and mucous membranes of human subjects<sup>4</sup>, and by the frequency with which agglutinins to it can be demonstrated in the absence of clinical infection. Humans are normally resistant to the pathological effects of *C. albicans*, but occasionally resistance is lost and clinical disease results. Resistance is also shown by laboratory animals infected experimentally. The intradermal injection of large doses of *C. albicans* cells into rabbits gives rise to a self-limiting disease. The organism spreads locally, exciting a cellular response, and an abscess is produced, the multiplying organism is extruded and within a few weeks the lesion heals. The intraperitoneal injection of massive doses

visceral organs

Intravenous injection of *C. albicans* cells, on the other hand, may cause a fatal infection in rabbits, guinea-pigs, and mice. The establishment of disease in the rabbit has long been regarded as pathognomonic of the presence of *C. albicans* in injected material. The disease is, however, only fatal if the infecting dose of pathogenic organisms exceeds a definite threshold<sup>11</sup>, the rabbit having a degree of natural immunity which can be overcome by force of numbers of pathogenic fungus cells. Intravenous injection of *C. albicans* in doses of 2 million organisms or less fails to produce death, whereas injections of 5 million organisms or more almost invariably do so (Table 8).

TABLE 8

<i>Number of animals</i>	<i>Organisms received</i>	<i>Result</i>
24	2 million or less each	All survived
43	5 million or more each	40 died within 7 days, 1 died after 18 days, 1 showed progressive disease after 30 days, 1 survived

In the case of *Cr. neoformans*, it is uncertain whether a permanently subclinical infection with this organism occurs in humans. Almost all of the clinical cases, which are coming to light in increasing numbers, ultimately prove fatal, and several cases have been reported of disease progressing to death from a comparatively trivial initial lesion. When any relatively rare and often fatal infection is

## IMMUNITY IN YEAST INFECTION

gaining recognition, most of the early cases reported are fatal ones. In consequence, the existence of subclinical disease tends to be overlooked. Weidman in 1935 coughed up an organism identified as *Cr. neoformans* and 15 years later, alive and well, he reported the fact<sup>9</sup>; it is possible that this represented a subclinical infection or, alternatively, the organism may have been a non-pathogenic variant. Many of the clinical cases of torulosis reported have been complications of some debilitating condition such as Hodgkin's disease or sarcoidosis, or of cortisone therapy with its well-known depression of immunity mechanisms.

There are well-marked differences in susceptibility of other animals to *Cr. neoformans* infection. Mice are extremely susceptible, particularly the white Swiss strain, and most strains of *Cr. neoformans* derived from human cases will kill these animals within 21 days of intraperitoneal or intracerebral injection of the organism. Rats, guinea-pigs and rabbits show an increasing gradient of resistance. It has been suggested that the relatively high resistance of the rabbit to this infection is due to the high body temperature (39.5° C.) of this animal, particularly as the organism itself shows a marked susceptibility to heat.

## ACQUIRED ACTIVE IMMUNITY

Many humans and rabbits possess agglutinins to *C. albicans*<sup>10</sup> (Tables 9 and 10). There have been several other surveys in the Western Hemisphere of human agglutinins<sup>1, 3, 6, 8</sup>. In the majority of cases such agglutinins are probably acquired, though the possibility of their being natural agglutinins cannot be ruled out. Females show agglutinins more often than males, suggesting that these

TABLE 9  
*CANDIDA ALBICANS* AGGLUTININS IN SERA OF  
HOSPITAL PATIENTS

	Number tested	Number positive	Per cent positive
Antenatal cases	1391	445	32.0
Other females	264	94	35.6
Males	362	99	27.3
TOTALS	2017	638	31.6

# ACQUIRED ACTIVE IMMUNITY

TABLE 10

## NATURAL AGGLUTININS TO *CANDIDA ALBICANS* IN RABBITS

(Number tested: 55)

No agglutinins detected in	36 (65%)
Some agglutinins detected in	19 (35%)
Titre less than 16 in	44 (80%)
Titre 16 or higher in	11 (20%)

antibodies are, in fact, acquired, since moniliasis occurs more frequently in females. As Norris and Rawson<sup>6</sup> have shown, there is much cross-immunity associated with various species of *Candida*, so these agglutinins are by no means necessarily specific.

It is important to establish whether the acquisition of agglutinins confers any resistance to the pathogenic effects of *C. albicans*. This has been studied in rabbits. Agglutinin formation is easily induced in these animals, either by single or multiple injections of sublethal doses of living organisms or by repeated injections of killed organisms. Whichever method is used, agglutinins develop<sup>11</sup> with titres ranging from approximately 1/32 to 1/320, but when the animals are challenged with a dose of *C. albicans* normally lethal to the rabbit, the acquisition of agglutinins does not protect them<sup>11</sup>. This observation apparently departs from the classical conception of immunity based on bacterial and virus studies, but the type of disease found in rabbits dead of systemic moniliasis has little in common with that seen in animals dead of a systemic bacterial disease, such as staphylococcal septicaemia, typhoid or tuberculosis. During the course of experimental infections the animals become less and less active, and may develop pareses and convulsions. Before death, or at death, they show a raised blood urea. The striking feature at post-mortem examination is the enlargement of the kidneys, macroscopically the lymph nodes and spleen appear normal and signs of septicaemia are absent. However, sections of the kidneys, and of other organs too, show that the *C. albicans* cells are multiplying freely in the tissues with or without the occurrence of a marked inflammatory reaction (Figs. 61, 62 and 63). A feature of the kidney lesions is the fibrinoid type of necrosis seen in the glomeruli<sup>2</sup> (Fig. 64).

The size of the infecting *C. albicans* cells is an obvious mechanical factor to be considered. Living organisms, about 7 $\mu$  in diameter, proliferate in the kidneys to produce large masses of cells, and the animals die in uraemia. However, death is not due simply to glomerular blockage. If it were, one would expect injections of killed *C. albicans* to produce similar effects, whereas, in fact, they do





FIG 62 —Section showing the distribution of *C. albicans* abscesses in the rabbit kidney. ( $\times 23$  Periodic acid Schiff and haematoxylin)



FIG 63 —Section showing marked inflammatory reaction in kidney of rabbit infected with *C. albicans* ( $\times 85$  Haematoxylin and eosin)

## ACQUIRED ACTIVE IMMUNITY

not Massive doses of formalin-killed organisms injected intra-

injected, either in the lungs, spleen, kidneys, or lymph nodes

Furthermore, in contrast to what happens with *C. albicans*, the injection of comparable doses of living cells of other *Candida* species (for example *C. tropicalis*) is not lethal, as might be the case if purely mechanical factors were operating.




FIG. 64.—Section showing amorphous deposit in glomerulus of kidney of rabbit infected with *C. albicans* ( $\times 550$  Periodic acid Schiff and haematoxylin)

Henrici<sup>5</sup> was the first to postulate that *C. albicans* elaborated a toxin, and though others have supported this hypothesis no toxic substance has yet been isolated. The cellular necrosis in the kidneys of animals dead from experimental moniliasis suggests either the action of a toxin or the occurrence of a local hypersensitivity reaction.

It is possible to produce erythema in the skin of rabbits by the injection of simple saline extracts of broth cultures of *C. albicans*. This also suggests that a toxin may be present and may indicate why the production of agglutinins does not appear to coincide with resistance.

Few attempts have been made to produce acquired immunity against experimental systemic infection with *Cr. neoformans*. Agglutinins, precipitins, and complement fixing antibodies

## IMMUNITY IN YEAST INFECTION

against this organism have been detected, not without some difficulty, both in patients with natural infections and in animals experimentally infected. Recently, complement fixing antibodies have been detected in actively immunized rabbits, using as antigen a heated ether-alcohol extract of alcohol-killed *Cr. neoformans*<sup>7</sup>. It remains to be seen whether the possession of these antibodies confers any resistance against *Cr. neoformans* infection. An extensive survey of natural antibodies against this yeast in humans and animals not known to be infected by it is required.

*Cr. neoformans* usually has an abundant capsule when freshly isolated from lesions, but this tends to be lost in subcultures. The possession of a capsule may contribute to an important degree to the virulence of this organism. If the yeast is unencapsulated when free living and when acting as a commensal organism, but encapsulated when producing disease, interesting immunological problems at once present themselves.

Finally, let us consider the conditions in which human disease due to *C. albicans* and *Cr. neoformans* is met with. Infection with *C. albicans* is virtually universal. Disease due to this fungus occurs in certain well-defined conditions which were characterized by Trousseau in his studies of thrush in Paris from 1843 onwards as "a local expression of a very bad state of the whole organism". Normally, the multiplication and spread of this yeast-like organism is held in check by the natural defence mechanisms of the body, but the following host factors have been observed to enhance susceptibility to disease.

- (1) Infancy
- (2) Debility
- (3) Interference with immunity mechanisms
  - (a) Systemic disease (for example Hodgkin's disease, leukaemia)
  - (b) Steroid therapy
  - (c) Depression of bone marrow activity
  - (d) Irradiation of whole body
  - (e) Drug addiction
- (4) Hormonal changes (diabetes, pregnancy, and so on)
- (5) Interference with the normal bacterial flora of the body (for example, effects of antibiotic therapy)
- (6) Mechanical or chemical damage to mucous membranes (due to smoking and so on)

## ACQUIRED ACTIVE IMMUNITY

Practically nothing is known of natural fluctuations in virulence of *C. albicans* from strain to strain, but one would expect these to exist.

With regard to *Cr. neoformans*, many cases of human infection have been associated with debilitating conditions, particularly those affecting immunity mechanisms such as Hodgkin's disease, or with steroid therapy. On the other hand, when freshly grown from lesions, the yeast possesses a capsule which has antigenic properties. It appears likely that in *Cryptococcus*, in contrast to *Candida* infections, variations in virulence of the fungus play a large part in the determination of disease.

## REFERENCES

- <sup>1</sup> Drake, C. H. (1945) "Natural Antibodies against Yeast-like Fungi as Measured by Slide-agglutination" *J. Immunol.*, **50**, 185.
- <sup>2</sup> Evans, W. E. D., and Winner, H. I. (1954) "The Histogenesis of the Lesions in Experimental Moniliasis in Rabbits" *J. Path. Bact.*, **67**, 531.
- <sup>3</sup> Fuentes, C., and Guarton, G. (1945) "Investigación de las Aglutininas Normales contra la *Candida albicans* en el Suero de los Seres Humanos" *Rev. med. cubana*, **56**, 104.
- <sup>4</sup> Helms, P. (1956) "The Occurrence of *Candida albicans* in Sputum in Denmark" *J. clin. Path.*, **9**, 372.
- <sup>5</sup> Henrici, A. T. (1940) "Characteristics of Fungous Diseases" *J. Bact.*, **39**, 113.
- <sup>6</sup> Norris, R. F., and Rawson, A. J. (1947) "Occurrence of Serum Agglutinins for *Candida albicans* and *Saccharomyces cerevisiae* in a Hospital Population" *Amer. J. clin. Path.*, **17**, 813.
- <sup>7</sup> Shaw, S., and Winner, H. I. (1957) Unpublished observation.
- <sup>8</sup> Todd, R. L. (1937) "Studies on the Yeast-like Organisms Isolated from the Mouths of Normal Persons" *Amer. J. Hyg.*, **25**, 212.
- <sup>9</sup> Weidman, F. D. (1950) Discussion of paper by Cawley and his colleagues, "Torulosis: a Review of the Cutaneous and Adjoining Mucous Membrane Manifestations" *J. invest. Derm.*, **14**, 327.
- <sup>10</sup> Winner, H. I. (1955) "A Study of *Candida albicans* Agglutinins in Human Sera" *J. Hyg. Camb.*, **53**, 509.
- <sup>11</sup> — (1956) "Immunity in Experimental Moniliasis" *J. Path. Bact.*, **71**, 234.

## FUNGOUS INFECTIONS FOLLOWING ANTIBIOTIC THERAPY

T. ANDERSON\*

STUDIES on *Candida albicans* infection in patients suffering from respiratory infections were carried out before and after antibiotic therapy.

The occurrence of *C. albicans* was estimated by rectal, throat and sputum cultures at the time of admission to hospital (Table 11). When the incidence of *C. albicans* in the sputum of various groups of patients was compared (Table 12), it was found that the proportion of patients in the various clinical categories harbouring this organism, even in large numbers, was similar. There was a trend in both sputum and saliva towards a poorer yield of yeasts as the pH rose, but this difference was not within the level of statistical significance.

Administration of antibacterial drugs permitted an overgrowth of fungi<sup>3</sup> which were insusceptible to the action of these agents (Tables 13 and 14). Sulphonamides seemed to be less liable to cause this. After treatment with a tetracycline the proportion of patients giving a heavy growth of *C. albicans* from sputum was almost doubled, and in the faeces the increase was very much greater<sup>4</sup>.

The results left no doubt that after treatment with antibiotics it was comparatively easy to isolate *C. albicans* from sputum or faeces. This ease of isolation did not mean, however, that the fungi were playing a pathogenic role in all cases<sup>1, 2</sup>. In order to study this aspect of the problem, 155 patients were observed during treatment for side-effects (Table 15). A number of patients experienced gastric

TABLE 11

ISOLATION OF *CANDIDA ALBICANS* FROM RECTUM, THROAT  
AND SPUTUM OF PATIENTS NEWLY ADMITTED TO HOSPITAL

	<i>Rectal swab</i>	<i>Throat swab</i>	<i>Sputum</i>
Total examined	362	291	367
Total showing heavy growth of <i>C. albicans</i>	12	36	119 (32 per cent)

\* With the co-operation of Jessie L. Sharp and A. J. Childs

# FUNGUS INFECTIONS FOLLOWING ANTIBIOTIC THERAPY

TABLE 12

PRESENCE OF *CANDIDA ALBICANS* IN THE SPUTUM IN VARIOUS GROUPS OF PATIENTS

	Total patients	Results of culture for <i>C. albicans</i>	
		+	++
			percentage
All patients	367	60	119 (32)
Patients under 40 years of age	110	22	30 (27)
Patients over 40 years of age	257	28	89 (34)
Chronic bronchitis	138	25	47 (34)
Tuberculosis	57	7	24 (42)
No history of chest disease	172	30	47 (28)
Definite pneumonia	208	33	62 (30)
Cor pulmonale	33	6	9 (27)

TABLE 13

ISOLATION OF *CANDIDA ALBICANS* FROM SPUTUM BEFORE AND AFTER CHEMOTHERAPY

When patient examined	Tetracyclines		Sulphonamides		Tetracycline + Nystatin	
	Number of patients examined	Heavy growth of <i>C. albicans</i>	Number of patients examined	Heavy growth of <i>C. albicans</i>	Number of patients examined	Heavy growth of <i>C. albicans</i>
On admission	53	13 24.5 per cent	33	12 36.4 per cent	25	4 16 per cent
3rd-5th day	53	25 47.1 per cent	33	10 30 per cent	25	6 24 per cent
7th-9th day	53	23 43.5 per cent	33	16 48.1 per cent	25	7 28 per cent

disturbances but this was most often co-related with the dose, form and frequency of administration of the antibiotic itself. The diarrhoea which occurred fairly frequently also seemed unlikely to be connected with the presence of fungus for the following reasons:

(a) It arose less frequently when the patient was on a diminished dietary intake. For example, it was less frequently observed in

# FUNGOUS INFECTIONS FOLLOWING ANTIBIOTIC THERAPY

T. ANDERSON\*

STUDIES on *Candida albicans* infection in patients suffering from respiratory infections were carried out before and after antibiotic therapy

The occurrence of *C. albicans* was estimated by rectal, throat and sputum cultures at the time of admission to hospital (Table 11). When the incidence of *C. albicans* in the sputum of various groups of patients was compared (Table 12), it was found that the proportion of patients in the various clinical categories harbouring this organism, even in large numbers, was similar. There was a trend in both sputum and saliva towards a poorer yield of yeasts as the pH rose, but this difference was not within the level of statistical significance.

Administration of antibacterial drugs permitted an overgrowth of fungi<sup>3</sup> which were insusceptible to the action of these agents (Tables 13 and 14). Sulphonamides seemed to be less liable to cause this. After treatment with a tetracycline the proportion of patients giving a heavy growth of *C. albicans* from sputum was almost doubled, and in the faeces the increase was very much greater<sup>4</sup>.

The results left no doubt that after treatment with antibiotics it was comparatively easy to isolate *C. albicans* from sputum or faeces. This ease of isolation did not mean, however, that the fungi were playing a pathogenic role in all cases<sup>1, 2</sup>. In order to study this aspect of the problem, 155 patients were observed during treatment for side-effects (Table 15). A number of patients experienced gastric

TABLE 11

ISOLATION OF *CANDIDA ALBICANS* FROM RECTUM, THROAT AND SPUTUM OF PATIENTS NEWLY ADMITTED TO HOSPITAL

	Rectal swab	Throat swab	Sputum
Total examined	362	291	367
Total showing heavy growth of <i>C. albicans</i>	12	36	119 (32 per cent)

\* With the co-operation of Jessie L. Sharp and A. J. Childs

## FUNGUS INFECTIONS FOLLOWING ANTIBIOTIC THERAPY

(b) the antibiotics were responsible in different degrees. Oxytetracycline, for instance, appeared to be the most common cause, (c) a reduction of the amount or frequency of drug administration diminished the incidence of diarrhoea

Glossitis was often associated with an absence of *C. albicans* and the only side-effect which was in any way related to fungous infection in this series was black tongue. Only one example of urinary infection by *C. albicans* has been seen in an elderly female patient. Among approximately 1,000 patients receiving broad spectrum antibiotics studied mycologically, no example of serious effects attributable to *C. albicans* has been detected.

## REFERENCES

- <sup>1</sup> Childs, A. J. (1956) "Effect of Nystatin on Growth of *Candida albicans* during Antibiotic Therapy" *Brit med J*, 1, 660
- <sup>2</sup> — (1957) "The Effect of Various Drugs on the Growth of *Candida albicans* during Antibiotic Therapy" *Scot med J*, 2, 400
- <sup>3</sup> Sharp, J. L. (1954) "The Growth of *Candida albicans* during Antibiotic Therapy" *Lancet*, 1, 390
- <sup>4</sup> — (1954) "A Clinical Study of Oxytetracycline (Terramycin) with Special Reference to the Growth of *Candida albicans* during Antibiotic Therapy" Thesis for M.D. Glasgow University Library



# FUNGUS INFECTIONS FOLLOWING ANTIBIOTIC THERAPY

TABLE 14

ISOLATION OF *CANDIDA ALBICANS* FROM RECTAL SWABS BEFORE AND AFTER CHEMOTHERAPY

When patient examined	Tetracyclines		Sulphonamides		Tetracycline + Nystatin	
	Number of patients examined	Heavy growth of <i>C. albicans</i>	Number of patients examined	Heavy growth of <i>C. albicans</i>	Number of patients examined	Heavy growth of <i>C. albicans</i>
On admission	110	2 1.8 per cent	69	2 3.1 per cent	25	2 8 per cent
3rd day	110	18 16.4 per cent	69	2 3.1 per cent	25	0
5th day	110	60 54.8 per cent	69	4 6.2 per cent	25	1 4 per cent
7th day	110	62 56.3 per cent	69	10 15.5 per cent	25	0
9th day	110	62 56.3 per cent	69	14 21.9 per cent	25	0

TABLE 15

SIDE-EFFECTS FROM TETRACYCLINES IN RELATION TO THE ISOLATION OF *C. ALBICANS*

Side-effect	Number of persons with side-effects	Results of culture for <i>C. albicans</i>			
		Negative	+	++	Origin
Gastric disturbance nausea, vomiting or epigastric pain	19	3	3	13	Faeces
Diarrhoea	44	3	8	33	Faeces
Atrophic glossitis	16	9	3	4	Throat
Black tongue	7	0	2	5	Tongue
Ano-rectal syndrome	4	1	2	1	Anus

Total persons included in this study 155

pneumonia patients who at the early stage of treatment were on a fluid diet than in healthy patients on a normal diet, yet in both groups the frequency of isolation of *C. albicans* was similar,

## CLINICAL PICTURE

innumerable hospitals of otherwise good standing, rubber gloves are regarded as a protection only for the gynaecologist and not for the patient, so that the same pair are worn throughout a whole clinic without changing and boiling between cases.

## AETIOLOGY

Pregnancy as an aetiological factor has already been mentioned. This is thought to be due, in part at least, to the very highly acid state of the vagina in pregnancy. Glycosuria also provides a very favourable environment for *C. albicans*. It is difficult, however, fairly to compare the incidence in the pregnant and the non-pregnant state since obstetrical and gynaecological patients do not as a rule attend the same clinic. The carrier state has already been mentioned and it is suggested that some fresh local event or complication is necessary to induce pathogenicity. Infection may be subpreputial in the male and introduced thus, or the anus may provide another source of infection, but it is doubtful if the patient can become clinically infected simply by direct inoculation without an accompanying alteration in local circumstances such as the effects of trauma, the presence of glycosuria or the local effects of pregnancy.

A new source of mischief, namely the wide spectrum antibiotics, now requires consideration. Stewart<sup>8</sup>, for example, found that oral tetracyclines are particularly likely to encourage a *C. albicans* infection in throat and sputum. Fortunately this problem does not occur to any extent in the field of gynaecology, partly because, with the exception of pelvic tuberculosis, surgeons on the whole prefer to treat chronic pelvic infections by surgery rather than by a prolonged course of antibiotics.

## CLINICAL PICTURE

Whether the patient is pregnant or diabetic, or neither, pruritus vulvae with superadded soreness is common to all clinically infected cases. Discharge is present in the vast majority but is less universal than pruritus, which is the dominant symptom. These symptoms can reduce the sufferer to a state of sleepless misery in which she is driven to adopt almost ritual methods of "expurgation", going from one antiseptic to the next. The clinical picture is often confused by local eczema which is the result of injudicious treatment. The infection can spread to the male partner, though usually in a very mild form, in the shape of a transient scrotal dermatitis. In all these cases specimens of vaginal discharge are taken for smear and culture

## VULVO-VAGINAL MONILIASIS

IAN DONALD

As a clinical problem vulvo-vaginal moniliasis has been with us in gynaecology for a long time, although in recent years it has come to be regarded as a minor entity. This is because vaginal discharges are nowadays investigated and the greater use now made of laboratory methods.

As a complication of pregnancy or of diabetes mellitus, infection of the vagina with *Candida albicans* has long been recognized. For instance, Liston and Cruickshank<sup>6</sup> recorded that 49 out of 200 cases of leucorrhoea in pregnancy were due to this fungus, and figures today would probably be higher. It is less generally recognized that monilial infections still account for a significant number of cases of vaginal discharge in the absence both of pregnancy and glycosuria. In 1952 a review of 585 cases of vaginal discharge at the Chelsea Hospital for Women showed the incidence of *C. albicans* to be 16.2 per cent, a surprisingly high figure<sup>4</sup>. Diagnosis in all these cases was established microscopically and only 6 of the 96 cases in this series were in fact pregnant. Out of 478 cases enrolled in the Leucorrhoea Clinic at the Western Infirmary, Glasgow, 36 cases have been proved due to *C. albicans* by smear and culture, an incidence of 7.5 per cent. Of these approximately half have glycosuria and none is pregnant.

Proper laboratory investigation undoubtedly yields high figures of incidence since a clinically latent infection without symptoms is quite common; for example, Dawkins, Edwards and Riddell<sup>3</sup> investigating 500 cases attending a Family Planning Centre found yeasts in no less than 57, of which 38 were due to *C. albicans* and the remaining 19 to 5 other species. Only 6 of the patients had clinical signs of infection and all of these were *Candida* cases.

It is certainly true that sufferers from this infection frequently enjoy symptomatic remissions while still showing positive cultures. This raises the possibility of a carrier state and emphasizes the need for a scrupulous technique in vaginal examination to avoid the possibility of transference of infection, which is even more readily perpetrated in the case of *Trichomonas vaginalis*. Unfortunately, in

## TREATMENT

examination and a note is also made of the pus/squame ratio, which often gives a better quantitative index of the clinical state than the bacteriological findings. Cultures are made on Nickerson's medium (Ortho) and incubated at room temperature for 5 days. *Candida* colonies appear brown or black in colour and this diagnostic aid should be of great use to practitioners who are removed from full bacteriological services. Considering the ease with which these cases can now be treated a readily made diagnosis is very important. The discharge itself is not by any means always copious and can often be recognized by one or two forms: the curdy type, which may be likened to damp bread, and the more glairy type, which is usually more profuse. The vagina may be considerably reddened and the vulva inflamed, excoriated, oedematous and eczematized. The skin changes often spread backwards around the anus. Where profound and chronic skin changes are present leukoplakia enters into the differential diagnosis. Any doubt on this matter justifies biopsy, bearing in mind the very appreciable risk of malignant change.

## TREATMENT

Many treatments have in the past aggravated the condition and produced sensitization phenomena, so that the last state of the patient was made worse than the first. The only reliable treatment was with aqueous gentian violet ( $\frac{1}{2}$ –1 per cent) and even this was frequently prescribed in too great a strength, so that a type of burn, sometimes severe, resulted. Painting out the vagina with this dye every day or two was more or less effective but relapses were common. The dye cannot be kept off underclothing and bed linen in spite of extravagant precautions and at every turn is likely to be a most demoralizing reminder to the patient of her complaint. The pregnant cases fared best of all since, though their misery was often intractable, they nearly always rapidly got better after delivery.

It is essential to test for glycosuria and to treat all cases of diabetes energetically. Relapses of moniliasis in diabetics are nearly always associated with recurrences of glycosuria due to inadequate control.

The general principles of treatment have lost none of their importance. The really acute case requires admission to hospital, where not the least benefit is that the patient is thereby denied access to soap and water and so-called harmless antiseptics, all of which aggravate the local skin condition. Local cleansing can more safely and satisfactorily be carried out with olive oil.

The advent of Nystatin (derived from *Streptomyces noursei*) has

## VULVO-VAGINAL MONILIASIS




FIG 65 —*C. albicans* in vaginal smear showing yeast cells and mycelial forms  
( $\times 1000$  Stained Gram)




FIG 66 —Degenerate filamentous structures of *C. albicans* in vaginal smear  
( $\times 1000$  Stained Gram)

## TREATMENT

The cases which failed to improve fared no better with oral tablets of Nystatin (500,000 units) given for 5 days in a dosage of 2 tablets twice a day; a second course of local Nystatin was found highly effective, however, provided that any recurrent glycosuria in diabetic cases was dealt with at the same time.

The place of surgery in the treatment of really resistant cases must still be mentioned. There is no doubt that continuing associated pelvic pathology, for example, an infected cervix with cervical erosion, can encourage persistence or recurrence of monilial infection. In such cases surgical measures are indicated. Diathermy coagulation of the endocervix is a most valuable therapeutic measure in eliminating this source of reinfection.

## ACKNOWLEDGEMENTS

The figures quoted above are given by courtesy of Dr Wallace Barr, in charge of the Leucorrhoea Clinic of the Western Infirmary, Glasgow, and the illustrations are provided by Dr I. W. Lominski.

## REFERENCES

- <sup>1</sup> Barr, W (1957) "Current Therapeutics—Nystatin" *Practitioner*, 178, 616
- <sup>2</sup> Childs, A. J (1956) "Effect of Nystatin on Growth of *Candida albicans*" *British Medical Journal*, 1, 100
- W (1953) "Yeasts in the Vagina" *Lancet*, 2, 1230
- of Vaginal Discharge"
- <sup>5</sup> Jennison, F. R., and Llywelyn-Jones, J. D (1957) "Treatment of Monilial Vaginitis: Clinical Trial of Nystatin" *Brit med J*, 1, 145
- <sup>6</sup> Liston, W. G., and Cruickshank, L. G (1940) "Leucorrhoea in Pregnancy: Study of 200 Cases" *J Obstet Gynaec, Brit Emp*, 47, 109
- <sup>7</sup> Stallworthy, J (1956) "'Nystatin' ('Mycostatin')" *Brit med J*, 1, 858
- <sup>8</sup> Stewart, G. T (1956) "Laboratory and Clinical Studies with Nystatin in Post-antibiotic Mycotic Infections" *Brit med J*, 1, 658

## VULVO-VAGINAL MONILIASIS

come as a very great therapeutic advance in this disease. Fortunately, this antibiotic does not appear to have any influence upon the natural flora of the vagina. Reports in this country by Stewart<sup>8</sup> and Childs in Glasgow<sup>2</sup> on the use of Nystatin in infections of the upper respiratory tract were soon followed by impressive accounts of its use locally in the vagina<sup>7, 5, 1</sup>. Symptoms were often relieved after the first day of treatment and results were, in general, better than those obtained in a control series treated with 1 per cent aqueous gentian violet. There were no side effects due to Nystatin. A week's course of treatment with pessaries containing 100,000 units of Nystatin is recommended; in 92 per cent of cases complete relief is initially obtained, often within a few hours. After a week's rest from treatment, further cultures are taken in order to detect the relapsing cases. Tables 16, 17, and 18 show the results of treatment with Nystatin in the three groups: (1) pregnant; (2) non-pregnant and without glycosuria; (3) diabetic.

TABLE 16  
PREGNANT SUBJECTS WITH MONILIASIS TREATED  
WITH NYSTATIN

No. of cases	76
No. with glycosuria (2 diabetics)	14
<i>Effect of treatment</i>	
Complete cure (bacteriological and symptomatic)	64 (84%)
Failure bacteriologically (but 5 symptomatic cures)	12
Relapse	10

TABLE 17  
NON-PREGNANT SUBJECTS WITHOUT GLYCOSURIA SUFFERING  
FROM MONILIASIS AND TREATED WITH NYSTATIN

No. of cases	18
<i>Effect of treatment</i>	
Complete cure	13
Symptomatic cure	1
Relapse	4

TABLE 18  
DIABETIC SUBJECTS WITH MONILIASIS TREATED WITH  
NYSTATIN

No. of cases	16
<i>Effect of treatment</i>	
Cured	12
Failure (2 with leukoplakia)	4

## TREATMENT

The cases which failed to improve fared no better with oral tablets of Nystatin (500,000 units) given for 5 days in a dosage of 2 tablets twice a day; a second course of local Nystatin was found highly effective, however, provided that any recurrent glycosuria in diabetic cases was dealt with at the same time.

The place of surgery in the treatment of really resistant cases must still be mentioned. There is no doubt that continuing associated pelvic pathology, for example, an infected cervix with cervical erosion, can encourage persistence or recurrence of monilial infection. In such cases surgical measures are indicated. Diathermy conisation of the endocervix is a most valuable therapeutic measure in eliminating this source of reinfection.

## ACKNOWLEDGEMENTS

The figures quoted above are given by courtesy of Dr. Wallace Barr, in charge of the Leucorrhoea Clinic of the Western Infirmary, Glasgow, and the illustrations are provided by Dr. I. W. Lominski.

## REFERENCES

- <sup>1</sup> Barr, W. (1957) "Current Therapeutics—Nystatin" *Practitioner*, 178, 616.
- <sup>2</sup> Childs, A. J. (1956) "Effect of Nystatin on Growth of *Candida albicans* During Antibiotic Therapy" *Brit med J.*, 1, 660
- <sup>3</sup> Dawkins, S. M., Edwards, J. M. B., and Riddell, R. W. (1953) "Yeasts in the Vaginal Flora: their Incidence and Importance" *Lancet*, 2, 1230
- <sup>4</sup> Donald, I. (1952) "Aetiology and Investigation of Vaginal Discharge" *Brit med J.*, 2, 1223
- <sup>5</sup> Jennison, F. R., and Llywelyn-Jones, J. D. (1957) "Treatment of Monilial Vaginitis: Clinical Trial of Nystatin" *Brit med J.*, 1, 145
- <sup>6</sup> Lominski, I. W. (1957) "Monilial Vaginitis in Pregnancy" *Brit med J.*, 1, 858
- <sup>7</sup> Lominski, I. W. (1957) "Monilial Vaginitis: Nystatin in



## CANDIDA ALBICANS IN VAGINAL SECRETIONS IN PREGNANCY

SYLVIA M. DAWKINS, JOAN M. B. EDWARDS AND  
YVONNE M. CLAYTON

VARIOUS observers have reported that yeasts, particularly *Candida albicans*, occur more frequently in the vagina during pregnancy than at other times<sup>3,9</sup>. Liston and Cruickshank<sup>6</sup> concluded that the incidence of moniliasis was greatest in the later stages of pregnancy, and Bland, Rakoff and Pincus<sup>2</sup> noted that infection by *C. albicans* was more readily established in the vagina during pregnancy. The raised glycogen content of the vaginal epithelium rather than greater acidity of secretions has been held mainly responsible for this increase in susceptibility<sup>4</sup>. After parturition, yeasts disappear for a time from the vagina<sup>7,8</sup> and it has been estimated that less than 10 per cent of infected pregnant women suffer from clinical recurrence of moniliasis during the post-natal period<sup>1</sup>.

### ANTE-NATAL AND POST-NATAL INVESTIGATION

Since no detailed investigation of yeast infections in pregnancy had been made in Britain, it was decided to carry out such a study in the Obstetric Unit of University College Hospital, London. This was similar in plan and conduct to the survey of non-pregnant patients attending four family-planning clinics reported by Dawkins, Edwards and Riddell in 1953<sup>5</sup>.

The first 3 or 4 patients attending the ante-natal clinic each week for examination at the sixteenth week of pregnancy were included in the investigation until a total of 250 was registered. Subsequently, as many of these patients as possible were followed up at approximately the twenty-eighth and thirty-sixth weeks of pregnancy and the eighth or tenth day post-natally. Swabs were also taken from babies' mouths. One medically qualified person was responsible for the great majority of the clinical observations and for taking specimens; deputies played only a very small role. Post-natal and babies' mouth swabs were taken by ward sisters. Clinical data were entered on a record card allotted to each patient, and culture results were recorded quite separately in order to avoid observer

# CANDIDA ALBICANS IN VAGINAL SECRETIONS

bias Age, parity and past clinical history were recorded. The result of routine examination for sugar in the urine was noted; diabetics were excluded from the investigation

As in the previous survey, it was necessary to pose a direct question about pruritus since patients show a reluctance to volunteer information upon this symptom unless it is distressing, possibly because many associate itching with lack of cleanliness. This reluctance is perhaps less explicable during pregnancy when greater attention tends to be paid to untoward symptoms. Care was taken that patients did not confuse soreness, burning sensation or frequency of micturition with pruritus vulvae; other symptoms, including pruritus ani, were also noted

Methods of examination.—At each stage examination consisted of inspection of the vulva and swabbing of the lower vagina and of the vaginal pool for culture purposes Sabouraud's dextrose agar and penicillin-streptomycin blood agar plates were inoculated on the same day as swabs were taken. Each plate was incubated for 48 hours at 37° C and the species and amount of any yeasts grown were recorded as in the previous survey. Only at 16 weeks was a speculum passed so that a note could be made of the condition of the vagina and cervix. Unfortunately, a number of patients were lost to the survey from various causes, such as premature birth, admission to hospital for various reasons, miscarriage, and change of day of attendance and address Of the 250 patients registered, 217 were examined at all three stages of pregnancy.

TABLE 19

OCCURRENCE OF YEAST-LIKE FUNGI IN VULVAL AND VAGINAL SWABS AT SOME STAGE OF PREGNANCY

<i>Yeast species isolated</i>	<i>Number of patients</i>
<i>Candida albicans</i>	50 (20 per cent)
<i>C. guilliermondi</i>	3
<i>C. tropicalis</i>	1
<i>C. pseudotropicalis</i>	1
<i>Torulopsis glabrata</i>	11 (4.4 per cent)
<i>Rhodotorula</i> sp	3
<i>Pullularia</i> sp	1
<i>Sporobolomyces</i> sp	1
Unclassified	4
Total for all yeasts	75 (30 per cent)

# CANDIDA ALBICANS IN VAGINAL SECRETIONS

TABLE 20  
CULTURE RESULTS AT 16, 28 AND 36 WEEKS OF PREGNANCY AND POST-NATAL

Stage of pregnancy	Number of patients	Yeasts cultured		
		<i>Candida albicans</i>	Other	Nil
16 weeks	250	29* (11.6 per cent)	15	206
28 weeks	232	36* (15.5 per cent)	16	180
36 weeks	226	35 (15.5 per cent)	10	181
Post-natal	194	6 (3.1 per cent)	3	185

\* One patient with thrush

TABLE 21  
CANDIDA ALBICANS ISOLATIONS IN PATIENTS CULTURED ON ALL THREE OCCASIONS (16, 28 AND 36 WEEKS)

16 weeks	28 weeks	36 weeks
		18+ (3 treated)
	21+ (4 treated)	3- (2 treated)
27+	6- (2 treated)	1+ 5-
	12+	10+ 2-
190-	178- (1 treated)	5+ 173- (1 treated)
Totals	27+ 190- 217	33+ 184- 217

+ = *C. albicans* grown  
- = *C. albicans* not grown

Culture statistics.—In the previous survey of non-pregnant subjects, yeasts were cultured from 57 of 500 (11 per cent) of them, 38 subjects (7 per cent) harbouring *C. albicans* and the remainder at least 5 other yeast species. Six cases of clinically recognizable thrush were recorded, and smears and cultures from these patients

## CANDIDA ALBICANS IN VAGINAL SECRETIONS

were all positive for *C. albicans*. Patients with severe pruritus, vulvitis, vaginitis, or profuse and curdy discharge harboured *C. albicans* significantly more often than those without these symptoms and signs

Of the 250 pregnant subjects examined in this later survey, yeasts were cultured from 75 patients (30 per cent) at some time or another during their pregnancy; 50 (20 per cent) of these had *C. albicans* in their secretions (Table 19). Two patients developed frank thrush. The incidence of *C. albicans* did not differ significantly at 16 weeks (11.6 per cent) from that at 28 or 36 weeks (15.5 per cent), but it was reduced at the post-natal examination (3.1 per cent) (Table 20). The incidence of other yeasts in the vaginal flora was similarly relatively unaffected by the stage of pregnancy, though the post-natal reduction is not as marked as for *C. albicans*. While the likelihood of obtaining a positive culture of *C. albicans* from this group remained at the same level throughout pregnancy there was some interchange of status in individual patients (Table 21). Of 217 patients followed to 36 weeks, only 18 (8.3 per cent) were positive for *C. albicans* on all three occasions, that is, at 16, 28 and 36 weeks, and 173 (79.7 per cent) were negative on all occasions. Of the remaining 26 patients (12 per cent of the total), 12 were culture positive on one occasion and 14 on two occasions. So few patients received specific antifungal treatment that it is considered unlikely that such treatment significantly influenced conclusions. Parity did not effect either the incidence of *C. albicans* or of other yeasts in the vaginal secretions.

*C. albicans* was grown from all patients with severe pruritus, and for severe and moderate pruritus cases taken together the incidence rates at 16, 28 and 36 weeks were 35, 58 and 42 per cent respectively, compared with 7, 10 and 12 per cent for comparable examinations in patients without or with only mild pruritus (Table 22). Such differences are statistically significant. The incidence of yeasts other than *C. albicans* was lower, not higher, in patients with pruritus, but the differences are not significant. Similarly, *C. albicans* occurred with greater frequency (33 per cent compared with 9 per cent) in the patients with severe or moderate vaginitis as assessed at 16 weeks (Table 23), but the occurrence of this yeast was not positively related to the presence of cervicitis (12.3 per cent in patients with cervicitis compared with 11.4 per cent in those without) (Table 24). The incidence of other yeasts did not differ significantly in these groups. Comparable to what was found for vaginitis, the incidence of *C. albicans* in cases of severe or moderate vulvitis was 24, 25 and 24 per cent at the 3 examination times compared with 10, 12 and 11 per cent in cases without or with only mild vulvitis.

# CANDIDA ALBICANS IN VAGINAL SECRETIONS

TABLE 22  
CULTURE RESULTS IN PATIENTS WITH PRURITUS VULVAE AT  
DIFFERENT STAGES OF PREGNANCY

	<i>Pruritus</i>	<i>Number of patients</i>	<i>Yeasts cultured</i>		
			<i>Candida albicans</i>	<i>Other</i>	<i>Nil</i>
16 weeks	Severe and moderate	40	14 (35 per cent)	1	25
	Mild or nil	210	15 (7 per cent)	14	181
	Totals	250	29	15	206
28 weeks	Severe and moderate	26	15 (58 per cent)	0	11
	Mild or nil	206	21 (10 per cent)	16	169
	Totals	232	36	16	180
36 weeks	Severe and moderate	26	11 (42 per cent)	0	15
	Mild or nil	200	24 (12 per cent)	10	166
	Totals	226	35	10	181

TABLE 23  
CULTURE RESULTS IN PATIENTS WITH VAGINITIS AT 16 WEEKS

<i>Vaginitis</i>	<i>Number of patients</i>	<i>Yeasts cultured</i>		
		<i>Candida albicans</i>	<i>Other</i>	<i>Nil</i>
Severe and moderate	30	10 (33 per cent)	0	20
Mild or nil	220	19 (9 per cent)	15	186
Totals	250	29	15	206

TABLE 24  
CULTURE RESULTS IN PATIENTS WITH CERVICITIS AT 16 WEEKS

<i>Cervicitis</i>	<i>Number of patients</i>	<i>Yeasts cultured</i>		
		<i>Candida albicans</i>	<i>Other</i>	<i>Nil</i>
Present	65	8 (12 per cent)	5	52
Absent	185	21 (11 per cent)	10	154
Totals	250	29	15	206

# CANDIDA ALBICANS IN VAGINAL SECRETIONS

TABLE 25

CULTURE RESULTS IN PATIENTS WITH VULVITIS AT DIFFERENT STAGES OF PREGNANCY

	Vulvitis	Number of patients	Yeasts cultured		
			<i>Candida albicans</i>	Other	Nil
16 weeks	Severe and moderate	33	8 (24 per cent)	1	24
	Mild or nil	217	21 (10 per cent)	14	182
	Totals	250	29	15	206
28 weeks	Severe and moderate	63	16 (25 per cent)	5	42
	Mild or nil	169	20 (12 per cent)	11	138
	Totals	232	36	16	180
36 weeks	Severe and moderate	76	19 (25 per cent)	5	52
	Mild or nil	150	16 (11 per cent)	5	129
	Totals	226	35	10	181

(Table 25); these differences are again significant, but are not so for other yeasts. In patients with curdy vaginal discharge the incidence rates of *C. albicans* at the 3 stages were 31, 59 and 38 per cent compared with 9, 12 and 13 per cent without this type of discharge. In patients with profuse vaginal discharge the incidence of *C. albicans* at the 3 stages were 11, 16 and 14 per cent compared with 12, 15 and 16 per cent for those without profuse discharge (Table 26). These rates could hardly be closer and this deviation from the conclusions reached in the survey of non-pregnant patients might be explained by excessive secretions during pregnancy masking any differences which may be associated with infection.

The number of patients found to have glycosuria was too small to justify valid conclusions being made upon the incidence of yeasts, in this group *C. albicans* was present in 33, 12 and 24 per cent of these few patients at the 3 examination times compared with 11, 16 and 15 per cent in subjects without glycosuria.

Mouth swabs from babies born of the first 100 patients were taken within 48 hours of birth, and the remainder between the sixth and thirteenth days. Of 201 mouth cultures, only 1 was positive by culture for *C. albicans*, vaginal cultures from the mother of this baby were also positive at the sixteenth, twenty-eighth and thirty-sixth weeks but were negative post-natally.

# CANDIDA ALBICANS IN VAGINAL SECRETIONS

TABLE 26

CULTURE RESULTS IN PATIENTS WITH PROFUSE VAGINAL DISCHARGE AT DIFFERENT STAGES OF PREGNANCY

	Discharge	Number of patients	Yeasts cultured		
			<i>Candida albicans</i>	Others	Nil
16 weeks	Profuse	80	9 (11 per cent)	4	67
	Not profuse	170	20 (12 per cent)	11	139
	Totals	250	29	15	206
28 weeks	Profuse	69	11 (16 per cent)	4	54
	Not profuse	163	25 (15 per cent)	12	126
	Totals	232	36	16	180
36 weeks	Profuse	70	10 (14 per cent)	2	58
	Not profuse	156	25 (16 per cent)	8	123
	Totals	226	35	10	181

**Conclusions.**—There seems little doubt that pregnancy creates conditions of increased vaginal susceptibility to colonization by *C. albicans* in particular and by other yeasts in general. The two surveys in which non-pregnant and pregnant states were compared were, however, carried out in different populations and over different periods in time. The incidence of *C. albicans* in the vagina did not increase significantly as pregnancy advanced but a dramatic fall in incidence occurred post-partum. Mouth cultures from babies born of these subjects, including those repeatedly shown to harbour *C. albicans* in the vagina during pregnancy, were with one exception negative for fungi on culture. There is no reason to believe that the very low incidence of *C. albicans* isolated from vaginal swabs taken post-partum, and also from babies' mouth swabs, was due to the delay in culture resulting from sending them through the post.

The same positive relationship between the incidence of *C. albicans* and severe and moderate pruritus and vulvitis, and also curdy discharge, was noted for these pregnant patients as was found in the non-pregnant group, again no such relationship existed for cervicitis. The one contradiction occurred in connexion with profuse vaginal discharge in the previous paper a significant (though only slight) increase in incidence of *C. albicans* occurred in patients with this sign, but the observation was not confirmed in this more recent investigation in pregnancy. The possible reason for this has been given.

# CANDIDA ALBICANS IN VAGINAL SECRETIONS

## ACKNOWLEDGEMENT

The statistical advice of Mr. B Benjamin of the General Register Office is acknowledged with gratitude

## REFERENCES

- <sup>1</sup> Bernstine, J B, and Rakoff, A. E. (1953) *Vaginal Infections, Infestations, and Discharges* Chap 20 Toronto; Blakiston
- <sup>2</sup> Bland, P. B, Rakoff, A. E., and Pincus, I. J. (1937) "Experimental Vaginal Moniliasis and Cutaneous Moniliasis a Clinical and Laboratory Study of Certain Monilias associated with Vaginal, Oral and Cutaneous Thrush" *Arch Derm Syph, Chicago*, 36, 760
- <sup>3</sup> Carter, B, Jones, C P, Ross, R A, and Thomas, W L (1940) "Vulvo-vaginal Mycoses in Pregnancy" *Amer J Obstet Gynec*, 39, 213.
- <sup>4</sup> Davis, M E, and Pearl, S (1938) "Biology of the Human Vagina in Pregnancy" *Amer. J Obstet Gynec*, 35, 77.
- <sup>5</sup> Dawkins, Sylvia M, Edwards, Joan M B, and Riddell, R W (1953) "Yeasts in the Vaginal Flora: Their Incidence and Importance" *Lancet*, 2, 1230
- <sup>6</sup> Liston, W G, and Cruickshank, L G (1940) "On Thrush with Special Reference to Vaginal Thrush" *Edin med J*, 47, 369
- <sup>7</sup> Rauramo, L (1950) "Some Observations on Vaginal Mycosis" *Acta obstet gynec scand*, 30, Suppl 7, 484
- <sup>8</sup> Waters, E G, and Cartwright, E. W (1939) "The Significance of Vulvo-vaginitis in Pregnancy." *J Amer med Ass*, 113, 30
- <sup>9</sup> Weinstein, L., and Wickerham, L J (1938) "The Yeast-like Fungi of the Human Vagina" *Yale J Biol Med*, 10, 553



## SKIN MONILIASIS IN INFANTS

J. P. BOUND

SKIN MONILIASIS is common in infancy, but is usually confined to the napkin area. In a recent investigation it was found that at least 3 per cent of the babies born in a London obstetric hospital had been affected by the age of 6 months. Other body flexures may be involved, and rarely the rash becomes widespread. Infection of the nails also seems to be rare in infancy.

The following description of monilial napkin rashes is based on the appearance in 42 cases found in 1 year among infants born in the Obstetric Hospital or attending the Infant Welfare Department of University College Hospital, London. In all cases cultures were made for the presence of *Candida albicans* in swabs from the lesions, it being shown that it could not be grown from swabs of other types of napkin rash or from the napkin area of healthy babies. The yeast was identified as *C. albicans* in 39 of the 42 cases. In infants with oral thrush but no napkin rash *Candida* could be grown from the perianal skin in about half the cases, but it should be noted that less than one-third of the babies with a monilial napkin rash had oral lesions.

The appearance of a monilial napkin rash is typical. The common sites to be affected are the buttocks and inner thighs, most cases have lesions in both areas. The genitalia and lower abdomen may also be involved and sometimes these parts, or the inner thighs, are affected while the buttocks remain clear. The early lesions consist of dull red areas which often coalesce, except peripherally. Desquamation often occurs, usually after the formation of flat, superficial vesicles. In isolated lesions the peripheral part of the thin white epithelium frequently remains behind as a collar, producing an appearance characteristic of skin moniliasis. Sometimes the condition begins as an intertriginous lesion of the groins, but the presence of white, macerated epithelium is diagnostic. This is the usual form taken by the rash in other body flexures, but occasionally the dry, desquamating, dull red rash is seen at these sites.

Without specific treatment monilial napkin rashes usually persist for many weeks. Not uncommonly the true nature of the eruption is unrecognized and it is attributed to a low standard of maternal care.

## SKIN MONILIASIS IN INFANTS

It will be clear from the foregoing description that monilial infection is readily distinguishable from two other common napkin rashes, namely, excoriated buttocks and ammonia dermatitis. Seborrhoeic dermatitis in the napkin area may resemble moniliasis, but desquamating white epithelium is not seen and there are typical lesions elsewhere. However, seborrhoeic dermatitis seems to predispose to monilial infection and it is advisable to look for the organism in all cases with involvement of the buttocks.

In the series of cases already mentioned, two factors that might be expected to play an important part in the aetiology of monilial napkin rashes were investigated. These were maternal thrush vaginitis and previous antibiotic therapy in the infants.

### THRUSH VAGINITIS

It was found that there was a significantly increased incidence of thrush vaginitis in the mothers of babies born in the hospital and who subsequently developed a monilial napkin rash compared with a sample of mothers delivered in the same year. *Twenty-seven per cent of mothers of babies with napkin rash had thrush vaginitis, and others may have had an asymptomatic infection. These findings, together with the fact that nearly half the infants developed rashes at home and the fact that less than one-third of them had oral thrush, suggested that the infection was often transferred to the infant's skin by the mother's hands when the napkin was changed. Monilial rashes occur chiefly in the first 6 weeks of life (in 85 per cent of cases) when the skin is sensitive and liable to irritation, particularly in the napkin area, and therefore likely to present conditions which permit C. albicans to thrive.*

### PREVIOUS ANTIBIOTIC THERAPY

The incidence of previous antibiotic therapy was not significantly greater in babies with monilial napkin rash compared with other babies born in the hospital, and only in 3 did rashes appear within 1 week of such therapy. It appears, therefore, that antibiotic therapy plays little part in the aetiology, although it may be a precipitating factor in a few cases.

### TREATMENT

Treatment by painting the skin with 1 per cent aqueous solution of gentian violet is satisfactory but has obvious disadvantages. The majority of cases were treated by the application of 0.1 per cent aqueous solution of merthiolate followed by a protective paste of titanium dioxide each time the napkin was changed. This method

## SKIN MONILIASIS IN INFANTS

does not stain the infant's clothes, and mothers carried it out effectively. The rash cleared up in 1 to 6 weeks, the average time being about 2 weeks. Recurrences were seen in 16 per cent of cases from 2 to 10 weeks after the first rash had cleared. They quickly responded to further treatment. One infant had two more recurrences before he was a year old. Nystatin ointment was used in a few cases; it cleared the rash effectively, but experience was too small to say if it has any advantage over the other method of treatment.

Skin moniliasis is common in infancy and should always be considered in the diagnosis of napkin rashes. Recognition is usually easy, but less than one-third have associated oral thrush. Treatment is simple and effective. Maternal thrush vaginitis is an important aetiological factor.

# INFANTILE MONILIASIS

## MORBID ANATOMY

MARTIN BODIAN

### CANDIDA INFECTION IN THE NEWBORN

In a recent review from New York (Taschdjian and Kozinn,<sup>1</sup> 1957) nearly 4 per cent of over 2,000 newborn infants had *Candida* (*Monilia*) in their mouths and practically all of these developed clinical thrush infection. *Candida* was found invariably in the stools of those who carried the organism in their mouths, and more than 50 per cent of these cases had cutaneous moniliasis in the perianal and diaper area. The autopsy findings of 7 cases investigated at The Hospital for Sick Children, Great Ormond Street, London, will be described to illustrate various aspects of *Candida* infections. In the newborn this infection is often associated with persistent vomiting which presumably leads to denudation of oesophageal mucosa. The following 4 cases, including 2 in premature infants, are examples.

*Case 1* was born after a gestation period of 32½ weeks and weighed 2 pounds 11 ounces. This was a possible case of Hirschsprung's disease presenting with symptoms of intestinal obstruction. Although a colostomy was carried out, the child did not improve and developed jaundice and bronchopneumonia, and died. At post-mortem examination there was extensive oesophageal and pharyngeal ulceration and bronchopneumonia, but no evidence of Hirschsprung's disease. The oesophagus was the seat of considerable infection with *Candida albicans* (Fig. 67).

*Case 2* presented with high jejunal atresia for which duodeno-jejunostomy was performed. Jaundice, subarachnoid haemorrhage and kernicterus of prematurity followed, and finally death from bronchopneumonia. At autopsy, *C. albicans* was present in areas of mucosal ulceration of the posterior pharyngeal wall, oesophagus and stomach. It was also present in both lungs.

*Case 3* had oesophageal atresia with a tracheo-oesophageal fistula as well as rectal agenesis and a high recto-urethral fistula. Treatment consisted in ligation of both fistulae, colostomy and oesophageal anastomosis. This anastomosis broke down, resulting in mediastinal infection and aspiration pneumonia. Yeasts and pseudomycelium of *C. albicans* were present in bronchioles (Fig. 68) and alveoli.

## INFANTILE MONILIASIS




FIG 67 —*Candida* infection of oesophagus (Case 1)



FIG 68 —Section of lung showing *Candida* infection of bronchioles (Case 3)  
( $\times 225$  Stained periodic acid Schiff and haematoxylin)

## MORBID ANATOMY

Case 4 presented with oral thrush infection and vomiting, and developed bronchopneumonia and died. At autopsy he was found to have bilateral cystic disease of the kidneys. *Candida* infection was found only in the mouth.

None of these newborn infants died as a result of *Candida* infection. Rather does invasion by this organism appear to be an index of debility particularly associated with severe congenital malformations and/or prematurity. All the infants described presented with severe persistent vomiting

### CANDIDA INFECTION IN OLDER CHILDREN

of the pancreas. The former cases were particularly those undergoing treatment with anti-metabolites and/or steroids, and the latter those who had received repeated courses of antibiotics or prolonged maintenance treatment with these drugs. This infection was also associated with nephrosis

In leukaemia there is an increased susceptibility to infections, including moniliasis. Antibiotics tend to prolong the life of these debilitated patients but may also increase the opportunity for invasion by *C. albicans*. Extensive ulceration of oropharynx and gastro-intestinal tract and a pseudo-membranous enterocolitis are commonly observed. The extensive membranes are formed of epithelial debris, large colonies of bacteria and sometimes of *Candida* hyphae and spores. These findings are particularly common in cases treated with cortisone

Winter and Foley<sup>2</sup> (1956) reported from the Children's Cancer Research Foundation in Boston that 41 per cent of children with untreated leukaemia and 59 per cent of cases of leukaemia treated with antibiotics and cortisone harboured *Candida*, compared with 15 per cent of a control series of approximately 1,000 children. In cases of fibrocystic disease of the pancreas, the incidence of *Candida* infection was 29 per cent compared with 15 per cent in the controls. There was an incidence of 31 per cent in nephrotic syndrome and of 60 per cent in diabetes mellitus

Case 5 is a case of leukaemia with *Candida* infection in a child aged 7 years with a symptomatic course of 7½ months. Treatment was with blood transfusions, Aminopterin and cortisone, which produced short remissions. At autopsy, there was extensive leukaemic infiltration of

## INFANTILE MONILIASIS



FIG 69 — Multiple gastric ulcers invaded by *Candida* in leukaemia (Case 5)



FIG 70 — Pseudomembranous colitis with *Candida* infection in leukaemia (Case 5)



FIG 71 — Section of ileum in leukaemia showing invasive *Candida* pseudomycelium and ulceration (Case 5) ( $\times 366$  Stained periodic acid Schiff and haematoxylin)

# MORBID ANATOMY



FIG 72.—Thrush oesophagitis (Case 6)



FIG 73 —Thrush proctitis (Case 6)



## INFANTILE MONILIASIS



FIG 69 —Multiple gastric ulcers invaded by *Candida* in leukaemia (Case 5)



FIG 70 —Pseudomembranous colitis with *Candida* infection in leukaemia (Case 5)



FIG 71 —Section of ileum in leukaemia showing invasive *Candida* pseudomycelium and ulceration (Case 5) ( $\times 366$  Stained periodic acid Schiff and haematoxylin)

# INFANTILE MONILIASIS

## PATHOLOGY

I. A B CATHIE

*Candida albicans* cannot be considered as a complete pathogen in children, the normal subject being insusceptible to infection by this yeast. Rather should it be thought of as a facultative pathogen requiring the assistance of some other abnormality or debilitating condition to establish itself as of more than nuisance value.

Many cases of clinical thrush never come to the notice of the clinical pathologist, being either ignored or treated on their merits without bacteriological confirmation. Furthermore, many cases of severe thrush are severe only because of the severity of the precipitating illness which permits moniliasis to become established, so that the major investigative work tends to be focused on the primary condition and not on the thrush. In considering the laboratory records on moniliasis from The Hospital for Sick Children, London, it is important to bear in mind these facts, and also that cases come to this hospital from a wide area, intake from local population and welfare clinics being minimal.

The strains of *Candida* isolated in 1956 at this hospital divide themselves automatically into those from the mouth, including cases of oral thrush, and those from other parts of the body.

### ORAL MONILIASIS

*C. albicans* was recorded in the mouth swabs of 29 babies, 17 of whom suffered from gastro-enteritis. This does not represent the incidence of mouth infection with this yeast, the 29 cases being those in whom the mouth lesion was sufficiently severe to call for investigation. Of the 17 cases of gastro-enteritis, oral moniliasis seems not to have been present on admission in any case but to have developed after a few days in hospital. These patients were all admitted to hospital in the acute phase of their illness with a history of one or two days duration only. It appears that the debilitating effect of acute infection necessary to render the baby a suitable subject for thrush does not take place suddenly, but needs some days for the appropriate conditions to be developed. Four of these babies had *C. albicans* in their stools but the possibility of monilial enterocolitis

## INFANTILE MONILIASIS

lymph nodes, liver, and kidneys. Monilial infection of areas of ulcerative pharyngo-oesophagitis, gastric ulceration (Fig. 69) and membranous enterocolitis, especially in the ileo-caecal region, was present (Figs. 70 and 71).

Case 6 is an example of bronchiectasis with *Candida* infection. This child aged 19 months had been well until pertussis infection and bronchopneumonia occurred at 6 months. Measles followed at 9 months and evidence of bronchiectasis was present from the age of 11 months. Thrush was persistently present in the mouth from 7½ months. Weight deteriorated from 24 pounds at 6 months to 15 pounds at 15 months. There was an extension of thrush to the uvula and epiglottis at this time and laryngeal stridor developed. Tracheotomy was performed but death followed. Post-mortem examination showed moniliasis with ulceration of the mouth, pharynx, larynx, oesophagus (Fig. 72), vulva, rectum (Fig. 73) and anus.

Case 7 exemplifies nephrosis with *Candida* infection. This child of 3 years of age suffered from a throat infection at 17 months and 2 weeks later developed a nephrotic syndrome. Oedema, albuminuria and hyper-cholesterolaemia were present. There were remissions with ACTH and later with cortisone. Urinary infection followed and then a rise in blood pressure and pyrexia prior to death. Autopsy showed nephrosis, acute pancreatitis of an annular pancreas and acute duodenitis. Moniliasis of the oesophagus and stomach was found.

In none of these instances was infection by *C. albicans* thought to have contributed materially to death. It was considered as an index of susceptibility to infection in a debilitated child produced by the leukaemic process, by the presence of abnormally viscid mucous secretions in a medium of high salt concentration in fibrocystic disease of the pancreas, and by other factors in other diseases. We have seen no instance of *Candida* septicaemia of the kind reported in the literature producing granulomatous lesions in various viscera, notably the kidneys and meninges.

## REFERENCES

- 1 Taschdjian, C. L., and Kozinn, P. J. (1957) "Laboratory and Clinical Studies on Candidiasis in the Newborn Infant" *J. Pediat.*, 50, 426
- 2 Winter, W. D., and Foley, G. E. (1956) "*Candida* Infections in Children with Neoplastic Disease. Influence of Therapy with Antibiotics and Steroid Hormones" *Pediatrics*, 18, 595

## TREATMENT

seem to suffer from the defect that they are either toxic or inactive when given systemically, and when administered topically suffer from the drawback that they are difficult to maintain *in situ* long enough to exert their fungicidal action. Local treatment with gentian violet continues to be used and thiomersalate, effective in high dilutions *in vitro*, has frequently been employed topically. Encouraging results have been obtained with pentamidine isethionate administered intravenously, and strains of *C. albicans* so far encountered have all been sensitive to 1.5 microgram per millilitre or less of this agent; in few cases only, however, has moniliasis called for such treatment. Usually, these infections resolve as the underlying disease process is corrected by general measures.

## INFANTILE MONILIASIS

comparable to that seen in the adult was not entertained. It is a matter for speculation whether the development of thrush in these cases of gastro-enteritis was, as is suggested, consequent upon the debilitating effect of the disease, or whether antibiotic therapy was responsible by removing bacterial competitors from the flora of the alimentary tract. The moniliasis, occurring as it did after the acute phase of gastro-enteritis, was more an obstacle to rapid recovery than a cause of clinical deterioration.

### NON-ORAL MONILIASIS

*C. albicans* was found in a variety of situations other than the mouth, including sputa, a mastoid cavity and the skin; there was little experience of thrush of the napkin area but 5 cases of peri-anal dermatitis were associated with *C. albicans*. Compared with adult findings it is of interest that *C. albicans* was not isolated from the 155 vaginal swabs investigated during 1956. One fatal case with generalized moniliasis was encountered, the yeast being grown from the lungs, pleura, peritoneum, gut and from the blood; this occurred in a baby with septicaemia following pneumonia and lung abscess. In a further fatal case, *C. albicans* was cultured from a post-mortem lung swab from a girl with multiple congenital anomalies, *Shigella sonnei* was also isolated but its origin was never elucidated. The various pathological conditions occurring in this patient included rectal agenesis, hydrocephalus, ulcerative colitis, Hirschsprung's disease, agammaglobulinaemia, congenital cystic kidney and nephrosis, any of which would produce a degree of debility sufficient to predispose to moniliasis. No case of moniliasis in this series was primary in nature, or the only disease process present.

The major clinical problem in another instance was generalized *Trichophyton* infection. One child undoubtedly died from pulmonary moniliasis, she was an old case of bronchiectasis in whom antibiotic therapy had removed every susceptible pathogen and commensal. *C. albicans* heavily infected the whole respiratory system and the bronchiectatic cavities, and no treatment was of avail.

### TREATMENT

Only seldom does thrush call for vigorous specific therapy, in severe infection only too often is the site of the moniliasis inaccessible to

the antibacterial antibiotics are of value in the treatment of moniliasis as judged by laboratory experience. Most of the new fungicides

## INFECTIONS DUE TO AEROBIC ACTINOMYCETES

In Table 27 are listed the main infections due to actinomyces. Some of these are systemic infections like actinomycosis, due to *Nocardia asteroides*<sup>13, 14</sup>, and nocardiosis, due to *Nocardia asteroides*. On the other hand, some infections are subcutaneous, the most important of these being the so-called actinomycetomas. Finally, there are cutaneous diseases, such as erythrasma, due to *N. minutus*, and trichonocardiosis axillaris due to *N. tenuis*.

### PATHOGENIC AEROBIC ACTINOMYCETES

Five species of aerobic actinomycetes are important from a clinical point of view, 2 belonging to the genus *Nocardia* (*N. asteroides* and *N. brasiliensis*) and 3 to the genus *Streptomyces* (*S. madurei*, *S. pelletieri*, and *S. somaliensis*).

*N. asteroides* is the main causative agent of systemic aerobic actinomycosis. This may involve numerous organs, the lungs being the most frequent. Pulmonary nocardiosis may simulate tuberculosis and confusion may further arise because *N. asteroides* is partially acid fast and frequently bacillary in form in specimens sent for diagnosis. Though disease may apparently be limited to organs other than the lungs, it is most likely that primary disease is pulmonary in nature. Infection of brain and meninges may give rise to symptoms signs simulating a brain tumour<sup>9, 13</sup>. Systemic nocardiosis is assumed, perhaps incorrectly, to be a rare condition.

*N. asteroides* may also cause subcutaneous disease of the "mycetoma" type. This is generally an infection of the foot or the leg, sometimes of the hand or the arm, which follows a traumatic introduction of the dermis of a pathogenic fungus (causing maduromycetoma) or an actinomycete (causing actinomycetoma). Less frequently the hand may be involved. Actinomycetoma tends to be a chronically slowly progressive infection characterized by multiple subcutaneous abscesses discharging pus containing white or pigmented granules through numerous fistulae. Bones are sometimes involved resulting in progressive osteolytic disease. Any of the 5 species mentioned above may cause this type of infection. Instances of systemic dissemination of disease following subcutaneous infection have been reported. Mycetomas are fairly frequent in all arid, tropical and subtropical areas.<sup>1, 2</sup>

# INFECTIONS DUE TO AEROBIC ACTINOMYCETES

F. MARIAT

ACTINOMYCETES are bacteria producing a filamentous growth of branching hyphae. Despite this fact, the pathogenic actinomycetes and the diseases they cause have received special attention by medical mycologists, so they may properly receive consideration in a symposium on fungous infections. Most of the pathogenic actinomycetes occur in Nature and belong to the soil saprophytic flora. Only the anaerobic species, *Actinomyces israeli*, is a normal inhabitant of the mouth and an obligate parasite.

The filaments of actinomycetes do not exceed 1 micron in diameter, they develop branches which come off at right-angles. Sometimes the hyphae break up into bacillary or coccoid elements. *In vivo*, the filaments may be free in the tissues or become aggregated into granules which may or may not be surrounded by clubs. *In vitro*, most of the actinomycetes can grow aerobically, but *A. israeli* is an anaerobe or micro-aerophile.

On adequate media, the aerobic actinomycetes grow as white or pigmented colonies, the surface of which is more or less wrinkled, glossy, downy or chalky. In culture some pathogenic strains produce filaments which become fragmented into bacillary or coccoid forms (genus *Nocardia*), some species of this genus are partially acid-fast. Other strains of actinomycetes (genus *Streptomyces*) develop a mycelium which does not fragment but which, under certain conditions, produces chains of conidia and sometimes spirals.

TABLE 27  
MAIN INFECTIONS DUE TO ACTINOMYCETES

SYSTEMIC	Actinomycosis Nocardiosis	<i>A. israeli</i> <i>N. asteroides</i> <i>N. brasiliensis</i>	Anaerobic culture
SUBCUTANEOUS	Mycetoma	<i>S. somaliensis</i> <i>S. pelletieri</i> <i>S. madurae</i>	Aerobic culture
CUTANEOUS	Erythrasma Trichonocardiosis	<i>N. minutissima</i> <i>N. tenuis</i>	Culture uncertain (diagnosis by direct examination only)

# INFECTIONS DUE TO AEROBIC ACTINOMYCETES

TABLE 29

CHARACTERISTICS OF CULTURES OF THE MOST IMPORTANT AEROBIC ACTINOMYCETES CAUSING NOCARDIOSIS AND ACTINOMYCETOMIA

	<i>Pu</i> (as)	<i>Pu</i> of				after 10-15 days on dextrose agar	<i>U</i> per <i>U</i>
<i>N. asteroides</i>	+	+	Yellowish-white to orange	Rapid 3-8 days	30-37° C	Smooth, soft, glabrous, irregularly folded (Figs 74b and 75b)	+
<i>N. brasiliensis</i>	+	± → +	Yellowish-ochreous-red	Rapid 3-8 days	30° C approximately	Hard colonies, folded, and often with chalky surface (Fig. 76b)	+ or -
<i>S. somaliensis</i>	-	-	Whitish, then brown or blackish	Rapid	30° C	Flat, wrinkled colonies, glossy and later dull (Fig 77b)	-
<i>S. pelletieri</i>	-	-	Pink-coral red	Slow 8-30 days	37° C	Heaped, glabrous, irregular, hard colonies (Fig 78b)	-
<i>S. madurae</i>	-	-	Whitish to red	Slow 8-20 days	37° C	Usually deeply folded with moist glabrous and waxy surface (Fig 79b)	-

TABLE 30

Species	Utilization of											Hydrolysis of				
	Urea	(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>	(NH <sub>4</sub> ) <sub>2</sub> HPO <sub>4</sub>	NH <sub>4</sub> NO <sub>3</sub>	KNO <sub>3</sub>	Xylose	Levulose	Galactose	Maltose	Starch	Mannitol	Paraffin	Gelatin	Serum	Ovalbumin	Starch
<i>N. asteroides</i>	+	+	+	+	+	-	+	-	-	-	+	-	-	-	-	-
<i>N. brasiliensis</i>	+	+	+	+	+	-	+	+	-	-	+	+	+	-	-	-
<i>S. somaliensis</i>	-	-	-	-	-	-	-	-	+	-	-	-	+	+	+	-
<i>S. pelletieri</i>	+	-	+	-	-	-	-	-	-	-	-	-	+	+	+	-
<i>S. madurae</i>	+	-	+	-	-	+	+	-	-	+	+	-	+	+	-	+



# INFECTIONS DUE TO AEROBIC ACTINOMYCETES

most important single investigation of these cases and one which, unfortunately, is often neglected. The most suitable media for primary isolation are nutrient agar, Sabouraud's dextrose agar, potato glycerol agar and Loewenstein-Jensen egg medium.

The properties of the aerobic actinomycetes causing human disease are summarized in Tables 28, 29 and 30. These concern such features as colonial morphology, staining properties, enzymatic activity, utilization of carbon and nitrogen compounds<sup>8, 11, 12</sup>. Figures 74-79 illustrate the characteristics of these organisms in tissues and in culture.

TABLE 28

MORPHOLOGICAL CHARACTERISTICS OF THE "GRAINS" OF ACTINOMYCETOMA IN PUS OR OTHER PATHOLOGICAL MATERIAL, AND GEOGRAPHIC DISTRIBUTION OF INFECTIONS

Species	Characteristics of the "grains" of actinomycetomas				Geographic distribution of infections
	Colour of "grains" in pus	Clubs	Staining by haematoxylin	Morphology	
<i>N. asteroides</i>	Yellowish-white	Rare	-	Consists of network of filaments, sometimes swollen at ends and frequently fragmented (Figs 74a and 75a)	America, Europe, Asia, Africa
<i>N. brasiliensis</i>	Yellowish	Rare	-	Irregular and variable in size made up of lobules (Fig 76a)	South and Central America, sometimes elsewhere
<i>S. somaliensis</i>	Yellow	Absent	-	Regular (approximately 1 mm diameter) with smooth edges. Composed of filaments embedded in hard cement, slits frequently seen in sections (Fig 77a)	Sudan, Somaliland, Ethiopia, Senegal, Nigeria
<i>S. pelletieri</i>	Red	Absent	+	Small (approximately 500 microns) and numerous. Smooth or denticulate edges. Main grain frequently fragmented in 2 or 3 secondary granules with geometrical shapes (Fig 78a)	Senegal, Nigeria, Brazil, Mexico, South Africa, India, Sudan
<i>S. madurae</i>	Yellowish-white to reddish	Frequent	+	Large "grains" several millimetres in diameter with lobulate edges. Clubs usually long, narrow, and sometimes branched (Fig 79a)	India, Asia, Africa, Europe, America



FIG 76—(a) Section of a mycetoma due to *N brasiliensis*  
(b) Culture of *N brasiliensis*




FIG 77—(a) Section through a "grain" in infection due to *S somaliensis*  
(b) Black colony of *S somaliensis*



FIG 74 —(a) Section showing a granule of *N. asteroides*  
(c) Culture of *N. asteroides*




FIG 75 —(a) Section of brain tissue from a fatal case of cerebral nocardiosis. Numerous delicate, branching, fragmented filaments of *N. asteroides* present. (b) Culture

## INFECTIONS DUE TO AEROBIC ACTINOMYCETES

### TREATMENT

The treatment of these infections is often difficult and surgery often becomes necessary; early diagnosis gives the best prognosis. Sulphonamides are frequently inhibitory to pathogenic species of *Nocardia* and *Streptomyces*. The few successfully treated cases of pulmonary or cerebral nocardiosis received sulphadiazine alone or in association with streptomycin.

When there is an extensive involvement of deep tissues, a mycetoma may have to be removed by amputation of an extremity. In such cases, sulphonamides should be given both pre-operatively and post-operatively, together with antibacterial agents for preventing secondary infection.

Mexican authors report good results in treating mycetomas due to *N. brasiliensis* with 4·4'-diaminodiphenyl sulphone (DDS) as in leprosy<sup>3, 4, 5</sup>. *In vitro*, *S. madurae* seems more susceptible than *N. brasiliensis* to this drug (10 out of 12 strains tested were susceptible to 15 micrograms per millilitre and all of the same 12 strains were susceptible to 30 micrograms per millilitre after a 3 weeks' incubation period)<sup>7</sup>. It would seem possible, therefore, that this sulphone might also be of value in the treatment of mycetomas due to *S. madurae*.

The infrequency with which diseases due to aerobic actinomycetes are diagnosed may be due in part to their being poorly known and therefore infrequently brought to mind in differential diagnosis. As for the true mycoses, increased frequency of identification of diseases is often the result of activity of groups of workers particularly interested in them. A large number of aerobic actinomycetes species have been falsely described as being pathogenic, a fact which may be explained by the relative difficulty of cultural diagnosis owing to their great variability and to the ease with which they may be confused with the more frequently occurring contaminant species.

### REFERENCES

- <sup>1</sup> Abbott, P. (1956) "Mycetoma in the Sudan" *Trans R Soc trop Med Hyg*, 50, 11.
- <sup>2</sup> Camain, R., Segretain, G., and Nazimoff, O. (1957) "Étude histopathologique des mycetomes du Sénégal et de la Mauritanie" *Sem Hôp Paris*, 5, 923.
- <sup>3</sup> Garcia, M. P. (1950) "Sulfonas en el tratamiento del micetoma: estudio de un caso" *Prensa med mex*, 15, 262.
- <sup>4</sup> Gonzales Ochoa, A., Shiels, J., and Vasquez, P. (1952) "Acción de la 4·4-diamino-difenilsulfona frente a *Nocardia brasiliensis* (estudios *in vitro* en la infección experimental y en clínica)" *Gac méd mex*, 82, 345.

# INFECTIONS DUE TO AEROBIC ACTINOMYCETES



FIG 78 —(a) Section of "grain" in a mycetoma due to *S. pelletieri*  
(b) Culture of *S. pelletieri*



FIG 79 —(a) Section of a mycetoma due to *S. madurae*  
(b) Culture of *S. madurae*

## BRONCHO-PULMONARY ASPERGILLOSIS

K. F. W. HINSON

IN the examples of broncho-pulmonary aspergillosis which will be discussed, *Aspergillus fumigatus* was the responsible fungus and was identified on cultural and morphological grounds. Other species have been described as causing the disease such as *A. niger*, *A. versicolor*, *A. nidulans* and *A. flavus* but there is little doubt that in Britain the infecting fungus is usually *A. fumigatus*. Since this is such a common laboratory contaminant, it is important to exclude this possibility especially if the diagnosis is based on cultural findings. Single isolations from sputum should not be stressed and the fungus should be demonstrated repeatedly. The specimen should be collected in a sterile glass jar, not waxed paper cartons, and inoculated on blood agar medium which has been spread with 1:1,000 streptomycin in order to inhibit commensal bacteria, or on Sabouraud's medium. Incubation at 37° C should continue for 48 hours.

It has been recognized for many years that this fungus occurs in infarcted areas of the lungs and it is probable that *A. fumigatus* makes a saprophytic invasion of infarcts in lungs affected by bronchiectasis or pneumoconiosis. An example occurred in a man aged 31 years, a french polisher, who had suffered for many years from bilateral bronchiectasis. Following an intravenous injection he developed thrombosis of an arm vein and died 3 days later from pulmonary embolism. Fig 80 illustrates the proliferation of the mycelium within alveolar spaces, alveolar walls and thrombosed vessels. The fungus forms its fruiting heads within an infarct (Fig 81) and the species may be identified with ease.

**Location and appearance.**—The commonest manifestation of this fungus disease is the mycetoma (Fig 82). Such cases usually give a long history of repeated small haemoptyses over months or years. Radiologically there is a cavity with a solid content which may be mobile. With one exception the mycetomas seen personally have been in the upper lobe; the exception was situated in the apical segment of the lower lobe. The wall of the cavity is almost always lined by epithelium of the respiratory type (Fig 83) and the content is a moist brown crumbling mass of mycelium. Some fibrin is present but there is little inflammatory exudation. The mycelium

## INFECTIONS DUE TO AEROBIC ACTINOMYCETES

- <sup>5</sup> Latapi, F., and Lavallo, P. (1954) *C R 8ème Congr. internat. Bot, Paris, Section 24, p 44*
- <sup>6</sup> Mackinnon, J. E., and Artagaveytia-Allende, R. C. (1956) "The Main Species of Pathogenic Aerobic Actinomycetes causing Mycetomas" *Trans R. Soc. trop Med Hyg.*, 50, 31
- <sup>7</sup> Mariat, F (1957) "Action *in vitro* 4-4-diamino-diphénylsulphone sur les actinomycètes aérobies pathogènes" *C R Acad Sci Paris*, 244, 3095.
- <sup>8</sup> — (1957) "Sur l'utilisation de divers composés carbonés et azotés par *Streptomyces madurae*, *S. pelletieri*, and *S. somaliensis*" *C.R Acad Sci Paris*, 245, 593
- <sup>9</sup> — (1957) "Sur le diagnostic mycologique des principales mycoses du système nerveux central" *Sem Hôp Paris*, 5, 901.
- <sup>10</sup> — (1957) "Les principaux actinomycètes aérobies responsables de mycetomes" *Sem Hôp Paris*, 5, 939
- <sup>11</sup> — (1958) "Physiologie des actinomycètes aérobies pathogènes" *Mycopathologia*, 9, 111.
- <sup>12</sup> — and Lavallo, P. (1955) "Sur l'utilisation de divers composés carbonés et azotés par *Nocardia asteroides* et *N. brasiliensis*" *C.R Acad Sci Paris*, 240, 255
- <sup>13</sup> McQuown, A. L. (1955) "Actinomycosis and Nocardiosis" *Amer J clin Path*, 25, 1
- <sup>14</sup> Prevot, A. R. (1953) *VIIth Internat Congr Bact* "Symposium on the Actinomycetales" Rome

## BRONCHO-PULMONARY ASPERGILLOSIS

K. F. W. HINSON

In the examples of broncho-pulmonary aspergillosis which will be discussed, *Aspergillus fumigatus* was the responsible fungus and was identified on cultural and morphological grounds. Other species have been described as causing the disease such as *A. niger*, *A. versicolor*, *A. nidulans* and *A. flatus* but there is little doubt that in Britain the infecting fungus is usually *A. fumigatus*. Since this is such a common laboratory contaminant, it is important to exclude this possibility especially if the diagnosis is based on cultural findings. Single isolations from sputum should not be stressed and the fungus should be demonstrated repeatedly. The specimen should be collected in a sterile glass jar, not waxed paper cartons, and inoculated on blood agar medium which has been spread with 1:1,000 streptomycin in order to inhibit commensal bacteria, or on Sabouraud's medium. Incubation at 37° C. should continue for 48 hours.

It has been recognized for many years that this fungus occurs in infarcted areas of the lungs and it is probable that *A. fumigatus* makes a saprophytic invasion of infarcts in lungs affected by bronchiectasis or pneumoconiosis. An example occurred in a man aged 31 years, a french polisher, who had suffered for many years from bilateral bronchiectasis. Following an intravenous injection he developed thrombosis of an arm vein and died 3 days later from pulmonary embolism. Fig 80 illustrates the proliferation of the mycelium within alveolar spaces, alveolar walls and thrombosed vessels. The fungus forms its fruiting heads within an infarct (Fig 81) and the species may be identified with ease.

**Location and appearance.**—The commonest manifestation of this fungus disease is the mycetoma (Fig 82). Such cases usually give a long history of repeated small haemoptyses over months or years. Radiologically there is a cavity with a solid content which may be mobile. With one exception the mycetomas seen personally have been in the upper lobe; the exception was situated in the apical segment of the lower lobe. The wall of the cavity is almost always lined by epithelium of the respiratory type (Fig 83) and the content is a moist brown crumbling mass of mycelium. Some fibrin is present but there is little inflammatory exudation. The mycelium



## BRONCHO-PULMONARY ASPERGILLOSIS




FIG 80 —*Aspergillus* mycelium permeating alveolar walls and a thrombosed vessel in a pulmonary infarct (Masson,  $\times 112$ )



FIG 81 —*Aspergillus fumigatus* within lung infarct. hyphae and sporing structures (Masson,  $\times 200$ ) (By courtesy of the Editor, Thorax.)

FIG 82 —Excised segment showing a bronchiectatic cavity 1 inch in diameter containing a mycetoma. There are 2 smaller cysts above (By courtesy of the Editor, Thorax.)



is strikingly outlined by silver impregnation methods (Fig 84). It is unusual for sporing structures to be present in the mycelial mass, but they may occasionally be found in freshly resected specimens.

Mycetomas are associated with other diseases causing slowly progressive pulmonary fibrosis. Several examples in cases of asbestosis have been met with in personal experience. The relationship is obscure as the fibrosis and bronchiectasis in this condition are

## BRONCHO-PULMONARY ASPERGILLOSIS



FIG. 83.—Section of cavity wall and mycelial mass of an aspergillus mycetoma (Haematoxylin and eosin,  $\times 150$ ) (By courtesy of the Editor, *Thorax*)




FIG. 84.—Silver impregnation preparation of section shown in Fig. 83 ( $\times 52$ )

FIG. 85.—Mycetomas in the upper zone of a fibrotic lung following sarcoidosis.



most severe in the lower lobes, yet in each instance the mycetoma was in the upper lobe. In those cases of sarcoidosis which proceed to fibrosis, mycetomas may develop. Fig. 85 shows a whole lung section with 2 such lesions in the upper lobe. Sarcoidosis had been diagnosed on lymph-node biopsy 8 years before death. Cavities

## BRONCHO-PULMONARY ASPERGILLOSIS




FIG 80 —*Aspergillus* mycelium permeating alveolar walls and a thrombosed vessel in a pulmonary infarct (Masson,  $\times 112$ )



FIG 81 —*Aspergillus fumigatus* within lung infarct hyphae and sporing structures (Masson,  $\times 200$ ) (B; courtesy of the Editor, Thorax)

FIG 82 —Excised segment showing a bronchiectatic cavity 1 inch in diameter containing a mycetoma. There are 2 smaller cysts above (B; courtesy of the Editor, Thorax)



is strikingly outlined by silver impregnation methods (Fig. 84). It is unusual for sporing structures to be present in the mycelial mass, but they may occasionally be found in freshly resected specimens.

Mycetomas are associated with other diseases causing slowly progressive pulmonary fibrosis. Several examples in cases of asbestosis have been met with in personal experience. The relationship is obscure as the fibrosis and bronchiectasis in this condition are

## BRONCHO-PULMONARY ASPERGILLOSIS

be slightly bloodstained, and often wheezing which may be severe. There is a blood eosinophilia of 1,000 or more per cubic millimetre. Radiographs show areas of collapse and consolidation.

With each febrile episode the changes may occur in different lobe or on different sides, or even from side to side and back again. Two of these cases were bronchoscoped during such an attack and bronchus was seen to be blocked by a tumour-like mass. Biopsy of this showed mucus and fibrin which contained sparse mycelial elements (Figs 87 and 88). Following this observation sputum




FIG 87—Bronchial biopsy. Inspissated mucus separated by layers of fibrin and some inflammatory cells ( $\times 52$ )



FIG 88—Silver impregnation preparation of section shown in FIG 87 ( $\times 112$ )

cultures were made and the fungus isolated repeatedly. Macroscopically, the sputum from such patients will often contain some brownish flecks which should be selected for inoculation. Occasionally these flecks will be aggregated into plugs which histologically resemble the bronchial biopsy. Once they are expectorated clinical improvement usually follows.

The course of this type of illness is prolonged for several years. One patient died in status asthmaticus and his bronchi were found to be occluded by this same type of allergic exudate.

## REFERENCE


- <sup>1</sup> Hinson, K. F. W., Moon, A. J., and Plummer, N. S. (1952) "Broncho-pulmonary Aspergillosis." *Thorax*, 7, 317.

## BRONCHO-PULMONARY ASPERGILLOSIS

which remain patent after the bacteriologically successful treatment of proven tuberculosis have also been observed to fill with a mass of mycelium.

**Empyemic infection.**—Infection of the pleural space may follow surgical intervention. During a difficult lobectomy a mycetoma ruptured into the pleura. A broncho-pleural fistula and an empyema developed. This was infected by proteus, staphylococci and *A. fumigatus*. At post-mortem examination the glistening wall of the empyema space was studded with sporing colonies of the fungus (Fig 86). Further examples of mixed infective empyemata have

FIG 86—Colonies of *Aspergillus fumigatus* on the wall of an empyema sac



been seen following pneumonectomy. In another case, a lobectomy for long-standing fibrocaceous tuberculosis, broncho-pleural fistulae and empyemata occurred. Staphylococci, *Mycobacterium tuberculosis* and *A. fumigatus* were present in the purulent fluids. When the pleura was excised some months later it was noted that a muscle graft which had been applied to the bronchial stump at the pneumonectomy was permeated by the mycelium. There was some evidence that cross-infection may have been responsible for this unfortunate occurrence.

**Differential manifestation.**—There is yet another manifestation of aspergillosis described by Hinson, Moon and Plummer<sup>1</sup> in which sensitization to the fungus leads to blockage of a bronchus by an outpouring of mucus, some Charcot-Leyden crystals and some eosinophilic polymorphs. In this condition there are repeated episodes of febrile illness with cough, purulent sputum which may

## PULMONARY ASPERGILLOSIS

hyphae are in contact with the surrounding polynuclear reaction (Fig. 89). This exemplifies the pathogenic form of the fungus.

**Broncho-pulmonary aspergilloma.**—Extracted from its cavity through a surgical excision the substance of a broncho-pulmonary aspergilloma is brown in colour, lobulated, and usually a few centimetres in diameter. In cross-section it shows no semblance of organization though it is zonated into stripes following the contours



FIG. 89.—Diffuse pulmonary aspergillosis. Colony of aspergillus with radiating branching filaments (Haematoxylin and eosin,  $\times 260$ ).

of the surface (Fig. 90). The mycetoma is found microscopically to consist of a network of fungous filaments, and the striped appearance seen macroscopically is related to differing densities of fungous filaments. Alternating rapid and slow growth phases of the fungous mass probably induces this zonation. The aspergillus filaments have a relatively constant diameter of from 4 to 6 microns; they are septate, little branched, intermingled and much ramifying. Protoplasmic detail is almost absent<sup>24</sup>, but the cell membrane is easily stained by dyes, particularly by haematoxylin and eosin. In some zones the filaments show hyphal swellings with little protoplasmic structure<sup>24</sup>, the largest measuring about 30 microns in diameter, these structures are round or irregular, and are single or, rarely, grouped<sup>24</sup>. In the vicinity of such a zone, two or three aspergillary fructifications of

## PULMONARY ASPERGILLOSIS: SOME ASPECTS OF THE PARASITIC FORMS OF *ASPERGILLUS*

G. SEGRETAİN

GROWTH of aspergillus in the lung was recorded about 100 years ago, and the first cases of clinical aspergillosis were described 60 years ago. Renon<sup>20</sup> reviewed this condition in a book in 1897, and since then many papers on this subject have been published. Nowadays, this infection is encountered relatively frequently in a new clinical form, "l'aspergillome broncheectasiant" or bronchial aspergilloma, which was described for the first time in 1938 by Deve<sup>4</sup>. Recently, Monod and his colleagues pointed to its rather common occurrence<sup>15, 17, 18</sup>. In 1956, Meyer and his colleagues<sup>14</sup> reviewed 21 cases of aspergilloma<sup>2, 4, 6, 7, 9, 10, 11, 13, 15, 17, 18, 26</sup>, while in the last 2 years 12 new cases have been found<sup>3, 5, 14, 16, 19, 21, 22, 23, 25</sup>. All of these cases have been described in the literature in Europe and the list is certainly not complete. In this form of infection, the *Aspergillus* forms a large compact body within a cavity lined by epithelium. In the two other types of pulmonary aspergillosis, localization of the fungus is different. In aspergillary bronchitis<sup>8, 20</sup>, the fungus grows only on the surface of the bronchial epithelium, while in diffuse pulmonary aspergillosis<sup>1, 12</sup> it grows within the pulmonary tissues.

**Aspergillary bronchitis.**—Bronchial casts have been observed in the sputum in aspergillary bronchitis. These casts consisted of mucus in which the fungus was growing as slender, slightly branching filaments approximating in diameter to those seen in saprophytic cultures. Typical organs of fructification develop, natural aeration of the bronchi appearing to favour sporulation. Instead of spreading over the surface of the bronchial mucosa the fungus may form little compact masses which are periodically expectorated. These rarely exceed half a centimetre in size and are formed by entangled fungous filaments which sometimes show fructifications within the mass<sup>24</sup>. The fungus is rarely invasive and the bronchial mucosa shows only superficial changes.

**Pulmonary aspergillosis.**—In contrast, in pulmonary aspergillosis the fungus forms small or large colonies consisting of filaments having a general radiating form. These filaments are short, twisted, frequently branched and of almost constant diameter; the peripheral

## PULMONARY ASPERGILLOSIS

Enjalbert and her colleagues have studied this last pathological finding<sup>5</sup> and have noted that the lobules of an aspergilloma represent zones of active fungous growth coming into contact with a lining . . . . . absent. In such areas the . . . . . contact with the cellular . . . . . Between the lobules the epithelium tends to be thickened.

In two cases of aspergilloma, some small fungous colonies have actually been observed at the periphery of the mass, round or oval in shape and formed by joining and radiating filaments. The filaments at the periphery of the colonies were less abundant, frequently branched, and in contact with the surrounding polymorphonuclear leucocytes<sup>5</sup>. These appearances, observed by crushing the



FIG 91—Crushed fungous mass of aspergilloma. Radiating and branching filaments representing the invasive form of the fungus (Phase contrast  $\times 520$ )

fungous mass (Fig 91), resemble the parasitic form of the fungus occurring in diffuse pulmonary aspergillosis, but are of rare incidence. The usual appearance of the fungus in contact with cellular reaction in the lung is similar to that of the general filamentous structure of a mycetoma (Fig 92).

Exceptionally the fungus occurs elsewhere than in the lung, it has been localized to a lymph node in which the filaments of aspergillus tended to be scattered, and to show round bulbous forms within



## PULMONARY ASPERGILLOSIS

abnormal appearance have been seen consisting of large and flattened sterigmata surrounding large vesicles<sup>5</sup>, but these are very rarely found.

### EVOLUTION OF ASPERGILLOMA

A series of chest radiographs published by Pesle<sup>19</sup> shows the evolution of an aspergilloma over the years. It would appear that the bronchial cavity increases in dimension *pari passu* with the



FIG 90—Section of a bronchial aspergilloma. The cavity contains a fragment of the zoned fungus mass (Haematoxylin and eosin)

growth of the fungous mass. *Aspergillus* hyphae do not, however, penetrate the modified bronchial epithelium lining the cavity. Rarely, in cases of aspergilloma, the fungus may invade the pulmonary tissues and as evidence of this it has been observed that (a) two or more bronchi may open in the same aspergilloma cavity<sup>4, 10</sup>, and (b) replacement of the normal bronchial lining cells by metaplastic pavement epithelium may occur.

## REFERENCES

- 4 Dévé, F. (1938) "Une nouvelle forme anatomo-radiologique de mycose pulmonaire primitive le méga-mycétome intra-bronchectasique" *Arch. Méd. Chir.*, 13, 337.
- 5 Enjalbert, L., Segretain, G., Eschapasse, H., Moreau, G., and Bourdin, M. (1957) "Deux cas d'aspergillose pulmonaire—Étude anatomo-pathologique" *Sem. Hôp. Paris*, 33, 830.
- 6 Even, Lechevallier, and Sors (1952) "L'aspergillome bronchectasiant." *Bull. Soc. méd. Hôp. Paris*, 68, 251.
- 7 Gerstl, B., Weidman, W. H., and Newman, A. V. (1948) "Pulmonary Aspergillosis" *Ann. intern. Med.*, 28, 662.
- 8 Hinson, K. F. W., Moon, A. J., and Plummer, N. S. (1952) "Broncho-pulmonary Aspergillosis" *Thorax*, 7, 317.
- 9 Léon-Kindberg, M., Parat, M., and Netter, H. (1936) "Tumeur mycosique du poulmon (Aspergillose pulmonaire primitive pseudo-cancéreuse)" *Pr. méd.*, 1834.
- 10 Macaigne, and Nicaud, P. (1926) "Aspergillose primitive du poulmon avec artérite pulmonaire oblitérante" *Bull. Soc. méd. Hôp. Paris*, 50, 183.
- 11 Métras, H., and Thomas, P. (1946) "'L'arnage en grelot' en radiologie pulmonaire" *Pr. méd.*, 644.
- 12 Meyer, A., Monod, O., Pesle, G., Roy, L., Zivy, P., and Kuentz, J. (1956) "L'aspergillome bronchique (trois nouvelles observations)." *Bull. Soc. méd. Hôp. Paris*, 72, 554.
- 13 Monod, O., Pesle, G., and Labeguerie, M. (1952) "L'aspergillome bronchectasiant" *J. franc. méd. Chir. thor.*, 6, 229.
- 14 — — and Meyer, A. (1957) "L'aspergillome bronchectasiant" *Sem. Hôp. Paris*, 33, 3588.
- 15 — — and Segretain, G. (1951) "L'aspergillome bronchectasiant" *Pr. méd.*, 1557.
- 16 — — — (1951) "Sur une forme nouvelle d'aspergillose pulmonaire l'aspergillome bronchectasiant" *Bull. Acad. méd., Paris*, 135, 508.
- 17 Pesle, G. (1956) "Evolution de l'aspergillome bronchectasiant A propos de 4 cas" *Pr. méd.*, 1563.
- 18 Renon, L. (1897) *Étude sur l'aspergillose chez les animaux et chez l'homme* Paris, Masson.
- 19 Riddell, R. W. (1956) "Fungous Diseases of Britain" *Brit. med. J.*, 2, 783.
- 20 Santy, P., and Touraine, R. (1956) "Un cas de méga-mycétome pulmonaire traité par exérèse" *Lyon méd.*, 195, 389.
- 21 Scarini, C. (1957) "Sur l'aspergillome bronchique A propos d'une observation" *Pr. méd.*, 547.
- 22 Segretain, G., and Vieu, M. (1957) "Formes parasitaires des *Aspergillus* dans l'aspergillome bronchique diagnostic biologique des aspergilloses broncho-pulmonaires" *Sem. Hôp. Paris*, 5, 1281.
- 23 Simonin, P., Franquet, R., Lochard, J., Briquel, P., and Pierson, B. (1957) "Sur un cas d'aspergillose broncho-pulmonaire" *Sem. Hôp. Paris*, 33, 3586.
- 24 Yesner, R., and Hurwitz, A. (1950) "A Report of a Case of Localized Pulmonary Aspergillosis Successfully Treated by Surgery" *J. thorac. Surg.*, 20, 310.

## PULMONARY ASPERGILLOSIS

giant cells, somewhat simulating the yeasts of *Blastomyces dermatitidis*




FIG 92 — Bronchial aspergilloma, network of filaments in contact with cellular reaction (Haematoxylin and eosin,  $\times 350$ )

## SUMMARY

Pulmonary aspergillosis occurs in different clinical forms. In aspergillary bronchitis the fungous growth is only on the surface of the bronchi. In broncho-pulmonary aspergilloma the parasite forms a compact body in a cavity lined by epithelium, the cavity increasing with the growth of the fungus. Finally, there is diffuse pulmonary aspergillosis.

In cases of aspergilloma in which culture of the fungus was achieved, *Aspergillus fumigatus* was the only organism isolated. The morphological appearance of the fungus differed according to its localization in the lung.

## REFERENCES

- <sup>1</sup> Bariéty, M., Poulet, J., Monod, O., and de Brux, J. (1957) "Aspergillose aiguë, purement pulmonaire, à forme de cancer bronchique" *Bull Soc Fr Mal Res* 71 307

## DIRECT BRONCHIAL SENSITIVITY TESTS

inhalation, though sometimes the symptoms recurred later. In some cases there was no immediate response, but asthma developed some hours later. In one patient transient diffuse lung shadows appeared after the inhalation (b) On occasion systemic reactions occurred, consisting of flushing, pallor, nausea and faintness. These were rapidly relieved by isoprenaline inhalation. Careful attention to graded concentrations of antigen for inhalation can minimize such reactions.

The patients in whose sputum *A. fumigatus* was found fell into the following groups, according to the clinical and pathological picture and to the skin and bronchial reactions on testing.

- (1) Asthma with allergic sensitivity to aspergillus antigen:  
(a) Recent origin; (b) long standing
- (2) Aspergillus mycetoma (a) With asthma and allergic sensitivity to aspergillus antigen; (b) without asthma or allergic sensitivity.
- (3) Patients with *A. fumigatus* in the sputum who did not show evidence of skin or bronchial sensitivity

### ASTHMA WITH ALLERGIC SENSITIVITY TO ASPERGILLUS ANTIGEN

Included in the clinical features in this group were recurrent transient lung shadows, eosinophilia in the peripheral blood, and the expectoration of plugs containing eosinophile cells and, on occasion, mycelial fragments.

**Asthma of recent origin.**—There were 4 patients in this group. In 2 of these there was a history of wheezing of only 12 weeks' duration. In all cases the bronchi reacted to the aspergillus extract inhalation. Prick tests with the aspergillus extract gave a positive reaction in all cases although in 1 the reaction was very weak.

**Asthma of long standing.**—In 8 patients the asthma had been present for many years and had become more frequent and chronic in recent years. In all these patients the bronchi reacted to the inhalation of the aspergillus antigen, and positive skin-test reactions were also elicited.

A brief outline of the clinical picture is given for some of these patients. One patient, 34 years old, had been asthmatic from childhood. During the past 6 years transient lung shadows were seen and a left spontaneous pneumothorax had occurred. Bronchograms showed marked bronchial dilatation at the sites of previous transient shadows. The sputum, which was scanty and mucopurulent, contained mostly eosinophile cells, and no bacterial pathogens were found. Skin tests showed a wide spectrum of skin hypersensitivity, positive reactions being elicited by extracts of *Aspergillus*,

## DIRECT BRONCHIAL SENSITIVITY TESTS IN BRONCHO-PULMONARY ASPERGILLOSIS

K. CITRON AND J. PEPYS

THIS report describes the investigation, by direct bronchial sensitivity testing, of the possible significance of the presence of *Aspergillus fumigatus* in the sputum. The reactions elicited by the inhalation of antigen extracts were compared with skin reactions to prick tests with these antigens. The results obtained suggest that hypersensitivity is of importance in determining the clinical pattern of aspergillus infection of the lung.

The technique of the direct bronchial test consists in the administration of inhalations of solutions of various antigens to the patient, and in measuring any resulting bronchial reaction by observing changes in the forced expiratory volume in the first second (F.E.V.<sub>1.0</sub>). This is a reliable measurement of the presence of bronchial obstruction. To start with, recordings of the forced expiratory volume are made on a light spirometer until consistent readings are obtained. This is followed by inhalations of a mist of the control material and of the test antigens and the taking of records after each of these.

In this study a Bright-Smith nebulizer capable of giving a fine mist (particle size diameter up to  $8\mu$ ) was employed for the test inhalations which were given for 60 seconds or less. An inhalation of Coca's fluid, the vehicle used for extracting the antigens, was given as the control and tracings were made. This was followed by inhalations of the antigen extracts. Concentrations of 1 and 10 per cent of the antigens were employed and the choice was carefully graded according to the patient's clinical and skin sensitivity. Tracings were repeated at intervals up to 15 minutes after the inhalation. When a fall in the F.E.V.<sub>1.0</sub> occurred, an inhalation of isoprenaline (1 per cent) was given, and further tracings were made during the recovery period. A fall in the mean F.E.V.<sub>1.0</sub> after the inhalation of the antigen, greater than that, if any, following the control inhalation, for the individual patient, was regarded as a positive response.

Reactions of the following type were observed after the inhalations: (a) A fall in the F.E.V.<sub>1.0</sub> with or without symptoms of asthma. The asthmatic symptoms were rapidly relieved by the isoprenaline.

## DIRECT BRONCHIAL SENSITIVITY TESTS

sensitization to the fungi, though they were unable to provide supporting evidence from skin tests for specific allergic sensitivity. The positive direct bronchial sensitivity test reactions and the skin-test reactions to aspergillus antigen in our cases supports, and adds evidence to, the role of allergic sensitivity to aspergillus antigen in the production of some of the clinical and pathological manifestations. This is particularly pertinent in relation to the bronchial tests

Positive skin-test reactions and clinical allergic reactions to mould spores, including those of the *Aspergillus* species, are widely recognized and commonly encountered. In subjects already sensitive or capable of being sensitized, the proliferation of the fungus in the bronchial tract may be expected to excite vigorous tissue reactions. Mucosal oedema, bronchospasm and hypersecretion of mucus may contribute to the bronchial obstruction which results in the areas of collapse consolidation so often seen. Such areas of collapse may in turn be the cause of the bronchiectasis at the sites of the transient shadows.

From the results of this investigation, it is concluded that hypersensitivity to aspergillus antigen plays an important part in determining clinical manifestations.

## ACKNOWLEDGEMENTS

The cultural studies in this work were performed by Miss Y. M. Clayton, B.Sc., and the antigens employed were prepared by Messrs. Duncan-Flockhart & Co. Ltd.

## REFERENCE

- <sup>1</sup> Hinson, K. F. W., Moon, A. J., and Plummer, N. S. (1952) "Bronchopulmonary Aspergillosis" *Thorax*, 7, 317

## DIRECT BRONCHIAL SENSITIVITY TESTS

*Cladosporium*, *Alternaria*, *Penicillium*, pollen and house dust. The inhalation test, however, showed bronchial sensitivity only to *Aspergillus*, *Cladosporium* and *Alternaria* extracts and not to the other antigens. The most marked reaction was elicited by the aspergillus antigen, with lesser reactions to *Cladosporium* and *Alternaria* antigens. *A. fumigatus* was found in 1 out of 12 sputum cultures.

The treatment in this case consisted of inhalations of a brilliant green solution (1 in 10,000), and specific hyposensitization by injection of an aspergillus extract under cover of cortisone. A progressive decline in the bronchial sensitivity to the aspergillus antigen has been demonstrated by serial bronchial sensitivity tests.

In 2 other cases, both long-standing asthmatics, recently incapacitated by the asthma in spite of cortisone treatment in one of them, bronchial and skin-test reactions were elicited by the aspergillus antigen. In 1 case *A. fumigatus* was found in the sputum after 17 specimens had been examined, and in the other after 23 specimens. It would seem that intensive search for this fungus is indicated by the sensitivity test reactions.

### ASPERGILLUS MYCETOMA

With asthma and allergic sensitivity to the aspergillus antigen.—There were 2 patients in this group, showing both bronchial and skin sensitivity to aspergillus antigen. In 1 case a mycetoma had developed from a lung abscess, but there were present, in addition, asthma, transient lung shadows and eosinophilia.

Without asthma.—The 2 cases in the group did not react to bronchial tests with aspergillus antigen in contrast to the group with asthma. One of the patients had sarcoidosis and a mycetoma, but no asthma or eosinophilia. The bronchial test was negative in this patient although a positive skin-test reaction was elicited.

### PATIENTS SHOWING NO EVIDENCE OF SKIN OR BRONCHIAL SENSITIVITY

In 7 cases, *A. fumigatus* was found in the sputum, but it was not possible to relate its presence to the clinical condition since both skin and bronchial tests were negative.

The patients with asthma of recent onset and with mycetoma referred to above are similar to those described by Hinson, Moon and Plummer<sup>1</sup> under the term broncho-pulmonary aspergillosis. They divided their cases into a saprophytic, an allergic and a septicæmic group. The saprophytic and allergic types comprise the patients described here. They emphasized the importance of

## FARMER'S LUNG

dust, he gradually improves both clinically and radiologically and he should be able to return to work in 2-4 months

Repeated episodes of this kind described in the second stage of disease gradually give rise to permanent scarring of the lung with fibrosis and occasionally bronchiectasis. Unless it has been possible to watch a case over a period of years a firm diagnosis in this third stage cannot be made, for it is impossible to differentiate it from many other causes of pulmonary fibrosis

### AETIOLOGY

The possibility that farmer's lung was a simple allergy was considered<sup>4</sup> and solutions from hay samples and moulds were made by extracting 1 gramme of chopped hay in 25 millilitres of sterile water overnight at 2° C. and then Seitz-filtering the extract. Similar extracts were made from 2-week to 4-week fluid cultures of individual moulds in glucose medium. Extracts of hay, whether good or mouldy, gave fairly constant positive results with intradermal tests in both farm workers and in a control subject, the response to mould extracts was poor. It seemed likely that the hay extracts contained a substance giving a histamine-like response. Evidence for simple allergy being responsible was unconvincing.

The sera of a significantly large number of these patients showed an increase in the *gamma*-globulin fractions. This could be interpreted as the result of the production of antibodies of unspecified nature, but was not regarded as of any diagnostic value. Mantoux tests were done in 12 cases and only 2 (16 per cent) were positive, as against 63.9 per cent of positives in the rural adult population in Devonshire.

The significance of moulds in the sputum of these patients is very doubtful, and histological studies of the lung seemed of paramount importance, a paper by Zettergren in 1950 appeared to be of significance in this respect<sup>6</sup>. The publication described the exposure of one group of rabbits to an atmosphere containing heavy concentrations of sterile threshing dust and another to sterile threshing dust containing *C. albicans*. Autopsy on the first group of rabbits showed "dust granulomas" in the lungs with foreign-body giant cells, in the second group a tuberculoid reaction ("fungal granulomas") occurred.

Histological studies were carried out on 2 patients on whom lung biopsy was performed.

*Case 1*—A young agricultural worker aged 27 years had been using mouldy hay to feed his cattle for one month prior to hospital admission.



## FARMER'S LUNG

C. J. FULLER

FARMER'S or thresher's lung was first described in England by Campbell in 1931<sup>1</sup>. Fawcitt, working in Cumberland and Westmorland, described further cases and carried out investigations from which he deduced that the condition was a bronchomycosis<sup>2,3</sup>. Tornell in Sweden published a further paper in 1945, in which he came to the conclusion that *Candida albicans* was the responsible fungus<sup>5</sup>.

Observations upon this condition seen in Devonshire were published in 1953<sup>4</sup>. It was shown that the presence of fungi in sputa from these patients did not prove the condition to be a true bronchomycosis, particularly as farm workers lived in an atmosphere laden with mould spores. Bronchoscopy of active cases showed some slight reddening of the bronchial mucosa, and bronchial swabs gave negative cultures in 3 and a growth of *Penicillium* sp. in one. It was suggested that farmer's lung was due to a tissue reaction to breakdown products of inhaled mould spores or grass particles.

### CLINICAL FEATURES

Farmer's lung can occur as an acute illness following exposure to heavy concentrations of hay or threshing dust. The symptoms are manifest in a few hours, as fever, malaise, shivering and a dry cough. A small amount of sticky sputum, sometimes blood-stained, may be

The chief symptom then is breathlessness severe enough to prevent work, and cough productive of a little purulent sputum. The patient is cyanosed, and fine crepitations are audible over the lung bases and breath sounds are weak. Radiological findings are characteristic and show fine mottling, particularly in the middle and lower lung zones, the apices usually show some degree of emphysema.

Provided the farm worker is kept away from further contact with

## FARMER'S LUNG

Differential diagnoses considered in Case 1 included tuberculosis and sarcoidosis and in Case 2 dust pneumonitis. In neither case was there any helpful evidence of mould spores or fungi growing in the lung tissue.

There is a similarity between Zettergren's "fungal granulomas" and the tuberculoid systems in Case 1, and between his "dust granulomas" and the foreign-body giant cell systems in Case 2. It is suggested that in farmer's lung a peculiar cellular reaction occurs in the lung tissue as a result of the inhalation of dust and mould spores giving rise to the clinical and radiological changes recorded in this disease.

## ACKNOWLEDGEMENT

Acknowledgement is made to Dr G Stewart Smith for his histological reports quoted above

## REFERENCES

- <sup>1</sup> Campbell, J M (1932) "Acute Symptoms following Work with Hay" *Brit med J*, 2, 1143
- <sup>2</sup> Fawcitt, R (1936) "Fungoid Conditions of the Lung" *Brit J Radiol*, 9, 172, 354
- <sup>3</sup> — (1938) "Occupational Diseases of the Lungs in Agricultural Workers." *Brit J Radiol*, 11, 378.
- <sup>4</sup> Fuller, C J (1953) "Farmer's Lung. Review" *Thorax*, 8, 59
- <sup>5</sup> Tornell, E (1946) "Thresher's Lung—a Fungoid Disease Resembling Tuberculosis or Morbus Schaumann" *Acta med scand*, 125, 191
- <sup>6</sup> Zettergren, L (1950) "Thresher's Lung (Pulmonary Moniliasis) An Experimental Investigation" *Acta Soc Med upsalien*, 55, 257

## FARMER'S LUNG

He was admitted to Exmouth Hospital on April 11th, 1956, with a history of breathlessness and cough. His Mantoux was negative at 1:1000, and in view of extensive mottling throughout both lungs a tentative diagnosis of farmer's lung was made. Lung biopsy was carried out on May 3rd, 1956, and at operation the surface and substance of the lung showed milary bodies indistinguishable from milary tuberculosis. Half the biopsy specimen was examined bacteriologically and half histologically. *Mycobacterium tuberculosis* was not isolated in culture nor by animal inoculation, nor was it found in repeated examinations of sputum, bronchial washings and gastric residues during the 3 months following operation. Histological examination of the biopsy material showed a large number of tuberculoid systems. These contained endothelial cells, and sometimes giant cells, in the periphery with a central ring of small round cells. Some of these systems showed central necrosis, but many of them did not contain giant cells, and simulated a sarcoid reaction. No foreign bodies were seen in the giant cells, nor was any doubly refractile material or dust present. Lipophages were numerous.

Clinical and radiological recovery followed and the patient returned to work 3 months after the biopsy was taken, he has been well since and a radiograph taken 10 months later was normal.

**Case 2**—A man aged 55 years had helped to thresh a rick of mouldy corn in a barn during January 1954. The same evening he developed a "chill" as did 2 other members of the threshing team to a lesser degree. A month later the patient was examined and was found to be suffering from exertional dyspnoea and fatigue. Crepitations and rhonchi were apparent and a radiograph showed a broad mediastinal shadow and areas of fine mottling at the lung bases. After bronchoscopy and tomography, surgical exploration of the right chest was carried out and a biopsy of lung taken, a retrosternal and partially calcified thyroid was observed. Histology of the biopsy material showed only an occasional focus of endothelial cells with a few giant cells. The tissue was, however, infiltrated with masses of small round cells including small numbers of plasma cells. Many scattered giant cells were present, mostly of foreign-body type containing spear-shaped clefts resulting from dissolved foreign-body material, possibly cholesterol. A small amount of brownish dust material was present, not within giant cells, but there were no doubly refractile particles. Lipophages were plentiful. The condition was considered to be a type of chronic pneumonitis around bronchioles which could well be a reaction to dust.

The patient made very slow progress towards resuming his life as an active farmer. Three months after the thoracotomy he was unable to

## SEROLOGICAL TESTS

reviewed by Parsons and Zerafonetis in 1945 were all that had been observed<sup>14</sup>. In contrast, in recent years the Public Health Service, Armed Forces, Veterans Administration and a number of universities have vigorously pursued investigations into the prevalence, pathology, distribution and therapy of this disease. Moreover, the geographic distribution of *H. capsulatum* is not well defined, either in the United States of America or in the many other countries where surveys for histoplasmin sensitivity have been carried out<sup>14</sup>. Great Britain, of course, is among those areas in which the degree of endemicity is not known.

repeatedly observed in certain types of the infection will be described, and the way in which serology may be used in detecting primary infections and in mapping geographic areas of high endemicity will be illustrated.

## SEROLOGICAL TESTS

The complement fixation test and the collodion agglutination test are the two serological procedures employed for histoplasmosis at the Walter Reed Army Institute of Research. The methods are described in detail in earlier reports<sup>7, 39</sup>.

In the complement fixation (CF) test two antigens are used, a standardized suspension of the whole yeast phase of *H. capsulatum* in buffered saline solution, and histoplasmin<sup>23</sup>. The latter is a filtered asparagine broth medium in which selected strains of *H. capsulatum* in the filamentous phase are grown for several months. The same type of preparation, following appropriate standardization, is used for skin testing and the collodion agglutination procedure.

### ADVANTAGES OF THE COLLODION AGGLUTINATION TEST

The collodion agglutination (CA) test employs as antigen minute particles coated with the non-particulate antigen, histoplasmin (Fig 93). The particles require 1 hour for sensitization after which they are agglutinated in the presence of serum from early cases of histoplasmosis. Serial dilutions of sera to be tested are made and to these antigen is added. After incubation for 2 hours, the tubes are centrifuged and read by the conventional 4 plus, 3 plus method. One person can routinely complete 100 tests in their entirety within a period of 4 hours. Some laboratories use the more time-consuming and less economical precipitin test instead<sup>39</sup>.

## SEROLOGICAL DIAGNOSIS AND EPIDEMIOLOGICAL ASPECTS OF HISTOPLASMOSIS

CHARLOTTE C. CAMPBELL

WITHIN the past decade there has been a revolutionary change in the clinical concept of histoplasmosis. Once regarded as a rare, slowly progressive and invariably fatal infection, it is now only the fatal outcome that is considered unusual among the countless persons who experience primary pulmonary infection.

Infection follows inhalation of spores of *Histoplasma capsulatum*, a fungus which exists saprophytically in the soils of many defined, and some as yet undefined, geographic areas. The first evidence of the benign infection came from the use of histoplasmin, an antigen derived from the causative fungus, in skin test surveys of healthy residents of the central United States of America who, despite pulmonary calcifications, failed to react to tuberculin<sup>9,30</sup>. The nature of the benign illness, or other mechanism leading to the widespread production of this sensitivity, was not known at that time. In a few years, however, there was conclusive evidence that primary histoplasmosis was an acute pneumonitis clinically indistinguishable from other and supposedly more common pneumonitic diseases of viral or bacterial aetiology. As in the latter infections, there was an acute onset with fever, malaise, sometimes nausea and vomiting, dyspnoea and dry cough. Radiological examination of the chest revealed varying degrees of unilateral or bilateral infiltration present in one or more lobes. The close study of persons involved in outbreaks or epidemics, and of increasing numbers of individual cases, further disclosed that such infections ranged from the clinically inapparent to the extremely severe.

While most persons apparently recovered, there were others in whom unhealed pulmonary lesions persisted and some in whom widely disseminated progressive disease terminated in death. In brief, the clinical spectrum of histoplasmosis is as broad and varied as that of many other infectious diseases.

There is, as yet, little evidence that histoplasmosis is a problem of importance in Great Britain. Nevertheless, it should be remembered that little more than 10 years ago this was also being said of the United States of America. The 78 fatal or moribund cases

# SEROLOGICAL TESTS

TABLE 31  
SEROLOGICAL REACTIONS IN PRIMARY PULMONARY HISTOPLASMOSIS

Days after onset	Complement fixation titre*	Collodion agglutination titre (Histoplasmin)
6	Negative	1:256
12	Negative	1:256
39	Negative	1:256
25	1:32	1:256
37	1:32	1:256
62	1:32	1:128
120	1:16	1:64

\* Whole yeast phase antigen. Skin reactions with histoplasmin negative throughout

TABLE 32  
TYPICAL SEROLOGICAL REACTIONS IN SERIAL SPECIMENS FROM PATIENTS WITH PRIMARY PULMONARY HISTOPLASMOSIS

Case No	Date after onset	Complement fixation titre		Collodion agglutination titre (Histoplasmin)
		WYP*	H†	
3		1:256	1:128	1:64+
	2 weeks later	AC‡	AC	1:32
	4 weeks later	1:256	1:128	1:16
6		AC	AC	1:32
	3 weeks later	Negative	1:64	1:8
11		Negative	Negative	1:64
	4 weeks later	Negative	1:64	Negative

\* WYP Whole yeast phase antigen of *H. capsulatum*  
† H Histoplasmin  
‡ AC Anticomplementary specimen

acquired by the casual passer-by as well as those who work directly with the organism

In Table 32, additional advantages of the test are illustrated. The first serum samples in cases 6 and 11 were anticomplementary and CF negative respectively, but because of the strong collodion reactions additional studies were made. Subsequent specimens on both of these patients had demonstrable CF antibody titres of 1:64 to histoplasmin.

## DIFFERENCES IN THE REACTIVITY OF THE TWO ANTIGENS USED IN THE COMPLEMENT FIXATION TEST

Complement fixing (CF) antibodies, although sometimes developing much later than agglutinins or precipitins, usually persist for




FIG 93—The collodion agglutination test (By courtesy of Medical Audio Visual Dept., Walter Reed Army Institute of Research, Washington)

The collodion test has many advantages over other serological tests. It may be performed with ease and rapidity. It may be used to demonstrate the presence of antibody in cases as early as 10–14 days after exposure to the fungus, usually by the time clinical symptoms are manifest. Moreover, agglutinins are observed in mild cases in which CF antibodies are never demonstrable, or do not arise until much later. Finally, the test is of value in sera which are anticomplementary. Agglutinins, like precipitins, are transitory and are seldom demonstrable in the chronic, slowly progressive cases. The collodion test, therefore, is always used in conjunction with, and not in the place of, the CF test.

These advantages are illustrated in Tables 31 and 32. The patient represented in Table 31 was an entomologist, aged 32 years, whose influenza-like episode was of 5 days' duration. The serum was tested on the sixth day after he returned to work and gave a strongly positive collodion agglutination test, but CF antibodies were not demonstrated until 2 weeks later when the patient had recovered clinically and after culture studies of the sputum, from which *H capsulatum* was isolated, were initiated. Histoplasmosis was suspected in this case because of the patient's frequent visits to our laboratory. The case is thus illustrative not only of the advantage of the CA test in detecting the primary case, but of the highly infectious nature of the agent. Laboratory infections can be

## SEROLOGICAL TESTS

of 1:32-1:512 with the whole yeast phase antigen that failed to react with histoplasmin. There was a third group of comparable size in which the reactions were essentially the same with both preparations<sup>23</sup>. In other words, it is estimated that sera from approximately one-third of the histoplasmosis cases would yield false negative CF reactions if one preparation were used to the exclusion of the other. Although the whole yeast antigen appears to be more highly reactive in sera from primary cases, and histoplasmin more so in sera from persons with residual lesions, cavitation or fibrosis, notable exceptions are observed even to these broad generalizations.

A much greater number of cases must be followed serologically from onset before an attempt can be made to interpret these differences, and for the present both types of preparation in the CF test should be used.

## THE USE OF SEROLOGICAL TESTS IN EPIDEMIOLOGICAL STUDIES

While serological tests are perhaps most useful in detecting primary infections, they frequently are also the means of indicating possible new areas of high endemicity. Histoplasmosis in what are presumed to be non-endemic areas is usually first recognized by visiting physicians, or those new to the community, who request serological tests that lead to its early diagnosis. When it is further ascertained that the patient has neither lived nor travelled in areas known to be endemic, a source of infection is looked for in his immediate environment. This, if found, leads to more definitive studies to determine the real prevalence of the infection in a geographic area in which the degree of endemicity is not known.

Such studies remind us that histoplasmosis is not a disease limited to the central United States of America, an impression that, unfortunately, has arisen because of the impressive investigations on histoplasmosis in that region. It is sometimes quite difficult to persuade physicians with practices outside the central United States of America that their patients have this "middle western" disease<sup>31</sup>.

The following case, in addition to the serological findings observed in many primary infections, exemplifies this sequence of events.

The patient, a white male research chemist aged 26 years, had always been in good health. One evening he developed a "chill" and sore throat and the following day his temperature was 103° F. and he suffered from rigors. Attacks of sweating, shortness of breath on the slightest exertion and a dry cough followed. He was treated with a variety of antibiotics and when there was no improvement after two weeks he



# HISTOPLASMOSIS: SERODIAGNOSIS AND EPIDEMIOLOGY

much longer periods. Particularly in non-primary cases, therefore, only the CF test is positive. Moreover, there are sometimes wide and as yet inexplicable differences in the reactivity of the whole yeast phase and histoplasmin antigens in the CF test. It is for this reason that both are used in this procedure.

The extent to which reactions with the two antigens vary is exemplified in Tables 33 and 34. Recently, complement fixation reactions were compared on the thousand sera most recently sent to our laboratory to be tested routinely for blastomycosis, coccidioidomycosis and histoplasmosis<sup>23</sup>. Of these, there were 146 specimens that fixed complement to titres of 1:32 or above with histoplasma antigens. It will be noted, however, that of the 41 sera listed in Table 33, 30 were negative with the whole yeast antigen but reacted to CF levels of 1:32-1:256 with histoplasmin. Of the 57 sera in Table 34, on the other hand, there were 34 that reacted to CF levels

TABLE 33

COMPARISON OF COMPLEMENT FIXATION TITRES OF 41 SERA (33 CASES) IN WHICH HISTOPLASMIN REACTED TO HIGHER TITRE THAN WHOLE YEAST ANTIGEN (WYP)

Number of sera	CF titre with WYP antigen	Number of sera with CF titre to histoplasmin at			
		1:32	1:64	1:128	1:256
30	1:8	14	10	4	2
5	1:8	4		1	
5	1:16		5		
1	1:32				1

TABLE 34

COMPARISON OF COMPLEMENT FIXATION TITRES IN 57 SERA (32 CASES) IN WHICH WHOLE YEAST PHASE ANTIGEN (WYP) REACTED TO HIGHER TITRE THAN HISTOPLASMIN

Number of sera	CF titre with histoplasmin	Number of sera with CF titre to WYP antigen at				
		1:32	1:64	1:128	1:256	1:512
34	1:4	19	8	4	1	2
5	1:8	2		1	2	
11	1:16		3	3	3	2
6	1:32			5	1	
1	1:64					1

## SEROLOGICAL TESTS

of 1:32-1:512 with the whole yeast phase antigen that failed to react with histoplasmin. There was a third group of comparable size in which the reactions were essentially the same with both preparations<sup>23</sup>. In other words, it is estimated that sera from approximately one-third of the histoplasmosis cases would yield false negative CF reactions if one preparation were used to the exclusion of the other. Although the whole yeast antigen appears to be more highly reactive in sera from primary cases, and histoplasmin more so in sera from persons with residual lesions, cavitation or fibrosis, notable exceptions are observed even to these broad generalizations.

A much greater number of cases must be followed serologically from onset before an attempt can be made to interpret these differences, and for the present both types of preparation in the CF test should be used.

## THE USE OF SEROLOGICAL TESTS IN EPIDEMIOLOGICAL STUDIES

While serological tests are perhaps most useful in detecting primary infections, they frequently are also the means of indicating possible new areas of high endemicity. Histoplasmosis in what are presumed to be non-endemic areas is usually first recognized by visiting physicians, or those new to the community, who request serological tests that lead to its early diagnosis. When it is further ascertained that the patient has neither lived nor travelled in areas known to be endemic, a source of infection is looked for in his immediate environment. This, if found, leads to more definitive studies to determine the real prevalence of the infection in a geographic area in which the degree of endemicity is not known.

Such studies remind us that histoplasmosis is not a disease limited to the central United States of America, an impression that, unfortunately, has arisen because of the impressive investigations on histoplasmosis in that region. It is sometimes quite difficult to persuade physicians with practices outside the central United States of America that their patients have this "middle western" disease<sup>31</sup>.

The following case, in addition to the serological findings observed in many primary infections, exemplifies this sequence of events

The patient, a white male, 45 years of age, was first seen in the hospital in 1954. He had been ill for several months, with a history of weight loss, anorexia, and fever. He had been treated with antibiotics and when there was no improvement after two weeks he

## HISTOPLASMOSIS. SERODIAGNOSIS AND EPIDEMIOLOGY

was admitted to hospital. Radiological examination of the chest revealed "dense, diffuse miliary disease which was grossly nodular" (Fig 94) and anti-tuberculosis therapy was initiated. On the following day a visiting physician familiar with histoplasmosis saw the patient and serological tests were advised.

As indicated in Table 35, both the CA and CF tests were strongly positive. Culture studies were immediately initiated and *H capsulatum* was recovered from gastric washings and sputum collected on the third day of hospitalization. The patient improved rapidly and was discharged after 1 month. Radiographs of the chest 3 years later revealed many tiny calcified nodules, now regarded as characteristic of healed miliary histoplasmosis. The patient maintains a residual CF titre of 1:8 with the whole yeast phase antigen and a strongly positive skin test.



FIG 94 —Pulmonary histoplasmosis. Radiograph showing diffuse nodular densities throughout both lung fields. (By courtesy of Dr James S Feffer, Washington.)

It should be noted that the patient's CF titres were not only higher but persisted for a much longer period with the whole yeast phase antigen than with the conidia antigen. Acid-fastness was no longer demon-

Because the same is true of CF antibodies in some of the milder

## SEROLOGICAL TESTS

cases, sera should be tested early and often in suspected cases. The marked cross reaction with blastomyces antigen is discussed in a later section.

TABLE 35

SEROLOGICAL REACTIONS IN PRIMARY PULMONARY HISTOPLASMOSIS. *H. CAPSULATUM* ISOLATED FROM PATIENT AND SOIL TO WHICH HE WAS EXPOSED

Period after onset	Complement fixation titre				Collodion agglutination titre (Histoplasmin)
	WYP*	H†	B‡	C§	
16 days	1:512	1:64	1:512	Negative	1:32
23 "	1:256	1:16	1:256	Negative	1:32
30 "	1:256	1:32	1:128	Negative	1:32
39 "	1:256	1:8	1:128	Negative	1:16
52 "	1:256	1:16	1:64	Negative	1:8
67 "	1:128	Negative	1:32	Negative	Negative
3 years	1:8	Negative	Negative	Negative	Negative

- \* WYP — Whole yeast phase antigen of *H. capsulatum*
- † H — Histoplasmin
- ‡ B — Yeast phase antigen of *Blastomyces dermatitidis*
- § C — Coccidioidin

There is little doubt, however, that it was the serological tests which provided the rapid, presumptive diagnosis during the active phase of this infection when cultural studies, which are so rarely carried out for *H. capsulatum*, are also most rewarding. Finally, when it was assured that the patient had neither served in the Armed Forces nor resided nor travelled beyond the north-eastern section of the United States of America, the source of his exposure was sought and found in his own garden. Ten days before onset of illness, he had cleared an area on which an old chicken house had stood. The soil samples collected from this area were laden with spores of *H. capsulatum*<sup>4</sup>. Moreover, a skin test survey of the county in which the patient resided revealed a high dermal sensitivity rate to histoplasmin<sup>2</sup>, indicating that other cases of primary infection were being overlooked or attributed to other causes in this area.

## EPIDEMIC HISTOPLASMOSIS

Histoplasmosis occurs in epidemics when a number of persons are exposed to a common source in Nature. Furcolow and his associates have studied approximately 30 of these outbreaks<sup>19, 40</sup> in addition to those described by Loosli and others<sup>3, 8, 22, 28, 29, 33</sup>. Epidemics usually come to be recognized only when at least one of the patients is sufficiently ill to require admission to hospital. For this reason, it is believed that even in areas known to be endemic many of the less severe cases are not detected.

# HISTOPLASMOSIS: SERODIAGNOSIS AND EPIDEMIOLOGY

The association between awareness and known prevalence of histoplasmosis is well-known. The epidemics reported from New York<sup>22</sup>, Maryland<sup>3, 28</sup>, North Carolina<sup>33</sup>, or even Venezuela<sup>8</sup> differ from those described by Loosli and Furcolow<sup>19, 29</sup> only in that they occurred in areas thought to be of low endemicity, but where few or no skin test studies have actually been done to determine the real prevalence of the infection.

In these outbreaks the serological test was used to good advantage. For example, an otherwise healthy butcher, aged 32 years, was admitted to a hospital in the District of Columbia with a severe, acute pneumonitic illness similar to that described in the preceding case (Figs. 93 and 94, and Table 35). A probable diagnosis of psittacosis was made, but positive serological reactions were observed with histoplasma antigens and not with those of the appropriate group of viruses. Moreover, it was learned that three other members of this man's family were experiencing milder but similar episodes of illness. His son recovered following 2 weeks of bed-rest at home, his wife after only 1 week, and another relative missed only several days at work because of "a very bad cold". As shown in Table 36, agglutinins were demonstrated in the sera from all 3 persons with the milder infections, as well as the father's whose grave illness required 3 months of hospital treatment. Complement

TABLE 36  
SEROLOGICAL REACTIONS IN A FAMILY OUTBREAK OF  
HISTOPLASMOSIS<sup>17</sup>

Case	Days after onset	Complement fixation titre		Collodion agglutination titre (Histoplasmin)
		WYP*	H†	
1 (Father)	15	1:64	Negative	1:64+
	41	1:64	Negative	1:16
	197	1:8	Negative	1:16
2 (Mother)	10	Negative	Negative	1:64
	43	Negative	Negative	1:64
	191	Negative	Negative	1:8
3 (Son)	10	1:64	Negative	1:32
	24	1:256	1:32	1:64
	191	1:128	1:256+	1:8
4 (Sister-in-law)	13	1:8	Not done	1:8
	27	1:64	Not done	1:64
	194	Negative	Not done	Negative

\* † See footnote to Table 35

## SEROLOGICAL TESTS

fixing antibodies were demonstrated with the whole yeast phase antigen in Case 1, and also to high titres of 1:128 and more than 1:256 with both antigenic preparations in Case 3, but were not demonstrable with either in Case 2. Prompted by the positive agglutination test, cultural studies were carried out and *H. capsulatum* was isolated from the sputum of Case 2 as well as of Case 1<sup>28</sup>.

The organism was also later isolated from the soil to which all 4 of these persons were exposed 10-14 days before the onset of illness. The soil had been contaminated with chicken excreta used as fertilizer<sup>3</sup>. This outbreak occurred within 5 miles of the city limits of the District of Columbia, where endemicity at that time was regarded as low. Since the time of this outbreak 64 cases of primary pulmonary histoplasmosis in local residents have been found with the help of serological tests, and in a recent unrelated skin test survey in one of the adjoining counties a high dermal sensitivity rate to histoplasmin was revealed<sup>13</sup>. The positive serological tests, and the isolation of *H. capsulatum* from local soils associated with a number of these cases<sup>5, 16</sup> had, in fact, long suggested that histoplasmosis was far more prevalent in these areas than was indicated by the few and very limited skin test studies previously made in this region.

### SEROLOGICAL TESTS IN AREAS OF HIGH ENDEMICITY

Serological studies are also helpful in regions where, for various reasons, histoplasmosis is believed to be endemic, even though the primary infections are not recorded. The Isthmus of Panama, where the first 3 cases of histoplasmosis, all fatal, were described by Darling in 1906, is a case in point<sup>10</sup>. Although a fourth case was not reported from Panama until 1951<sup>12</sup> there have since been several others, all of the fatal type<sup>35</sup>. In addition, Tucker<sup>42</sup> reported a dermal sensitivity rate of more than 60 per cent in the indigenous population, and Ajello isolated *H. capsulatum* from Panamanian soil<sup>3</sup>. Despite these findings there were no reports of the primary infection.

In 1955 the Walter Reed Army Institute of Research began a co-operative study with physicians at Gorgas Hospital on the isthmus. Within a period of 1 year positive serological reactions were obtained in 81 patients with acute pneumonitic infections who were admitted to the chest diseases wards at that institution. As shown in Table 37, there were 60 cases on whom only a single serum was tested and a total of 15 sera that were anticomplementary. Nevertheless, the latter were all positive in the CA test, as were a number of others with low CF titres of 1/8-1/32. Complement

# HISTOPLASMOSIS: SERODIAGNOSIS AND EPIDEMIOLOGY

The association between awareness and known prevalence of histoplasmosis is well-known. The epidemics reported from New York<sup>22</sup>, Maryland<sup>3, 28</sup>, North Carolina<sup>33</sup>, or even Venezuela<sup>8</sup> differ from those described by Loosli and Furcolow<sup>19, 29</sup> only in that they occurred in areas thought to be of low endemicity, but where few or no skin test studies have actually been done to determine the real prevalence of the infection.

In these outbreaks the serological test was used to good advantage. For example, an otherwise healthy butcher, aged 32 years, was admitted to a hospital in the District of Columbia with a severe, acute pneumonic illness similar to that described in the preceding case (Figs 93 and 94, and Table 35). A probable diagnosis of psittacosis was made, but positive serological reactions were observed with histoplasma antigens and not with those of the appropriate group of viruses. Moreover, it was learned that three other members of this man's family were experiencing milder but similar episodes of illness. His son recovered following 2 weeks of bed-rest at home, his wife after only 1 week, and another relative missed only several days at work because of "a very bad cold". As shown in Table 36, agglutinins were demonstrated in the sera from all 3 persons with the milder infections, as well as the father's whose grave illness required 3 months of hospital treatment. Complement

TABLE 36  
SEROLOGICAL REACTIONS IN A FAMILY OUTBREAK OF  
HISTOPLASMOSIS<sup>17</sup>

Case	Days after onset	Complement fixation titre		Collodion agglutination titre (Histoplasmin)
		WYP*	H†	
1 (Father)	15	1:64	Negative	1:64+
	41	1:64	Negative	1:16
	197	1:8	Negative	1:16
2 (Mother)	10	Negative	Negative	1:64
	43	Negative	Negative	1:64
	191	Negative	Negative	1:8
3 (Son)	10	1:64	Negative	1:32
	24	1:256	1:32	1:64
	191	1:128	1:256+	1:8
4 (Sister-in-law)	13	1:8	Not done	1:8
	27	1:64	Not done	1:64
	194	Negative	Not done	Negative

\* † See footnote to Table 35

## SEROLOGICAL TESTS

The conversion of skin tests from negative to positive is another primary criterion for determining whether a recent infection is one of histoplasmosis. However, as exemplified by the cases in Table 38, conversion does not always occur during the earliest stages of the infection. Humoral antibodies frequently are demonstrable much earlier than skin test conversion.

### SEROLOGICAL TESTS IN POST-PRIMARY HISTOPLASMOSIS

In order to counteract the early concept that histoplasmosis was rare and invariably fatal, its benignity has perhaps been overstressed, leaving many clinicians with the impression that the morbidity it produces is negligible. While this is true in many cases, there is increasing evidence that problems relating to the treatment of residual and often undetected infections with *H capsulatum* now surpass those in tuberculosis. The development of special histological stains for fungi<sup>20, 21, 27</sup> led to the discovery that many of the granulomatous lesions heretofore attributed to tuberculosis were, in fact, caused by *H capsulatum*<sup>11, 37</sup>. "Histoplasmomas" are being found in an increasing number of asymptomatic and mildly symptomatic individuals whose multiple or single unhealed lesions are first discovered in routine radiological examinations. In many others, there is cavitation and fibrosis. Finally, there are the frankly disseminated and probably incurable infections. To these must be added persons with histoplasmosis associated with sarcoidosis<sup>24, 25, 36</sup> and, as recently pointed out by Furcolow in his study of patients in sanatoria, those with tuberculosis and histoplasmosis<sup>18</sup>.

The serological patterns observed in non-primary cases vary to some extent with the type, duration and sometimes severity of disease, but it is still impossible to relate serological findings with prognosis<sup>6</sup>. The sera of some chronic cases with pulmonary or extra-pulmonary lesions, and even of some persons with disseminated disease, give negative serological results. On the other hand, there are others with complement fixing titres exceeding 1:2,048 at the time of death<sup>5</sup>. While a negative reaction is not a criterion for excluding infection, a positive one often provides the first clue that a chronic and undetermined illness is one of histoplasmosis.

The reactions recorded in Table 39 were observed in a chronically ill person, and indicate that serological tests and the testing of serial specimens are frequently contributory to the diagnosis of the post-primary case.

This patient was a well-developed though chronically ill Negro female, aged 35 years, who was admitted to the hospital with abdominal



# HISTOPLASMOSIS: SERODIAGNOSIS AND EPIDEMIOLOGY

TABLE 37

SEROLOGICAL RESULTS IN 108 SERA FROM 81 PERSONS WITH PRESUMPTIVE PRIMARY PULMONARY HISTOPLASMOSIS (PANAMA CANAL ZONE)

Number of cases	Specimens	Number of sera	Complement fixation test		
			Positive	Negative	Anticomplementary
60	Single sera				
	1. Collodion positive	35	16	14	5
	2. Collodion negative	20	20	0	0
	3. Collodion not done	5	5	0	0
21	Multiple sera (48)				
	1. Collodion positive	32	15	7	10
	2. Collodion negative	16	16	0	0

TABLE 38

SKIN TEST F  
PRESUMPTIV  
AND GOVER  
PANAMA

LY  
ES  
HE

Number of cases	Skin tests with PPD	Histoplasmin skin tests		
		Positive first test	Converted (4-14 weeks)	Negative
28	Negative	18	9	1
17	Positive	12	5	0
45		30	14	1*

\* Disseminated case

fixing titres in the majority, however, ranged from 1.64 to 1.256. Unfortunately, cultural studies were not done, but as shown in Table 38 additional data in 45 of these cases reported by Cleve and Young revealed that skin test reactions to histoplasmin converted from negative to positive in 14 of the 45 persons, or 31 per cent, during a 4-14 week period of observation<sup>43</sup>. *H. capsulatum* was also later isolated from one of the patients with a CF titre of 1.32 when he was returned to the United States of America because of a residual lung lesion<sup>43</sup>. On the basis of positive serological reactions it is now estimated that, of the hundreds of cases admitted to Gorgas Hospital with what, prior to this study, was termed "pyrexia of unknown origin", primary pulmonary histoplasmosis comprised a high proportion.

## SEROLOGICAL TESTS

### ADDITIONAL EPIDEMIOLOGICAL CONSIDERATIONS

The distribution of *H. capsulatum*, even in areas known to be endemic, appears to be patchy rather than continuous<sup>45</sup>. It is, therefore, possible to find a high dermal sensitivity rate in one section of a small county and a low one only a few miles distant. This may be attributed to certain reservoirs that meet the nutritional requirements of the fungus in the one area but not in another. These requirements are provided in soils high in nitrogenous content, plentifully supplied with moisture and protected from the direct rays of the sun<sup>15</sup>, such as may be found in caves, wooded areas, cellars, clock towers, silos and old chicken houses<sup>3, 8, 19, 22, 28, 29, 33</sup>. The latter have been associated with an impressive number of cases of histoplasmosis since the affinity of *H. capsulatum* for soils contaminated with the excreta of chickens or other fowls was first pointed out by Zeidberg and Ajello in 1952<sup>44</sup>.

Histoplasmosis is, however, not entirely a disease of rural inhabitants. Five of the 7 cases briefly presented in this report were residents of suburban housing developments which were farmlands only a few years before. In these new communities throughout the United States of America, gardening is a common pursuit for which chicken compost is in great demand. Primary histoplasmosis is therefore kept in mind in suburban and urban residents<sup>26</sup> as well as in rural communities.

## REFERENCES

- <sup>1</sup> A . . . . .
- <sup>2</sup> A . . . . .
- <sup>3</sup> Campbell, C. C. (1957) "A Family Outbreak of Histoplasmosis II Epidemiologic Studies" *J. Lab. clin. Med.* 50, 841
- <sup>4</sup> — (1953) Unpublished data
- <sup>5</sup> — and Emmons, C. W. (1957) "Histoplasmosis in the District of Columbia, Maryland and Virginia" *Clin. Proc. Child Hosp. (Wash.)*, 13, 225
- <sup>6</sup> — and Binkley, G. E. (1953) "Serologic Diagnosis with Respect to Human Sera" *Publ. Hlth Rep. (Wash.)*, 64, 551
- <sup>7</sup> Campins, H., Zubillaga, C., Lopez, L. G. and Dorante, M. (1956) "An Epidemic of Histoplasmosis in Venezuela" *Amer. J. trop. Med. Hyg.* 5, 590
- <sup>8</sup> Christie, A. and Peterson, J. C. (1946) "Benign Histoplasmosis and Pulmonary Calcification" *Amer. J. Dis. Child.* 71, 460

# HISTOPLASMOSIS: SERODIAGNOSIS AND EPIDEMIOLOGY

symptoms of 3 months' duration Her temperature varied from 102° to 105° F., and there was generalized infiltration throughout both lung

fungous antigens, and when blastomycin gave a positive result serological tests were carried out In 2 specimens taken over a 5-day interval, the agglutination test was positive for histoplasmosis, while the CF reactions were inconclusive with both antigens for this disease and positive with the blastomyces antigen at a level of 1:64 (Table 39) Six weeks later a third serum sample was sent and on this occasion a significant CF titre of 1:256 was obtained with histoplasmin, while that with the blastomyces antigen had decreased to 1:16 Belated culture studies led to the isolation of *H capsulatum* from the patient's gastric washings and sputum on three separate occasions. This patient, now ambulatory, does not appear to be clinically worse, although her CF antibody has increased to the very high titre of 1:1,024.

## THE PROBLEM OF SEROLOGICAL CROSS-REACTIONS

The fungi that produce the systemic mycoses have common antigens that cross-react in both skin and serological tests<sup>6, 17, 32, 41</sup>. Blastomyces antigen is especially troublesome in this regard, cross-reacting to a marked degree with the sera of some patients with histoplasmosis (Tables 35 and 39) and not at all in others. Cross-reactions, though common and often difficult to interpret, do not invalidate the usefulness of these tests, and even where they are most extensive, attention may be directed to the possibility of a mycotic infection so that cultural and additional serological studies can then be more intensively pursued

TABLE 39  
SEROLOGICAL REACTION IN NON-PRIMARY HISTOPLASMOSIS  
ASSOCIATED WITH SARCOIDOSIS

Date after onset	Complement fixation titre				Collodion agglutination titre (Histoplasmin)
	WYP*	H†	B‡	C§	
16 weeks (?)	Doubtful	Negative	1 64	Negative	1 64
17 "	Doubtful	Doubtful	1 64	Negative	1 128
23 "	Negative	1 256	1 16	Negative	1 32
25 "	Negative	1 512	1 8	Negative	1 32
29 "	Negative	1 1024	Negative	Negative	1 16
32 "	Negative	1 1024	Negative	Negative	Negative

\*. †. ‡ § See footnote to Table 35

† Antigen insufficiency, test unsatisfactory

## REFERENCES

- <sup>29</sup> Loosli, C. G., Grayston, J. T., Alexander, E. R., and Tanzi, F. (1952) "Epidemiological Studies of Pulmonary Histoplasmosis in a Farm Family." *Amer. J Hyg.*, 55, 392
- <sup>30</sup> Palmer, C. E. (1945) "Non-tuberculous Pulmonary Calcification and Sensitivity to Histoplasmin" *Publ Hlth Rep (Wash.)*, 60, 513
- <sup>31</sup> — (1946) "Geographic Differences Sensitivity to Histoplasmin among Student Nurses" *Publ Hlth Rep (Wash.)*, 61, 475
- <sup>32</sup> — and Edwards, P. Q. (1957) "Cross Reactions with Fungus Skin Testing Antigens and their Interpretations" *Proceedings Symposium on Coccidioidomycosis*, February 1957.
- <sup>33</sup> Parrot, T., Taylor, G., Poston, M. A., and Smith, D. T. (1955) "An Epidemic of Histoplasmosis in Warrenton, North Carolina" *Sth med J.*, 48, 1147
- <sup>34</sup> Parsons, R. J., and Zarafonietis, C. J. D. (1945) "Histoplasmosis in Man Report of Seven Cases and Review of Seventy-one Cases" *Arch Intern Med.*, 75, 1
- <sup>35</sup> Peabody, J. W. (1956) "Histoplasmosis: Unravelling the Panamanian Puzzle" *New Engl J Med.*, 255, 409
- <sup>36</sup> Pinkerton, H., and Iverson, L. (1952) "Histoplasmosis: Three Fatal Cases with Disseminated Sarcoid-like Lesions" *Arch Intern Med.*, 90, 456
- <sup>37</sup> Puckett, T. F. (1953) "Pulmonary Histoplasmosis: A Study of Twenty-two Cases with Identification of *H. capsulatum* in Resected Lesions" *Amer Rev Tuberc.*, 67, 453
- <sup>38</sup> Salvin, S. B., and Furcolow, M. L. (1954) "Precipitins in Human Histoplasmosis" *J Lab clin Med.*, 43, 259
- <sup>39</sup> Saslaw, S., and Campbell, C. C. (1949) "A Collodion Agglutination Test for Histoplasmosis" *Publ Hlth Rep (Wash.)*, 64, 424
- <sup>40</sup> Schwartz, J., and Baum, G. L. (1957) "The History of Histoplasmosis, 1906 to 1956" *New Engl J Med.*, 256, 253
- <sup>41</sup> Smith, C. E., Saito, M. T., Beard, R. R., Rosenberger, H. G., and Whiting, E. G. (1949) "Histoplasmin Sensitivity and Coccidioidal Infection: I. Occurrence of Cross Reaction" *Amer J publ Hlth.*, 39, 722
- <sup>42</sup> Tucker, H. A. (1951) "Histoplasmin Sensitivity in the Panama Canal Zone: A Correlated Clinicopathologic Study of One Thousand Patients, with Speculations as to the Present Status of *Histoplasma capsulatum* on the Isthmus of Panama" *Arch Derm Syph., N Y.*, 64, 713
- <sup>43</sup> Young, R. V., Cleve, E. A., and Mastellari, A. (1957) "Acute Pulmonary Histoplasmosis on the Isthmus of Panama" *Arch intern Med.*, 100, 430
- <sup>44</sup> Zeidberg, I. D., Ajello, L., Dillon, A., and Runyon, L. C. (1952) "The Isolation of *Histoplasma capsulatum* from Soil" *Amer J publ Hlth.*, 42, 930
- <sup>45</sup> — Dillon, A., and Gass, R. S. (1951) "Some Factors in the Epidemiology of Histoplasmin Sensitivity in Wilhamson County, Tennessee" *Amer J publ Hlth.*, 41, 80

# HISTOPLASMOSIS: SERODIAGNOSIS AND EPIDEMIOLOGY

- 10 Darling, S. T. (1906) "Protozoon General Infection Producing Pseudo-tubercles in Lungs and Focal Necroses in Liver, Spleen and Lymph Nodes" *J. Amer. med. Ass.*, 46, 1283.
- 11 Davis, E. W., Peabody, J. W., and Katz, S. (1946) "The Solitary Pulmonary Nodule" *J. thorac. Surg.*, 32, 728.
- 12 Draheim, J. H., Mitchell, J. R., and Elton, N. W. (1951) "Histoplasmosis Fourth case report from the Canal Zone" *Amer. J. trop. Med.*, 31, 753
- 13 Edwards, L. B., Peeples, W. J., and Berger, Anne G. (1958) "Prevalence of Sensitivity to Tuberculin and Histoplasmin among High School Students in Montgomery County, Maryland" *Pediatrics*, 21, 389
- 14 Edwards, P. Q., and Kier, J. H. (1956) "World-wide Geographic Distribution of Histoplasmosis and Histoplasmin Sensitivity." *Amer J trop Med Hyg*, 5, 235
- 15 Emmons, C. W. (1952) "Isolation of *Histoplasma capsulatum* from Soil" Proceedings of the Conference on Histoplasmosis. US Dept Health, Educ and Wel Monograph No 39, p 237
- 16 — (1954) "The Significance of Saprophytism in the Epidemiology of the Mycoses" *Trans N Y Acad Sci*, 17, 157.
- 17 — Olson, B. J., and Eldridge, W. W. (1945) "Studies of the Role of Fungi in Pulmonary Disease I Cross Reactions of Histoplasmin." *Publ Hlth Rep (Wash)*, 60, 1383
- 18 Furcolow, M. L., and Brasher, C. A. (1956) "Chronic Progressive (Cavitary) Histoplasmosis as a Problem in Tuberculosis Sanatoriums" *Amer Rev Tuberc*, 73, 609
- 19 C — — — — — "Occurrence of Histoplasmosis  
*Amer J publ Hlth*, 43, 665
- 20 G — — — — — "in Tissue Sections" *Amer J.*
- 21 Grocott, R. G. (1955) "Gomori's Methenamine Silver Nitrate Technic for Fungi in Tissue Sections and Smears" *Amer J clin. Path*, 25, 975
- 22 Hazen, E. L., Little, G. N., and Mordant, V. (1956) "Isolation of *Histoplasma capsulatum* from Two Natural Sources in the Mohawk Valley, one the Probable Point Source of Two Cases of Histoplasmosis" *Amer J publ Hlth*, 46, 880
- 23 Hill, G. B., and Campbell, C. C. (1956) "A Further Evaluation of Histoplasmin and Yeast Phase Antigens of *Histoplasma capsulatum* in the CF Test" *J Lab clin Med* 48, 255
- 24 Israel, H. L., Delamater, E., Sones, M., Willis, W. D., and Mirmelstein, A. (1951) "An Investigation of the Relationship of Chronic Disseminated Histoplasmosis and Sarcoidosis" *Bull N Y Acad Med*, 27, 403.
- 25 — — — — — (1952) "Chronic Disseminated Histoplasmosis An Investigation of its Relationship to Sarcoidosis" *Amer J Med*, 12, 252
- 26 Kier, J. H., Campbell, C. C., Ajello, L., and Sutliff, W. D. (1954) "Acute Bronchopneumonic Histoplasmosis following Exposure to Infected Garden Soil" *J Amer med Ass*, 155, 1230
- 27 Kligman, A. M., and Mescon, H. (1950) "The Periodic Acid-Schiff Stain for the Demonstration of Fungi in Animal Tissue" *J Bact*, 60, 415
- 28 Kolb, K. P., and Campbell, C. C. (1957) "A Family Outbreak of Histoplasmosis I Clinical, Laboratory and Follow-up Studies" *J. Lab clin. Med*, 50, 831.

## REFERENCES

- <sup>20</sup> Loosli, C. G., Grayston, J. T., Alexander, E. R., and Tanzi, F. (1952) "Epidemiological Studies of Pulmonary Histoplasmosis in a Farm Family" *Amer J Hyg*, 55, 392.
- <sup>21</sup> Palmer, C. E. (1945) "Non-tuberculous Pulmonary Calcification and Sensitivity to Histoplasmin" *Publ Hlth Rep (Wash)*, 60, 513
- <sup>22</sup> — (1946) "Geographic Differences Sensitivity to Histoplasmin among Student Nurses." *Publ Hlth Rep (Wash)*, 61, 475
- <sup>23</sup> — and Edwards, P. Q. (1957) "Cross Reactions with Fungus Skin Testing Antigens and their Interpretations" *Proceedings Symposium on Coccidioidomycosis*, February 1957.
- <sup>24</sup> Parrot, Y., Taylor, G., Poston, M. A., and Smith, D. T. (1955) "An Epidemic of Histoplasmosis in Warrenton, North Carolina" *Sth med J*, 48, 1147
- <sup>25</sup> Parsons, R. J., and Zarafonitis, C. J. D. (1945) "Histoplasmosis in Man Report of Seven Cases and Review of Seventy-one Cases" *Arch intern Med*, 75, 1
- <sup>26</sup> Peabody, J. W. (1956) "Histoplasmosis Unravelling the Panamanian Puzzle" *New Engl J Med*, 255, 409
- <sup>27</sup> Pinkerton, H., and Iverson, L. (1952) "Histoplasmosis Three Fatal Cases with Disseminated Sarcoid-like Lesions" *Arch Intern Med*, 90, 456
- <sup>28</sup> Puckett, T. F. (1953) "Pulmonary Histoplasmosis A Study of Twenty-two Cases with Identification of *H. capsulatum* in Resected Lesions" *Amer Rev Tuberc*, 67, 453
- <sup>29</sup> Salvan, S. B., and Farcolow, M. L. (1954) "Precipitins in Human Histoplasmosis" *J Lab clin Med*, 43, 259
- <sup>30</sup> Saslaw, S., and Campbell, C. C. (1949) "A Collodion Agglutination Test for Histoplasmosis" *Publ Hlth Rep (Wash)*, 64, 424
- <sup>31</sup> Schwarz, J., and Baum, G. L. (1957) "The History of Histoplasmosis, 1906 to 1956" *New Engl J Med*, 256, 253
- <sup>32</sup> Smith, C. E., Saito, M. T., Beard, R. R., Rosenberger, H. G., and Whiting, E. G. (1949) "Histoplasmin Sensitivity and Coccidioidal Infection I Occurrence of Cross Reaction" *Amer J publ Hlth*, 39, 722
- <sup>33</sup> Tucker, H. A. (1951) "Histoplasmin Sensitivity in the Panama Canal Zone A Correlated Clinicopathologic Study of One Thousand Patients, with Speculations as to the Present Status of *Histoplasma capsulatum* on the Isthmus of Panama" *Arch Derm Syph, N Y*, 64, 713
- <sup>34</sup> Young, R. V., Cleve, E. A., and Mastellari, A. (1957) "Acute Pulmonary Histoplasmosis on the Isthmus of Panama" *Arch intern Med*, 100, 430
- <sup>35</sup> Zeldberg, L. D., Ayello, L., Dillon, A., and Runyon, L. C. (1952) "The Isolation of *Histoplasma capsulatum* from Soil" *Amer J publ Hlth*, 42, 930
- <sup>36</sup> — Dillon, A., and Gass, R. S. (1951) "Some Factors in the Epidemiology of Histoplasmin Sensitivity in Williamson County, Tennessee" *Amer J publ Hlth*, 41, 80

## HISTOPLASMIN TESTING IN DIFFERENT GEOGRAPHIC AREAS

PHYLLIS Q EDWARDS

HISTOPLASMIN testing is a most useful epidemiological tool for defining the geographic distribution and prevalence of infection with *Histoplasma capsulatum*. It is important to recognize, however, that not all histoplasmin sensitivity is caused by histoplasma infection and to distinguish, where possible, specific from non-specific reactions. For histoplasmin testing, as for tuberculin, a standardized antigen is essential for the interpretation of results and for comparison of findings from one area to another. General application of the traditional millimetre criterion for a positive reaction may give, as in reactions to tuberculin, misleading results in some areas. By carefully measuring all reactions and presenting the results as percentage frequency distributions, the pattern of the distribution can be made which provides a basis for making the distinction required between specific and non-specific histoplasmin sensitivity. Additional evidence can be obtained from study of the frequency of pulmonary calcifications.

The map shown in Fig. 95 was prepared one year ago and shows where histoplasmin testing surveys had been carried out and the percentage of reactions reported as positive in each locality<sup>2</sup>. It illustrates that sensitivity to histoplasmin is prevalent in the Americas, particularly in the east-central part of the United States of America, the Central American countries, and some regions of South America. Europe seems to be free, but so far as can be judged from the few scattered surveys reported from Africa and Asia, low prevalence endemic areas may exist in east-central Africa, perhaps also in the Union of South Africa, and in some parts of south-east Asia (Indonesia, the Philippines and Viet-Nam). The map was compiled from data in which the percentages of positive reactions were reported in the traditional form as reactions measuring more than a specified size, usually 5 millimetres.

### SKIN SENSITIVITY

Both animal experiments and studies in man have shown that skin sensitivity to histoplasmin may result from infection with other fungus organisms<sup>4,5,9</sup>. We know, for example, that persons

# HISTOPLASMIN TESTING




FIG. 95 — Reported prevalences of histoplasmin sensitivity in different parts of the world<sup>2</sup> (By courtesy of the Editor of *Amer J trop Med Hyg*)



## HISTOPLASMIN TESTING

infected with *Coccidioides immitis* often react to histoplasmin as well as to coccidioidin. Histoplasmin sensitivity due to infection with other fungi is also thought to occur. In order, then, to define the geographic distribution and prevalence of histoplasma infection, it is necessary to distinguish between the histoplasmin sensitivity caused by histoplasma infection, which may be referred to as specific sensitivity, and that caused by other fungus infections, or non-specific sensitivity. Results of testing in different geographic areas have revealed striking variations in the pattern of response to histoplasmin<sup>1, 3, 8</sup>. One characteristic pattern of reactions is found in areas where histoplasmosis is prevalent, as evidenced by clinical disease and high frequencies of pulmonary lesions and calcifications in persons who react to histoplasmin but not to tuberculin. Another and quite different pattern characterizes the sizes of the reactions of an essentially negative population, where neither histoplasmosis nor coccidioidomycosis nor any other sensitizing agent appears to be present. Still another kind of pattern is found in areas where coccidioidomycosis or some other cross-sensitizing infection is prevalent but histoplasmosis is not.

These several different kinds of patterns are illustrated in material collected by the United States Public Health Service during a two-year period from 1949 to 1951. During that period, young men from all parts of the country were examined radiologically and tested with histoplasmin, coccidioidin and tuberculin as they arrived at a training centre in California for military service. Most of the histoplasmin tests were given by intradermal injection of 0.1 millilitre of a 2:1,000 dilution of the product identified as H-40, prepared by the Public Health Service. Coccidioidin C-24, prepared by Dr Charles E. Smith, and the international standard PPD tuberculin, PPD-S, prepared by Dr Florence Seibert, were used for the other two tests. The testing was done by a team trained to use uniform techniques and to measure and record the size of the induration of the reactions.

Results obtained from nearly 40,000 white men between the ages of 17 and 21 years who had lived all their lives in their home counties were used to study the response to histoplasmin in different geographic areas throughout the country<sup>3, 6, 8</sup>.

In the United States of America histoplasmin sensitivity is highly prevalent in the east-central area, extending roughly from the Mississippi valley in the west to the Appalachian mountains in the east, from the Great Lakes in the north to the Gulf of Mexico in the south (Fig 96). In some localities within that area, more than 80 per cent of the young adults have histoplasmin reactions measuring

## HISTOPLASMIN TESTING

5 millimetres or more. Clinical cases of histoplasmosis are diagnosed frequently in that area and subclinical cases with benign pulmonary infiltrations or calcified lesions are very common. The area is endemic for histoplasmosis. Most of the eastern coastline, as well as the entire north-west, is essentially free from this fungous infection, and in the south-west, where coccidioidomycosis is endemic, the prevalence of histoplasmin reactions measuring 5 millimetres or more exceeds 30 per cent in some areas.




FIG 96 —Prevalence of histoplasmin sensitivity in young adults (By courtesy of the Editor of *Dis Chest*)

Fig 97 shows the percentage of coccidioidin reactions measuring 5 millimetres or more throughout the United States of America. The high prevalence area is sharply limited to southern California, Arizona, New Mexico and the western part of Texas. Coccidioidomycosis is endemic in these south-western states, as evidenced by large numbers of clinical and subclinical cases of the disease arising locally. From the middle of Texas and eastward across the histoplasma endemic area, the prevalence of coccidioidin sensitivity is well below 5 per cent, and it is negligible in the north-west and south-east.

In interpreting the results of testing with histoplasmin, the pattern of response as shown by the sizes of the reactions can be expected

## HISTOPLASMIN TESTING

to indicate whether specific sensitivity is involved, because it is known that reactions caused by infection with the homologous organism are generally larger than reactions caused by infection with some heterologous organism<sup>3, 4, 5, 9</sup>.




FIG 97 —Prevalence of coccidioidin sensitivity in young adults (By courtesy of the Editor of *Dis Chest*)

## FREQUENCY DISTRIBUTIONS

Frequency distributions by size of reaction to histoplasmin in the histoplasmosis endemic area are given in Fig 98. The results are for recruits from 9 east-central states, in which area most of the reactions to histoplasmin can probably be ascribed to specific histoplasma infection. Groups of counties within the 9 states were combined according to the prevalence of sensitivity: counties with a prevalence of more than 70 per cent were combined and called Area D, counties with from 50 to 70 per cent were called Area E, with from 30 to 50 per cent, Area F, and with from 10 to 30 per cent, Area G. The sizes of the reactions for each area are plotted along the horizontal axis, and the percentages of reactions of specified sizes are shown by the height of the corresponding column.

The frequency of reactions measuring 4 millimetres or more in Area D is about 83 per cent, in Area E about 67 per cent, in Area F 45 per cent, and in Area G 18 per cent. In each instance, the reactions distribute themselves into two groups, one at the left

## HISTOPLASMIN TESTING

composed of 0, 1, 2 and some 3 and 4 millimetre reactions and the other towards the right, in a form resembling the normal probability curve, with reactions measuring from 2, 3 and 4 millimetres up to more than 25 millimetres. It can be assumed that the population in each area is composed of two groups of persons, some who have been infected with *Histoplasma* and some who have not. The two




FIG. 98.—Histoplasmin reactions in navy recruits from the east-central states

groups of reactions in each distribution are interpreted as representing the infected and the uninfected groups in the population. Persons with 2-4 and perhaps 5 millimetre reactions, in the range where the two groups overlap, are a mixture of some infected and some uninfected. Most of the infected, however, have fairly large reactions of 10-11 millimetres average diameter, and most of the uninfected have no measurable induration.

Several implications may be drawn from these results about the

## HISTOPLASMIN TESTING

nature of specific histoplasmin sensitivity. First, the positive (specific) reactions are distributed fairly symmetrically around a central value, which represents the mean or average size reaction. Secondly, the average size of specific reactions does not vary with the prevalence of infection, whether it is as high as 80 per cent or down to only 20 per cent. The only important difference between the four distributions is the relative proportion of large (positive) and very small (negative) reactions. In the endemic area, the 5 millimetre criterion is too high for estimating the percentage of positive reactions. Many of the 5, 4 and even 3 and 2 millimetre reactions certainly belong to the positive group. The traditional 5 millimetre criterion would, if applied here, underestimate the percentage of infected in the population.

In an essentially negative population, on the other hand, the 5 millimetre criterion would overestimate the percentage of infected persons.

As illustrated by the results shown in Fig 99 for lifetime residents of 5 north-western states, more than 99 per cent of the reactions belong to the negative group at the left-hand part of the scale. Many of the 4 and 5 millimetre reactions, and even some of the 6 and 7 millimetre reactions, are interpreted as negative. The very small group of large reactions centering around 10-11 millimetres probably represents the positive group, which can be most efficiently separated from the negative group at about the 7-8 millimetre level. To make the customary separation arbitrarily at 5 millimetres would result, here, in overestimating, by about 100 per cent, the proportion of specific reactions, as about equal numbers of infected and uninfected would be classified as positive.

A very different pattern of response is found in the south-west, where *Coccidioides* is highly prevalent. Histoplasmin reactions in that area, as shown in Fig 100, form a step-like distribution from a high frequency at 0-1 millimetre to successively lower frequencies along the scale towards the larger sizes. The main difference between this distribution and the one for the north-west is the relative increase in the proportion of small reactions. A great many more persons living in the south-west react with 3-5 and up to 9 or 10 millimetres than in the north-west. The small group of subjects showing large reactions probably represents specific sensitivity to histoplasmin, but most of the small reactions must be interpreted as non-specific sensitivity, in this instance to cross-reactions resulting from coccidioid infection. This is clearly indicated by the distributions in the lower part of Fig 100 where the total population has been subdivided into two groups: those with a coccidioidin reaction of less

# HISTOPLASMIN TESTING




FIG 99—Histoplasmin reactions in navy recruits from 5 north-western states





FIG 100—Histoplasmin reactions in navy recruits from the south-western states

## HISTOPLASMIN TESTING

than 4 millimetres (left) and those with a coccidioidin reaction of 4 millimetres or more (right). Most of the small histoplasmin reactions are found in persons who also react to coccidioidin. Simply to report that some 10 per cent of the histoplasmin reactions measure 5 millimetres or more would obscure the fact that at least two-thirds of them cannot be interpreted as specific for histoplasmal infection.




FIG 101 —Histoplasmin reactions in navy recruits from Kansas, Oklahoma, Texas and Louisiana

A somewhat similar pattern of histoplasmin reactions is found in another section of the country. Fig 101 shows the frequency distribution of reactions for lifetime residents of 4 adjacent states lying east of the coccidioid endemic area and on the western fringe of the histoplasmal endemic area (Kansas, Oklahoma, Texas and Louisiana). Some, perhaps most, of the large reactions can be interpreted as specific for histoplasmal infection, but the small reactions filling in the range between specific and negative reactions

## HISTOPLASMIN TESTING

undoubtedly represent sensitization by some other infection. Thus, although some 30 per cent of the reactions measure 4 millimetres or more, about two-thirds of them are interpreted as non-specific. They cannot, in this instance, be attributed to coccidioidal infection as the population in this area is essentially free of coccidioidin sensitivity, nor can they be ascribed to histoplasma infection because the pattern of the distribution is so different from that found in the histoplasma endemic area.

Another way of trying to distinguish between specific and non-specific sensitivity is by studying the relation between pulmonary calcifications and size of reactions. A high degree of correlation exists between specific histoplasmin sensitivity and pulmonary calcification<sup>7</sup>, so if histoplasmin sensitivity is associated with a very low frequency of calcification in some area, there is good reason to believe that at least some of the reactions are not caused by histoplasma infection. This was found to be the case in the studies made in the states referred to in Fig 101, supporting the conclusion that the bulk of the histoplasmin reactions in this zone are non-specific reactions owing to sensitization by some other agent whose identity is unknown at the present time.

In Fig 102, frequency distributions are given for histoplasmin reactions in Sudan, Indonesia and India, where general population groups were tested by World Health Organization teams, using H-42 from the Public Health Service in a dilution of 1:100<sup>1</sup>. In Equatoria, the distribution shows the characteristic bimodal pattern, where the population clearly separates itself into two groups, one very likely infected by *Histoplasma*, the other uninfected. The point of separation between the two groups might be made at about 8 millimetres. In the endemic area of the United States of America, the point of separation is considerably lower, but this difference probably reflects only a difference in measuring the sizes of the reactions, for we have reason to believe that the reader in Sudan measured uniformly larger than the readers in the United States of America. The important point, however, is that the pattern of the distributions in the two regions is very similar, both show two fairly distinct groups of reactions which can, with some confidence, be interpreted as representing specific and negative reactions. In each case, a fair estimate can thus be made of the prevalence of histoplasma infection in the locality. In Kedisan, on the island of Bali, the small percentage of large reactions recorded may represent specific sensitivity, whereas the great mass of small reactions should probably be interpreted as non-specific, in Darjeeling, India, the population appears to consist essentially of negative reactors.



## HISTOPLASMIN TESTING




FIG 102—Histoplasmin reactions in 3 different countries  
(By courtesy of the Editor of *Amer J trop Med Hyg*)

## ACKNOWLEDGEMENT

We would like to thank the Editor of *The Lancet* for permission to reproduce this article

## REFERENCES

- Edwards, P Q, Geser, A G, Kjølbye, E H, Mejer, J H, and Worm Christensen, O (1956) "Histoplasmin Testing in Africa and Southern Asia" *Amer J trop Med Hyg*, 5, 224
- and Kiaer, J H (1956) "World-wide Geographic Distribution of Histoplasmosis and Histoplasmin Sensitivity" *Amer J trop Med Hyg*, 5, 235
- and Palmer, C E (1957) "Prevalence of Sensitivity to Coccidioidin, with Special Reference to Specific and Nonspecific Reactions to Coccidioidin and to Histoplasmin" *Dis Chest*, 31, 35

## REFERENCES

- 4 Emmons, C W, Olson, B J, and Eldridge, W W (1945) "Studies of the Cross-reactions of Histoplasmin"  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523

## RADIOLOGY OF PULMONARY MYCOSES

J. W. PIERCE

ONLY very rarely can one look at a radiograph and say that a fungous disease is responsible for the appearances seen, and even less frequently is it possible to implicate any particular fungus. Like bacteria, pathogenic fungi enter the body through the respiratory tract and on reaching the lungs produce pneumonia. The shadowing which results may be of several different types. It may take the form of finely scattered miliary mottling or the coarser, broncho-pneumonic type of mottling; it may present as localized denser areas of consolidation of varying size involving up to a whole lobe, and in addition the *dimorphic fungi* may produce, during the stage of invasion, a primary tubercle-like picture with shadows in the lung fields and enlarged hilar nodes. Most pathogenic fungi can produce most of these pictures, so that it is seldom possible to recognize the causative organism from the examination of a single film. The position is, however, not quite hopeless diagnostically, because at some stage in the course of these diseases most of them produce a fairly characteristic, if not absolutely typical, radiological picture.

In general the radiological appearances of fungous diseases resemble those seen in chronic tuberculosis or in the chronic suppurative pneumonias. When the infection is widespread throughout the lungs the appearances usually resemble the coarser broncho-pneumonic type of mottling rather than the finer streaking and mottling seen in sarcoid or cases of diffuse interstitial fibrosis. It is important to note that the time to think of a fungous disease is not when an unusual lung picture is first seen, but later, when the course of the disease and the response to treatment prove to be abnormal.

### ACTINOMYCOSIS AND NORTH AMERICAN BLASTOMYCOSIS

These diseases will be dealt with together because both can produce several different types of shadow and because they illustrate how confusing may be the similarity between one mycotic disease and another. Fig 103 shows the widely spread broncho-pneumonic mottling in all zones in a case of actinomycosis. Fig 104 comes from a case of North American blastomycosis, and in both the disease has given rise to fibrosis, displacement of the hilum and a distorted vascular pattern. These types of the two diseases are



FIG 103—Actinomycosis, broncho-pneumonic motting in all zones.

FIG 104—North American blastomycosis, broncho-pneumonic motting in all zones



virtually indistinguishable in radiographs. Both diseases may also produce more dense pulmonary consolidation, sometimes on one side with smaller secondary areas of involvement on the other, and in this type the diseases are again indistinguishable. There is, however, one fairly characteristic picture which sometimes occurs in actinomycosis when thickening of ribs may result from periosteal new bone formation (Fig 105). Though highly characteristic, this appearance cannot be considered as absolutely conclusive since

## RADIOLOGY OF PULMONARY MYCOSES

periostitis may arise in chronic empyemata. In actinomycosis, however, rib involvement often occurs without an empyema, and may appear early in the disease.



FIG 105 —Actinomycosis, periostitis of ribs

### TORULOSIS

*Torulosis* is a localized form of this disease and has mostly

to involve the hilar glands. At most, they may produce some obstructive pneumonia distal to the main lesion, behaving in this respect like benign tumours of the lung. They may be very large and some may cavitate. Torulosis may also present as scattered small rounded shadows throughout the lungs, the appearances being indistinguishable from other causes of widespread pulmonary mottling.

### ASPERGILLOSIS

At least 2 main varieties of this disease are described. The most interesting is the *saprophytic* or *mycetoma* type which takes the form of a solid mass of fungus growing in a cavity. These masses may be found in any pre-existing cavities, most commonly in cases of tuberculosis, or in cavitated infarcts, they do not appear to invade bronchiectatic cavities, as all the cases so far encountered have been in the upper zones. This fungus does not itself appear to cause cavitation. The characteristic radiological picture of a mycetoma is

## RADIOLOGY OF PULMONARY MYCOSES




FIG 106a —Torulosis, toruloma seen as fairly well-defined lesion situated in the right middle lobe



FIG 106b —Torulosis, same case as shown in 106a, lateral view

that ... (Fig ... can be ... unattached within the cavity ... The persistence of such a mass in a

## RADIOLOGY OF PULMONARY MYCOSES

cavity over weeks or months is almost pathognomonic of an aspergillus mycetoma. Similar appearances may be met with in a cavitating neoplasm (though it is extremely rare for cavitation to occur around the periphery of a tumour), in cases where there is a blood clot in a cavity following a haemoptysis, or where there is a dead shrinking hydatid cyst. These last 3 alternatives all concern dead




FIG 107.—Aspergillosis; mycetoma

tissues which would be expected, in time, to change and ultimately to disappear, mycetomas may persist unchanged for months and may even show gradual enlargement. How they originate is not known with certainty but in the following case their development has been observed. The next figures illustrate the development of an aspergillus mycetoma in a young female patient with well-controlled tuberculosis who suddenly began to produce sputum in profusion containing plentiful *Aspergillus fumigatus*. Two very large distension cavities with fluid levels and considerable thickening of their walls were demonstrated (Fig 108a). Three months later the cavities had become smaller and it appeared that the thickened lining of one had crumpled to form a mass within the space which remained. One year later this mass was seen to be discrete and to have air around it (Fig 108b). This suggests that the thickened affected wall may become displaced and may thus constitute

## RADIOLOGY OF PULMONARY MYCOSES



FIG 108a—Aspergillosis,  
thick-walled distension ca-  
vities (21 12 53)



FIG 108b—Aspergillosis,  
same case as shown in  
Fig 108a Mycetoma forma-  
tion in right upper zone  
(28 1 55)

repeated episodes of fever, the expectoration of mucoid plugs, and the occurrence of transient areas of pneumonic consolidation. Figure 109a shows the radiograph of a patient suffering from such an episode, 6 months later all the shadowing had cleared. Two years later the shadowing returned in a different position with a small extension on the other side (Fig 109b), and after a further month additional changes were to be seen. Such a clinical course coupled with these appearances, especially if associated with the expectoration of bronchial casts, is highly suggestive of this type of aspergillosis.



## RADIOLOGY OF PULMONARY MYCOSES

### COCCIDIOIDOMYCOSIS

During the stage of invasion this fungus may give rise to pneumonia producing areas of consolidation in the lung, the shadows resembling those seen in any ordinary bacterial or viral pneumonia. In cases where the infection is overwhelming, the disease may spread as a miliary mottling throughout both lungs. In addition, the initial infection may closely simulate primary tuberculosis with discrete foci in the lung and enlarged hilar glands, both of which may later calcify.




FIG 109a—Aspergillosis, allergic type. Areas of pneumonic consolidation (2 1 53)



FIG 109b—Aspergillosis, same case as shown in Fig 109a, new areas of consolidation (12 10 56)

The course of the disease is usually benign, the shadows clearing and leaving, at most, small calcified foci. An occasional area of consolidation may cavitate, or may partially resolve, leaving behind a few isolated rounded opacities which are indistinguishable from those seen in pulmonary tuberculosis, and which may be visible for years. Sometimes a cavity will remain after the surrounding consolidation has cleared, and may persist for many months or years as a smooth thin-walled cavity, usually without fluid, and liable to changes in size with alteration in tension (Fig 110). This appearance is highly suggestive of coccidioidomycosis, and is almost diagnostic in persons living in the endemic area.

## RADIOLOGY OF PULMONARY MYCOSES

### HISTOPLASMOSIS

Histoplasmosis may also occur in several different forms. The disease may present with one or more areas of pneumonia (which unlike those of coccidioidomycosis do not cavitate), with an isolated lung lesion and enlarged glands as in primary tuberculosis, or with widespread small foci densely scattered throughout both lungs.

The initial stage of invasion usually heals without permanent lung damage, but both glands and lung lesions are very liable to calcify.



FIG 110—Coccidioidomycosis, thin-walled cavity

(Figs 111a and 111b) These rather dense, regular, rounded opacities are the most characteristic appearance of histoplasmosis, but they are not easily distinguishable from those found in tuberculosis. On the whole, they are a little more densely calcified, tend to remain discrete with less evidence of aggregation, and to be more evenly scattered over the lung fields without the predominantly upper zone distribution of the calcified foci of tuberculosis.

This fungus can also produce a form of chronic fibrosing lung disease which can exactly mimic chronic pulmonary tuberculosis, even to progressive fibrosis and cavitation (Figs 112a and 112b).

The only 2 cases of acute histoplasmosis found in this country were both in patients who had lived in endemic areas, though both had been in England for 5 years. Both patients died from the acute disseminated form of the disease, the spread in both cases following shortly on a biopsy, in one case of a laryngeal lesion thought to be tuberculous, the other of a tonsillar ulcer.





FIG 111a —Histoplasmosis; widespread patchy consolidation and glandular enlargement

FIG 111b —Histoplasmosis, same case as shown in Fig 111a, 4 years later. Calcified nodules



## RADIOLOGY OF PULMONARY MYCOSES





FIG 112a—Histoplasmosis, lesions closely resembling chronic pulmonary tuberculosis

FIG 112b—Histoplasmosis, same case as shown in Fig 112a, 5 years later. Cavitation and fibrosis on right side





**PART II**

**TREATMENT  
OF MYCOTIC DISEASES**



# THE MODE OF ACTION OF ANTI-FUNGAL DRUGS

GORDON T. STEWART\*

In this study 5 groups of drugs were compared in mode of action *in vitro* against 5 groups of fungi. The drugs, 10 in number, represented widely differing substances: polyenes, diamidines, quinolines, aliphatic substances and triphenylmethane dyes. The organisms were from the main pathogenic groups, at least 2 different varieties of each genus being represented.

## RESULTS

These substances varied considerably in activity (Table 40). The widest range was shown by 2 chlorinated oxyquinolines, which were strongly inhibitory to all the organisms tested at concentrations of 10  $\mu$ g per millilitre or lower. The highest degree of activity against any one organism was that of amphotericin B against *Candida albicans* and *Microsporum audouinii*, and of pentamidine against *Aspergillus niger*. Activity of this order (1  $\mu$ g. per millilitre) is fairly specific, and is not part of a general anti-protoplasmic toxicity.

The components of activity shown by these various drugs were as follows

### DIRECT EFFECTS UPON THE MORPHOLOGY OF THE ORGANISMS

This was studied by microscopy of living cells from cultures containing the various drugs. It is technically important, in direct comparisons of this kind, to use the drugs in soluble forms but, at the same time, to exclude any independent or adjuvant effects contributed by the solvents. In our experiments, the solvent (dimethyl formamide) was present at a final strength of 1 per cent in all preparations, control and test, at which strength it appeared to be quite inert.

Direct microscopic observation of living, unstained preparations showed that none of the drugs possessed an immediate, cytotoxic effect. The earliest visible effect was the inhibition of budding in the yeast-like organisms in 3-8-hour cultures, best shown by the polyene antibiotics and the halogenated oxyquinolines. Thereafter, abnormal morphological changes gradually began to occur in hyphae and spores, but only with certain drugs.

\* With the technical assistance of R. J. Holt



## THE MODE OF ACTION OF ANTI-FUNGAL DRUGS

**Hyphae.**—The two halogenated oxyquinolines at 2  $\mu$ g. per millilitre caused swelling and vacuolation in cultures of *A. niger* (Fig 113). The hyphae were especially thin and rarefied where conidia were forming. This type of change was obvious after 24–48 hours' growth. Rimocidin (10  $\mu$ g. per millilitre; Davisson and his colleagues<sup>2</sup>) caused similar though less obvious changes, and also affected visibly the hyphae of *Aspergillus fumigatus* and *Trichophyton mentagrophytes*.




FIG 113 — *Aspergillus niger*. (a) Normal hyphae. (b) Effect of chlorhydroxyquinoline (5  $\mu$ g. per millilitre), swelling and vacuolation of hyphae ( $\times 360$ )

**Spores.**—Rimocidin (5  $\mu$ g. per millilitre) began to act upon *C. albicans* in 4 hours. At 8 hours, the majority of the spores showed slight swelling and vacuolation and, by 24 hours, this change was very marked indeed. When studied by interference microscopy (Fig 114), the changes in the refractility and other optical properties of the cells were very striking. This rimocidin effect was present even while a proportion of the cells were budding, so it obviously did not affect all phases of growth. Nystatin, in contrast, caused an absolute cessation of budding without causing comparable cytoplasmic changes, though some shrinkage and loss of refractility were evident at 8 hours. This recalls the observation of Blank<sup>1</sup> who found by electron microscopy that nystatin caused intracellular lysis slowly, in 3–8 days, without damaging the cell wall.

## RESULTS




FIG 114.—*Candida albicans*. (a) Normal cells. (b) Effect of rumodicin (2 µg per millilitre); swollen cells with abnormal vacuolation and granulation of cytoplasm ( $\times 360$ ).




FIG 115.—*Aspergillus niger*. (a) Normal conidiophores and hyphae. (b) Effect of chlorhydroxyquinoline (15 µg per millilitre), abnormal conidiophores, defective sporulation ( $\times 90$ ).

## THE MODE OF ACTION OF ANTI-FUNGAL DRUGS

Another conspicuous effect was that of the halogenated oxyquinolines upon the sporing of *A. niger*. The vesicles developed, but were almost devoid of mature spores or pigment and "bald" in appearance (Figs 115, 116).

### EFFECTS UPON CELL DIVISION

The polyene antibiotics, pentamidine and the halogenated oxyquinolines were all readily fungistatic, in that complete inhibition of cell division could usually be attained at levels of not more than




FIG 116—*Aspergillus niger* (a) Normal sporulation (b) Effect of chlorhydroxyquinoline, normal spore-bearing vesicle with absence of spores ( $\times 360$ )

20  $\mu\text{g}$  per millilitre (Table 40), which should be attainable therapeutically in many types of lesion. There were, however, some important exceptions.

Nystatin, in spite of its profound effect upon *Candida* and *Microsporum* species, was much less active towards species of *Aspergillus* and *Trichophyton*, whereas amphotericin B (also a polyene) was highly active against these organisms, suggesting that the hexaenic or heptaenic form conferred greater activity than the diene-tetraene structure of nystatin. None of the 3 antibiotics was active against the actinomyces, which is not surprising in view of their origin from the *Streptomyces* species, but the oxyquinolines and pentamidine were fully active. In general terms, higher concentrations of

TABLE 40  
EFFECT OF VARIOUS GROUPS OF DRUGS IN VITRO UPON REPRESENTATIVE PATHOGENIC FUNGI

Group of drugs	Name of drug	Minimum fungistatic concentration in $\mu\text{g}$ per millilitre against				
		<i>Candida</i> <i>C. albicans</i>	<i>Actinomyces</i> <i>N. asteroides</i>	<i>Aspergillus</i> <i>A. niger</i>	<i>Trichophyton</i> <i>T. mentagrophytes</i>	<i>Microsporum</i> <i>M. audouinii</i>
Polyene antibiotics $(\text{CH}=\text{CH})_n$	Nystatin	10	$\geq 20$	$> 20$	$> 20$	2
	Amphotericin B	1	$> 20$	20	5	1
Other antibiotics	Rimocidin	15	$\geq 20$	5	10	10
Diamidines 	Pentamidine	20	10	1	$\geq 20$	2
Quinolines (Halogenated)	Chlorhydroxy-quinoline	5	5	5	10	2
	Dichlorhydroxy-quinoline	5	5	10	10	1
Aliphatic alcohols and acids 	n-Propanol	600		12,000		
	Undecylenic acid	{100}	$> 20$	$\geq 20$	$\geq 20$	2
Triphenylmethanes 	Gentian violet	{100}	$\geq 20$	$\geq 20$	$\geq 20$	20

## THE MODE OF ACTION OF ANTI-FUNGAL DRUGS

all the drugs were required to inhibit the growth of *Aspergillus* and *Trichophyton* than that of *Microsporum* or *Candida*. Organisms growing at subinhibitory concentrations of these substances were successively subcultured into media containing rising levels of the same substances, without showing intensification of growth. It seemed that, in spite of the lack of lysis, drug-resistance *in vitro* was not easily acquired.




FIG 117—The effect of various drugs upon the growth of *Candida albicans* *in vitro*

### FUNGICIDAL EFFECTS

Interference with growth, and fungistasis, were relatively easily obtained *in vitro*. Fungicidal effects (lysis of inoculum and sterile subculture) were rare (Fig 117). Even cells which had been greatly altered in appearance by rimocidin or the oxyquinolines seemed able to revive and propagate normally in drug-free subcultures. Amphotericin B was the only drug which lowered the blastospore count and actually killed the bulk of the inoculum of *Candida*. The oxyquinolines, pentamidine and amphotericin were partly lethal to *A. niger* and *A. fumigatus*, and the oxyquinolines had some destructive action upon *T. mentagrophytes*.

## RESULTS

### METABOLIC INTERFERENCE

Carbohydrates are key substances in the metabolism of pathogenic fungi. Thus laevulose, dextrose and maltose greatly enhance, in that order, the growth of *Candida*. There are a number of points of interaction between the carbohydrate metabolism of fungi and their inhibition by drugs. The polyenes were found to be 20-40 times more active against *Candida* in laevulose than in dextrose (Fig 118) whereas the oxyquinolines and pentamidine were correspondingly more active in dextrose than in laevulose. This was




FIG 118.—The effect of nystatin and pentamidine upon *Candida albicans* in plain peptone water, dl (+) dextrose peptone water, and dl (–) laevulose peptone water

independent of pH change, and no such interactions were exhibited by these sugars against undecylenic acid, rimocidin or gentian violet. A similar, antagonistic effect was shown by dextrose against the action of the polyenes on *A. niger*.

The difference in the interaction of dextrose and laevulose suggested that isomerism might be a factor. This was borne out by the fact that *n*-propanol was much more active than its isomer against *Saccharomyces*, *Candida* and *Aspergillus* (Fig 119). Such inhibitory action on the part of alcohols was influenced also by aliphatic-chain length, as ethanol, propanol and butanol were

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

E. DROUHET

*The fungous diseases, often chronic and sometimes fatal, are among the most difficult infections to control. Bacterial infections can be controlled by vaccines, antisera and numerous antibacterial substances. Viral infections, though lacking specific treatment, can be prevented by immunization. These measures are not available, however, for the mycotic infections.*

Numerous antifungal agents are active *in vitro*, but few are effective *in vivo*. The great majority of chemical antifungal agents are effective only in the superficial mycoses by local applications; few can be used by the oral route (Table 41)<sup>7, 36, 38, 39, 43, 45</sup>.

## ANTIFUNGAL DIAMIDINES AND ANTIBIOTICS









The aromatic diamidines are effective by oral or parenteral routes in the systemic blastomycoses, but toxic side-effects limit their use. More promising than synthetic chemical agents for the treatment of fungous diseases are the antifungal antibiotics. The various antibiotics so far isolated may be divided after Waksman<sup>60</sup> into 3 broad groups on the basis of their respective antimicrobial spectra (Table 42). Besides the antibiotics with antibacterial and anti-actinomycotic spectra there is another category of antibiotics (including tyrothricin and gliotoxin) which is active both on bacteria and fungi but too toxic for therapeutic use, the last and most interesting category for fungous treatment includes antibiotics which are selectively antifungal such as actidione (cycloheximide) and the polyenes ( $\text{CH}=\text{CH}$ )<sub>n</sub>.

**Actidione.**—This is highly active *in vitro* on one pathogenic fungus only, *Cryptococcus neoformans*. In animals, actidione affords no protection to mice infected with this yeast, but in humans<sup>40</sup> it has some activity by intrathecal, intravenous and intramuscular routes (Table 48).

**Polyenes.**—The most interesting antifungal antibiotics are the polyenes, products of *Streptomyces*, possessing in common a conjugated polyene chromophore<sup>48</sup>. They appear to possess generally similar chemical properties but can be classified by examination of their ultraviolet absorption spectra into 4 subgroups, corresponding to the presence of 4, 5, 6 or 7 conjugating double bonds.

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS









TABLE 41  
CHEMICAL STRUCTURE AND THERAPEUTICAL USE OF SOME  
PRINCIPAL ANTIFUNGAL AGENTS

Chemical antifungal agents	Therapeutic use	
	Route of administration	Fungous diseases
Heavy metals: Hg, Ag, Cu, Zn (salts)	Local	Superficial mycoses
Halogens: I <sup>(1)</sup> , Br, Cl	Local (1) Oral or parenteral	Superficial mycoses (1) Sporotrichosis
Sulphur compounds		
   <p>dithio-carbamate (2)</p> <p>rhodamine (3)</p> <p>tetraethylthiuram disulphide (4)</p>	(4) Local	(4) Superficial mycoses
Fatty acids		
$\text{CH}_2=\text{CH}-(\text{CH}_2)_8-\text{COOH}$ undecylenic acid (5)	(5) (6) Local (5) (6) Oral (7) Local	(5) (6) Superficial mycoses (5) (6) Digestive moniliasis (7) Superficial mycoses
$\text{CH}_3(\text{CH}_2)_6\text{COOH}$ caprylic acid (6)		
$\text{CH}_3-\text{CH}_2-\text{COOH}$ propionic acid (7)		
Quaternary ammonium compounds		
 <p>(8)</p>	(8) Local	Superficial mycoses
Antihistamines		
chlorocyclizine HCl methaphenilene HCl diphenhydramine HCl, etc	Local	Dermatomycoses
Compounds with Benzene Nucleus		
Benzoic derivatives		
    <p>benzoic acid (9)</p> <p>salicylic acid (10)</p> <p>p-hydroxybenzoic acid (11)</p> <p>ethyl vanillate (12)</p>	(9) (10) Local (11) (12) Oral	(9) (10) Superficial mycoses (11) Digestive moniliasis (12) Histoplasmosis






# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 41 (continued)

Chemical antifungal agents	Therapeutic use	
	Route of administration	Fungous diseases
<b>Sulphonamides, sulphones</b> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">   <chem>Nc1ccc(S(=O)(=O)N)cc1</chem>              sulphanilamide (13)         </div> <div style="text-align: center;">   <chem>Nc1ccc(C(=O)O)cc1</chem>              p amino benzoic acid (14)         </div> <div style="text-align: center;">   <chem>Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1</chem>              diaminodiphenyl sulphone (15)         </div> </div>	(13) Oral (15) Oral	(13) Anaerobic actinomycosis, South American blastomycosis, (15) Nocardiosis
<b>Phenol derivatives</b> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">   <chem>Oc1ccccc1</chem>              phenol (16)         </div> <div style="text-align: center;">   <chem>Cc1ccccc1O</chem>              cresol (17)         </div> <div style="text-align: center;"> <p>pentaethylene glycolic ether of dichlorocresol (18)</p> </div> </div>	(18) Local	Superficial mycoses
<b>Benzothiazoles</b> 2-dimethyl-amino-6-(β diethyl-amino-ethoxy) benzothiazol (19)	(19) Local	Superficial mycoses
<b>Dyes: Triphenylmethane group</b> <div style="text-align: center;">   <chem>CN(C)c1ccc(cc1)C(=C2C=CC(=CC2)N(CC)CC)c3ccccc3</chem>              malachite green (20)         </div>	(20) Local	Superficial mycoses
<b>Quinones</b> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">   <chem>ClC1=CC(=C(Cl)C(=C1)Cl)Cl</chem>              tetrachloropara-benzoquinone (21)         </div> <div style="text-align: center;">   <chem>COc1c2ccccc2c(=O)c3ccccc31=O</chem>              2-methoxy-1,4-naphthoquinone (22)         </div> </div>	(21) (22) Local	Dermatomycoses

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 41 (continued)

Chemical antifungal agents	Therapeutic uses	
	Route of administration	Fungal diseases
<p>Quinolines</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>5,7-dichloro-8-hydroxy-quinoline (23)</p> </div> <div style="text-align: center;">  <p>5-chloro-7-iodo-8-hydroxy-quinoline (24)</p> </div> </div> <p>Aromatic diamidines</p> <div style="text-align: center;">  <p>(25)</p> </div>	<p>(23) Oral (24) Local</p> <p>(25) Oral and perfusion</p>	<p>(23) Digestive moniliasis (24) Superficial mycoses</p> <p>North American blastomycosis Coccidioidomycosis</p>

**Nystatin, Candicidin and Euclin.**—The comparative fungal spectra of various antifungal antibiotics are given in Table 43. Nystatin, a tetraene polyene antibiotic discovered by Hazen and Brown<sup>27</sup> in 1950, has a spectrum of activity similar to that of amphotericin B.

as *C. neoformans*, *Blastomyces dermatitidis* and *Histoplasma capsulatum*. Amphotericin B (a heptaene) is particularly active on deep-seated fungi<sup>22, 53, 59</sup>. Euclin, a new antibiotic of unknown composition, inactive against *Candida*, is highly inhibitory to fungi causing the deep-seated mycoses, as well as on some bacteria and actinomycetes<sup>62</sup>.

**Nystatin in animal studies and human therapy.**—Data on the toxicity of the antifungal antibiotics is summarized in Table 44 while Tables 45 and 46 show their therapeutic activity in experimental mycoses. The numerous studies on various animals show a definite activity and low toxicity of nystatin by the oral route and very favourable activity in systemic mycoses by the parenteral route but not by the oral route, due to poor absorption<sup>1, 3, 15, 23, 31</sup>.

The first antifungal antibiotic that found a large application in human therapy was nystatin. The need to control post-antibiotic complications due to *Candida* was satisfied by this antibiotic, even

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 42  
A CLASSIFICATION OF THE PRINCIPAL ANTIBIOTICS

<i>Antibiotic activity</i>	<i>Antibiotics</i>	<i>Producing organism</i>
Antibacterial and anti-actinomycotic	Penicillin Streptomycin Chloramphenicol Chlortetracycline Oxytetracycline Neomycin	<i>Penicillium notatum</i> , <i>P. glaucum</i> <i>Streptomyces griseus</i> <i>S. venezuelae</i> <i>S. aureofaciens</i> <i>S. rimosus</i> <i>S. fradiae</i>
Antibacterial and Antifungal	Tyrothricin Thiolutin Clavacin Streptothricin Actinomycin Gliotoxin Trichothecin	<i>Bacillus brevis</i> <i>Streptomyces albus</i> <i>Aspergillus clavatus</i> <i>S. lavendulae</i> <i>S. antibioticus</i> <i>Trichoderma</i> <i>Trichothecium roseum</i>
Antifungal	Cycloheximide (actidione) Polyenes: Tetraenes Nystatin Rimocycin Antimycin Chromin Amphotericin A Pentaenes Eurocidin Fungichromin Fungichromatin Filipin Hexaenes Flavacide Mediocidin Heptaenes Candicidin Candimycin Aſcosin Trichomycin Amphotericin B	<i>Streptomyces griseus</i> , <i>S. noursei</i>  <i>S. noursei</i> <i>S. rimosus</i> <i>S. aureus</i> <i>S. antibioticus</i> <i>S. sp</i> <i>S. sp</i> <i>S. sp</i> <i>S. sp</i> <i>S. filipinensis</i> <i>S. sp</i> <i>S. sp</i> <i>S. griseus</i> <i>S. griseus</i> <i>S. canescens</i> <i>S. hachyoensis</i> <i>S. sp</i>

in infants and children in whom blood-borne dissemination of *C. albicans* from intestinal capillaries<sup>11</sup>, or by extension from the bronchi and the lungs<sup>35</sup>, may be particularly dangerous. It also controls chronic cases of onychia due to *C. albicans* resistant to ordinary treatment<sup>26</sup>. Table 47 summarizes the results with nystatin in the hands of various authors<sup>12, 13, 14</sup>.

My, I, and had the therapeutic activity of nystatin in 46 cases of  
laboratory  
were cases

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 43  
COMPARATIVE SPECTRA OF VARIOUS ANTIFUNGAL ANTIBIOTICS

Test organism	Minimum inhibitory concentration in µg/ml of*						
	Cycloheximide Actidione	Polyene antibiotics					Euclon
		Nystatin Tetraene	Candididin Heptamene	Trichomy- cin Heptamene	Amphotericin B Tetraene	Amphotericin B Heptamene	
<i>Candida albicans</i>	> 1 000	3 12	2 5	0 7	4 7	3 7	120 8
<i>C. tropicalis</i>	> 1 000	3 12	5 0	0 7	4 7	> 40	
<i>Geotrichum</i>	> 1 000	6 25	2 5	0 3	12 5	> 40	
<i>Deep fungi</i>							
<i>Cryptosporidium neoformans</i>	0 24	1 56	1	0 17	3 1	0 6	0 07
<i>Sporotrichum schenckii</i> (Y)	> 1 000	12 5	200	50	3 9	0 14	
<i>Blasotrichum dermatitidis</i> (Y)	> 1 000	1 56	1	0 3	1 2	0 6	
<i>Histoplasma capsulatum</i> (Y)	> 1 000	1 56	1	0 7	0 8	0 04	0 03 0 07
<i>Coccidioides immitis</i>	> 1 000	1 56	500			+	
<i>Dermatophytes</i>							
<i>Trichophyton mentagrophytes</i>	> 1 000	12 5	500	50	9 4	1 4	2 3
<i>T. tonsurans</i>	> 1 000	6 25	500		5 5	> 40	
<i>T. rubrum</i>	> 1 000	12 5	500		4 7	30	
<i>Microsporum audouinii</i>		6 25	500		1 2	1 9	0 5 1 2
<i>M. canis</i>		6 25	500	0 3	9 4	30	
<i>M. gypseum</i>		2 5	500		7 5	> 40	
<i>Epidermophyton floccosum</i>		3 12	500	0 3	1 6	0 9	0 03 0 07 0 28
<i>Monosporium apiospermum</i>	25	200			6 3	> 40	
<i>Cladophium werneckii</i>	12 5	12 5			6 3	> 40	
<i>Phialophora verrucosa</i>					4	> 40	<i>N. asteroides</i> 2 3
<i>Aspergillus fumigatus</i>	400	3 12		> 50	6 3	> 40	
<i>Penicillium sp.</i>	100	13					
<i>Actinomyces</i>	0	0	0	0	0	0	0 7-16
<i>Bacteria</i>	0	0	0	0	0	0	

\* M I C for 4 days established in agar medium except for Trichomycin and Euclon (Y)=Yeast phase

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 44

## TOXICITY OF SOME ANTIFUNGAL ANTIBIOTICS ON ANIMALS

Antibiotics	Chemical nature		Acute toxicity, LD 50 in mg/kg.			
			Route of administration			
			Oral	Sub-cutaneous	Intra-peritoneal	Intra-venous
Nystatin	Polyenes	Tetraene	3,000 mg (800,000 U)	150 mg	20-26 mg (30,000 U)	
Trichomycin		Heptaenes	250-1,000 mg	17.9 mg (4,300 U)	2.2 mg (4,200 U)	2.2 mg (4,300 U)
Amphotericin B			> 280 mg	280 mg		20 mg
Ascocin			500 mg	168 mg	8.6 mg	12.5 mg
Candididin					14 mg	
Antibiotic 1968			> 500 mg			250 mg
Actidione	Cyclo-heximide			110 mg	138 mg	
Euclin			430 mg	153 mg	130 mg	

of generalized moniliasis with thrush, diarrhoea, vulvo-vaginitis and multiple abscesses, and 25 were cases of digestive moniliasis. A rapid clinical recovery was obtained in all cases and *Candida* decreased in numbers, or disappeared completely, from the mouth, stool, urine or blood when nystatin was administered in powder form. Daily doses of nystatin can reach or exceed  $1\frac{1}{2}$  million units for infants, 2 to 3 million units for children and 6 to 10 million units for adults, and can be continued at this level for many days. There is a remarkable lack of toxicity. The powdered substance is the most adequate preparation for the treatment of digestive moniliasis, because generally the whole gastro-intestinal tract is involved in such cases, beginning at the oral cavity. Clinical relapses occurred in several cases, particularly where thrush was unrelated to antibiotic therapy. No resistant strains of *C. albicans* were encountered. In

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 45  
THERAPEUTIC ACTIVITY OF NYSTATIN IN  
EXPERIMENTAL MYCOSES

Experimental mycosis	Route of administration	Experimental animals	Therapeutic effect	References
Systemic moniliasis	Parenteral	Mice	Favourable	5, 6, 27, 44, 54
Systemic moniliasis	Parenteral	Rabbits	Favourable	15
Systemic moniliasis	Parenteral	Embryonated eggs	Favourable	53
Systemic moniliasis	Oral	Rabbits	No effect	13
Digestive moniliasis	Oral	Mice	Favourable	34
Digestive moniliasis	Oral	Rabbits	Favourable	14, 27, 28
Digestive moniliasis	Oral	Dog	Favourable	50
Dermatophytosis	Local	Guinea-pig	Favourable	46
Systemic cryptococcosis	Parenteral	Mice	Favourable	8, 27, 29
Systemic coccidioidomycosis	Parenteral	Mice	Favourable	6, 46
Systemic sporotrichosis	Parenteral	Mice, hamsters	Fair	6, 42
Blastomycosis	Parenteral	Mice	Favourable	28
Blastomycosis	Oral	Mice, hamsters	No effect	18
Histoplasmosis	Parenteral	Mice	Favourable	8, 28
Histoplasmosis	Parenteral	Mice, hamsters	Favourable	17

localized broncho-moniliasis of adults, results of oral nystatin are not always satisfactory because of the poor absorption of this antibiotic, as Stewart<sup>57</sup> demonstrated

In vaginitis, good results were obtained in many trials<sup>4, 14, 15, 25, 26, 32</sup>, even when several relapses occurred. These relapses, which are usually seen in pregnant women and are often due to an intestinal focus or to reinfection by the husband, were cured by a second course of treatment.

In cutaneous moniliasis, the topical application of nystatin is very effective<sup>34</sup>, even in cases of chronic onychia. Grupper<sup>26</sup> from Hôpital Saint Louis obtained the best results by combining topical nystatin applications with Sabouraud's procedure of removing all infected foci from the bases of the nails to allow penetration of the antibiotic to the deepest layers of keratin. In chronic cases of moniliasis, intensive search is advisable to establish primary conditions (endocrine factors, avitaminosis, and so on) predisposing to fungal infection and sometimes responsible for resistance to antifungal therapy.

Response to nystatin was offered as proof that *C. albicans* might be responsible for angiocholecystitis by Crismer and his colleagues<sup>10</sup>,

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 46  
THERAPEUTIC ACTIVITY OF SOME ANTIFUNGAL ANTIBIOTICS  
IN EXPERIMENTAL MYCOSES

Antibiotics	Experimental mycoses	Route of administration	Animals	Therapeutic effect	References
Candidin	Digestive moniliasis	Oral	Mice	Favourable	33
	Systemic moniliasis	Parenteral	Mice	Favourable	
	Blastomycosis	Parenteral	Mice	Favourable	
	Sporotrichosis	Parenteral	Mice	Favourable	
	Histoplasmosis	Parenteral	Mice	Fair	
	Cryptococcosis	Parenteral	Mice	Fair	
Trichomycin	Moniliasis	Oral or parenteral	Mice, rats, rabbits	Favourable	30
	Trichophytosis	Local	Guinea-pig	Favourable	
Ascocin	Moniliasis	Parenteral	Mice	Favourable	29 19
	Histoplasmosis	Parenteral	Mice	Favourable	
Antibiotic 1968	Systemic moniliasis	Parenteral	Mice	Favourable	6
	Sporotrichosis	Parenteral	Mice	Favourable	
	Histoplasmosis	Parenteral	Mice	Favourable	
Euclin	Blastomycosis	Oral or parenteral	Mice	Favourable	62
Amphotericin A	Moniliasis	Oral	Mice	No effect	33
	Moniliasis	Parenteral	Mice	Favourable	
	Histoplasmosis	Oral	Mice	Fair	
	Blastomycosis	Oral	Mice, hamsters	No effect	
Amphotericin B	Moniliasis	Oral	Mice	Favourable	53
	Moniliasis	Parenteral	Mice	Favourable	55 56
	Coccidioidomycosis	Oral or parenteral	Mice	Favourable	46
	Cryptococcosis	Oral or parenteral	Mice	Favourable	41, 53
	Histoplasmosis	Oral	Mice	Favourable	41 53
	Histoplasmosis	Parenteral	Mice, hamsters	Favourable	17
	African histoplasmosis	Oral	Mice, hamsters	Favourable	16
	Blastomycosis	Oral	Mice, hamsters	Favourable	18

who observed 2 cases, with *C. albicans* in the bile, in whom persistent fever for several months was rapidly controlled by nystatin

*Nystatin in prophylaxis*—Prophylactic administration of nystatin prevented all cases of thrush in the Centre for Premature Infants in Paris<sup>55</sup> over the last 2 years, in abdominal surgery nystatin combined with different antibacterial agents has been used for sterilization of the bowel<sup>52, 55</sup>.

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 47  
THERAPEUTIC USE OF NYSTATIN IN HUMAN MONILIASIS

Clinical form of moniliasis (condidiasis)	Number of cases	Age-group I = Infants C = Children A = Adults	Route of administration	Doses of Nystatin		Results E = excellent G = good R = relapse F = Failure	References
				daily in millions U.	period d = days w = weeks m = months		
Generalized	13	3I, 7C, 3A	Oral	0.5-1.5	4-8d	13E, 1R	13
Digestive	25	20I, 3C, 2A	Oral	0.5-1.5	2-8d	25E, 7R	13
Septicaemic	1	A	Intravenous	0.4	6d	E	49
Oral	49	A	Oral	0.5-2	3d-3m	19E, 29G, 1F	64
Vaginal	17	A	Local	0.1	1-6w	9E, 8G	46
Cutaneous	63	A	Local	0.1	1-12w	25E, 34G, 4F	
Onychia	39	A	Local + nail treatment	0.1	1-4m	32E, 5G, 2F	
Mucous	14	A	Local + oral	0.1-1.5	3-15d	11E, 3G, 1R	26
Mucocutaneous	17	6C, 11A	Local	0.1-1.5	3-35d	13E, 3G, 1F	
Generalized cutaneous	8	C, A	Local + oral + cortisone	1-5	3-80d	7E, 1G	
Onychia	19	A	Local	0.1	2-6w	9G, 10F	51
Generalized cutaneous	3	2C, 1A	Oral	0.5-1	1w	3G	
Oral	4	C	Oral	0.4		4G	
Vulvo-vaginitis	20	A	Local	0.4	10d	20G	
Brain abscess	1	A	Intramuscular			F	57
Pharyngitis + bronchitis	12	A	Oral	1-2	7-10d	9E, 2G, 1F	2
Oral	8	2C, 6A	Oral			7E, 1F	4
Vagina	20	A	Local + oral	0.2	5d	20E	32
Vaginal	58	A	Local	0.1	6d	58E, 11R	10
Angiocholitis	2	A	Oral	3-5		2E	47
Abdominal	2	A	Oral	2	1w	2E	



# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 48

## THERAPEUTIC USE OF SOME ANTIFUNGAL AGENTS IN CLINICAL CASES OF MYCOSES

Antibiotics	Fungal disease	Number of cases	Route of administration	Results E=excellent G=good f=fair F=failure	References
Nystatin	Dermatophytosis (60 <i>Trichophyton rubrum</i> , 26 <i>T. mentagrophytes</i> , 7 other)	93	Local	4E, 7G, 48f, 34F	24
	Coccidioidomycosis	10	Oral	1G, 9F	46
		2	Intramuscular	2F	46
		5	Intravenous	2G, 3F	46
	Histoplasmosis	1	Intravenous	F	
		2	Oral	2F	
		4	Intravenous	4F	38,39
	Cryptococcosis	2	Oral	2F	40
		2	Intravenous	2F	38,39
	Brain abscesses with <i>Cladosporium trichoides</i>	1	Oral and intramuscular	F	
Candicidin	Moniliasis				
	Cutaneous	1	Local	E	20
	Vaginal	1	Local	E	21
Trichomycin	Moniliasis				
	Cutaneous		Local	E	30
	Vaginal		Local	E	9
	Digestive		Oral	E	30
Ascosin	Tinea capitis	102	Local	53G, 49F	
Actidione	Cryptococcosis	19	Intravenous, intramuscular and intrathecal	2G, 4f, 13F	40
Amphotericin B	Histoplasmosis	1	Oral	G	38,39

**Conclusion.**—In the mycoses other than moniliasis, the results with nystatin are unsatisfactory (Table 48). In dermatomycosis, there is no favourable response<sup>24</sup>, and, in the systemic mycoses, the drug is ineffective when given orally because of poor absorption. Local reaction limits its use intramuscularly. By the intravenous route (200,000–400,000 units in 6 hours perfusion daily) a good blood level of antibiotic is obtained but high fever and chills limit its use to very severe infections<sup>46</sup>.

## THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

Other antifungal antibiotics have found little application in clinical cases, as is shown in Table 48.

Experimental studies in animals with amphotericin B by oral or parenteral routes have shown remarkable activity in the hands of several workers (Table 46)<sup>41, 53, 56</sup>, notably in the blastomycosis of hamsters and of mice<sup>18</sup>. In our experiments 100 per cent of control animals were dead after 3 weeks as well as the animals treated with

TABLE 49

**RESULTS OF CULTURES FROM THE LIVER, SPLEEN AND LUNGS OF ANIMALS INFECTED WITH *BLASTOMYCES DERMATIDITIS* AND TREATED WITH ANTIBIOTICS**

Treatment	Per cent positive cultures						
	0	20	40	60	80	100 per cent	
Control or Amphotericin A	+	+	+	+	+	+	Liver
	+	+	+	+	+	+	Spleen
	+	+	+	+	+	+	Lungs
Nystatin	+	+	+	+	+	+	Liver
	+	+	+	+	+	+	Spleen
	+	+	+	+	+	+	Lungs
Amphotericin B or Amphotericin AB	0						Liver
	0						Spleen
	0						Lungs
Control or Amphotericin A	+	+	+	+	+	+	Liver
	+	+	+	+	+	+	Spleen
	+	+	+	+	+	+	Lungs
Nystatin	+	+	+	+	+	+	Liver
	+	+	+	+	+	+	Spleen
	+	+	+	+	+	+	Lungs
Amphotericin B or Amphotericin AB	0						Liver
	0						Spleen
	0						Lungs

Hamsters

Mice

nystatin or with amphotericin A. All animals treated with amphotericin B remained alive at the end of this experiment, no macroscopic lesions were observed and cultures of spleen, liver and lungs were negative (Table 49).

In African histoplasmosis we obtained similar good results<sup>16</sup>. Preliminary clinical results with oral and intravenous amphotericin B in cryptococcal meningitis and in disseminated histoplasmosis reported by Lehan and his colleagues<sup>38, 39</sup> permit us to hope for the eventual control of systemic and deep mycoses.

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

TABLE 48  
THERAPEUTIC USE OF SOME ANTIFUNGAL AGENTS  
IN CLINICAL CASES OF MYCOSES

Antibiotics	Fungal disease	Number of cases	Route of administration	Results E=excellent G=good f=fair F=failure	References
Nystatin	Dermatophytosis (60 <i>Trichophyton rubrum</i> , 26 <i>T. mentagrophytes</i> , 7 other)	93	Local	4E, 7G, 48f, 34F	24
	Coccidioidomycosis	10	Oral	1G, 9F	46
		2	Intramuscular	2F	46
		5	Intravenous	2G, 3F	46
	Histoplasmosis	1	Intravenous	F	
		2	Oral	2F	
		4	Intravenous	4F	38,39
Candidin	Moniliasis Cutaneous	2	Oral	2F	40
		2	Oral	2F	38,39
	Brain abscesses with <i>Cladosporium trichoides</i>	1	Oral and intramuscular	F	
Candidin	Moniliasis Cutaneous Vaginal	1	Local	E	20
		1	Local	E	21
Trichomycin	Moniliasis Cutaneous Vaginal Digestive		Local	E	30
			Local	E	9
			Oral	E	30
Ascocin	Tinea capitis	102	Local	53G, 49F	
Actidione	Cryptococcosis	19	Intravenous, intramuscular and intrathecal	2G, 4f, 13F	40
Amphotericin B	Histoplasmosis	1	Oral	G	38,39

**Conclusion.**—In the mycoses other than moniliasis, the results with nystatin are unsatisfactory (Table 48). In dermatomycosis, there is no favourable response<sup>24</sup>, and, in the systemic mycoses, the drug is ineffective when given orally because of poor absorption. Local reaction limits its use intramuscularly. By the intravenous route (200,000–400,000 units in 6 hours perfusion daily) a good blood level of antibiotic is obtained but high fever and chills limit its use to very severe infections<sup>46</sup>.

# BIBLIOGRAPHY AND REFERENCES

- 16 Drouhet, E. (1958). "Action de l'amphotéricine B dans l'histoplasmosc africaine à grandes formes." *Bull Soc. Pat. exot.*, 51, 76
- 17 — Schwarz, J., and Bingham, E. (1956) "Evaluation of the Action of Nystatin (Mycostatin) on *Histoplasma capsulatum* *in vitro* and in Hamsters and Mice." *Antibiot. and Chemother.*, 6, 23
- 18 — and Wilkinson, R. (1957). "Action thérapeutique de l'amphotéricine B dans la blastomycose expérimentale." *Ann. Inst. Pasteur*, 93, 631
- 19 Emmons, C. W., and Haberman, R. T. (1953) "Ascospores in the Treatment of Experimental Histoplasmosis in Mice." *Antibiot. and Chemother.*, 3, 1204
- 20 Fox, J. L. (1955). "Candididin, a New Antifungal Antibiotic. First Report." *Antibiot. Med.*, 1, 349
- 21 Franks, A. G., Taschdjian, C. L., and Thorpe, G. A. (1954) "Effect of Candididin in Intertriginous and Paronychia Moniliasis." *J. invest. Derm.*, 23, 75
- 22 Gold, W., Stout, H. A., Pagano, J. F., and Donovan, R. (1955-6) "Amphotericins A and B, Antifungal Antibiotics Produced by a Streptomyces. I—*In vitro* Studies." In *Antibiotics Annual*, p 579 New York, MD Publications
- 23 Gordon, L. E., and Smith, C. E. (1955) "Mycostatin and Amino-stilbamidine Treatment of Experimental Coccidioidomycosis." In *Therapy of Fungus Diseases*. An international symposium, p 249 Ed by T. H. Sternberg and V. D. Newcomer. Boston; Little, Brown.
- 24 Graham, J. H., Wright, E. T., Newcomer, V. D., and Sternberg, T. H. (1955) "The Use of Nystatin as a Topical Antifungal Agent." In *Therapy of Fungus Diseases*. An international symposium, p 220 Boston, Little, Brown.
- 25 G... .. (1955) "..."
- 26 G... ..  
2253
- 27 Hazen, E. L., and Brown, R. (1951) "Fungicidin, an Antibiotic Produced by a Soil Actinomycete." *Proc. Soc. exp. Biol., N.Y.*, 76, 93
- 28 — Brown, R., and Little, G. N. (1955) "Moniliasis in Experimental Animals: Prophylaxis and Therapy with Nystatin (Mycostatin)." In *Therapy of Fungus Diseases*. An international symposium, p 199 Boston, Little, Brown
- 29 H... .. (1955) "..."
- 30 "..."
- 31 Huang, N. N., Kendall, N., Lambert, A. J., and High, R. H. (1955-6) "Effects of Nystatin on *Candida albicans*..."

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

## BIBLIOGRAPHY AND REFERENCES

- 1 Baum, G. L., Rubel, H., and Schwarz, J. (1956-7) "Treatment of Experimental Histoplasmosis" In *Antibiotics Annual*, p. 878, New York; MD Publications
- 2 Beckmann, A. J., and Navarro, J. E. (1955) "Pneumonia Complicating Oral Thrush Treated with Mycostatin, a New Antifungal Antibiotic." *J. Pediat*, **46**, 587
- 3 Bernard, J., Mathé, G., and Drouhet, E. (1955) "Les infections à *Candida* au cours des hémopathies décompensées et leur traitement par la nystatine" *Sang*, **26**, 490
- 4 Bret, A. J., and Bardiaux, M. (1956) "Traitement des mycoses vaginales par un nouvel antibiotique antifongique, la nystatine ou fongicide" *Presse méd*, **84**, 671
- 5 Brown, R., Hazen, E. L., and Mason, A. (1953) "Effect of Fungicin (Nystatin) in Mice Infected with Lethal Mixtures of Aureomycin and *Candida albicans*" *Science*, **117**, 609
- 6 Campbell, C. C. (1955) "Therapeutic Activity of Mycostatin in Mice Infected with *Histoplasma capsulatum*, *Coccidioides immitis*, *Cryptococcus neoformans*, *Candida albicans* or *Sporotrichum Schenckii*" In *Therapy of Fungus Diseases* An international symposium, p. 255. Ed. by T. H. Sternberg and V. D. Newcomer. Boston, Little, Brown
- 7 — Carson, L. F., and Moursund, W. H. (1955) "Tinea Pedis in U.S. Army Troops Stationed in Puerto Rico and the Comparative Effectiveness of an Antihistamine (Diphenylpyraline) and Undecylenic Acid in its Treatment" In *Therapy of Fungus Diseases* An international symposium, p. 112. Ed. by T. H. Sternberg and V. D. Newcomer. Boston, Little, Brown
- 8 — Hill, G. B., and Brooks, B. E. (1955-6) "Therapeutic Activity of a New Antibiotic, 1968, in Mice with Experimental Histoplasmosis, Sporotrichosis and Moniliasis" In *Antibiotics Annual*, p. 240, New York, MD Publications
- 9 Chappaz, G., and Bertrand, P. (1957) "La Trichomycine, antibiotique actif contre les *Trichomonas* et le *Candida albicans*" *Presse méd*, **65**, 425
- 10 Crismer, R., Demelonne-Jaminon, G., Dreze, Ch., and Dubois, J., commentaires de Drouhet, E. (1957) "Deux observations d'angiocholite à *C. albicans* traitée par la nystatine" *Rev. méd.-chir. Mal. For.*, **32**, 13
- 11 Debré, R., Mozziconacci, P., Drouhet, E., Drouhet, V., and Hoppeler, A. (1955) "Les infections à *Candida* chez le nourrisson" *Ann. paediat.*, **184**, 129
- 12 Dobias, B. (1955) "Cutaneous Moniliasis in Paediatrics. Diagnosis and Treatment with Nystatin" In *Therapy of Fungus Diseases* An international symposium, p. 205. Ed. by T. H. Sternberg and V. D. Newcomer. Boston, Little, Brown
- 13 Drouhet, E. (1955) "Traitement des infections mycosiques à *Candida albicans* par un nouvel antibiotique antifongique, la nystatine" *Presse méd*, **63**, (1), 620
- 14 — (1955) "Therapeutic activity of Nystatin (Mycostatin) in *Candida* infections" In *Therapy of Fungus Diseases* An international symposium, p. 211. Ed. by T. H. Sternberg and V. D. Newcomer. Boston, Little, Brown
- 15 — (1957) "Antifongiques et thérapeutique des mycoses" *Sem. Hôp. Paris*, **5**, 843

## BIBLIOGRAPHY AND REFERENCES

- Administration of Neomycin-polymyxin" *Antibiotics Annual*, p. 681  
New York; MD Publications
- 53 Sternberg, T. H., Tarbet, J. E., and Egeberg, R. O. (1955-6) "Antifungal Effects of Nystatin on the Fecal Flora of Animals and Man Preliminary report" In *Antibiotics Annual*, p. 199 New York, MD Publications
- 54 — and Jambor, W. P. (1955) "The Effect of Nystatin (Mycostatin) on Experimental Candidiasis in Mice and Embryonated Eggs" In *Therapy of Fungus Diseases* An international symposium, p. 195 Boston; Little, Brown
- 55 Sternberg, T. H., Tarbet, J. E., Newcomer, V. D., Huddleson, H. G., Weir, R. H., Wright, E. T., and Egeberg, R. O. (1953-4) "Antifungal Effects of Nystatin on the Fecal Flora of Animals and Man Preliminary report" In *Antibiotics Annual*, p. 199 New York, MD Publications
- 56 — Wright, E. T., and Oura, M. (1955-6) "A New Antifungal Antibiotic, Amphotericin B" In *Antibiotics Annual*, p. 566 New York, MD Publications
- 57 Stewart, G. T. (1956) "Laboratory and Clinical Studies with Nystatin in Post-antibiotic Mycotic Infections" *Brit med J*, **1**, 658
- 58 Tull, A. A., McCann, E. J., and Egeberg, R. O. (1955-6) "Antifungal Effects of Nystatin on the Fecal Flora of Animals and Man Preliminary report" In *Antibiotics Annual*, p. 199 New York, MD Publications
- 59 — and Egeberg, R. O. (1955-6) "Antifungal Effects of Nystatin on the Fecal Flora of Animals and Man Preliminary report" In *Antibiotics Annual*, p. 199 New York, MD Publications
- 60 W. — and Egeberg, R. O. (1955-6) "Antifungal Effects of Nystatin on the Fecal Flora of Animals and Man Preliminary report" In *Antibiotics Annual*, p. 199 New York, MD Publications
- 61 Weiss, W., Eisenberg, G. M., Sass, D. K., Kayser, H. L., and Flippin, H. F. (1955-6) "Microbiological Studies and Preliminary Clinical Experiences with Nystatin" In *Antibiotics Annual*, p. 842 New York, MD Publications
- 62 West, M. K., Verwey, W. F., and Miller, A. K. (1955-6) "The Biological Activity of Eukin" In *Antibiotics Annual*, p. 231 New York, MD Publications
- 63 Whiffen, A. T. (1919) "The Bacteriostatic and Antibiotic Activity of Eukin" *Bact*, **56**, 283
- 64 W. — and Egeberg, R. O. (1955-6) "Antifungal Effects of Nystatin on the Fecal Flora of Animals and Man Preliminary report" In *Antibiotics Annual*, p. 199 New York, MD Publications

# THE THERAPEUTIC USE OF ANTIFUNGAL AGENTS

- Nystatin and Amphotericin B." In *Antibiotics Annual*, p. 128 New York, MD Publications.
- 35 Larroche, J. C. (1957) "Candidose pulmonaire chez les prématurés" *Sem Hôp. Paris*, 33, 829
- 36 Latapi, F., and Laval, P. (1954). "Emploi des sulfones et de l'isoniazide dans le traitement des mycétomes" 8ème Congr. Internat Bot., Paris Section 24, p 44
- 37 Lechevalier, H. (1953) "Les antibiotiques antifongiques produits par les actinomycètes La Candidine" *Presse méd.*, 61, 1327.
- 38 Lehan, P. H., Furcolow, M. L., Brasher, C. A., and Larsh, H. W. (1956-7) "Therapeutic Trials with the Newer Antifungal Agents" In *Antibiotics Annual*, p 467. New York; MD Publications
- 39 — Yates, J. L., Brasher, C. A., Larsh, H. W., and Furcolow, M. L. (1957) "Experiences with the Therapy of Sixty Cases of Deep Mycotic Infections" *Dis. Chest.*, 32, 597.
- 40 Littman, M. L., and Zimmerman, L. E. (1956) *Cryptococcosis*. New York; Grune and Stratton
- 41 Louria, D. B., Feder, W., and Emmons, C. W. (1956-7) "Amphotericin B in Experimental Histoplasmosis and Cryptococcosis" In *Antibiotics Annual*, p 870 New York; MD Publications
- 42 Mariat, F. (1955) "The Action of Nystatin on the Growth of *Sporotrichum schenckii* and on its Behavior *in vivo*" In *Therapy of Fungus Diseases* An international symposium, p 233 Boston, Little, Brown
- 43 Metzger, W. I., Wright, L. T., and DiLorenzo, J. C. (1954) "Effect of Esters of Parahydroxybenzoic Acid on *Candida* and Yeast-like Fungi" *J. Amer. med. Ass.*, 155, 351
- 44 Millberger, H., and Blank, E. (1954) "Versuche zur Nachprüfung der Wirkung von Mycostatin auf die experimentelle *Candida albicans* Infektion der weissen Maus" *Naturwissenschaften*, 41, 503.
- 45 Mountain, D. C., and Krumenacher, F. P. (1953) "Oral Undecylinic Acid in the Prevention of the So-called Monilial Complications Secondary to the Use of Aureomycin, Chloramphenicol and Terramycin" *Amer. J. med. Sci.*, 225, 274
- 46 Newcomer, V. D., Wright, E. T., Sternberg, T. H., Graham, J. H., Weir, R. H., and Egeberg, R. O. (1955-6) "Evaluation of Nystatin in the Treatment of Coccidioidomycosis in Man" In *Antibiotics Annual*, p 831 New York, MD Publications
- 47 Ochoa, A. G. (1955) "Two Cases of Abdominal Wall Moniliasis after Colostomy Treated with Nystatin" In *Therapy of Fungus Diseases*. An international symposium, p 228 Boston, Little, Brown
- 48 Oroshnik, W., Vining, L. C., Mebane, A. D., and Taber, W. A. (1955) "Polyene antibiotics" *Science*, 121, 147
- 49 Rabot, D. (1956) "Septicémie à *Candida albicans* traitée par la Mycostatine en perfusion intra-veineuse" *Thèse Fac. Med. Paris*, 5, 1291
- 50 Rimbaud, P., Harant, H., Rioux, J. A., and Caron, J. (1957) "Étude du

## THEORETICAL ASPECTS

The following approaches to treatment of ringworm require consideration:

### DISTURBANCE OF THE HOST-PARASITE BALANCE

Inflammatory reactions, particularly in follicle infections, are essentially curative. Eczematous reactions which may occur when a patient becomes sensitive to a fungicide applied locally are not in any way curative, and can only be regarded as an attempt on the part of the patient to rid himself of the fungicide and not the fungus.

### INHIBITION OF FUNGAL GROWTH

This may be effected by the use of fungistatics or fungicides so that the outward growth of the keratin casts off infection, this has been accepted therapy for many years. Further studies are required on the action of inhibitors on dermatophytes<sup>2, 3</sup>

### MODIFICATION OF FUNGAL GROWTH

A knowledge of factors which determine in dermatophytes the change from parasitic to saprophytic growth and the reverse might make it possible to induce a change in behaviour of fungal growth on the human body. A small group of cases of scalp infections due to *Microsporum audouinii* was treated by keeping the affected areas covered with a medium similar to Sabouraud's agar at a high humidity, no beneficial effect was recorded. This is an approach which requires greater knowledge of metabolism of ringworm organisms.

### TEMPORARY INHIBITION OF KERATIN FORMATION

X-rays or thallium, or depilating agents, have been used for this purpose which is practicable only for hair infection, though theoretically possible for nails. Its efficacy in dealing with follicular infections is illustrated by the fact that radiological epilation, if complete, may be effective without the local use of fungicides. Chloroprene and certain sterols bring about depilation but do not at present seem to have any value for therapeutic purposes.

### MODIFICATION OF KERATINS

The structure of keratins may be altered by physical or chemical means and such changes may result in inability of an infecting fungus to survive. Fungi are also susceptible to alterations in humidity and probably also to changes in oxygen and carbon dioxide tension<sup>4</sup>.

Keratin may be disorganized by the breakdown of cross-linkages



# TREATMENT OF FUNGOUS INFECTIONS OF THE SKIN

## THEORETICAL ASPECTS

A. J. E. BARLOW

THE dermatophytes have three main sites of parasitic growth: (1) the horny layer; (2) the hair follicle in its lower two-thirds; and (3) the nail plate

In response to infection, including fungous infections, the human host can react in two main ways: (a) inflammation of varying degrees of acuteness, with the possible later development of immunity; and (b) hypersensitivity.

Curative and in such infections there is no problem of treatment. This type of reaction may also occur as the result of local treatment of anthropophilic infections, and in such instances the value of a fungicidal agent is frequently attributed incorrectly to its action on the infecting fungus rather than to its action on the skin structures. It is probable that treatment has in some way disturbed the host-parasite balance so that the host has reacted to the infection with inflammation, a reaction by which it rids itself of the parasite. Hypersensitive reactions characterize infections of the horny layer by *Trichophyton mentagrophytes* and certain other fungus species. It is arguable how far such reactions are curative.

There is little doubt that treatment problems do not occur to the same extent in those fungous infections in which the host reacts vigorously as in those where little or no reaction results, for example, infections due to anthropophilic species. Accuracy of diagnosis and careful assessment of cure are essential when handling these infections. Diagnosis should always be confirmed not only by cultural identification but also by assessment of the extent of the infection microscopically, for *T. rubrum* may be most ubiquitous and may occur in most unexpected sites. Clinical impression of cure is insufficient; infected palms, soles and nails can look normal to the extent that even the patient may be convinced of cure yet the fungus may be shown to persist within them. Cure should imply inability to identify the fungus in areas where previously it was present, and normality of appearance of tissues from a clinical point of view.

## THEORETICAL ASPECTS

with keratin. The resultant compound may no longer be fungicidal and may also act as a barrier to further penetration.

In a thin sheet of soft keratin, as in the smooth skin, fungus may be superficial enough for its growth to be inhibited by a fungicide applied to the skin surface, but in the thicker horny layer of the sole and palm it is remote from effective fungicidal concentrations. Similarly, the fungus may be vulnerable in the shallow follicle of a lanugo hair, but protected in the deeper follicle of a terminal hair.

This has been in accord with our experience, not only with a variety of fungicides but also with cross-linking agents. By virtue of the fact that the cross-linking agent, ninhydrin, combines with amino-acids to give coloured compounds, its degree of penetrability into keratin may easily be assessed. This chemical has been used in *T. rubrum* infections of the palms and soles in the presence of surface agents and alcohol; after prolonged soaking the skin becomes purple. By superficial paring with a scalpel, fungus can be demonstrated in the horny layer stained in the same way as the keratin. In the deeper horny layer, however, the fungus is unstained. The effect of ninhydrin on lesions of the thin keratin of the dorsum of the foot was to abate the infection as with conventional fungicides, but infection of the sole was unaffected.

*T. rubrum* infections can, in our experience, be cleared from smooth skin with Whitfield's ointment, aniline dyes and fungicides used on conventional lines. It is doubtful, therefore, whether there is any wisdom in searching for new fungicides at this stage in our knowledge, and whether the assessment of fungicidal potency using *in vitro* culture methods is of real value. In such methods the fungus is in its mycelial form, and different from its parasitic form; furthermore, the fungus is very vulnerable in cultures.

For opening up keratin, lithium bromide, sodium metabisulphite, urea and thioglycolates have been used, and treatment has followed with cross-linking agents, including ninhydrin, dibromopropane and picric acid. The inability to obtain adequate penetration of keratin has always proved an insuperable obstacle. Keratolytics which produce more gradual degradation and which could be used over prolonged periods have also been used in the hopes that their action would overtake keratin production, give rise to a thinner horny layer and thereby allow better penetration of fungicides. Salicylic and benzoic acids were employed for this purpose in relatively high concentrations and were used in patients suffering from long-standing *T. rubrum* infection of the palms and soles and of many nails. The affected parts were soaked for half an hour daily in warm water and then painted with a solution of the two acids in spirit. Very

## TREATMENT OF FUNGOUS INFECTIONS OF THE SKIN

between molecules by chemical agents (for example, keratolytic substances), or may possibly be made more "resistant" by the use of cross-linking agents<sup>1</sup>. The physical and chemical differences between soft and hard keratins are of importance in this respect in explaining the differences in behaviour of these keratins to both types of reagents.

Disulphide bonds, salt linkages, and hydrogen bonds are the main linkages between keratin molecules, and individual reagents may act predominantly on one particular linkage. Reducing agents such as sulphides, sodium metabisulphite and thioglycolates show their main action on disulphide bonds, whereas acids and alkalis act on salt linkages, and lithium bromide on hydrogen bonds. Keratolytics are used in the treatment of fungous infections to open up keratins so that fungistatic agents are more likely to reach sites of active fungal growth, but in so doing they probably increase the possibilities of fungal invasion. It would, in theory, seem possible that keratins might be made impervious to fungal attack by the effect of cross-linking agents applied locally or by such agents administered systemically if excreted in keratins, sweat or sebum. The influences of other organisms on the skin surface also require consideration, for it is possible that they may produce antibiotic fungicides, or alternatively, substances which themselves modify keratins.

Most attention has been directed to the topical use of fungistatic substances and here the vexed question of penetration arises. Penetration of keratin must be distinguished from percutaneous absorption implying the passage of substances through the skin into the systemic circulation. Reagents which pass through the skin do not necessarily have the ability to diffuse into keratin. Percutaneous absorption is most likely to be a property of substances which are fat-soluble and probably takes place through the sebaceous glands. For therapeutic purposes it would appear necessary to obtain adequate concentrations of fungistatic agents in the deeper part of the soft keratin of the horny layer, in the lower two-thirds of the hair follicle, and in the nail plate. Such penetration depends on many factors, not the least being the penetrability of soft and hard keratins themselves. Their structure is such that it is likely to be opened by water, alkalis and reducing agents, and permeation is most likely to be accomplished by molecules of small size. These are accepted facts in the textile and tanning industries.

It is necessary also to consider the effect of a chemical agent on keratin itself. Many fungicides appear to act by combining with the proteins of a fungus and will probably, therefore, combine also

## THEORETICAL ASPECTS

with keratin. The resultant compound may no longer be fungicidal and may also act as a barrier to further penetration.

In a thin sheet of soft keratin, as in the smooth skin, fungus may be superficial enough for its growth to be inhibited by a fungicide applied to the skin surface, but in the thicker horny layer of the sole and palm it is remote from effective fungicidal concentrations. Similarly, the fungus may be vulnerable in the shallow follicle of a lanugo hair, but protected in the deeper follicle of a terminal hair.

This has been in accord with our experience, not only with a variety of fungicides but also with cross-linking agents. By virtue of the fact that the cross-linking agent, ninhydrin, combines with amino-acids to give coloured compounds, its degree of penetrability into keratin may easily be assessed. This chemical has been used in *T. rubrum* infections of the palms and soles in the presence of surface agents and alcohol; after prolonged soaking the skin becomes purple. By superficial paring with a scalpel, fungus can be demonstrated in the horny layer stained in the same way as the keratin. In the deeper horny layer, however, the fungus is unstained. The effect of ninhydrin on lesions of the thin keratin of the dorsum of the foot was to abate the infection as with conventional fungicides, but infection of the sole was unaffected.

*T. rubrum* infections can, in our experience, be cleared from smooth skin with Whitfield's ointment, aniline dyes and fungicides used on conventional lines. It is doubtful, therefore, whether there is any wisdom in searching for new fungicides at this stage in our knowledge, and whether the assessment of fungicidal potency using *in vitro* culture methods is of real value. In such methods the fungus is in its mycelial form, and different from its parasitic form; furthermore, the fungus is very vulnerable in cultures.

For opening up keratin, lithium bromide, sodium metabisulphite, urea and thioglycolates have been used, and treatment has followed with cross-linking agents, including ninhydrin, dibromopropane and picric acid. The inability to obtain adequate penetration of keratin has always proved an insuperable obstacle. Keratolytics which produce more gradual degradation and which could be used over prolonged periods have also been used in the hopes that their action would overtake keratin production, give rise to a thinner horny layer and thereby allow better penetration of fungicides. Salicylic and benzoic acids were employed for this purpose in relatively high concentrations and were used in patients suffering from long-standing *T. rubrum* infection of the palms and soles and of many nails. The affected parts were soaked for half an hour daily in warm water and then painted with a solution of the two acids in spirit. Very

## TREATMENT OF FUNGOUS INFECTIONS OF THE SKIN

free exfoliation rapidly occurred and after a month of treatment no fungus could be found in either the palms or soles, although it was still present in the nails of these patients. Treatment was continued for a further month after which 15 nails were removed under general anaesthesia. The nail beds were then treated with ninhydrin and brilliant green, which in one instance produced a very acute inflammatory reaction. The nails grew again but, although of normal appearance, they were found to contain fungus one month later.

These cases have since relapsed with clinical evidence of nail infection although the palms and soles are still free from fungus. This experience appears to contradict the common belief that nail reinfection after removal is due to extension of infection from the adjacent skin, and that a prerequisite before nail avulsion is clearance of fungus from the surrounding skin areas.

At the present state of knowledge, there appears to be no place for surgical removal of nails infected with *T. rubrum*, with the possible exception of solitary nail involvement.

Various keratolytics applied to infected nails have also proved ineffective. There is unlikely to be any notable advance in treatment of intractable *T. rubrum* infections until more is understood of the fundamental factors controlling the parasitism of this fungus.

## REFERENCES

- <sup>1</sup> Barlow, A. J. E., and Chattaway, F. W. (1955). "The Attack of Chemically Modified Keratin by Certain Dermatophytes." *J. invest. Derm.*, **24**, 65.
- <sup>2</sup> — — and Thompson, C. C. (1953). "Effect of Inhibitors on the Metabolism of *Microsporum*." *Biochem. J.*, **55**, 31.
- <sup>3</sup> Chattaway, F. W., Thompson, C. C., and Barlow, A. J. E. (1956). "The Action of Inhibitors on Dermatophytes." *Biochem. J.*, **63**, 648.
- <sup>4</sup> Chin, B., and Knight, S. G. (1957). "The Growth of *Trichophyton mentagrophytes* and *Trichophyton rubrum* in Increased Carbon Dioxide Tensions." *J. gen. Microbiol.*, **16**, 642.



## TREATMENT OF FUNGOUS INFECTIONS OF THE SKIN

In some cases, ointments seem to help by inducing an inflammatory reaction. Dithranol, phenyl mercuric nitrate, or other fungicides allegedly more powerful than Whitfield's ointment, do not appear to produce earlier resolution of infection.

If *M. audouini* is proved to be responsible it is rarely possible to succeed with topical remedies and recourse must be had to radiological epilation. Individual variations of response occur to radiotherapy and it may be that in a batch of 30 affected children one or more may fail to epilate completely, either at margins between the 5-inch diameter fields of 450r each, or in three converging lines where the wooden rods of the applicator have partially screened the rays. It is helpful to pare down these rods to minimize this screening effect. An exposure of 500r instead of 450r to each field also lessens the risk of incomplete irradiation in places without risk of scarring alopecia. (There can well be a +30 per cent or a -10 per cent variation in the radiation received at different sites.) Dr. Walter Shanks has suggested the replacement of the rods by two converging beams of light which when focused would enable distance to be judged accurately without interference with the passage of x-rays.

After treatment, the children continue to wear linen skull-caps and a fungicidal ointment is applied to the affected areas. During the phase of epilation the scalp is examined periodically with Wood's light. Preferably there should be no interference with the natural shedding of the individual hairs but occasionally it may be necessary to assist epilation by the gentle use of forceps or adhesive plaster. The absence of fluorescing hairs on 3 consecutive examinations at weekly intervals is the criterion of cure. A determined search must be made, using Wood's light, with the aid of the local authority, for other cases in the child's environment. Subclinical infections may be found. All infected cases should be treated concurrently as far as possible.

Cases which fail to epilate fully in part of the affected area are a serious problem unless puberty is close and spontaneous clearance therefore likely. Recourse may be had either to local irritant applications (for example dithranol) with a view to encouraging epilation, or to repeat radiological epilation of the affected area only (with due warning to the parents of the hazard involved). Thallium acetate is too toxic for serious consideration.

**Other infections.**—Anthropophilic endothrix types of infection due to *Trichophyton sulphureum*, *T. violaceum*, *T. tonsurans* and *T. schoenleini* are also treated by radiological epilation, there is no tendency to spontaneous resolution at puberty. All but the last of these 4 fungous infections are specially difficult to follow up since

## PRACTICAL ASPECTS

Wood's light is of no avail, and cure can only be established by careful inspection with a hand lens and by microscopic examination of any suspected hairs that remain.

Infections due to *T. mentagrophytes* and *T. verrucosum* (*T. discoides*): These zoophilic infections present as kerion, and respond well to manual epilation and to the application of a fungicidal ointment. The temptation to incise a kerion should be resisted.

### RINGWORM OF THE BEARD

This infection, the true fig-like sycosis barbae, due to *T. mentagrophytes* or *T. verrucosum*, responds well to manual epilation accompanied by the topical application of fungicides. If the least evidence of keloid formation develops, then a course of radiological treatment is indicated, such as 150r repeated weekly up to a total of 600r.

### RINGWORM OF THE GLABROUS SKIN (*tinea corporis*, *tinea circinata*)

Treatment of this type of ringworm is not usually a difficult problem but examination must be made for coincident involvement of the scalp or nails. The application of magenta paint or of Whitfield's ointment is usually adequate and the lesion should be kept covered with a dressing to prevent inoculation of other sites. Affected lanugo hairs should be manually epilated if they do not fall spontaneously.

### RINGWORM OF THE HANDS

from that of other glabrous sites and pustular folliculitis is dealt with by manual epilation. *Trichophyton rubrum* infections are particularly resistant to all forms of treatment.

### RINGWORM OF THE AXILLAE AND GROINS

This condition is rare in females but relatively common in males. It may be due to *Epidermophyton floccosum*, *T. rubrum* or occasionally other *Trichophyta*. Resolution, except in *T. rubrum* infections, may follow the application of magenta paint at night and the use of a 3 per cent salicylic acid dusting powder by day. Concurrent treatment of other sites is essential.

### RINGWORM OF THE FEET

Enquiry must be made into the wearing of unsuitable footwear such as Wellington boots, shoes with crepe rubber soles, clogs at



## TREATMENT OF FUNGOUS INFECTIONS OF THE SKIN

work, coarse-knit woollen socks or shrunken socks. Orthopaedic disabilities such as pes planus or hallux valgus, also perniosis and hyperidrosis, may need attention. The patient is instructed to wear white cotton in-socks which must be changed daily and boiled. He should have his own bath-mat and he should scrub the bath immediately after use, to wash away infected epidermal debris. Magenta paint is applied twice a day to any active lesions, and 3 per cent salicyclic acid dusting powder or 25 per cent zinc peroxide powder is shaken from a canister between the toes and into the socks on rising. These two remedies appear to be as effective as any proprietary fungicide. Secondary infection is treated by potassium permanganate (1 in 8,000) soaks, an appropriate antibiotic is sometimes indicated but often a 25 per cent zinc peroxide powder is more useful. In this way, infections with *E. floccosum* and *T. mentagrophytes* may be brought under control, but *T. rubrum* remains a law unto itself and no method of treatment is consistent in its efficacy.

### RINGWORM OF THE NAILS

There is no method available for curing ringworm of the nails. Spontaneous resolution occasionally seems to occur, and extirpation of the nails may not be followed by recurrence in all of them.

### PITYRIASIS VERSICOLOR

This infection due to a yeast-like organism affects the trunk more than the limbs. Treatment necessitates investigation into hygienic practices, thus, there may be infrequent bathing and a habit of sleeping in a vest. Hyperidrosis may be present and general causes for this symptom must be excluded.

## TREATMENT AND CONTROL OF CHILDHOOD RINGWORM

J. M. BEARE

Scalp ringworm in the United Kingdom is usually due to one of 4 important fungi<sup>16</sup>. Unfortunately, there is no known fungicide which when applied to scalp ringworm will shorten the duration of the disease other than, perhaps, by producing a chemical reaction which may cause the affected hair to fall out more quickly than it would do spontaneously. It is customary to rely upon symptomatic treatment but it is equally important to see that the source of infection is eliminated.

The treatment of the infected child depends largely on the degree of inflammation associated with the infection, but the management of the outbreak, whether large or small, depends on the fungus responsible.

In a case of scalp ringworm, a clinical diagnosis can usually be made by noting: (a) the degree of inflammatory response, (b) the size of the lesion in relationship to duration of infection, (c) the presence or absence of associated body lesions, (d) the presence or absence of fluorescence under Wood's light, (e) the history of possible contact with an infected animal (such as, cow, dog or cat), and (f) the name and address of the child and the school that the child attends<sup>2</sup>.

### COMMON VARIETIES OF SCALP RINGWORM

*Microsporum audouinii* infections.—In the majority of these infections there is no reaction at all<sup>3</sup>, only 2 per cent showing obvious inflammation. At times of epidemics this fungus was found to be the most common cause of patchy dandruff in young children, the child usually having no other signs. There is a considerable spontaneous cure rate and though infections will abate at puberty delay in treatment results in further spread of infection. In one outbreak of infection in a small town, no less than 27 per cent of the male school population were infected, and in some streets every child had scalp ringworm.

must be almost unique. It is therefore essential to render the child

free of infection at the earliest possible moment and this can be achieved only by radiological epilation. Besides treating the child it is important to find the source of infection and evidence of spread of infection to other children. Every child in the home, the neighbourhood and the school should be examined with Wood's light; by such means we have eliminated an epidemic which involved over 1,000 children.

*Trichophyton sulphureum* infections.—This is the main cause of human tinea capitis now that *M. audouinii* infection has abated, and it may well become troublesome in Great Britain during the next few years. It is already causing concern in America<sup>4, 12</sup>, and in New Zealand<sup>5</sup>. Whittle<sup>19</sup> has reported cases from the Cambridge area. The condition is much less common than the animal varieties of ringworm and is usually symptomless though 28 per cent of cases are inflammatory<sup>1</sup>. Tinea corporis is far more common in infections by this organism than in those due to *M. audouinii*, and occasionally the nails are infected causing changes similar to and as intractable as those due to *Trichophyton rubrum*. Scalp infections, whether inflammatory or non-inflammatory, often remit and radiological epilation should not be hurriedly instituted. Furthermore, these cases are not so contagious as *M. audouinii* infections, and it is rare to get more than one child with scalp infection in a single household. One can therefore temporize with a sticky ointment and a cover of the child's own hair over the infected area. A certain proportion, however, will require radiological epilation eventually.

The condition does not give fluorescence under Wood's light, so it is always difficult to find the source of infection, but the contacts in the home and school should be examined carefully since body ringworm due to this fungus is common.

*Microsporum canis*.—Dog and cat ringworm is common all over the country and is much more common among cats than dogs. It is doubtful whether there is much spread of infection from child to child. In outbreaks investigated personally, all cases had direct contact with an infected animal. It is, therefore, unnecessary to keep these children away from school<sup>14</sup> provided that the affected parts are covered (scalp lesions with greased normal hair) and that mixing at games is prevented. Body lesions are more common than scalp lesions and the two may be found together in the same child. Fifty per cent of all scalp infections are inflammatory<sup>2</sup>. Non-inflammatory cases do not require radiological epilation and infections will clear within 6 months.

It is important in *M. canis* infections to discover the animal source of disease<sup>8</sup> and to have the animal destroyed because it cannot be

## TREATMENT AND CONTROL OF CHILDHOOD RINGWORM

effectively treated. In one outbreak a seven-year-old tomcat was responsible for infecting his kittens and they in turn the children receiving them as pets<sup>11</sup>. Adults handling the kittens were likewise infected as were dogs which came into contact with the kittens. This particular tomcat was directly responsible for infecting 22 humans (including 8 adults), 13 kittens and 2 dogs. Local catteries are invariably responsible for large-scale outbreaks of *M. canis* infections<sup>10</sup>.

Cats and dogs can easily be examined under Wood's light for fluorescent hairs, but considerable experience is required since small areas of infected fur behind ears or around the nose are difficult to find. Ringworm in dogs is much more easily seen clinically and diagnosis is seldom in doubt. Cat and dog claws are often infected<sup>9, 20</sup>.

*Trichophyton verrucosum* (*T. discoides*) infection.—This is the common cause of cattle ringworm in Britain. It invariably causes an inflammatory reaction requiring treatment by poultices and by removal of loose infected hairs, radiological epilation is never necessary. These cases are probably not infectious but, since spores from the fungus are known to remain alive for years in byres, fences and scratching posts<sup>17</sup>, young cattle become infected year after year. This is of little economic importance as healing is spontaneous within 4 months<sup>13</sup>.

In the North of Ireland almost every farm worker gets ringworm at some time in his life. Beard infections are often the most severe and often leave permanent scars.

*Other fungi causing infections.*—*Trichophyton mentagrophytes* is an uncommon infection, the animal source of which frequently remains in doubt (for example, cattle, mice). *Trichophyton equinum* occurs on gypsies' horses. *Trichophyton schoenleini*, causing favus, *Trichophyton violaceum* and *Microsporum gypseum* are very uncommon causes of tinea capitis in the British Isles. Whittle<sup>18</sup> described a small outbreak due to *M. gypseum*, a fungus which may be a soil inhabitant<sup>6, 7</sup>.

## REFERENCES

- <sup>1</sup> Beare, J. M. (1956) "Tinea capitis due to *Trichophyton sulphureum*" *Brit J Derm.*, 68, 193.
- <sup>2</sup> — and Cheeseman, E. A. (1951) "A Localized Outbreak of Tinea capitis (*M. audouinii*) in Northern Ireland." *Arch Dis Child*, 26, 149.
- <sup>3</sup> — — (1951) "Tinea capitis. Review of 1,004 Cases." *Brit J Derm.*, 63, 165.

# TREATMENT AND CONTROL OF CHILDHOOD RINGWORM

- 4 Chernosky, M. E., Friedman, L., and Krafchuk, D (1956) "The Growing Problem of Tinea capitis due to *Trichophyton tonsurans*" *Bull Tulane Med Fac*, 16, 31.
- 5 Fox, P. B., and Rush-Munro, F. M (1953) "Tinea capitis due to *Trichophyton sulphureum*" *N Z. med. J*, 52, 488
- 6 Gordon, M. A (1953) "Occurrence of the Dermatophyte, *Microsporum* ... .."
- 7 "....." *Microsporum Science*, 116, 208
- 8 La Touche, C. J. (1955) "The Importance of the Animal Reservoir of Infection in the Epidemiology of Animal-type Ringworm in Man" *Vet Rec*, 67, 666
- 9 — (1955) "Onychomycosis in Cats Infected by *Microsporum canis* Bodin" *Ibid*, 67, 578
- 10 — (1957) "The Epidemiology of Some Fungus Diseases with Especial Reference to Ringworm" *Med Pr*, 1, 412
- 11 Lawson, G. T. N., and McLeod, W. G (1957) In the Press
- 12 Reiss, F (1954) "*Trichophyton tonsurans* Ringworm, a Contribution to the Epidemiology and Rare Clinical Manifestations" *Brit J Derm*, 66, 239
- 13 Sellers, K. C., Sinclair, W. B. V., and La Touche, C. J (1956) "Preliminary Observations on Natural and Experimental Ringworm in Cattle" *Vet Rec*, 68, 729
- 14 Thomas, B. A (1953) "*M. canis* Ringworm and Loss of Schooling." *Brit. med J*, 1, 536
- 15 Walby, A. L (1952) "Tinea capitis (*M. audouinii*) in a Residential School" *Brit med J*, 1, 1114
- 16 Walker, J (1950) "The Dermatophytoses of Great Britain; Report of a 3 Years' Survey" *Brit J Derm*, 62, 239
- 17 — (1955) "Possible Infection of Man by Indirect Transmission of *Trichophyton discoides*" *Brit med J*, 2, 1430
- 18 Whittle, C. H (1954) "A Small Epidemic of *M. gypseum* Ringworm in a Plant Nursery" *Brit J Derm*, 66, 353
- 19 — (1956) "A Survey of Fungous Infection in the Cambridge Area, 1948-55" *Ibid*, 68, 1
- 20 Young, A. M (1956) "Chronic Diffuse Ringworm due to *Microsporum canis* in a Dog Involving Two Claws" *Vet Rec*, 68, 606

## TREATMENT OF VAGINAL MONILIASIS

R. F. JENNISON\*

### NYSTATIN AND GENTIAN VIOLET

PREGNANT and non-pregnant women with vaginal moniliasis from 5 out-patient units were referred to a special clinic for investigations and treatment by methods already described<sup>3, 4</sup>. The patients were divided into two comparable groups; each group was treated on 3 alternate days, one group having 2 pessaries containing 100,000 units of nystatin inserted, the other being painted with 1 per cent gentian violet. After treatment, 86 per cent of the 35 nystatin patients were free from *Candida* as compared with only 47 per cent of the 34 women treated with gentian violet, differences which are statistically significant. The 5 failures with nystatin were all pregnant. Six patients were withdrawn from the gentian-violet series because of local reactions and, together with 12 gentian-violet failures, were treated with nystatin. All 6 patients who reacted badly to gentian violet were cured by one course of nystatin. There were 4 failures with nystatin out of 12 patients who had not been cured by gentian violet. Three of these received a second course of nystatin and 2 were cured.

The results in all the 53 women who were treated with nystatin either primarily or secondarily are shown in Table 50. A notable feature of the nystatin treatment was the rapidity with which symptoms disappeared.

The results of follow-up one month later showed that 21 per cent of the nystatin-treated patients had relapsed, compared with 46 per cent of those treated with gentian violet. These patients had only short courses of nystatin and the results were regarded as extremely promising, especially when the ease of treatment with pessaries was compared with the previous system of painting with gentian violet.

**Sensitivity tests.**—These were carried out by both blotting paper disc and serial tube dilution techniques on all organisms isolated (Fig. 120). For routine use, discs containing 12.5 and 6.2  $\mu$ g. of nystatin were selected. In 90 strains tested at these strengths, the

\* Acknowledgement for co-operation is made to the consultant staff of Saint Mary's Hospitals, Manchester, to the resident surgical officers, Dr J. D. Uywelyn-Jones, P. A. Maholis and R. M. Thomson and to Mr P. Stenton for assistance with the laboratory work.

# TREATMENT AND CONTROL OF CHILDHOOD RINGWORM

- <sup>4</sup> Chernosky, M E, Friedman, L, and Krafchuk, D (1956) "The Growing Problem of Tinea capitis due to *Trichophyton tonsurans*" *Bull Tulane Med Fac*, 16, 31.
- <sup>5</sup> Fox, P B, and Rush-Munro, F M (1953) "Tinea capitis due to *Trichophyton sulphureum*" *N Z. med J*, 52, 488
- <sup>6</sup> Gordon, M A (1953) "Occurrence of the Dermatophyte, *Microsporum*  
*canis*, 200  
*Science*,
- <sup>8</sup> La Touche, C. J (1955) "The Importance of the Animal Reservoir of Infection in the Epidemiology of Animal-type Ringworm in Man" *Vet Rec*, 67, 666
- <sup>9</sup> — (1955) "Onychomycosis in Cats Infected by *Microsporum canis* Bodin" *Ibid*, 67, 578
- <sup>10</sup> — (1957) "The Epidemiology of Some Fungus Diseases with Especial Reference to Ringworm" *Med Pr*, 1, 412
- <sup>11</sup> Lawson, G T N, and McLeod, W G (1957) In the Press
- <sup>12</sup> Reiss, F (1954) "*Trichophyton tonsurans* Ringworm, a Contribution to the Epidemiology and Rare Clinical Manifestations" *Brit J Derm*, 66, 239
- <sup>13</sup> Sellers, K C, Sinclair, W B V, and La Touche, C J (1956) "Preliminary Observations on Natural and Experimental Ringworm in Cattle" *Vet Rec*, 68, 729
- <sup>14</sup> Thomas, B A (1953) "*M. canis* Ringworm and Loss of Schooling" *Brit med J*, 1, 536
- <sup>15</sup> Walby, A L (1952) "Tinea capitis (*M. audouinii*) in a Residential School." *Brit med J*, 1, 1114
- <sup>16</sup> Walker, J (1950) "The Dermatophytoses of Great Britain, Report of a 3 Years' Survey" *Brit J Derm*, 62, 239
- <sup>17</sup> — (1955). "Possible Infection of Man by Indirect Transmission of *Trichophyton discoides*" *Brit med J*, 2, 1430
- <sup>18</sup> Whittle, C H (1954) "A Small Epidemic of *M. gypseum* Ringworm in a Plant Nursery" *Brit J Derm*, 66, 353
- <sup>19</sup> — (1956) "A Survey of Fungous Infection in the Cambridge Area, 1948-55" *Ibid*, 68, 1
- <sup>20</sup> Young, A M (1956) "Chronic Diffuse Ringworm due to *Microsporum canis* in a Dog Involving Two Claws" *Vet Rec*, 68, 606

## TREATMENT OF VAGINAL MONILIASIS

after 2 days' growth, suggesting that the early effect of nystatin at these concentrations was mainly fungistatic and not fungicidal. A concentration of 25  $\mu\text{g}$  per millilitre of nystatin prevented all growth. The fungicidal powers were investigated further by estimating the rate at which *Candida* was killed when incubated in 50  $\mu\text{g}$ . of nystatin per millilitre (Fig. 121). When the initial concentration of yeasts was of the order of 1 million per millilitre the viable count rapidly fell and all the organisms were dead at 24 hours. With initial concentrations




FIG. 121 — Rate of decline of viable counts of yeasts in presence of 50  $\mu\text{g}$  per millilitre of nystatin (By courtesy of the Department of Medical Illustration, Royal Infirmary, Manchester)

of 100 million yeast cells per millilitre the organisms were not killed in 24 hours, though they were considerably reduced in number.

The relationship between concentration of the antibiotic and number of organisms was of great importance in these *in vitro* studies, and the rapid relief of symptoms in patients treated with nystatin suggested that concentrations of the appropriate proportions were in fact being obtained in the vagina.



# TREATMENT OF VAGINAL MONILIASIS

TABLE 50

RESULTS OF TREATMENT OF VAGINAL MONILIASIS WITH  
NYSTATIN IN PREGNANT AND NON-PREGNANT WOMEN

	<i>Patients</i>	<i>Cured</i>	
		<i>Number</i>	<i>Per cent</i>
Pregnant	22	18	82
Non-pregnant	31	29	93
Total	53	47	88




FIG. 120. Zones of inhibition around discs containing nystatin.

zones of inhibition were 10–22 millimetres. All strains of *Candida* isolated at this time and tested by this method were found to be sensitive. The average minimal inhibitory concentration of nystatin was 3.2  $\mu$ g per millilitre after 1 day and 12.5  $\mu$ g per millilitre

## TREATMENT OF VAGINAL MONILIASIS

### AMPHOTERICIN B

Recently another anti-fungal antibiotic (amphotericin B) has been available and a small trial has been conducted. In all, 54 women were treated with vaginal tablets containing 25 milligrams or 50 milligrams of amphotericin B. One tablet was inserted each night for 15 nights. Nineteen women were treated with 25 milligram tablets, but 2 did not attend after completion of treatment. Four of the remainder were pregnant and the treatment had no effect. Of the other 13, 11 were free from yeasts at the end of treatment but 2 of these had recurred 1 week later. Thirty-five women were treated with 50 milligram tablets, 4 of whom did not attend after treatment. Seven were pregnant and only 1 was cleared; 21 of the other 24 were free from yeasts at the end of treatment but 5 recurred within 2 weeks.

The overall cure rate estimated 1-2 weeks after the cessation of treatment was 53 and 54 per cent respectively, with the 25 milligram and 50 milligram tablets. The amphotericin tablets seemed, therefore, to be very much less effective in pregnancy than nystatin and slightly less effective in non-pregnant women. The recurrence rate appeared to be higher than that following nystatin therapy.

### REFERENCES

- <sup>1</sup> Barr, W (1957) "Current Therapeutics, 113—Nystatin" *Practitioner*, 178, 616
- <sup>2</sup> Browne, A. D (1957) "Nystatin Therapy in Monilial Vulvo-vaginitis" *J. Irish med. Ass.*, 40, 86
- <sup>3</sup> Jennison, R. F., and Llywelyn-Jones, J. D (1957) "Treatment of Monilial Vaginitis, a Clinical Trial of Nystatin" *Brit. med. J.*, 1, 145
- <sup>4</sup> — and Stenton, P (1957) "Sensitivity of *Candida* Strains to Nystatin" *J. clin. Path.*, 10, 219
- <sup>5</sup> Pace, H. R., and Schantz, S. I (1956) "Nystatin (Mycostatin) in the Treatment of Monilial and Non-monilial Vaginitis" *J. Amer. med. Ass.*, 162, 268

# TREATMENT OF VAGINAL MONILIASIS

## TREATMENT SUMMARY

The results of treatment of all patients treated with nystatin or gentian violet and adequately followed up in the years 1956-57 are summarized in Table 51. The recent improvement in results is probably explained by the longer course of treatment latterly employed. Since the end of 1955, there have been 91 per cent of cures out of 172 pregnant and non-pregnant women with vaginal moniliasis treated with nystatin as compared with 57 per cent of cures in 71 women treated with gentian violet. Oral tablets were combined with pessaries in 9 patients, but there was no evidence that the addition of such oral therapy was of any value.

TABLE 51

RESULTS OF TREATMENT AND FOLLOW-UP IN PATIENTS WITH VAGINAL MONILIASIS (1956-57)

	<i>Number treated</i>	<i>Number cured</i>	<i>Per cent cured</i>	<i>Per cent cured in earlier trial (1955-56)</i>
Nystatin	119	78 (+36)*	96	86
Gentian violet	35	17 (+ 6)*	66	47

\*Clinically cured only

The majority of the courses of nystatin treatment have consisted of 1 pessary nightly for 15 nights. Although most patients were cured by this 2-week course, a number, especially among the pregnant women, required longer or repeated courses. The length of the course of treatment also seems to have an effect on the relapse rate. Using 1 pessary nightly for 1 week, Barr<sup>1</sup> treated 64 women of whom 10 became reinfected later, giving a relapse rate of at least 15 per cent. Using a similar dosage, Browne<sup>2</sup> treated 25 women, with a relapse rate of 20 per cent. Pace and Schantz<sup>3</sup> treated 38 women with a similar course, with 29 per cent relapses, whereas in 2 smaller groups treated with 2 pessaries nightly for 1 week and 1 pessary nightly for 2 weeks, less than 15 per cent relapsed.

In our first series when only 2 pessaries on 3 occasions were used, the relapse rate 1 month after treatment was 21 per cent, but when the 2-week course was instituted, only 5 patients required a second course and 5 recurred later out of 113 treated, a relapse rate of less than 9 per cent.




FIG. 122 —Chest radiograph of patient with actinomycosis of the right lung erroneously diagnosed as carcinoma and treated by pneumonectomy (By courtesy of the Editors of *Thorax* )

of sulphonamides, the prognosis improved considerably. Some patients, however, failed to respond to one sulpha drug and yet responded well to another, particularly to sulphadiazine. There were cases in which no effective form of sulphonamide was found. There are many cases in the literature reported as cured based on a follow-up period of only a few months. Such cures are not acceptable since actinomycosis is often a disease comparable in its chronicity to tuberculosis. Results of cure should be based on a follow-up over some years.

**Penicillin.**—This has made it possible to cure almost all cases of actinomycosis provided high enough doses are given for a sufficiently long period. Only 2 cases encountered failed to respond clinically to penicillin. In one of these Garrod found that the culture of *A. israeli* grown was initially fully sensitive *in vitro* to penicillin but its sensitivity decreased tenfold during treatment, in the other the actinomycete had cultural characteristics which were very atypical of *A. israeli*. *In vitro* penicillin-sensitivity tests are not always reliable. For example, one case in which the organism initially grown was reported elsewhere as being highly penicillin-resistant *in vitro*

## TREATMENT OF ACTINOMYCOSIS

O. S. TUBBS

ACTINOMYCOSIS is the one form of fungous disease which responds well to treatment. The experience recorded below deals with 23 patients seen at the Thoracic Unit of St. Bartholomew's Hospital, London, and in which the disease was predominantly in the thorax. They are included in a review of the subject describing the results of treating 85 cases by Bates and Cruickshank<sup>1</sup>.

### DIAGNOSIS AND TREATMENT

The successful treatment of actinomycosis depends almost entirely upon making the correct diagnosis. It should be emphasized that many cases of infection of the chest by *Actinomyces israeli* do not present with the classical findings of multiple discharging sinuses, the occurrence of which makes diagnosis easy. The cases in which the diagnosis is most likely to be missed are those with a chronic pulmonary lesion producing a radiological shadow which may be ascribed to carcinoma or to some chronic infection other than actinomycosis. As a result the patient may be submitted unnecessarily to resection of a lobe or even a whole lung (Fig 122). This is brought out clearly in the paper by Bates and Cruickshank for 7 of the 85 cases underwent resection of a lobe or lung and in none of these 7 cases was a correct pre-operative diagnosis made. Prior to the introduction of the sulphonamides, treatment aimed at improving the general condition of the patient, and increasing resistance to the disease by vaccines. Massive doses of iodides were given by mouth presumably to aid absorption of fibrous tissue. Oxidizing agents, such as zinc peroxide, were applied locally to destroy anaerobic conditions favouring the growth of *A. israeli*. Radiotherapy was sometimes used with a view to increasing local resistance to the disease. Surgery was employed primarily to drain empyemas and abscesses and to excise diseased portions of the chest wall. Successful results from surgery occurred almost entirely in cases with localized empyema (Figs 123 and 124).

Before the sulphonamides and antibiotics became available, the results of treatment were very bad indeed, Bates and Cruickshank found that during this era, out of 29 patients whom they studied, only 4 are known to have recovered. Following the introduction




FIG 125—Chest radiograph showing bilateral loculated empyema due to actinomycosis (By courtesy of the Editors of Thorax)

FIG. 126—Chest radiograph of same patient as Fig. 125 following bronchopneumonic spread of the infection. (By courtesy of the Editors of Thorax)





FIG. 123.—Chest radiograph of male aged 53 years with large unilocular right-sided actinomycotic empyema (*By courtesy of the Editors of Thorax*)

FIG. 124 —Chest radiograph of same patient as Fig 123 after drainage of the empyema



## TREATMENT OF ACTINOMYCOSIS

from hospital.  
pneumonic spre.  
1,000,000 units c  
hospital He re

.. ..



FIG. 128.—Long-standing actinomycosis of the chest wall involving the sternum (By courtesy of the Editors of *Thorax*)

**Other antibiotics.**—For the very exceptional case which proves resistant to penicillin alone, either an additional drug known to be effective in combination with penicillin should be administered (for example, streptomycin) or, alternatively, the penicillin may be omitted and some other antibiotic drug given, preferably chosen on the basis of *in vitro* sensitivity test results. One patient whose organism proved resistant to penicillin *in vitro* and who also failed to respond clinically to penicillin was given a long course of terramycin. This led to marked improvement in an extremely chronic suppuration of the chest wall of 15 years' duration (Fig 128). Terramycin apparently eradicated the *A. israeli*, but death occurred later from secondary haemorrhage from an internal mammary artery, the patient having repeatedly refused resection of the osteomyelitic sternum.

### CONCLUSIONS

In general, surgery rarely has any part to play in the treatment of thoracic actinomycosis. The majority of cases are cured by the administration of penicillin.



## TREATMENT OF ACTINOMYCOSIS

responded to penicillin therapy in dramatic fashion. (A subculture of the organism was subsequently examined by Garrod and found to be as sensitive as the Oxford staphylococcus) Penicillin therapy should, therefore, be proceeded with as soon as *A. israeli* is isolated regardless of the results of sensitivity tests

Penicillin should be given in sufficient amount and continued for long enough to make as sure as possible that the patient is cured on a single course of treatment. From an analysis of those cases which relapsed it may be concluded that 2,000,000 units given 8-hourly for 6 weeks followed by 600,000 units of distaquaine penicillin given daily for another 6 weeks are necessary to make the




FIG. 127 —Chest radiograph of same patient as Figs. 125 and 126 following final course of penicillin (By courtesy of the Editors of *Thorax*)

chance of relapse remote The following case is described as an example of relapse occurring due to inadequate penicillin therapy:

A man aged 42 years first came to hospital with an empyema on the right side from which micro-aerophilic streptococci were grown He was given 13 days' treatment with 400,000 units of penicillin daily for this streptococcal infection He subsequently returned with a subcutaneous abscess in the right axilla and with an empyema on the other side (Fig 125) both of which were drained Loculation of the empye-

## TREATMENT OF ACTINOMYCOSIS

of pus in the pleural cavity should be drained by rib-resection. Chronic pulmonary infection usually clears up with penicillin therapy alone but exceptionally the disease may cause much bronchiectasis and fibrosis and this may call for resection if symptoms arise as the result of secondary infection. In this case the operation is done, *not* for actinomycosis, but for structural damage caused by the infection.

## REFERENCE

- <sup>1</sup> Bates, M., and Cruickshank, G (1957). "Thoracic Actinomycosis " *Thorax*, 12, 99

## TREATMENT OF ACTINOMYCOSIS




FIG 129—Localized abscess in left pectoral region due to actinomycosis (By courtesy of the Editors of *Thorax*)





FIG 130—Same patient as shown in Fig 129, 5 months later following penicillin treatment (By courtesy of the Editors of *Thorax*)

## THE ALLERGIC TYPE

This attack subsided but was followed by another (Fig. 133) affecting the basal zone on the right side and also giving rise to left lower lobe collapse which persisted for a year. Subsequently, more shadows were seen in other zones (Figs 134 and 135) and the left lower lobe



(a)



(b)

FIG 132 a, b, c—Resolution of right upper lobe consolidation in 2 weeks, July 1949



(c)

began to re-expand and finally appeared normal. Bronchograms showed saccular bronchiectasis of the right upper lobe, the original site of the pneumonia. At bronchoscopy, a rounded tumour-like mass was seen to be occupying the left lower lobe bronchus. In

## TREATMENT OF ASPERGILLOSIS

N. S. PLUMMER


BRONCHO-PULMONARY ASPERGILLOSIS may be divided into 3 main types: (a) allergic, (b) saprophytic, including aspergillus mycetoma, (c) septicaemic or pyaemic.

### THE ALLERGIC TYPE

It should perhaps be stated that when the allergic type of aspergillosis was described in 1952<sup>1</sup> no reference had been seen to this condition in the literature. Later, however, such a reference was found in the *Manual of Clinical Mycology* by Conant and his colleagues<sup>2</sup> in which it was stated briefly that sensitization had occurred to the



(a)



(b)


FIG 131 a, b —Resolution of right upper lobe consolidation in 3 weeks, 1947

aspergillus, giving rise to prolonged illness in which transient lung shadows were seen by radiography. The main features of the condition are recurrent attacks of pyrexia, typical allergic sputum with plugs, the finding of *Aspergillus fumigatus* in the sputum, blood eosinophilia, and changing serial radiograph shadows.


**Case history.**—The first patient with this condition seen by the author, in 1947, had a pneumonic episode which resolved in about 3 weeks (Fig 131). In 1949 the disease recurred (Fig 132) with fever, expectoration of copious sputum, but no asthmatic symptoms.

## THE ALLERGIC TYPE

administration appeared to affect the course of disease and the sputum remained positive for *A. fumigatus*. The patient became ill intermittently with similar episodes over a period of 4 years. For the last 4 years, however, fungus has not been detected in her sputum



(a)



(b)

FIG 134 a, b, c—September 1950, the lower lobe is beginning to re-expand




(c)

in spite of many culture examinations. Evidence of sensitization as indicated by blood eosinophilia and transient lung shadows has vanished completely and the patient is now essentially a case of bronchiectasis with minor exacerbations of bronchitis.

Presence of pneumonia and bronchiectasis.—It is important to note,

## TREATMENT OF ASPERGILLOSIS

each episode the patient responded well to penicillin, by the fourth day of therapy the temperature fell, the sputum became more mucoid and showed fewer brownish-yellow plugs containing aspergillus. The plugs did not, however, disappear entirely from the




(a)



(b)

FIG 133 —(a) Consolidation in right lower lobe and collapse of left lower lobe, November 1949  
(b, c) Also middle lobe consolidation and collapse of left lower lobe, April 1950




(c)

sputum by the time the next pyrexial episode occurred and blood eosinophilia persisted. 4,4'-diamidinophenylamine hydrochloride was given by inhalation, but detectable blood levels of the drug were not recorded. The same drug was administered intravenously until a total of 1.2 grammes had been given. Neither route of

## THE ALLERGIC TYPE

administration appeared to affect the course of disease and the sputum remained positive for *A. fumigatus*. The patient became ill intermittently with similar episodes over a period of 4 years. For the last 4 years, however, fungus has not been detected in her sputum



(a)



(b)



(c)

FIG 134 a, b, c—September 1950, the lower lobe is beginning to re-expand


in spite of many culture examinations. Evidence of ventilation as indicated by blood eosinophilia and transient lung shadows has vanished completely and the patient is now essentially a case of bronchiectasis with minor exacerbations of bronchitis.

Presence of pneumonia and bronchiectasis.—It is important to note,



## TREATMENT OF ASPERGILLOSIS

therefore, that the allergic type of aspergillosis may ultimately resolve spontaneously. Treatment with penicillin has been used in another case with similar good effect, presumably because of the superadded bacterial pneumonia almost invariably present. Antibacterial antibiotics should not be withheld on account of the presence of fungus in the sputum. In another case cortisone and hydroxystilbamidine




(a)



(b)

FIG 135 —(a, b) Recurrence in right upper lobe with resolution in 2 weeks, January 1951 (c) June 1951, the left lower lobe has almost fully re-expanded



(c)

(2-hydroxy-4 4'-diamidinostilbene) in combination were administered. A total dosage of  $2\frac{1}{2}$  grammes of hydroxystilbamidine was given over about 3 weeks but it had, apparently, no effect in hastening the recovery of a pneumonic episode.

Sometimes after years of illness with recurring symptoms, radiological shadows and fungus-positive sputum, patients recover. The eosinophilia disappears and chest radiographs become normal yet

## THE SAPROPHYTIC TYPE

*A. fumigatus* continues to appear in sputum samples. Treatment by surgery may be contemplated in view of the fact that in all the author's cases there has been underlying bronchiectasis. In 3 such cases removal of a lobe infected by aspergillus was followed by the development of recurring lung shadows in the other lung and the sputum remained fungus-positive.

## THE SAPROPHYTIC TYPE

The saprophytic type of aspergillosis comprises a heterogeneous group of conditions in which *A. fumigatus* secondarily invades lungs affected by pulmonary tuberculosis, sarcoidosis, bronchiectatic cysts, abscesses, bronchial carcinoma, pneumonia and other processes. In such cases, it is doubtful whether specific treatment of the aspergillosis is necessary since treatment of the primary lung disease will probably lead to recovery from the fungous infection. In cases of pneumonia where there is free invasion of the lung by the aspergillus it is probable that the fungous infection is superimposed upon bacterial infection due, for example, to staphylococcus. Though it would seem reasonable to treat such patients with an antifungal drug no benefit was apparent in 4 cases treated with hydroxystilbamidine. In such cases, treatment with an antibacterial antibiotic has usually been effective, although *A. fumigatus* has persisted in the sputum.

bronchial epithelium; in 2 cases where this was absent granulation tissue surrounded the mass. In some instances a mycetoma has given rise to no symptoms during a 10-year period prior to resection. Recurrent haemoptysis frequently occurs, however, and this is the usual way the patient presents for treatment. Mycetomas can usually be resected fairly readily though complications may follow such a procedure (for example, bronchial fistula leading to empyema). Experience has led to the conclusion that aspergillus mycetomas should not be treated by surgery unless there is evidence that such enlargement is taking place as to render them dangerous to the health of the patient, or unless exact diagnosis is in doubt. It is conceivable that their presence could produce a condition of hypersensitivity to aspergillus of the kind described above, but this occurred in 3 patients after resection. In 1 case it was found that a typical mycetoma was sited within a necrotic carcinoma.

Treatment of empyema infected secondarily with *A. fumigatus* is very difficult. On theoretical grounds one should instil an antifungal

## TREATMENT OF ASPERGILLOSIS

drug into the empyema cavity, but in 2 or 3 cases so treated this was not effective in removing the fungus.

The septicaemic type of aspergillosis has not been encountered

## CONCLUSIONS

It is, perhaps, not surprising that the parenteral administration of antifungal drugs is ineffective in broncho-pulmonary aspergillosis since, in the majority of cases, the fungus lies beyond the reach of the blood stream—for example, in the lumen of a bronchus or cyst. Furthermore, in cases of local or systemic invasion by fungus there is usually, if not always, some underlying condition such as pneumonia or abscess formation or some debilitating disease like carcinoma or agranulocytosis to be reckoned with. Administration of iodides has been tried but without any apparent effect on the course of the disease

## REFERENCES

- <sup>1</sup> Hinson, K. F. W., Moon, A. J., and Plummer, N. S. (1952) "Broncho-pulmonary Aspergillosis" *Thorax*, 7, 317
- <sup>2</sup> Conant, N. F., Smith, D. T., Baker, R. D., Callaway, J. L., and Martin, D. S. (1944) *Manual of Clinical Mycology*. 1st ed. Philadelphia and London, Saunders.

# EXPERIENCES WITH THE THERAPY OF 60 CASES OF DEEP MYCOTIC INFECTIONS

M. L. FURCOLOW\*

With the exception of actinomycosis and nocardiosis the commonly employed antimicrobial agents have proved to be ineffective in deep mycotic infections. Recently we have used a new antibiotic, amphotericin B, in the treatment of histoplasmosis and cryptococcosis with promising preliminary results.

Criteria for the diagnosis of histoplasmosis, are described in detail elsewhere<sup>9</sup>.

## REVIEW OF ANTECEDENT THERAPEUTIC TRIALS

### AROMATIC DIAMINES

Following a report by Elson<sup>8</sup> in 1945, a series of reports<sup>4, 5, 22, 27</sup> appeared in the literature indicating favourable results obtained with stilbamidine and later 2-hydroxystilbamidine in the treatment of blastomycosis. Of the 5 cases of systemic blastomycosis treated by our group results have likewise been favourable. All of our cases received 2-hydroxy-4:4'-stilbenedicarboxamide (2-hydroxystilbamidine, Merrell) intravenously in a daily dose of 225 milligrams. In 3 cases complete resolution occurred after a 30-day course of therapy. The remaining 2 patients required a second course before complete recovery.

In view of the remissions produced in blastomycosis, 2 cases of chronic progressive cavitary histoplasmosis and one with disseminated disease were treated with a similar therapeutic regime without demonstrable effect. *In vitro* studies<sup>23</sup> indicated that the body fluid levels required to inhibit the growth of *Histoplasma capsulatum* far exceed those which can be attained.

With the development and availability of the analogue, 2-amino 4:4'-stilbenedicarboximide (Aminostilbamidine, Merrell), 3 patients with cavitary histoplasmosis were treated with 250 milligrams intravenously daily for 30-60 days. No definite therapeutic effect could be demonstrated.

**MRD-112.**—In 1949, Tilford and his colleagues<sup>25</sup> described the

\* In collaboration with P. H. Lehan, J. Lewis Yates, C. A. Brasher and H. W. Larsh.

Acknowledgment:—The author wishes to thank the following physicians who co-operated in the study: Oklahoma and Texas: Doctors M. Fitzpatrick, Marion J. Rogers and R. Weber.

## THE THERAPY OF DEEP MYCOTIC INFECTIONS

properties of  $\beta$ -diethylaminoethyl fencolate (MRD-112, Merrell) Since then various reports on the "beneficial effect" of MRD-112 on the course of cavitary histoplasmosis have appeared<sup>12, 19, 20, 21</sup>. We have undertaken clinical trials with this agent in a total of 14 patients; 2 with cryptococcal meningitis, 2 disseminated histoplasmosis and 10 cavitary histoplasmosis. All received daily intravenous doses from 150 to 250 milligrams for periods of 30 to 60 days. The administration of MRD-112 did not alter the course or fatal outcome in either cryptococcal meningitis or disseminated histoplasmosis. Similarly, no effect was demonstrated among those with cavitary histoplasmosis.

**Ethyl vanillate.**—Christie and his colleagues<sup>3</sup> in 1951 reported favourable results with ethyl vanillate in the treatment of disseminated histoplasmosis. Since that time a number of favourable results and failures have been reported in the literature<sup>7, 17, 28</sup>. Although we have had no experience with this drug, the apparently erratic results obtained by others and the narrow therapeutic index led us to search for a better therapeutic agent.

**Nystatin.**—In 1951 Hazen and Brown<sup>11</sup> described an antifungal agent derived from several species of *Streptomyces*. This antibiotic was first called "fungicidin" but subsequently renamed nystatin (mycostatin, Squibb). Animal studies by Campbell<sup>2</sup> revealed that nystatin was an effective *in vivo* antifungal agent. Negligible absorption from the gastro-intestinal tract precluded the use of oral nystatin in the treatment of the deep mycotic infections. Trials with an intravenous preparation were undertaken in 4 patients with cavitary histoplasmosis and 1 with cavitary coccidioidomycosis. In 4 of these marked side reactions consisting of chills, fever, nausea and vomiting prevented a full course of therapy. One case with cavitary histoplasmosis received 200,000 units daily for 62 days without demonstrable therapeutic or toxic effects.

**Amebicide CT 686.**—This compound [1, 2-Bis-para (n-hexyl-methylaminomethyl) phenoxy ethane dihydrochloride] showed considerable activity *in vitro*<sup>13</sup> against a variety of fungi. Since it was relatively soluble in water, therapeutic trials with an oral preparation were undertaken. Fourteen cases of cavitary histoplasmosis received oral doses ranging from 48 to 300 milligrams daily for a

## THERAPEUTIC TRIALS WITH AMPHOTERICIN B

Members of the Squibb Institute of Medical Research and their

## THERAPEUTIC TRIALS WITH AMPHOTERICIN B

associates have recently isolated and described a new antifungal antibiotic derived from a soil *Streptomyces*<sup>2, 10, 11, 26</sup>. Studies by this group have indicated that amphotericin B is a weak base and is amphoteric as demonstrated by its greater solubility in acidic or basic aqueous alcoholic solvents. While the exact chemical structure of this compound is not known, its molecular formula has been established as  $C_{46}H_{73}NO_{20}$ . Ultra-violet absorption maxima indicate that there is a conjugated hexaenic or heptaenic system in amphotericin B.




Fig. 136—Comparison of the concentrations of 6 antifungal agents necessary to produce 50 per cent inhibition of the yeast phase of pathogenic fungi recently isolated from clinical cases

### IN VITRO STUDIES

*In vitro* studies by Gold and his colleagues<sup>10</sup> have revealed that amphotericin B does not have antibacterial activity but is effective in inhibiting the growth of the yeast and yeastlike fungi. Recent *in vitro* studies<sup>14</sup> in this laboratory with 5 strains of yeast phase *Histoplasma capsulatum* have shown that less than 0.1 µg per millilitre of amphotericin B was needed to produce 50 per cent inhibition of all strains. Fig. 136 compares the relative activity of amphotericin B

TABLE 52  
CRYPTOCOCCAL MENINGITIS. SUMMARY OF CLINICAL AND LABORATORY DATA ON CASES  
TREATED WITH AMPHOTERICIN B

Pre-treatment		Therapeutic regime			Post-treatment		Comments
Case number and clinical condition	Cultures	Route, dose and frequency	Number of doses	Clinical response	Cultures		
1 (56 W M ) Moribund	Spinal fluid + Gastric Urine +	Oral 2 gm /q d	4	Expired	Positive	Post mortem denied	
2 (50 W F ) Good	Spinal fluid +	Oral 2 gm /q d	30	Good	Negative	Improving prior to therapy Asymptomatic 1 year	
3 (63 W M ) Moribund	Spinal fluid +	Intravenous 50 mg /q d	7	Expired	Positive	Diabetic--5 years Post-mortem culture positive	
4 (37 W M ) Poor	Spinal fluid + Skin +	Intravenous 50 mg /q d 80 mg /q d 100 mg /q o d	4 9 4	Good	Negative Negative	Concomitant lymphoma. Skin lesions healed. Asymptomatic--5 months	
5 (62 W M ) Poor	Spinal fluid +	Intravenous 100 mg /q d 50 mg /q d 50 mg /q o d	8 4 10	Fair	Negative	Well--5 months CSF protein remains elevated	
6 (31 W F ) Fair	Spinal fluid +	Intravenous 50 mg /q d 100 mg /q o d	13 27	Good	Negative	Asymptomatic--4 months Spinal fluid normal	

## THERAPEUTIC TRIALS WITH AMPHOTERICIN B

and Lounia<sup>18</sup> have shown that in mice amphotericin B is an effective *in vivo* antifungal agent with a high therapeutic index.




FIG. 137—(Case 4 in Table 52) Chronic cutaneous lesion overlying the 11th rib posteriorly as it appeared the day therapy was instituted. Present without change for 3 months. *C. neoformans* recovered from lesion.




FIG. 138—Same lesion as it appeared approximately 2 weeks after instituting intravenous amphotericin B therapy. No evidence of recurrence after 4 months.

**Cryptococcosis.**—All the cases in this series presented clinical evidence of meningitis and *Cryptococcus neoformans* was readily recovered from the spinal fluid. In each instance pathogenicity was confirmed by intracerebral mouse inoculation. Table 52 outlines the pre-treatment status and cultures, the therapeutic regime and response of these patients. It should be noted that 3 out of 6 patients recovered, 1 improved and 2 (admitted *in extremis*) died.



# THE THERAPY OF DEEP MYCOTIC INFECTIONS

TABLE 53  
DISSEMINATED HISTOPLASMOSES. SUMMARY OF CLINICAL AND LABORATORY DATA ON CASES TREATED WITH AMPHOTERICIN B

Pre-treatment		Therapeutic regime		Post-treatment		Comments
Case number and clinical condition	Cultures	Route, dose and frequency	Number of days treated	Clinical response	Cultures	
7 (4 W.F.) Fair	Bone marrow - Lymph node +	Oral 1 gm /q d 2 4 gm /q d	90 120	Temporary improvement Questionable	Negative Negative	Relapse after discontinuation of therapy Has persistent hepatosplenomegaly
8. (50 W.M.) Poor	Bone marrow + Sputum + Laryngeal lesion +	Oral 2 gm /q d 4 gm /q d	60 78	Temporary improvement Expired	Negative Not done	1 week after discontinuing therapy cultures again positive Received cortisone for adrenal insufficiency. Suddenly expired 3 months after therapy
9 (5mo C.F.) Moribund	Bone marrow +	Intravenous 5 mg /q d	3	Expired		Post-mortem cultures positive
10 (69 W.M.) Moribund	Sputum +	Intravenous 50 mg /q d	2	Expired		Post mortem denied
11 (69 W.M.) Moribund	Sputum + Bone marrow +	Intravenous 100 mg /q d 50 mg /q d 50 mg /q o d, oral 2 gm /q d	6 15 34	Good	Negative	Asymptomatic 6 months Received oral therapy 2 additional months
12 (56 W.M.) Poor	Oral ulcer +	Intravenous 50 mg /q d 100 mg /q o d	23 17	Good	Negative	Complete healing oral lesion. 20 lb weight gain Asymptomatic 4 months

## THERAPEUTIC TRIALS WITH AMPHOTERICIN B

Despite repeated cultures, in no instance was the organism recovered after 2 weeks or more of intravenous therapy. One case had, in addition to meningitis, several cutaneous lesions of 3 months' duration due to *C. neoformans*. Figs 137 and 138 present the rather dramatic healing of one of these lesions while under therapy. In all but 1 case the cerebrospinal fluid cell count, sugar and protein reverted to normal.

**Histoplasmosis.**—As a result of our interest in this disease and our geographical location suitable cases were readily available. All cases selected for therapeutic trial were proved by isolation of the fungus by culture. Division of cases into the various classifications is based on criteria previously outlined by Furcolow<sup>9</sup>.

**Progressive disseminated histoplasmosis**—Six cases of this almost universally fatal entity received amphotericin B (Table 53). The first 2 cases received only oral drug and in both instances temporary clinical improvement and negative cultures were obtained while under active therapy. Both patients relapsed approximately 1 month after the therapy was stopped. The remaining 4 cases received intravenous therapy. While 2 of these patients expired, only 3 doses were administered before their demise. The remaining cases demonstrated rather dramatic clinical improvement and cultural conversion. One case had a granulomatous ulcerating lesion on the floor of the mouth shown to be due to *H. capsulatum*. Figs 139 and 140 depict this lesion prior to and 3 weeks after therapy was instituted.

**Chronic progressive pulmonary histoplasmosis**—Six patients who were classified in this category were selected for therapeutic trials with oral and intravenous amphotericin B. Of these, 5 had cavitory diseases and the remaining case had long-standing apical disease without cavitation. Only cases in which *H. capsulatum* had been repeatedly isolated from the sputum were selected for study. In an effort to minimize the possible effect of bed-rest and general supportive measures all cases were observed for 2-3 months before therapy was instituted. Only 1 patient (Case 17) had significant clinical and radiographic improvement on bed-rest alone. Drug therapy was withheld in this case until his clinical status and radiographs were stable.

The problems of evaluation of therapy on a short-term basis for this type of disease are comparable to those with advanced pulmonary tuberculosis. The criteria used in evaluating response to therapy were (a) changes in clinical status, (b) radiograph changes, (c) complement fixation titre changes, (d) conversion of sputum cultures. A summary of the clinical and laboratory data on these

TABLE 53  
DISSEMINATED HISTOPLASMOSES. SUMMARY OF CLINICAL AND LABORATORY DATA ON CASES  
TREATED WITH AMPHOTERICIN B

Pre-treatment		Therapeutic regime		Post-treatment		Comments
Case number and clinical condition	Cultures	Route, dose and frequency	Number of days treated	Clinical response	Cultures	
7. (4 W F) Fair	Bone marrow -	Oral 1 gm i/q d	90	Temporary improvement	Negative	Relapse after discontinuation of therapy
	Lymph node +	2 4 gm i/q d	120	Questionable	Negative	Has persistent hepatosplenomegaly
8 (50 W M) Poor	Bone marrow +	Oral 2 gm i/q d 4 gm i/q d	60 78	Temporary improvement	Negative	1 week after discontinuing therapy cultures again positive
	Sputum +			Expired	Not done	Received cortisone for adrenal insufficiency Suddenly expired 3 months after therapy
9 (5mo C F) Moribund	Bone marrow +	Intravenous 5 mg i/q d	3	Expired		Post-mortem cultures positive
10 (69 W M) Moribund	Sputum +	Intravenous 50 mg i/q d	2	Expired		Post mortem denied
11 (69 W M) Moribund	Sputum +	Intravenous 100 mg i/q d 50 mg i/q d 50 mg i/q o d oral 2 gm i/q d	6 15 34	Good	Negative	Asymptomatic 6 months. Received oral therapy 2 additional months
	Bone marrow +					
12. (56 W M) Poor	Oral ulcer +	Intravenous 50 mg i/q d 100 mg i/q o d	23 17	Good	Negative	Complete healing oral lesion 20 lb weight gain Asymptomatic 4 months

THERAPEUTIC TRIALS WITH AMPHOTERICIN B

Pre-treatment				Regime		Post-treatment				Comments
Case number and condition	Radiograph	C F titre	Sputum	Route, dose* and frequency	Number of doses	Clinical response	Radiograph improvement	C F titre	Sputum	
			Amount	Cul-ture					Amount	Cul-ture
13, 42 W M ) Fair	Far advanced cavitation bi-laterally	1 32	30-60 ml	+	Oral 4-6 gm	130	Good	Slight to moderate	5-10 ml	-
14, 64 W M ) Poor	Far advanced cavitation bi-laterally	1 256	30-90 ml	+	Oral 4-8 gm q d Intravenous 100 mg q d	240 9	Fair	Moderate following intravenous	15-30 ml	+
15, 37 W M ) Fair	Moderately advanced cavitation bi-laterally	1 8	50-60 ml	+	Oral 4 mg q d Intravenous 50 mg T I W	50 31	Good	Marked	5-10 ml	-
16, 18 W M ) Fair	Far advanced cavitation bi-laterally	1 8	30-60 ml	+	Oral 4 gm q d Intravenous 66 mg T I W	50 31	Mod Good	Moderate	3-5 ml	-
17, 35 W M ) Fair	Moderately advanced non-cavity apical disease	1 64	15-20 ml	+	Oral 4-6 gm q d Intravenous 50 mg T I W	55 33	Good	Slight to moderate	1 16	-
18, 37 C M ) Fair	Far advanced cavitation rt upper lobe	1 32	90-100 ml	+	Oral 4 gm q d Intravenous 50 mg B T W	84 48	Mod Good	Moderate	30-40 ml	-

\* T I W 1 times weekly, B T W 2 times weekly



FIG. 139—(Case 12 in Table 53) Ulcerating granulomatous lesion involving the major portion of the floor of the mouth. Culture and biopsy revealed *H. capsulatum*. Ulcerative disease has destroyed both sublingual caruncles.

FIG. 140—(Same case as in Fig. 139) Complete healing of lesion after 3 weeks of intravenous amphotericin B. A small fistulous track through which both submaxillary ducts empty can be seen to the right of the attachment of the frenulum.



patients is presented in Table 54. It should be noted that Cases 13 and 14 received largely prolonged oral therapy. Both these cases showed clinical improvement and slight to moderate radiographic change but sterilization of the sputum was obtained in Case 13 only. The remaining 4 cases received oral and intravenous amphotericin B. In all these cases clinical and radiographic improvement as well as sterilization of the sputa was accomplished. In only one instance, however, was cavity closure noted. Figs. 141, 142, 143 and 144 demonstrate the typical pulmonary lesions and their response to amphotericin B.

TABLE 54  
CHRONIC PROGRESSIVE PULMONARY HISTOPLASMOSIS SUMMARY OF CLINICAL AND LABORATORY  
DATA ON CASES TREATED WITH AMPHOTERICIN B

Pre-treatment				Regime		Post-treatment				Comments
Case number and condition	Radiograph	CF titre	Sputum	Route, dose* and frequency	Number of doses	Clinical response	Radiograph improvement	CF titre	Sputum	
			Amount						Amount	
13 (42 W M) Fair	Far advanced cavitation bilaterally	1:32	30-60 ml	Oral 4-6 gm	330	Good	Slight to moderate	1:16	5-10 ml	Cavity (11.5 cm) right sub apex disappeared. Cultures negative for 9 months
14 (64 W M) Poor	Far advanced cavitation bilaterally	1:256	10-40 ml	Oral 4-8 gm q d intravenous 100 mg q d	240 9	Fair	Moderate following intravenous	1:132	15-10 ml	Improved remarkably with intravenous drug, but received tetracycline at same time
15 (37 W M) Fair	Moderately advanced cavitation bilaterally	1:8	50-60 ml	Oral 4 mg q d intravenous 50 mg T T W	50 31	Good	Marked	1:8	5-10 ml	Febriile response following intravenous injection daily Under therapy 4 months
16 (38 W M) Fair	Far advanced cavitation bilaterally	1:8	30-60 ml	Oral 4 gm q d intravenous 66 mg T T W	50 31	Mod Good	Moderate		3-5 ml	Under therapy 4 months 10 lb weight gain
17 (35 W M) Fair	Moderately advanced non cavity apical disease	1:64	15-20 ml	Oral 4-6 gm q d intravenous 50 mg T T W	55 33	Good	Slight to moderate	1:16		Improved on bed-rest alone, further improvement following intravenous therapy Under therapy 4 months
18 (57 C M) Fair	Far advanced cavitation rt upper lobe	1:32	90-100 ml	Oral 4 gm q d intravenous 50 mg B T W	84 48	Mod Good	Moderate		30-40 ml	Followed for 6 months since therapy started

\* T T W 3 times weekly B C W 2 times weekly



FIG 141 —(Case 18 in Table 54) Chronic progressive cavitary histoplasmosis with marked involvement of the right upper lobe Prior to therapy.

FIG 142 —Same case as Fig 141 Considerable clearing in both lungs, more marked in the right, after oral amphotericin B (1 gramme q i d Nov 1-Dec 30, 1956, and Feb 28-Mar 16, 1957) plus IV amphotericin B 50 milligrams twice weekly Nov 5, 1956-Apr 11, 1957



*Severe acute pulmonary histoplasmosis*—A case of severe "epidemic" histoplasmosis was selected to observe the effect of the drug on the acute form of the disease. There was a prompt clinical response with fall in temperature and rapid radiographic clearing which was closely coincident with intravenous administration of the drug (Fig 145). It should be cautioned that the course is difficult

## THERAPEUTIC TRIALS WITH AMPHOTERICIN B

FIG 143 —(Case 15 in Table 54) Bilateral apical histoplasmosis with cavitation just prior to treatment



FIG 144 —Same case as Fig 143. Marked reduction in parenchymal disease after 3 months' therapy with amphotericin B

to interpret since recovery is the rule in this form of histoplasmosis, but, on the basis of past experience, it is our opinion that this illness was significantly shortened.

**Dosage and administration.**—The oral preparation used in these studies was administered as 200-milligram tablets of crystalline



## THE THERAPY OF DEEP MYCOTIC INFECTIONS

**amphotericin B** Administration in dosages up to 8 grammes daily presented no problems; however, poor absorption from the gastrointestinal tract makes this a questionable route of administration. Temporary improvement of several cases while under oral therapy indicated that this drug even in extremely low levels exerts some *in vivo* fungistatic effect.




FIG. 145 —Depicts the temperature curve and response of a case of severe acute pulmonary histoplasmosis to amphotericin B therapy. Note rapid fall in temperature curve following intravenous amphotericin B.

Intravenous amphotericin B used in this series of cases was administered as a colloidal suspension of estimated particle size 3 microns. The desired dose of amphotericin B was suspended in a 5 per cent aqueous solution of dextrose in a concentration of 1 milligram of drug per 5–10 millilitres of water. Administration of the drug over a 6-hour period greatly reduced the incidence of side reactions. Studies by Louria, Feder and Emmons<sup>18</sup> indicated that amphotericin B serum levels of 0.7 to 1.5  $\mu\text{g}$  per millilitre offered

comparable levels were demonstrated in humans receiving a dose

## THERAPEUTIC TRIALS WITH AMPHOTERICIN B

equivalent to 1 milligram per kilogram body-weight. Levels above 0.1  $\mu\text{g}$  per millilitre were found to persist for approximately 18 hours. One case receiving 1.7 milligrams per kilogram body-weight maintained a serum level of 0.3  $\mu\text{g}$  per millilitre for 30 hours after the drug was administered. From this data it is evident that a dose equivalent to at least 1 milligram per kilogram body-weight is desirable. The persistence of the drug in the serum with higher doses indicates that such doses could be given every other day. Despite adequate amphotericin B serum levels, measurable spinal fluid levels ( $>0.06 \mu\text{g}$  per millilitre) were not detected among the spinal fluids assayed.

*Toxic manifestations and side reactions*—No evidence of either acute or chronic toxicity was noted in any of the patients receiving the oral form of amphotericin B. Several of these patients received a total dose in excess of 1,000 grammes without ill effect. In many cases receiving intravenous therapy supplemented by oral drug, minor upper gastro-intestinal symptoms and headache were noted.

The colloidal suspension of amphotericin B administered intravenously to the cases in this series resulted in several rather consistent and undesirable side reactions. In almost every instance, shaking chills followed by a "spike" in temperature, during administration of the drug, were noted. It has been our experience that careful premedication with antihistamines and antipyretics will reduce these to a minimum. Chemical phlebitis was troublesome but its incidence was not prohibitive if the drug was given slowly over a 6-hour period. In several instances the drug infiltrated into the surrounding subcutaneous tissues. Although this resulted in mild discomfort and redness at the site, no serious complications resulted.

Repeated haematopoietic, hepatic and renal function studies failed to show any evidence of toxicity. In only 1 patient was there any evidence of possible toxic effect. In this case a transient rise in the blood urea nitrogen followed a dose of amphotericin B equivalent to approximately 1.4 milligrams per kilogram body-weight. This may have been related to persistent vomiting due to increased intracranial pressure, and resultant dehydration. Following rehydration the blood urea nitrogen returned to normal. In this same patient the drug was discontinued earlier than planned because of the development of generalized pruritus.

## DISCUSSION

This study, conducted over the past several years, was designed to "screen" promising antifungal agents. Clinical trials conducted on

## THE THERAPY OF DEEP MYCOTIC INFECTIONS

**amphotericin B** Administration in dosages up to 8 grammes daily presented no problems; however, poor absorption from the gastrointestinal tract makes this a questionable route of administration. Temporary improvement of several cases while under oral therapy indicated that this drug even in extremely low levels exerts some *in vivo* fungistatic effect.




FIG. 145—Depicts the temperature curve and response of a case of severe acute pulmonary histoplasmosis to amphotericin B therapy. Note rapid fall in temperature curve following intravenous amphotericin B.

Intravenous amphotericin B used in this series of cases was administered as a colloidal suspension of estimated particle size 3 microns. The desired dose of amphotericin B was suspended in a 5 per cent aqueous solution of dextrose in a concentration of 1 milligram of drug per 5–10 millilitres of water. Administration of the drug over a 6-hour period greatly reduced the incidence of side reactions. Studies by Louria, Feder and Emmons<sup>18</sup> indicated that amphotericin B serum levels of 0.7 to 1.5  $\mu\text{g}$  per millilitre offered excellent protection and resulted in negative cultures of mice experimentally infected with *H. capsulatum* or *C. neoformans*. Using a modification of the bioassay technique described by Littman<sup>16</sup>, comparable levels were demonstrated in humans receiving a dose

## REFERENCES

### SUMMARY

Experiences with the treatment of over 60 cases of deep mycotic infections with 7 antifungal agents are reviewed. Favourable results in the treatment of cryptococcal meningitis and histoplasmosis with a new antibiotic, amphotericin B, are reported.

## REFERENCES

- <sup>1</sup> Baum, G. L., Rubel, H., and Schwarz, J. (1956-57) "Treatment of Experimental Histoplasmosis." In *Antibiotics Annual*, p. 878. New York: Medical Encyclopedia Inc.
- <sup>2</sup> Campbell, C. C., Hodges, E. P., and Hill, G. B. (1954). "Therapeutic Effect of Nystatin (Fungicidin) in Mice Experimentally Infected with *Histoplasma capsulatum*." *Antibiot and Chemother*, 4, 406.
- <sup>3</sup> Christie, A., Middleton, J. G., Peterson, J. C., and McVickar, D. L. (1951) "Treatment of Disseminated Histoplasmosis with Ethyl Vanillate." *Pediatrics*, 7, 7.
- <sup>4</sup> Cummins, C. R., Bairstow, B., and Baker, L. A. (1953) "Stilbamidine in Treatment of Disseminated Blastomycosis." *A.M.A. Arch intern Med*, 92, 98.
- <sup>5</sup> Curtis, A. C., and Harrell, E. R., Jr. (1952) "Use of Two Stilbene Derivatives (Dactinomycin and Stilbamidine) in the Treatment of Experimental Histoplasmosis." *Antibiotics Annual*, p. 866. New York: Medical Encyclopedia Inc.
- <sup>6</sup> D. — — — — — Ivers, also on  
of the Hydrogenation Product and Isolation of Mycosamine, an Acetolysis Product." In *Antibiotics Annual*, p. 866. New York: Medical Encyclopedia Inc.
- <sup>7</sup> Ellis, F. F., Jr., Scott, R. J., and Miller, J. M. (1952) "Treatment of Progressive Disseminated Histoplasmosis with Ethyl Vanillate and Propamidine." *Antibiot and Chemother*, 2, 347.
- <sup>8</sup> Elson, W. O. (1945) "The Antibacterial and Fungistatic Properties of Propamidine." *J. Infect. Dis.*, 76, 193.
- <sup>9</sup> Furcolow, M. L. (1956) "The Clinical Diagnosis of Histoplasmosis." *Postgrad. Med.*, 20, 369.
- <sup>10</sup> Gold, W., Stout, H. A., Pagano, J. F., and Donovan, R. (1955-56) "Amphotericins A and B, Antifungal Antibiotics Produced by a Streptomyces. I. *In vitro* Studies." In *Antibiotics Annual*, p. 579. New York: Medical Encyclopedia Inc.
- <sup>11</sup> Hazen, E. L., and Brown, R. (1951) "Fungicidin, an Antibiotic Produced by a Soil Actinomycete." *Proc. Soc. exp. Biol. N.Y.*, 76, 93.
- <sup>12</sup> Howson, C. R., Brewer, L. A., III, Oatway, W. H., Jr., and Rouff, E. A. (1956) "Progressive Pulmonary Histoplasmosis with Bilateral Resection and Chemotherapy." *Ann. intern. Med.*, 44, 985.
- <sup>13</sup> Larsh, H. W. Unpublished data.
- <sup>14</sup> — — — — — Silberg, S. L., and Hinton, A. (1956-57) "Use of the Tissue Culture Method in Evaluating Antifungal Agents." In *Antibiotics Annual*, p. 918. New York: Medical Encyclopedia Inc.
- <sup>15</sup> Lehan, P. H., Brasher, C. A., Larsh, H. W., and Furcolow, M. L. (1957) "Evaluation of Clinical Aids to the Diagnosis of Chronic Progressive Cavitary Histoplasmosis." *Amer. Rev. Tuberc.*, 75, 938.

## THE THERAPY OF DEEP MYCOTIC INFECTIONS

38 patients with cryptococcal meningitis or progressive histoplasmosis with 2 hydroxystilbaminidine, aminostilbamidine, MRD-112, mycostatin, and amebacide were disappointing. In only 1 patient was either clinical improvement or cultural conversion attained.

Among the patients treated with amphotericin B, preliminary results were dramatic, with both clinical improvement and cultural conversion. Poor absorption from the gastro-intestinal tract makes the present oral preparation of questionable value. Studies are now in progress to find some means of enhancing absorption from the gastro-intestinal tract. The intravenous preparation is moderately well accepted by the patient in its present state and "adequate" blood levels are easily obtainable.

The problems of short follow-up periods and spontaneous remissions even among those forms of mycotic infections generally considered fatal must be considered. This may well account for the response noted in any single case treated with amphotericin B. It is, however, unlikely that this can explain the consistently favourable response and conversion of cultures in all patients receiving a significant amount of intravenous drug. It is difficult to explain the dramatic response obtained in cryptococcal meningitis in the light of our inability to demonstrate drug levels in the cerebrospinal fluid. It may be that only small amounts of drug are necessary and the bioassay technique employed does not detect such levels. *In-vitro* studies and clinical trials now proceeding in patients with blastomycosis and coccidioidomycosis indicate that this agent may well be a "broad spectrum" antifungal antibiotic.

The moderate radiographic improvement noted among those with chronic progressive cavitary histoplasmosis is not surprising if one considers the underlying pathological changes. The fact that marked reduction in sputum and cultural conversion was attained is considered to be a highly significant finding. Recently we have followed some 30 cases of chronic progressive pulmonary histoplasmosis by frequent cultures for varying periods up to 2 years. Of the 300 cultures performed, *H. capsulatum* was recovered in 75 per cent of the specimens<sup>15</sup>. It appears to us that the therapy of histoplasmosis with amphotericin B may well be in the same stage as that of tuberculosis in the early streptomycin era. Combined drug therapy may be the solution to the problem<sup>1</sup>. Although surgery has been of definite value in appropriate cases, fear of complications with an organism resistant to therapy has been a major deterrent to this approach. The availability of a specific therapeutic agent will undoubtedly make this approach more feasible.

# INDEX

## A

Acrocyanosis, *T. rubrum* infection and, 61

Acridione,  
therapeutic use, 192  
toxicity, 198

*Actinomyces israeli*, 5, 7  
pulmonary infection due to, 18  
subcutaneous infection due to, 14

*Actinomyces*, 5, 7  
infections due to aerobic, 114-122  
culture, characteristics, 117  
findings on, 114  
DOS in treatment, 121  
diagnosis, laboratory, 115-120  
identification of species, 117  
main types of, 114  
morphological characteristics of  
species, 116  
pathogenic species, 113  
physiological properties, 117  
treatment, 121  
penicillin, 227-231  
dosage, 230  
sulphonamides, 227  
Tetramycin 231

*Actinomyces* lesions, 14

*Actinomyces*, 114  
diagnosis, need for accurate, 226  
histological appearances, 29  
radiographic appearance of pulmonary  
170-172, 228-230  
surgery, place in treatment, 226  
treatment, 225-233

*Allescheria boydii*, tissue reaction to, 29

Amebicide CT 686,  
clinical trials with, 242, 243, 254  
effectiveness of, 243

Ammonosulfamidine in histoplasmosis,  
241-242, 254

Ammonium compounds, quaternary anti-  
fungal uses, 193

Amphotericin B,  
cryptococcal meningitis, in, 241, 244,  
245, 247  
dosage, 244, 246, 249, 251-253  
effectiveness, 187  
evaluation of therapy, 247-248  
experimental results, 203  
histoplasmosis, in, 241, 243, 246,  
247-251  
inhibitory action of, 243  
intravenous administration of, 252-  
253

oral administration of, 252  
physical characteristics of, 242-243  
therapeutic trials with, 242-253  
toxicity, 198, 253  
vaginal moniliasis treated by, 225

Anisomycin effectiveness of, 243

Antibiotic 1968, toxicity, 198

Antibiotic therapy,

comparative spectra, 197  
fungal infections following, 84-87  
napkin rash, monilial, and previous,  
101

Antifungal drugs,

comparative effectiveness, 187, 192,  
202, 243

mode of action, 183-191, 209-212

adjuvants, effect of, 189-191

agents used, 183, 193

cell-division, effects of drugs on  
186-188

comparison of effectiveness, 187, 188,  
193-203

data on, 187, 193-203

fungicidal effects, 183

halogenated oxyquinolines, 183-184,  
193

hyphae, effects on 184

metabolic interference, 189-191

morphology of organisms, direct  
effects on, 183-186

penetration into skin, 210

polyenes, 183, 192

results, 183-191, 202

spores, effects on 184-186

therapeutic use 192-207

acridione 192

antibiotics, 192

classification, 196

antihistamines 193

benzoic derivatives, 193

benzothiazoles, 194

candididin, 193

diamidines, 192 241-242

aromatic, 193

dyes, 194

Eucrin, 195

fatty acids, 187, 193

halogens, 193

heavy metals 193

nystatin, 85, 104, 184 186 191, 199,  
201, 221-225

phenol derivatives, 194

polyenes, 187, 190, 192

quaternary ammonium compounds,  
193

quinolines 195

quinones 194

skin infections in 208-216

spectra, comparative of antibiotics,  
197

sulphonamides 84, 194

sulphones 194

sulphur compounds, 193

toxicity, 198, 253

Antihistamines, antifungal uses, 193

Ascosin toxicity 198

Aspergilloma, evolution of, 22-23, 123,  
130-132 174

# THE THERAPY OF DEEP MYCOTIC INFECTIONS

- <sup>16</sup> Littman, M. L. (1957) "Preliminary Observations on the Intravenous Use of Amphotericin B, an Antifungal Antibiotic, in the Therapy of Acute and Chronic Coccidioidal Osteomyelitis" Symposium on Coccidioidomycosis Phoenix, Arizona, February, 1957
- <sup>17</sup> Locket, S., Atkinson, E. A., and Grieve, W. S. M. (1953) "Histoplasmosis in Great Britain. Description of a Second Case of Disseminated Histoplasmosis: Treatment by Ethyl Vanillate." *Brit. med. J.*, 2, 857.
- <sup>18</sup> Louria, D. B., Feder, N., and Emmons, C. W. (1956-57) "Amphotericin B in Experimental Histoplasmosis and Cryptococcosis" In *Antibiotics Annual*, p. 870 New York, Medical Encyclopedia Inc
- <sup>19</sup> Ludwig, K. A., Murray, F. J., Smith, J. K., Thompson, C. R., and Werner, H. W. (1954) "Laboratory Studies on  $\beta$ -Diethylaminoethyl Fencholate, a new Antifungal Agent," *Antibiot and Chemother.*, 4, 56
- <sup>20</sup> Michael, M., Jr., and Vogel, R. A. (1954) "Histoplasmosis—Report of a Case, with Observations on Management" *New Eng J Med*, 251, 884
- <sup>21</sup> Polk, J. W., Brasher, C. A., de Castro, J., and Buckingham, W. W. (1956) "The Surgical Treatment of Pulmonary Histoplasmosis with an Evaluation of MRD-112 as a Possible Adjunct" *J thorac Surg*, 31, 148
- <sup>22</sup> Schoenbach, E. B., Miller, J. M., and Long, P. H. (1952) "The Treatment of Systemic Blastomycosis with Stilbamidine" *Ann intern Med*, 37, 31.
- <sup>23</sup> Seabury, J. H., and Artis, D. (1946) "In vitro Susceptibility of *Histoplasma capsulatum* to Therapeutic Agents" *Proc Soc exp Biol N Y*, 61, 15
- <sup>24</sup> Steinberg, B. A., Jambor, W. P., and Suydam, L. O. (1955-56) "Amphotericins A and B Two New Antifungal Antibiotics Possessing High Activity Against Deep-seated and Superficial Mycoses" In *Antibiotics Annual*, p. 574 New York, Medical Encyclopedia Inc
- <sup>25</sup> Tilford, C. H., Doerle, L. A., Van Campen, M. G., and Shelton, R. S. (1949) "Aminoesters of I-Substituted Alicyclic Carboxylic Acids" *J Amer chem Soc*, 71, 1705
- <sup>26</sup> Vandeputte, J., Wachtel, J. L., and Stiller, E. T. (1955-56) "Amphotericins A and B, Antifungal Antibiotics Produced by a Streptomycete II The Isolation and Properties of the Crystalline Amphotericins" In *Antibiotics Annual*, p. 587 New York, Medical Encyclopedia Inc
- <sup>27</sup> Weinberg, B. J., Lawrence, C. H., and Buchholz, A. (1954) "Systemic Blastomycosis Treated with 2-Hydroxystilbamidine" *AMA Arch intern Med*, 94, 493
- <sup>28</sup> Zinneman, H. H., and Hall, W. H. (1953) "Chronic Pharyngeal and Laryngeal Histoplasmosis Successfully Treated with Ethyl Vanillate A Case Report" *Minn Med*, 36, 249

# INDEX

## A

- Acrocyanosis, *T. rubrum* infection and, 61
- Actidione,  
therapeutic use, 192  
toxicity, 198
- Actinomyces israeli*, 5, 7  
pulmonary infection due to, 18  
subcutaneous infection due to, 14
- Actinomycetes, 5, 7  
infections due to aerobic, 114-122  
culture, characteristics, 117  
findings on, 114  
DDS in treatment, 121  
diagnosis, laboratory, 115-120  
identification of species, 117  
main types of, 114  
morphological characteristics of  
species, 116  
pathogenic species, 115  
physiological properties, 117  
treatment, 121  
penicillin, 227-231  
dosage, 230  
sulphonamides, 227  
Terramycin, 231
- Actinomycetoma, lesions, 14
- Actinomycosis, 114  
diagnosis, need for accurate, 226  
histological appearances, 29  
radiographic appearance of pulmonary,  
170-172, 228-230  
surgery, place in treatment, 226  
treatment, 225-233
- Allescheria boydi*, tissue reaction to, 29
- Amebicide CT 686,  
clinical trials with, 242, 243, 254  
effectiveness of, 243
- Aminostilbamidine in histoplasmosis,  
241-242, 254
- Ammonium compounds, quaternary, anti-  
fungal uses, 193
- Amphotericin B,  
cryptococcal meningitis, in, 241, 244,  
245, 247  
dosage, 244, 246, 249, 251-253  
effectiveness, 187  
evaluation of therapy, 247-248  
experimental results, 203  
histoplasmosis, in, 241, 243, 246,  
247-251  
inhibitory action of, 243  
intravenous administration of, 252-  
253  
oral administration of, 252  
physical characteristics of, 242-243  
therapeutic trials with, 242-253  
toxicity, 198, 253  
vaginal moniliasis treated by, 225
- Anisomycin, effectiveness of, 243
- Antibiotic 1968, toxicity, 198
- Antibiotic therapy,  
comparative spectra, 197  
fungal infections following, 84-87  
napkin rash, monilial, and previous,  
103
- Antifungal drugs  
comparative effectiveness, 187, 192,  
202, 243  
mode of action, 183-191, 209-212  
adjuvants, effect of, 189-191  
agents used, 183, 193  
cell-division, effects of drugs on  
186-188  
comparison of effectiveness, 187, 188,  
193-203  
data on, 187 193-203  
fungicidal effects, 188  
halogenated oxyquinolines, 183-184,  
193  
hyphae, effects on, 184  
metabolic interference, 189-191  
morphology of organisms, direct  
effects on, 183-186  
penetration into skin, 210  
polyenes, 183, 192  
results, 183-191, 202  
spores, effects on 184-186  
therapeutic use, 192-207  
actidione, 192  
antibiotics, 192  
classification, 196  
antihistamines, 193  
benzoic derivatives, 193  
benzothiazoles, 194  
candididin, 195  
diamidines, 192, 241-242  
aromatic, 195  
dyes, 194  
Euclin, 195  
fatty acids, 187, 193  
halogens, 193  
heavy metals, 193  
nystatin, 85, 104, 184, 186, 191, 199,  
201, 221-225  
phenol derivatives, 194  
polyenes, 187, 190, 192  
quaternary ammonium compounds,  
193  
quinolines, 195  
quinones, 194  
skin infections, in, 208-216  
spectra, comparative, of antibiotics,  
197  
sulphonamides, 84, 194  
sulphones, 194  
sulphur compounds, 193  
toxicity, 198, 253
- Antihistamines, antifungal uses, 193
- Ascom toxicity, 198
- Aspergiloma, evolution of, 22-23, 123,  
130 132, 174



# INDEX

**Aspergillosis, broncho-pulmonary, 22,**  
 123-137, 172-175  
 allergic, 234-239  
   bronchograms in, 235  
   bronchoscopy in, 235  
   sensitization in, 237  
   symptoms and signs of, 234-235  
   treatment of, 235-237, 240  
 aspergilloma, evolution of, 22-23, 123,  
 130-132, 174  
 bronchitic form, 128-129  
 broncho-pulmonary form, 129-130  
 clinical aspects, 128-133  
 culture of fungus, 123  
*differential manifestation in*, 126  
 empyemic infection in, 126  
 historical aspects, 128  
 hypersensitivity and clinical pattern of  
 infection, 134, 137  
*location and appearance*, 123-126  
 mycetoma, occurrence in, 123-126  
 pulmonary form, 129  
 radiology in pulmonary form, 172-175  
   allergic type, 174-175, 176  
   saprophytic or mycetoma type, 172-  
 174  
 saprophytic, 239-240  
   treatment of, 239-240  
 sensitivity tests, direct bronchial, in,  
 134-137  
   absence of sensitivity, 136-137  
   aspergillus mycetoma, 136  
   asthma with allergic sensitivity, 135-  
 136  
   method, 134  
   reactions, types of, 134-135  
   species involved, 123  
   treatment of, 234-240  
   types, clinical, 128  
*Aspergillus flatus*, broncho-pulmonary  
 infection, 123  
*Aspergillus fumigatus*, 3, 10, 22, 237, 239  
 broncho-pulmonary infection due to,  
 123-127 (*see also* Aspergillosis)  
 halogenated oxyquinolines, effect on,  
 184  
 mycelium and spore structure, 3  
 pulmonary infection due to, 18, 22, 23  
 sputum, in, significance, 134  
 staining of, 35  
*Aspergillus nidulans*, broncho-pulmonary  
 infection, 123  
*Aspergillus niger*,  
 broncho-pulmonary infection, 123  
 drug therapy, comparative effective-  
 ness, 187  
 oxyquinolines, effect of, 184, 185, 186  
*Aspergillus versicolor*, broncho-pulmon-  
 ary infection, 123  
 Asthma, sensitivity tests in broncho-  
 pulmonary aspergillosis, 134-135  
 Axillae, ringworm of, treatment 215

## B

Bacteria and fungi, difference between  
 75-76

Beard, treatment of ringworm, 215  
 Benzoic derivatives, antifungal uses, 19  
 Benzothiazoles, antifungal uses, 194  
 Bi-refringence of fungi, 33  
*Blastomyces*, staining of, 35  
*Blastomyces brasiliensis*, 46  
*Blastomyces dermatitidis*, 5, 6, 47, 243  
   antibiotic therapy, culture results after,  
 203  
   pulmonary infection in, 18  
 Blastomycosis,  
 Amphotericin B, use in, 203  
 North American, 22, 31, 47  
   radiology in, 170-172  
 South American, 31, 46  
 therapeutic trials in, 247  
 Bronchiectasis,  
 aspergillosis, allergic, underlying, 237,  
 238  
*C albicans* infections, and, 110  
 Bronchomycosis, 138-141 (*see also*  
 Farmer's lung)

## C

Candididin,  
 effectiveness, 243, 245  
 therapeutic use, 195  
 toxicity, 198  
*Candida albicans*, 4, 5  
 acquired immunity to, size of infecting  
 cell, and, 79  
 agglutinins to, 78-79  
 antibiotic therapy, infection following  
 84-87  
 diabetes mellitus in relation to infection,  
 88  
 drug therapy, comparative effective-  
 ness, 187, 188, 243  
 glycosuria and infection with, 88, 89  
 infantile infections, 105-113 (*see also*  
 Moniliasis, infantile)  
 innate immunity, 77  
 leukaemia and infection, 107-108  
 lung infection due to, 18, 138-141 (*see*  
*also* Farmer's lung)  
 nystatin therapy, 184, 196-202  
 predisposing factors to infection 11, 13  
 pregnancy in relation to infection 88  
 pulmonary infection due to, 18  
 Rimocidin, effect on, 184, 185  
 size of, 75  
 skin infection in infants, 102-104 (*see*  
*also* Napkin rash)  
 sputum, in, 84, 85  
 subclinical infection, permanent 77  
 sulphonamide therapy and infection  
 with, 84  
 susceptibility, enhancing factors, 82  
 pregnancy, 100  
 tetracycline therapy and infection with,  
 84, 89  
 tissue reaction to, 28  
 toxin liberation, 81  
 vaginal secretions in pregnancy, in,  
 94-101  
 virulence, fluctuations in, 83

# INDEX

- Candida albicans*—continued  
vulvo-vaginal infections in pregnancy, 95 (see also Pregnancy)  
*Candida guilliermondii*, vulvo-vaginal infections in pregnancy, 95  
*Candida pseudotropicalis*, vulvo-vaginal infections in pregnancy, 95  
*Candida tropicalis*, vulvo-vaginal infections in pregnancy, 95  
Candidiasis. See Moniliasis  
Cervicitis, *C. albicans* infection in pregnancy, and, 97-98  
Chemotherapy, *C. albicans* infections in relation to, 84-87  
Chlorhydroxyquinoline, effectiveness, 187  
Chromoblastomycosis, tissue response in, 14  
Classification of fungi, 5  
*Coccidioides*, nerve tissue mistaken for, 38  
*Coccidioides immitis*, 18, 20  
pulmonary infection due to, 22  
Coccidioidin reactions, geographical distribution, 161-162  
Coccidioidomycosis, 22, 31, 43  
radiology in pulmonary, 176  
Collodion agglutination test, 143-145  
Cortisone in allergic aspergillosis, 238  
Cryptococcal meningitis,  
amphotericin B in, 244, 245  
therapy in, 242, 244, 245, 247, 254, 256  
results of, 247  
Cryptococcosis. See Torulosis  
*Cryptococcus neoformans*, 3, 4, 44, 45  
243, 245, 247, 252  
acquired immunity, and, 81-82  
acidrone therapy, 192  
animal susceptibility to, 78  
chronic non-specific non-suppurative inflammatory reaction to, 27-28  
innate immunity, 77-78  
nerve tissue mistaken for, 38  
pathogenicity, confirmation of, 245  
pulmonary infection due to, 18, 21-22  
size of, 75  
subclinical infection, permanent, 77  
tissue reaction absent in, 23, 26  
Cure, criteria of, 208

## D

- Dandruff in ringworm, 217  
DDS, actinomycetes infections, in, 121  
Deep mycotic infections, therapy in, 241-257  
Dermatophytes, 3, 7-13, 50  
comparison, parasitic and saprophytic, 13  
habitat in soil, 50  
infection, mode of, 51-52  
sites of parasitic growth, 208  
tissues invaded, 8  
Diabetes mellitus, *C. albicans* infection and, 88  
Diagnosis,  
histological, aids to, 33-37  
simulation of fungi by other structures, 37

- Diamidines, aromatic, antifungal uses, 195  
4 4'-diamidinophenylamine hydrochloride in aspergillosis, 236-237  
4 4'-Diaminodiphenyl sulphone actinomycetes infections, in, 121  
Dichlorhydroxyquinoline, effectiveness, 187  
Dimorphic fungi, 5  
Drugs, antifungal. See Antifungal drugs  
Dust inhalation, infection due to, 18  
Dyes, antifungal, 103, 113, 183, 494, 221

## E

- Ectothis infection, 8  
Empyema infected with *A. fumigatus*,  
treatment of, 239-240  
Endothrix infection, 8  
Environment, tinea pedis in miners, and, 69  
*Epidermophyton floccosum*, 8  
axilla or groin infection, treatment, 215  
feet infection, treatment, 216  
nail invasion by, 8  
tinea pedis due to, 70  
Erythrasma, 5, 114  
causative fungus, 5, 11  
Ethyl vanillate, clinical trials with, 242  
Euclin,  
therapeutic use, 195  
toxicity, 198

## F

- Farmer's lung, 138-141  
aetiology, 139-140  
allergy, and, 139  
case reports, 139-141  
causative fungi, 138  
clinical features, 138-139  
differential diagnosis, 141  
histological studies in, 139-141  
sera, findings, 139  
Favus, 9  
Feet,  
normality degrees of in miners, 68  
*T. rubrum* infections, 56-57  
treatment, 215-216  
Fluorescence in infected hairs, 8  
Filamentous fungi, 3  
Fungi and bacteria, difference between, 75-76  
Fungicides. See Antifungal drugs  
Fungicidal effects, 188, 223

## G

- Gastro-enteritis, moniliasis, infantile, and, 111  
Gentian violet,  
effectiveness, 187  
napkin rash, monilial, in, 103  
vaginal moniliasis treatment, in, 221

# INDEX

Glabrous skin, ringworm of, treatment, 215  
 Glans penis, *T. rubrum* infection, 59  
 Glucose tolerance curves in *T. rubrum* infection, 61  
 Glycosuria, *C. albicans* infections, and, 88, 89, 99  
 Grindley stain, 34  
 Groins, treatment of, ringworm, 215

## H

Haemoptysis in aspergillosis, 239  
 Hair,  
     species attacking, 7, 8  
     *T. rubrum* infection, 57  
 Halogens, antifungal uses, 193  
 Hands, *T. rubrum* infection, 57-58  
     treatment, 215  
 Histopathological observations, 25-49  
     comparative morphology of non-myceliate fungi, 40  
     identification of fungi, aids to, 33-37  
     optical aids to identification of fungi, 33-34  
     staining techniques for identification of fungi, 34-35  
*Histoplasma capsulatum*, 18, 19, 45, 241, 243, 247, 248, 252, 254  
     geographic distribution, 158, 159-161  
     polarizing-microscopic view, 34  
     pulmonary lesions due to, 18, 19, 22  
     tissue reaction to, 27  
*Histoplasma duboisii*, 46  
     polarizing-microscopic view, 34  
     tissue reaction to, 27, 31  
 Histoplasmin testing in different geographic areas, 142, 158-169  
     frequency distribution, 162-168  
     skin sensitivity, 158-161  
     other fungal infections, in, 160  
     coccidioidomycosis, in, 164  
 Histoplasmosis,  
     acute pulmonary, amphotericin B in, 250-251  
     African type, 46  
     amphotericin B, use in, 203  
     cavitary, therapeutic trials in, 241-242, 250  
     combined drug therapy in, 254  
     disseminated,  
         amphotericin B in, 246-247  
         therapy in, 241, 242  
     epidemic, 149-151  
         serological tests, usefulness of, 150-151  
     infection, mode of, 142  
     post-primary, serological tests in, 153-154  
     progressive pulmonary, chronic, treatment with amphotericin B in, 247-249  
     pulmonary,  
         endemic areas, in, serological tests, value of, 152  
         serological reactions in, 149, 152

Histoplasmosis—continued  
     radiographic appearances of pulmonary, 148, 177-179  
     rural and suburban communities, in, 155  
     serological tests, 143-155  
         antigens used in complement fixation, differences in reactivity, 143-147  
         collodion agglutination test, advantages, 143-145  
         complement fixation tests, 143  
         cross-reactions, problem of, 154  
         endemic areas, usefulness in, 151-153  
         epidemic studies in, 150-151  
         epidemiological studies, use in, 147-155  
     post-primary histoplasmosis, 153-154  
     reactions in, 145, 149  
     sarcoidosis, cross-reactions in, 154  
     skin test reactions in endemic areas, 152  
     surgery in, 254  
     tissue reaction in, 27  
*Hormodendrum pedrosi*, 14, 16, 47  
 Hydroxystilbamidine in aspergillosis, 238, 239  
 Hypersensitivity to fungi, 126, 137, 142, 158, 208, 234

## I

Industrial Epidermophytosis Committee of the Medical Research Council, constitution, 67  
 Iodides in actinomycosis, 226

## K

Keratin,  
     inhibition of formation, treatment by temporary, 209  
     invading fungi, 5, 7-13  
     modification in treatment, 209-212  
     penetration by antifungal agents, 211  
*Keratinomyces ajelloi* in soil, 50-51  
 Keratolytics, therapeutic use, 210

## L

Leucorrhoea,  
     *C. albicans* causing, in pregnancy, 88  
     incidence of fungous infections, 88  
 Leukaemia, and *C. albicans* infection, 107-108  
 Lobectomy in allergic aspergillosis, 239

## M

*Madurella* species, 14, 15  
     subcutaneous infection by, 14  
 Maduromycetoma, lesions, 14, 15  
 Maduromycosis, tissue reaction in, 29, 32

# INDEX

*Malassezia furfur*, 5  
 appearance in skin scrapings, 11  
 tissue reaction, 9  
 Merthiolate in treatment of monilial  
 napkin rash, 103  
 Metals, heavy, antifungal uses, 193  
*Microsporum audouinii*,  
 drug therapy, comparative effective-  
 ness, 187  
 hair invasion by, 8  
 scalp infections, treatment, 213-214,  
 217-218  
 tissues invaded, 7, 8  
*Microsporum canis*,  
 hair invasion by, 8  
 scalp infections, treatment, 213-214,  
 218-219  
*Microsporum equinum*, 8  
*Microsporum gypseum*,  
 hair invasion by, 8  
 scalp infections, treatment, 213-214,  
 219  
 soil in, 30-51  
 Moniliasis,  
 bronchial, nystatin in treatment, 199  
 causative fungus, 5  
 cutaneous, 9, 99  
 infantile, 103-113  
   bronchiectasis, and, 107, 110  
   gastro-enteritis, and, 111  
   incidence, 105, 111, 112  
   leukaemia, and, 107-108  
   morbid anatomy, 105-110  
   non-oral, 112  
   oesophageal infection, 105, 106  
   older children, in, 107-110  
   oral, 111-112  
   pathology 111-113  
   resistance to, lowered, 111  
   sites, 111, 112  
   susceptibility as index of, 110, 111  
   treatment, 112-113  
 nystatin in treatment, 196, 198, 201  
 skin of, infants, in, 102-104 (see also  
   Napkin rash)  
 vaginal, treatment, 221-225 (see also  
   vulvo-vaginal, below)  
 vulvo-vaginal, 88-93  
   aetiology, 89  
   clinical picture, 89-91  
   culture in diagnosis, 91  
   gentian violet in treatment, 91  
   nystatin in treatment 91-93, 221-  
   224  
   pregnancy, in, 94 (see also Pregnancy)  
   surgical measures in, 93  
   transmission by examiners, 88-89  
   treatments, 91-93, 221-225  
     amphotericin B, with, 225  
     gentian violet, with, 91, 221  
     nystatin, with, 91-93, 221-224  
     concentrations used, 222-223  
     duration of course, 224  
     results, 221-222  
     summary of results, 224  
   vaginal smears in diagnosis, 89, 91

MRD-112, clinical trials with, 242, 243,  
 254  
 Mucocarmine stain, 36  
 Mucormycosis, 22, 24  
 Mycetoma, 114, 115  
   aspergillus, 239  
     sensitivity tests in, 136  
   broncho-pulmonary aspergillosis, in,  
     123-126  
   diseases occurring in, 124-125  
   sarcoidosis, in, 125-126  
   surgical complications in, 239  
   treatment, 121  
 Mycoses, radiology of pulmonary, 170-  
 179 (see also Radiology)

## N

Nails, infection,  
 removal of nails and, 212  
 species invading, 7, 8  
 treatment, 216  
*T. rubrum* infection, 63  
 Napkin rashes, monilial, 102-104  
 antibiotic therapy in aetiology, 103  
 differentiation, 103  
 gentian violet therapy, 103  
 maternal thrush vaginitis, and, 103  
 merthiolate therapy, 104  
 nystatin therapy, 104  
 Nepara 1112, effectiveness of, 243  
 Ninhydrin, therapeutic, 211  
*Nocardia* species, subcutaneous infection  
 by, 14  
*Nocardia asteroides*, 5  
   culture characteristics, 117  
   identification of, 117  
   infection due to, 115  
   morphological characteristics, 116, 118  
*Nocardia brasiliensis*  
   culture characteristics, 117  
   identification of, 117  
   infection due to, 115  
   morphological characteristics, 116, 119  
*Nocardia minutissima*, 5  
   appearance in skin scrapings, 11  
   tissue reaction, 9  
*Nocardia tenuis*, 5  
 Nocardiosis, 114  
 Nystatin,  
   antifungal effects, 184  
   *Candida albicans* infections, in, 196, 202  
   cell-division effects on, 186  
   clinical trials with, 242  
   effectiveness, 187  
   experimental mycoses, activity in, 199  
   napkin rash, monilial, in, 103  
   prophylaxis, in, 200  
   therapeutic use 195-202  
   toxicity 198  
   vaginal moniliasis, in treatment of,  
     91, 92, 221, 224

# INDEX

- Glabrous skin, ringworm of, treatment, 215  
 Glans penis, *T. rubrum* infection, 59  
 Glucose tolerance curves in *T. rubrum* infection, 61  
 Glycosuria, *C. albicans* infections, and, 88, 89, 99  
 Grindley stain, 34  
 Groins, treatment of, ringworm, 215

## H

- Haemoptysis in aspergillosis, 239  
 Hair,  
     species attacking, 7, 8  
     *T. rubrum* infection, 57  
 Halogens, antifungal uses, 193  
 Hands, *T. rubrum* infection, 57-58  
     treatment, 215  
 Histopathological observations, 25-49  
     comparative morphology of non-myceliate fungi, 40  
     identification of fungi, aids to, 33-37  
     optical aids to identification of fungi, 33-34  
     staining techniques for identification of fungi, 34-35  
*Histoplasma capsulatum*, 18, 19, 45, 241, 243, 247, 248, 252, 254  
     geographic distribution, 158, 159-161  
     polarizing-microscopic view, 34  
     pulmonary lesions due to, 18, 19, 22  
     tissue reaction to, 27  
*Histoplasma duboisii*, 46  
     polarizing-microscopic view, 34  
     tissue reaction to, 27, 31  
 Histoplasmin testing in different geographic areas, 142, 158-169  
     frequency distribution, 162-168  
     skin sensitivity, 158-161  
         other fungal infections, in, 160  
         coccidioidomycosis, in, 164  
 Histoplasmosis,  
     acute pulmonary, amphotericin B in, 250-251  
     African type, 46  
     amphotericin B, use in, 203  
     cavitary, therapeutic trials in, 241-242, 250  
     combined drug therapy in, 254  
     disseminated,  
         amphotericin B in, 246-247  
         therapy in, 241, 242  
     epidemic, 149-151  
         serological tests, usefulness of, 150-151  
     infection, mode of, 142  
     post-primary, serological tests in, 153-154  
     progressive pulmonary, chronic, treatment with amphotericin B in, 247-249  
     pulmonary,  
         endemic areas, in, serological tests, value of, 152  
         serological reactions in, 149, 152

- Histoplasmosis—continued  
     radiographic appearances of pulmonary, 148, 177-179  
     rural and suburban communities, in, 155  
     serological tests, 143-155  
         antigens used in complement fixation, differences in reactivity, 145-147  
         collodion agglutination test, advantages, 143-145  
         complement fixation tests, 143  
         cross-reactions, problem of, 154  
         endemic areas, usefulness in, 151-153  
         epidemic studies in, 150-151  
         epidemiological studies, use in, 147-155  
         post-primary histoplasmosis, 153-154  
         reactions in, 145, 149  
         sarcoidosis, cross-reactions in, 154  
         skin test reactions in endemic areas, 152  
         surgery in, 254  
         tissue reaction in, 27  
*Hormodendrum pedrosoi*, 14, 16, 47  
 Hydroxystilbamidine in aspergillosis, 238, 239  
 Hypersensitivity to fungi, 126, 137, 142, 158, 208, 234

## I

- Industrial Epidermophytosis Committee of the Medical Research Council, constitution, 67  
 Iodides in actinomycosis, 226

## K

- Keratin,  
     inhibition of formation, treatment by temporary, 209  
     invading fungi, 5, 7-13  
     modification in treatment, 209-212  
     penetration by antifungal agents, 211  
*Keratinomyces ajellii* in soil, 50-51  
 Keratolytics, therapeutic use, 210

## L

- Leucorrhoea,  
     *C. albicans* causing, in pregnancy, 88  
     incidence of fungous infections, 88  
 Leukaemia, and *C. albicans* infection, 107-108  
 Lobectomy in allergic aspergillosis, 239

## M

- Madurella* species, 14, 15  
     subcutaneous infection by, 14  
 Maduromycetoma, lesions, 14, 15  
 Maduromycosis, tissue reaction in, 29, 32

# INDEX

- Staining techniques, identification of fungi by, 34-37
- Strabomycin in blastomycosis, 241
- Streptomyces muluiae*, infection due to, 115
- culture characteristics, 117
- identification of, 117
- morphological characteristics, 116, 120
- Streptomyces pelletieri*, infection due to, 115
- culture characteristics, 117
- identification of, 117
- morphological characteristics, 116, 120
- Streptomyces somaliensis* infection due to, 115
- culture characteristics, 117
- identification, 117
- morphological characteristics, 116, 119
- Subcutaneous infections, fungi causing, 14
- Sulphonamides,
- antifungal uses, 194
- C. albicans* infection following 84
- Sulphones, antifungal uses, 194
- Sulphur compounds, antifungal uses, 193
- Surgery,
- actinomycosis, in 226, 231
- aspergillosis, in 239
- histoplasmosis, in 254
- Susceptibility of tissues, 8, 14
- Systemic infections, causative fungi, 18-24
- T**
- Terminology, 5
- Terramycin in actinomycosis, 231
- Tetracycline,
- C. albicans* infection following 84, 89
- side effects and *C. albicans* infection, 86
- Therapy. See Antifungal drugs
- Thiomersalate in infantile moniliasis, 113
- Thresher's lung, 138-141 (see also Farmer's lung)
- Thrush (see also Moniliasis)
- oral, 105-109, 111-113
- prophylaxis with nystatin 200
- vaginal, 94-100, 103-104, 221-225
- Tinea infections (see also specific fungi and conditions)
- capitis, sea incidence, 52
- causative fungi 5
- circinata, treatment 215
- corporis, treatment 215
- epidemiology, 51-52
- living conditions and susceptibility, 52-53
- pathogenesis 50-55
- pedis in miners, 67-71
- environment effect of, 69
- epidemiological field survey, 67-70
- first accounts of, 67
- incidence, 68
- laboratory findings, 69
- length of employment and exposure, 70

- Tinea infections—continued
- pedis, in miners—continued
- observer error, assessment of 68
- species isolated, 70
- Trichophyton rubrum*, due to, 68
- underground and surface workers, 69
- Tissue reactions in fungal infections, 25-33
- absence of 25, 26
- Candida albicans*, to, 28
- chronic non-specific non-suppurative inflammatory reaction, 27-28
- chronic suppuration with histiocytosis, 30
- chronic suppurative reaction, 28, 29
- foreign body reaction, 33
- Histoplasma capsulatum*, to, 27
- Histoplasma duboisii*, to, 27
- intracellular parasitism, 27
- suppurating tuberculoïd granulomatous reaction, 29, 30, 31
- tuberculoïd granulomatous reaction, 31-33
- Toruloma, 21, 28, 172, 173
- radiography, 172, 173
- Torulopsis glabrata*, in vulvo-vaginal infections in pregnancy 93
- Torulosis, 44, 45
- histological appearances, 38, 40
- radiology in pulmonary 172, 173
- tissue reaction in, 23, 31
- Treatment drug therapy. See Antifungal drugs
- Trichomycin, toxicity, 198
- Trichonocardiosis axillaris, 114
- causative fungus, 5
- Trichophyton test, *T. rubrum* infection, in 61
- Trichophyton discoides* (see *Trichophyton ferrugineum*)
- Trichophyton equinum*, 8
- Trichophyton interdigitale* (see *Trichophyton mentagrophytes*)
- Trichophyton mentagrophytes*, 8, 12, 13
- beard infection treatment, 215
- drug therapy, comparative effectiveness, 187
- feet infection, 70
- treatment, 216
- hair invasion by, 8
- halogenated oxyquinolines, effect of, 184
- ringworm as a predominant cause of, 64
- scalp infections, treatment, 215, 219
- soil, in, 50-51
- Trichophyton quinckeianum*, 8
- Trichophyton rubrum*, 8, 9
- Trichophyton rubrum* infections, 56-71
- acrocyranosis, and, 61
- axilla or groin infection, treatment, 215
- clinical picture, exceptions to, 56-61
- community facilities, and, 65
- deep filamentous invasion of keratin layer, 9
- distribution, 59
- epidemiology, 63-66

# INDEX

## O

*O* ...

## P

Pathogens, role of fungi as human, 3-24  
Penicillin, ...

Phenol derivatives, antifungal uses, 194  
*Phialophora* species, 14, 16 (see also *Hor-  
modendrum pedrosoi*)  
subcutaneous infection by, 14, 16  
Pigments of *Trichophyton rubrum*, 72-  
74  
Pityriasis versicolor, 5, 11  
causative fungi, 5  
treatment, 216  
Pneumonia, aspergillosis, associated with,  
238, 239  
Polarizing microscope, identification of  
fungi by, 33  
Polyenes, therapeutic use, 192  
Pregnancy, *C. albicans* in vaginal secre-  
tions in, 88, 94-101  
antenatal investigations, 94-101  
babies, mouth swabs from, 99  
cervicitis in relation to culture results,  
97-98  
culture results in, 96-97  
examination, method in survey, 95  
glycosuria, and, 99  
post-natal investigations, 94-101  
pruritus in relation to culture results,  
97-98  
record taking in investigations, 94-95  
species isolated, other, 95  
susceptibility to, 100  
treatment, 221-225 (see also Moniliasis)  
vaginitis in relation to culture results,  
97-98  
vulvitis in relation to culture results, 99  
*n*-Propanol, effectiveness, 187  
Prophylaxis of thrush, 200  
Pruritus vulvae, *C. albicans* infection  
causing, in pregnancy, 89, 95  
culture results in relation to, 97-98  
*Pullularia* species, in vulvo-vaginal infec-  
tions in pregnancy, 95  
Pulmonary infections, causative fungi,  
18-24

## Q

Quinolines, antifungal uses, 195  
Quinones, antifungal uses, 194

## R

Radiology in pulmonary mycoses, 170-  
179  
actinomycosis, 170-172, 228-230  
aspergillosis, 172-175  
blastomycosis, North American, 170-  
172  
coccidioidomycosis, 176  
histoplasmosis, 177-179  
shadowing, type of, 170  
torulosis, 172  
Resistance, drug, 188  
Rhinosporidiosis, 44  
*Rhinosporidium seeberi*, 44  
*Rhizopus* species, 22, 23  
pulmonary infection due to, 18, 22  
tissue reaction absent in, 26  
*Rhodotorula* species and vulvo-vaginal  
infections in pregnancy, 95  
Rimocidin,  
antifungal effects, 184-186  
effectiveness, 187  
morphological effects, 184  
Ringworm (see also specific fungi and  
conditions)  
children, in, treatment, 217-220  
environment and susceptibility, 52  
fungi of, 3  
mode of infection, 51-52  
tissues invaded, 8

## S

Salicylic acid, 211, 216  
Scalp, ringworm, treatment, 213-215,  
217-219  
Scrotum, *C. albicans* infections, 89  
Shoes, unsuitable, 215-216  
Silver impregnation stains, 36, 124  
Skin,  
infections,  
causative fungi, 5, 7-13  
treatment, 208-216  
cure, criteria of, 208  
disturbance of host parasite  
balance, 209  
inhibition of fungal growth,  
209  
keratin formation, temporary in-  
hibition, 209  
keratin modification, 209-212  
modification of fungal growth, 203  
practical aspects, 213-216  
theoretical aspects, 208-212  
moniliasis, in infants, 102-104 (see also  
Napkin rash)  
Species of fungi, pathogenic, 3-7  
*Sporobulomycetes* species, in vulvo-vaginal  
infections in pregnancy, 95  
Sporotrichosis, 14, 17, 30, 48  
*Sporotrichum schenckii*, 17, 48, 243  
subcutaneous infection by, 14  
tissue reaction to, 30  
Sputum, *C. albicans* in, 84, 85





# INDEX

*Trichophyton rubrum* infections—*cont.*  
 familial, 61, 64  
 feet, affecting, 56-57, 70  
 glans penis, lesions on, 59  
 glucose tolerance curves in, 61  
 hair, involving, 57  
 hand, 10  
 incidence, 63  
   increasing, 56  
   rise in, 63  
 lesions, appearance on skin, 10  
 miners, in, 67-71  
 mixed infections, 59-60  
 nail invasion by, 8, 56-57, 63  
 pigments of, 72-74  
   absorption spectra, 73  
   early work on, 72  
   extraction of, technique, 73  
   isolation of, 72  
   paper chromatography in isolation of, 74  
 sex and age incidence, 65  
 sites on trunk, head and limbs, 59-61  
 skin infections, treatment, 211  
 source of infection, investigation of, 64  
 tissues invaded, 7, 8  
 treatment, 61-62  
   resistance to, 62, 64  
   trichophytin test in, 61  
*Trichophyton schoenleinii*, 8  
 hair and nail invasion by, 8  
 scalp infections, treatment, 214-215, 219  
 tissue reaction in, 9  
*Trichophyton sulphureum*, 8  
 hair and nail invasion by, 8  
 scalp infections, treatment, 214-215, 218  
*Trichophyton tonsurans*, scalp infections, treatment, 214-215  
*Trichophyton verrucosum*, 8  
 beard infection, treatment, 215  
 hair invasion by, 8  
 lesions, appearance on skin, 16  
 scalp infections, treatment, 215, 219  
*Trichophyton violaceum*, 8  
 hair and nail invasion by, 8  
 scalp infections,  
   sex incidence, 53  
   treatment, 214-215, 219

## U

Uncultured fungi, 9  
 Undecylenic acid, effectiveness, 187  
 United Kingdom, types of ringworm in, 217

## V

Vaginal discharge, pregnancy, in, culture results, 100  
 Vaginal moniliasis, treatment, 221-225  
 Vaginal secretions, *C. albicans* in, during pregnancy, 94-101  
 Vaginitis,  
   *C. albicans* infection in pregnancy, and, 97-98  
   maternal thrush, and monilial napkin rash, 103  
   nystatin in treatment, 199  
 Vulvitis, *C. albicans* infection in pregnancy, and, 97-98  
 Vulvo-vaginal moniliasis, 88-93  
   transmission of infection, 88-89

## W

Whitfield's ointment, 211, 213  
 Wood's light, in diagnosis, 8, 213, 214, 217  
 World Health Organization, histoplasmosis, survey, 167

## Y

Yeasts, 3-7  
 Yeast infections, immunity in, 75-83  
   acquired active immunity, 78-82  
   bacteria and fungi, difference between, 75  
   innate immunity, 77-78  
   pregnancy, in, 94-101  
   size of infecting organisms and, 75  
   susceptibility, and, 82  
   susceptibility, factors influencing, 82  
   virulence, and, 83  
   stimulation by other structures, 37-40  
 Yeast-like fungi, 5

